Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases (Review)

Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C

This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2009, Issue 3

http://www.thecochranelibrary.com
Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases (Review)

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases

Goran Bjelakovic1, Dimitrinka Nikolova1, Lise Lotte Gluud1, Rosa G Simonetti2, Christian Gluud1

1Cochrane Hepato-Biliary Group, Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 3344, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. 2Divisione di Medicina, Ospedale V.Cervello, Palermo, Italy

Contact address: Goran Bjelakovic, Cochrane Hepato-Biliary Group, Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 3344, Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9, Copenhagen, DK-2100, Denmark. goranb@junis.ni.ac.yu. (Editorial group: Cochrane Hepato-Biliary Group.)

Cochrane Database of Systematic Reviews, Issue 3, 2009 (Status in this issue: Edited, commented)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
DOI: 10.1002/14651858.CD007176

This version first published online: 23 April 2008 in Issue 2, 2008. Re-published online with edits: 8 July 2009 in Issue 3, 2009.
Last assessed as up-to-date: 19 February 2008. (Help document - Dates and Statuses explained)

This record should be cited as: Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. Cochrane Database of Systematic Reviews 2008, Issue 2. Art. No.: CD007176. DOI: 10.1002/14651858.CD007176.

ABSTRACT

Background

Animal and physiological research as well as observational studies suggest that antioxidant supplements may improve survival.

Objectives

To assess the effect of antioxidant supplements on mortality in primary or secondary prevention randomised clinical trials.

Search strategy

We searched The Cochrane Library (Issue 3, 2005), MEDLINE (1966 to October 2005), EMBASE (1985 to October 2005), and the Science Citation Index Expanded (1945 to October 2005). We scanned bibliographies of relevant publications and wrote to pharmaceutical companies for additional trials.

Selection criteria

We included all primary and secondary prevention randomised clinical trials on antioxidant supplements (beta-carotene, vitamin A, vitamin C, vitamin E, and selenium) versus placebo or no intervention. Included participants were either healthy (primary prevention trials) or had any disease (secondary prevention trials).

Data collection and analysis

Three authors extracted data. Trials with adequate randomisation, blinding, and follow-up were classified as having a low risk of bias. Random-effects and fixed-effect meta-analyses were performed. Random-effects meta-regression analyses were performed to assess sources of intertrial heterogeneity.

Main results

Sixty-seven randomised trials with 232,550 participants were included. Forty-seven trials including 180,938 participants had low risk of bias. Twenty-one trials included 164,439 healthy participants. Forty-six trials included 68,111 participants with various diseases (gastrointestinal, cardiovascular, neurological, ocular, dermatological, rheumatoid, renal, endocrinological, or unspecified). Overall,
the antioxidant supplements had no significant effect on mortality in a random-effects meta-analysis (relative risk [RR] 1.02, 95% confidence interval [CI] 0.99 to 1.06), but significantly increased mortality in a fixed-effect model (RR 1.04, 95% CI 1.02 to 1.06). In meta-regression analysis, the risk of bias and type of antioxidant supplement were the only significant predictors of intertrial heterogeneity. In the trials with a low risk of bias, the antioxidant supplements significantly increased mortality (RR 1.05, 95% CI 1.02 to 1.08). When the different antioxidants were assessed separately, analyses including trials with a low risk of bias and excluding selenium trials found significantly increased mortality by vitamin A (RR 1.16, 95% CI 1.10 to 1.24), beta-carotene (RR 1.07, 95% CI 1.02 to 1.11), and vitamin E (RR 1.04, 95% CI 1.01 to 1.07), but no significant detrimental effect of vitamin C (RR 1.06, 95% CI 0.94 to 1.20). Low-bias risk trials on selenium found no significant effect on mortality (RR 0.90, 95% CI 0.80 to 1.01).

Authors’ conclusions

We found no evidence to support antioxidant supplements for primary or secondary prevention. Vitamin A, beta-carotene, and vitamin E may increase mortality. Future randomised trials could evaluate the potential effects of vitamin C and selenium for primary and secondary prevention. Such trials should be closely monitored for potential harmful effects. Antioxidant supplements need to be considered medicinal products and should undergo sufficient evaluation before marketing.

**PLAIN LANGUAGE SUMMARY**

No evidence to support antioxidant supplements to prevent mortality in healthy people or patients with various diseases

Previous research on animal and physiological models suggest that antioxidant supplements have beneficial effects that may prolong life. Some observational studies also suggest that antioxidant supplements may prolong life, whereas other observational studies demonstrate neutral or harmful effects. Randomised trials have largely been neutral. We need evidence from randomised trials to decide if antioxidant supplements should be used for prevention.

**BACKGROUND**

Oxidative stress may play a role in the pathogenesis of cancer and cardiovascular disease, the leading causes of death in middle- and high-income countries (Sies 1985; Halliwell 1999). Diet provides numerous vitamins and trace elements that are essential for good health. Several observational studies have shown a significant positive association between higher intake of fruits and vegetables and reduced risk of chronic diseases (Block 1992; Ames 1993; Wilcox 2004). However, exactly which specific dietary constituents of fruits and vegetables might be beneficial is not clear. Furthermore, causal inferences are hard to establish from observational studies. Antioxidants have attracted most attention as promising preventive agents. Fruits and vegetables are sources of numerous micronutrients and some of these, including beta-carotene, vitamin A, vitamin C, vitamin E, and selenium have antioxidant potential. Many people take antioxidant supplements believing to improve their health (Balluz 2000; Millen 2004; Radimer 2004; Nichter 2006).

Whether antioxidant supplements are beneficial or harmful is uncertain (Herbert 1997; Caraballoso 2003; Vivekananthan 2003; Bjelakovic 2004; Stanner 2004; Miller 2005; Berger 2005). Antioxidants may play dual roles, acting as double-edged swords (Bjelakovic 2007b). Excessive antioxidants can adversely affect key physiological processes. The results of our recent systematic review and meta-analyses of the role of antioxidant supplements for prevention of gastrointestinal cancers were unforeseen (Bjelakovic 2004). We found that antioxidant supplements significantly increased mortality in the antioxidant group with the fixed-effect model meta-analysis but not with the random-effects meta-analysis (Bjelakovic 2004). The effect of antioxidant supplements on mortality has also been assessed in several large trials on primary and secondary prevention of diseases ([HPS 2002Low](#); [ATBC 2003Low](#); [CARET 2004Low](#); [SUVIMAX 2004Low](#); [HOPE TOO 2005Low](#); [WHS 2005Low](#)). The results of the individual trials are equivocal. Furthermore, none of the trials had sufficient statistical power to identify the effect of antioxidants on mortality. Accordingly, we performed a systematic review of randomised trials on antioxidant supplements for primary and secondary prevention.

**OBJECTIVES**

Our aim was to assess the effect of antioxidant supplements (beta-carotene, vitamin A, vitamin C, vitamin E, and selenium) on overall mortality in primary or secondary prevention randomised clinical trials.
METHODS

Criteria for considering studies for this review

Types of studies
All primary and secondary prevention randomised clinical trials, irrespective of trial design, blinding, publication status, publication year, or language. From cross-over trials, only the first trial period was considered.

Types of participants
Adult participants (age 18 years or over) who were
- healthy participants or were recruited among the general population (primary prevention);
- diagnosed with a specific disease in a stable phase (secondary prevention).

We excluded tertiary prevention trials, ie, randomised trials in which antioxidant supplements were used to treat a specific disease or nutritional defects, like trials with patients with acute, infectious, or malignant diseases (except non-melanoma skin cancer). We excluded trials including children and pregnant women since they may be in need of certain antioxidant supplements.

Types of interventions
We considered for inclusion trials that compared antioxidant supplements (ie, beta-carotene, vitamin A, vitamin C, vitamin E, and selenium) at any dose, duration, and route of administration versus placebo or no intervention.

The antioxidants could have been administered
- separately or in any combination among themselves; or
- in combination with other vitamins; or
- in combination with trace elements without antioxidant function.

Concomitant interventions were allowed if used equally in both intervention arms of the trial.

Types of outcome measures
Our sole outcome measure was all-cause mortality.

Data collection and analysis

The present review is based on our protocol on antioxidant supplements for preventing gastrointestinal cancers (Bjelakovic 2003) adopted to assess overall mortality. An abbreviated version of the review has previously been published (Bjelakovic 2007a).

Inclusion criteria application
Two of the three authors (GB and DN or RGS) independently assessed trial eligibility without blinding of the study authors. We listed excluded trials with the reasons for exclusion. Disagreement was resolved by discussion or in consultation with LLG or CG.

We contacted authors of the trials for missing information.

Data extraction
Participant characteristics, diagnosis, and interventions
From each trial we recorded first author; country of origin; country income category (low, middle, high) (World Bank 2006); number of participants; characteristics of participants: age range (mean or median) and sex ratio; participation rate; dropout rate; trial design (parallel, factorial, or crossover); type of antioxidant; dose; duration of supplementation; duration of follow-up (ie, duration of intervention plus post-intervention follow-up); and co-interventions.

Trial characteristics
We recorded the date, location, sponsor of the trial (known or unknown and type of sponsor) as well as publication status.

Assessment of methodological quality
We defined the methodological quality as the confidence that the design and report restrict bias in the intervention comparison (Schulz 1995; Moher 1998; Kjaergard 2001). Due to the risk of overestimation of intervention effects in randomised trials with inadequate methodological quality (Schulz 1995; Moher 1998; Kjaergard 2001), we assessed the influence of methodological quality of the four components below as reported in the trials. When this information was not available, we asked the authors of the trial publications to provide it.

Generation of the allocation sequence
- Adequate, if the allocation sequence was generated by a computer or random number table. Drawing of lots, tossing of a coin, shuffling of cards, or throwing dice was considered as adequate if a person who was not
otherwise involved in the recruitment of participants performed the procedure.

- Unclear, if the trial was described as randomised, but the method used for the allocation sequence generation was not described.
- Inadequate, if a system involving dates, names, or admission numbers were used for the allocation of patients.

**Allocation concealment**

- Adequate, if the allocation of patients involved a central independent unit, on-site locked computer, identically appearing numbered drug bottles or containers prepared by an independent pharmacist or investigator, or sealed envelopes.
- Unclear, if the trial was described as randomised, but the method used to conceal the allocation was not described.
- Inadequate, if the allocation sequence was known to the investigators who assigned participants or if the study was quasi-randomised.

**Blinding (or masking)**

- Adequate, if the trial was described as double blind and the method of blinding involved identical placebo or active drugs.
- Unclear, if the trial was described as double blind, but the method of blinding was not described.
- Not performed, if the trial was not double blind.

**Follow-up**

- Adequate, if the numbers and reasons for dropouts and withdrawals in all intervention groups were described or if it was specified that there were no dropouts or withdrawals.
- Unclear, if the report gave the impression that there had been no dropouts or withdrawals, but this was not specifically stated.
- Inadequate, if the number or reasons for dropouts and withdrawals were not described.

Trials with adequate generation of the allocation sequence, adequate allocation concealment, adequate blinding, and adequate follow-up were considered low-bias risk trials (high methodological quality) (Kjaergard 2001; Gluud 2006a). We appended ‘Low’ to the references of these trials. Trials with one or more unclear or inadequate quality components were classified as high-bias risk trials (low methodological quality) (Kjaergard 2001; Gluud 2006a). We also reported on whether the investigators had performed a sample-size calculation and used intention-to-treat analysis (Gluud 2001).

**Statistical analyses**

We performed the meta-analyses according to the recommendations of The Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2006). For the statistical analyses, we used RevMan Analyses (RevMan 2003), STATA 8.2 (STATA Corp, College Station, Tex), Sigma Stat 3.0 (SPSS Inc, Chicago, Ill), and StatsDirect (StatsDirect Ltd, Altrincham, England).

We analysed the data with both random-effects (DerSimonian 1986) and fixed-effect (DeMets 1987) model meta-analyses. We presented the results of random-effects model analyses. When statistically significant results are obtained in either the random- or fixed-effect model, we present both analyses. Results are presented as the relative risk (RR) with 95% confidence intervals (CI). We assessed heterogeneity with I², which describes the percentage of total variation across studies due to heterogeneity rather than chance (Higgins 2002).

Random-effects meta-regression analyses were performed to assess potential covariates that could predict intertrial heterogeneity, ie, which covariates that were statistically associated with estimated intervention effects. The included covariates were bias risk (low or high), type and dose of supplement, single or combined antioxidant experimental supplement regimen, duration of treatment, and type of prevention (primary or secondary). We also performed subgroup analyses comparing the primary and secondary prevention trials. Furthermore, we performed sensitivity analyses excluding trials using small dose antioxidant supplements in both the experimental and control study groups. The exclusion of trials using small dose antioxidant supplements in both the experimental and control study groups was based on the fact that addition of, eg, a vitamin pill could be a confounder. We observed that selenium seemed to have a beneficial effect on gastrointestinal cancer development (Bjelakovic 2004). The sensitivity analysis removing selenium trials from our analysis to evaluate their influence on our conclusions was therefore not a post hoc decision.

The influence of trials with zero events in the treatment or control group was assessed by re-calculating the random-effects meta-analyses with 0.5, 0.05, and 0.005 continuity corrections (Sweeting 2004; Bradburn 2007). We also performed additional meta-analyses including one large hypothetical trial with one event in the treatment and control group and a sample size corresponding to the total number of participants in the zero events trials.

All our analyses followed the intention-to-treat principle. We accounted all of the participants for each trial and performed the analyses irrespective of how the original trialists had analysed the data. Participants lost to follow-up were considered survivors. For trials with a factorial design, we based our results on ‘at the margins’ analysis, comparing all groups that received antioxidant supplements with groups that did not receive antioxidant supplements (McAlister 2003). This entails a risk of interaction between the antioxidant and the other intervention(s) assessed, whether significant or not in the individual trial. Due to the risk of confounding in factorial trials assessing other interventions, we conducted post-hoc sensitivity analysis including only factorial trial data, which
could not be affected of such confounding (ie, 'inside the table' analysis) (McAlister 2003). To determine the effect of a single antioxidant we also performed 'inside the table' analysis (McAlister 2003) in which we compared the single antioxidant intervention with the placebo or no intervention. In the trials with parallel group design with more than two arms and additional therapy, we compared only antioxidant intervention with placebo or no intervention. For cross-over trials we included only data from the first period (Higgins 2006).

Comparison of intervention effects was conducted with test of interaction (Altman 2003).

We performed adjusted rank correlation (Begg 1994) and regression asymmetry test (Egger 1997) for detection of bias. A P < 0.10 was considered significant.

RESULTS

Description of studies

See: Characteristics of included studies; Characteristics of excluded studies; Characteristics of ongoing studies.

Search results

Database searches yielded 16111 references (Figure 1). Exclusion of duplicates and irrelevant references left 1201 references describing 815 trials. To obtain additional information we wrote to authors of about 500 eligible trials. More than one hundred authors responded.
Figure 1. Flow diagram of identification of randomised trials for Inclusion

- **CENTRAL**: 2548
- **MEDLINE**: 2263
- **EMBASE**: 1572
- **Web of Science**: 8884
- **Reading References**: 844

**Total Number of References**: 16,111

- **Duplicates**: 12,703
- **Not Relevant**: 59
- **Trials in Patients with Cancer (Except Non-melanoma Skin Cancer)**: 151
- **Trials in Acute and Infectious Diseases**: 592
- **Trials in Infants and Children**: 983
- **Trials in Pregnant and Lactating women**: 422

**Total Number of Excluded References**: 14,910

**1201 References** on **815 Studies**

- **Total Number of Excluded References**: 815
  - **On Trials with No Deaths in Any Arm**: 405
  - **Did Not Fulfill Inclusion Criteria**: 245
  - **Not Randomised Clinical Trials**: 70
  - **Insufficient Clinical Trials**: 24
  - **Ongoing Trials**: 4

- **Total Number of Excluded Studies**: 748

**386 References** on **67 Included Trials**
We excluded 815 references dealing with 748 studies. After further evaluation we excluded 339 studies because they were not randomised trials or did not fulfil our inclusion criteria. The remaining 409 were randomised trials examining antioxidant supplements. Four of these were still ongoing. The authors of the 405 trials did not report data on mortality (these trials are shown at http://ctu.rh.dk). The majority of these were small phase I or phase II trials with short duration of follow-up without assessment of clinical outcome measures. We contacted the authors and about one fifth of them confirmed that mortality was indeed zero.

We included 386 references describing 67 randomised trials fulfilling our inclusion criteria and able to provide data for our analyses (Table 1; Table 2) (http://ctu.rh.dk). This corresponds to a median of 6 references per included trial (range 1 to 44 references per trial).

Table 1. Characteristics of included trials with low risk of bias

| Trial   | Design | Number participants | Mean age | Suppl (Follow-up)-y | Beta-carotene (mg) | Vitamin A (IU) | Vitamin C (mg) | Vitamin E (IU) | Selenium (µg) |
|---------|--------|---------------------|----------|---------------------|-------------------|----------------|----------------|----------------|---------------|
| SCPS 1990 | Parallel | 1805 | NA | 5 (5) | 50 |
| Murphy 1992 | Parallel | 109 | NA | 0.003 (0.25) | 200000 |
| NIT2 1993 | Parallel | 3318 | 54 | 6 (6) | 15 | 10000 | 180 | 60 | 50 |
| PPS 1994 | 2 x 2 | 864 | 61 | 4 (4) | 25 | 1000 | 440 |
| Pike 1995 | Parallel | 47 | 69 | 1 (1) | 2666 | 90 | 45 |
| AMDS 1996 | Parallel | 71 | 72 | 1.5 (1.5) | 12 | 750 | 200 | 50 |
| CHAOS 1996 | Parallel | 2002 | 62 | 1.4 (1.4) | 600 |
| NPCT 1996 | Parallel | 1312 | 63 | 4.5 (7.4) | 200 |
| PHS 1996 | 2 x 2 | 22071 | 53 | 12 (12.9) | 25 |
Table 1. Characteristics of included trials with low risk of bias (Continued)

| Study           | Design   | Sample Size | Risk of Mortality | Duration | Treatment | Control | TAU       | Risk of Bias |
|-----------------|----------|-------------|-------------------|----------|-----------|---------|-----------|--------------|
| SKICAP AK 1997  | Parallel | 2297        | 63                | 3.8 (3.8)| 25000     |         |           |              |
| MINVI-TAOX 1999 | 2 x 2    | 725         | 84                | 2 (2)    | 6         | 120     | 16.5      | 100          |
| NSCPT 1999      | 2 x 2    | 1621        | 49                | 4.5 (4.5)| 30        |         |           |              |
| Correa 2000     | 2 x 2 x 2| 976         | 51                | 6 (6)    | 30        |         |           | 2000         |
| Jacobson 2000   | Parallel | 112         | 42                | 0.5 (0.5)| 12        | 500     | 400       |              |
| SPACE 2000      | Parallel | 196         | 65                | 1.42 (1.42)|          |         |           | 800          |
| AREDS 2001      | 2 x 2    | 4757        | 68                | 6.3 (6.3)| 15        | 500     | 400       |              |
| Desnuelle 2001  | Parallel | 288         | 64                | 1 (1)    |           |         |           | 500          |
| HATS 2001       | 2 x 2    | 160         | 53                | 3 (3)    | 25        | 1000    | 800       | 100          |
| Graat 2002      | 2 x 2    | 652         | NA                | 1 (1)    | 1.2       | 2000    | 60        | 272          | 25           |
| HPS 2002        | 2 x 2    | 20536       | NA                | 5 (5)    | 20        | 250     | 660       |              |
| REACT 2002      | Parallel | 297         | 68                | 3 (3)    | 18        | 750     | 660       |              |
| VEAPS 2002      | Parallel | 353         | 56                | 3 (3)    |           |         |           | 400          |
| WAVE 2002       | 2 x 2    | 423         | 65                | 3 (3)    | 1000      | 800     |           |              |
| White 2002      | Parallel | 100         | 63                | 0.23 (0.23)|          |         |           | 1000         | 223          |
| Wluka 2002      | Parallel | 136         | 64                | 2 (2)    |           |         |           | 500          |
Table 1. Characteristics of included trials with low risk of bias (Continued)

| Study          | Design     | N1  | N2  | Risk of death | N1 | N2 | N1 | N2 |
|----------------|------------|-----|-----|--------------|----|----|----|----|
| ASAP 2003      | 2 x 2      | 520 | NA  | 6 (6)        | 250| 272|
| ATBC 2003      | 2 x 2      | 29133| 57  | 6.1 (14.1)   | 20 | 50 |
| Collins 2003   | 2 x 2      | 52  | 67  | 0.5 (2.5)    | 400|
| Prince 2003    | Crossover  | 61  | 58  | 0.25 (0.25)  | 3  | 150| 74.5| 75 |
| Allsup 2004    | Parallel   | 164 | 83  | 0.15 (0.5)   | 2666| 120| 60 | 60 |
| CARET 2004     | Parallel   | 18314| 58  | 4 (10)       | 30 | 25000|
| DATOR 2004     | Parallel   | 24  | 51  | 0.5 (4.5)    | 750|
| LAST 2004      | Parallel   | 61  | 75  | 1 (1)        | 10 | 2500| 1500| 500| 200|
| Meydani 2004   | Parallel   | 617 | 84  | 1 (1)        | 200| 100|
| Mezey 2004     | Parallel   | 51  | 48  | 0.25 (1)     | 1000|
| SUVIMAX 2004   | Parallel   | 13017| 49  | 7.54 (7.54)  | 120| 33 | 100|
| VECAT 2004     | Parallel   | 1193| 66  | 4 (4)        | 500|
| DATATOP 2005   | 2 x 2      | 800 | 61  | 2.6 (13)     | 2000|
| Graf 2005      | Parallel   | 160 | 58  | 1.5 (1.5)    | 5000|
| HOPE TOO 2005  | 2 x 2      | 9541| 66  | 4.5 (7)      | 400|
Table 1. Characteristics of included trials with low risk of bias (Continued)

| Trial        | Design          | Number participants | Mean age | Suppl (Y) | Beta-carotene (mg) | Vitamin A (IU) | Vitamin C (mg) | Vitamin E (IU) | Selenium (μg) |
|--------------|-----------------|---------------------|----------|-----------|-------------------|----------------|----------------|----------------|---------------|
| Limburg 2005 | 2 x 2           | 360                 | 47       | 0.83 (0.83)|                   |                |                |                | 200           |
| MAVIS 2005   | Parallel        | 910                 | 72       | 1 (1)     | 2666              | 60             | 10             |                |               |
| Mooney 2005  | Parallel        | 284                 | 37       | 1.25 (1.25)|                   |                |                |                | 500           |
| Tam 2005     | Parallel        | 39                  | 46       | 0.23 (2.67)|                   |                |                |                | 500           |
| WHS 2005     | 2 x 2           | 39876               | 55       | 10.1 (10.1)| 25                |                |                |                | 300           |
| Witte 2005   | Parallel        | 32                  | NA       | 0.75 (0.75)| 2666              | 500            | 400            | 50             |               |
| Rayman 2006  | Parallel        | 501                 | 67       | 0.5 (0.5) |                   |                |                |                | 200           |

Abbreviation:
NA, not available.
Blank cells indicate that the supplement was not part of the trial.

Table 2. Characteristics of included trials with high risk of bias

| Trial                  | Design          | Number participants | Mean age | Suppl (Y) | Beta-carotene (mg) | Vitamin A (IU) | Vitamin C (mg) | Vitamin E (IU) | Selenium (μg) |
|------------------------|-----------------|---------------------|----------|-----------|-------------------|----------------|----------------|----------------|---------------|
| Gillilan 1977          | Crossover       | 52                  | 57       | 0.5       |                   |                |                |                | 1600          |
| Mckeown-Eysen 1988     | Parallel        | 185                 | 58       | 2         |                   | 400            | 400            |                |               |
| Penn 1991              | Parallel        | 30                  | 84       | 0.077     | 8000              | 100            | 50             |                |               |
| Chandra 1992           | Parallel        | 96                  | 74       | 1         | 16                | 1333           | 80             | 44             | 20            |
| NITI 1993              | 1/2 (2 x 2 x 2 x 2) | 29584              | NA       | 5.25      | 15                | 5000           | 120            | 33             | 50            |
Table 2. Characteristics of included trials with high risk of bias  (Continued)

| Trial            | Design | Participants | Events | Number of events | Follow-up | Years of supplementa tion |
|------------------|--------|--------------|--------|------------------|-----------|---------------------------|
| de la Maza 1995  | Parallel | 74 | 50 | 1 | 500 | |
| Takamatsu 1995  | Parallel | 147 | 47 | 6 | 136 | |
| ter Riet 1995   | 2 x 2 | 88 | NA | 0.23 | 1000 | |
| Hogarth 1996    | 2 x 2 | 106 | 83 | 0.083 | 8000 | 500 |
| ADCS 1 1997     | 2 x 2 | 341 | 73 | 2 | 2000 | |
| Girodon 1997    | 2 x 2 | 81 | 84 | 2 | 6 | 120 | 15 | 100 |
| Bonelli 1998    | Parallel | 304 | NA | 5 | 6000 | 180 | 30 | 200 |
| GISSI 1999      | 2 x 2 | 11324 | 59 | 3.5 | 330 | |
| de Waart 2001   | Parallel | 218 | 60 | 1.8 | 400 | |
| PPP 2001        | 2 x 2 | 4495 | 64 | 3.6 | 330 | |
| Stevic 2001     | Parallel | 28 | 57 | 1 | 1200 | 31.5 | |
| You 2001        | 2 x 2 x 2 | 3411 | NA | 3.25 | 15 | 500 | 200 | 75 |
| Sasazuki 2003   | 2 x 2 | 439 | 57 | 5 | 15 | 500 | |
| Takagi 2003     | Parallel | 93 | 63 | 5 | 600 | |
| ADCS 2 2005     | Parallel | 516 | 73 | 3 | 2000 | |

Abbreviation:

NA, not available.

Blank cells indicate that the supplement was not part of the trial.

The years of follow-up are the same as the years of supplementation.
The included trials are described in detail in the Table of included studies and in Table 1 to Table 3.

**Table 3. Participants and outcome measures of included trials with a high risk of bias**

| Trial           | Inclusion criteria       | Outcome measures                          | Type of prevention |
|-----------------|--------------------------|-------------------------------------------|--------------------|
| Gillilan 1977   | Coronary artery disease  | Improvement of angina pectoris            | Secondary          |
| Mckerown-Eyssen 1988 | Removed colorectal adenomas | Newly diagnosed colorectal adenomas    | Secondary          |
| Penn 1991       | Elderly long-stay patients | Cell-mediated immune function            | Secondary          |
| Chandra 1992    | Elderly individuals      | Infectious morbidity                      | Primary            |
| NIT1 1993       | General population       | Cancer incidence, cancer mortality, all-cause mortality | Primary            |
| de la Maza 1995 | Alcoholic cirrhosis      | Liver function, mortality, hospitalisation rates | Secondary          |
| Takamatsu 1995  | General population       | Any illness                               | Primary            |
| ter Riet 1995   | Nursing home patients with pressure ulcers | Wound status and clinometric changes    | Secondary          |
| Hogarth 1996    | Elderly medical in-patients | Weight, serum albumin levels, activities of daily living, cognitive functioning, length of stay | Secondary          |
| ADCS 1 1997     | Probable Alzheimer disease | Death, institutionalisation, loss of ability to perform two of three basic activities of daily living | Secondary          |
| Girodon 1997    | Elderly individuals      | Infectious morbidity                      | Primary            |
| Bonelli 1998    | Removed colorectal adenomas | Newly diagnosed colorectal adenomas    | Secondary          |
| GISSI 1999      | Recent myocardial infarction | All-cause mortality, non-fatal myocardial infarction, non-fatal stroke, cardiovascular death | Secondary          |
| de W aart 2001  | Male cigarette smokers  | Progression of atherosclerosis           | Primary            |
Table 3. Participants and outcome measures of included trials with a high risk of bias (Continued)

| Study (Year) | Group/Diagnosis | Outcome Measures | Status |
|--------------|-----------------|-----------------|--------|
| PPP 2001     | Elderly with at least one of the major cardiovascular risk factors | Cardiovascular death, non-fatal myocardial infarction and stroke, all-cause mortality, total cardiovascular events, angina pectoris, transient ischaemic attacks, peripheral artery disease, revascularization procedures | Primary |
| Stevic 2001  | Probable or definitive amyotrophic lateral sclerosis | Survival and rate of disease progression | Secondary |
| You 2001     | General population | Prevalence of dysplasia, gastric cancer, chronic atrophic gastritis, intestinal metaplasia | Primary |
| Sasazuki 2003| Chronic atrophic gastritis | Blood pressure | Secondary |
| Takagi 2003  | Liver cirrhosis  | Tumour free survival and cumulative survival rate | Secondary |
| ADCS 2 2005  | Amnestic mild cognitive impairment | Alzheimer's disease | Secondary |
**Trial characteristics**

Out of the 67 included trials, 39 trials used parallel-group design, 26 trials used factorial design (22 trials $2 \times 2$; 3 trials $2 \times 2 \times 2$; 1 trial half replicate of $2 \times 2 \times 2 \times 2$), and 2 trials used cross-over design (Pocock 2004).

In 54 trials (81%), the antioxidants were provided at no cost from pharmaceutical companies. In the rest of the trials, funding was not reported.

The trials were conducted in Europe, North and South America, Asia, and Australia. Sixty-one trials came from high-income countries and 6 trials came from lower-middle-income countries (NIT1 1993; NIT2 1993Low; de la Maza 1995; Correa 2000Low; Stevic 2001; SIT 2001).

**Participants**

A total of 232,550 participants were randomly assigned in the 67 trials. The number of participants in each trial ranged from 24 to 39,876 (Table 1; Table 2). The mean age was 62 years (range, 18 to 103 years). The mean proportion of women was 45% in the 63 trials reporting sex.

Twenty-one trials were primary prevention trials including 164,439 healthy participants; 46 trials were secondary prevention trials including 68,111 participants with gastrointestinal (n = 10 trials), cardiovascular (n = 9), neurological (n = 6), ocular (n = 5), dermatological (n = 5), rheumatoid (n = 2), renal and cardiovascular (n = 1), endocrinological (n = 1), or unspecified (n = 7) diseases. Main outcome measures in the primary prevention trials were cancer and mortality (cause-specific and all-cause mortality), and in the secondary prevention trials they were progression of disease and mortality (cause-specific and all-cause mortality) (Table 4; Table 3).

| Table 4. Participants and outcome measures of included trials with a low risk of bias |
|---|---|---|---|
| Trial | Inclusion criteria | Outcome measures | Type of prevention |
| SCPS 1990 | History of BCC or SCC | Newly diagnosed BCC or SCC | Secondary |
| Murphy 1992 | Elderly nursing-home residents | Bacterial infections | Secondary |
| NIT 2 1993 | Esophageal dysplasia | Cancer incidence, cancer mortality, all-cause mortality | Secondary |
| PPS 1994 | Removed colorectal adenomas | Newly diagnosed colorectal adenomas | Secondary |
| Study      | Participants                                      | Outcome Measures                                                                 | Type  |
|------------|---------------------------------------------------|-----------------------------------------------------------------------------------|-------|
| Pike 1995  | Elderly individuals                              | Immune indices                                                                    | Primary |
| AMDS 1996  | Age-related macular degeneration                  | Outcome of age-related macular degeneration.                                      | Secondary |
| CHAOS 1996 | Coronary artery disease                           | Non-fatal myocardial infarction and cardiovascular death                          | Secondary |
| NPCT 1996  | History of BCC or SCC                             | Incidence of SCC and BCC, cancer incidence, cancer mortality, all-cause mortality | Secondary |
| PHS 1996   | Male physicians                                   | Incidence of cancer and CVD and all-cause mortality                               | Primary |
| SKICAP AK 1997 | History of BCC or SCC                        | Newly diagnosed SCC and BCC                                                       | Secondary |
| MINVITAOX 1999 | Institutionalized elderly patients               | Delayed-type hypersensitivity skin response, humoral response to influenza vaccine, and infectious morbidity and mortality | Secondary |
| NSCPT 1999 | History of BCC or SCC                             | Newly diagnosed SCC and BCC                                                       | Secondary |
| Correa 2000 | Multifocal atrophic gastritis with or without intestinal metaplasia and dysplasia | Change of gastric precancerous lesions                                              | Secondary |
| Jacobson 2000 | Heavy smokers                                    | DNA damage                                                                        | Primary |
| SPACE 2000 | Stable haemodialysis patients with a documented medical history of CVD | Acute myocardial infarction (fatal and nonfatal), ischaemic stroke, peripheral vascular disease, unstable angina, CVD mortality, all-cause mortality | Secondary |
| AREDS 2001 | Aged-related macular degeneration                 | Increase in nuclear, cortical or posterior subcapsular opacity grades, cataract surgery, loss of visual acuity | Secondary |
| Desnuelle 2001 | Probable or definitive amyotrophic lateral sclerosis | Change in functional status, survival, bulbar function                         | Secondary |
Table 4. Participants and outcome measures of included trials with a low risk of bias  (Continued)

| Study     | Diagnosis/risk factor                                      | Outcome Measure                                      | Bias Risk |
|-----------|------------------------------------------------------------|------------------------------------------------------|-----------|
| HATS 2001 | Coronary artery disease                                    | Change in coronary stenosis, first cardiovascular event (death, myocardial infarction, stroke or revascularization) | Secondary |
| Graat 2002| Elderly individuals                                       | Acute respiratory tract infections                   | Primary   |
| HPS 2002  | Coronary and other occlusive arterial disease or diabetes | Major coronary events, fatal and non-fatal vascular events, cancer, other morbidity | Secondary |
| REACT 2002| Cataract                                                   | Cataract progression                                  | Secondary |
| VEAPS 2002| Healthy individuals (serum LDL cholesterol >3.37 mmol/L)  | Rate of change in the right distal common carotid artery intima-media thickness | Primary   |
| WAVE 2002 | Coronary artery disease                                    | Progression of coronary artery disease                | Secondary |
| White 2002| Patients with Barrett’s oesophagus on long-term acid suppression therapy | Prevention of potentially premalignant modifications to DNA in the human stomach | Secondary |
| Wluka 2002| Knee osteoarthritis                                       | Change in cartilage volume                           | Secondary |
| Collins 2003| Patients with peripheral arterial diseaseWalking ability and perceived quality of life | Walking ability and perceived quality of life         | Secondary |
| Prince 2003| Primary biliary cirrhosis                                  | Change in patient fatigue                            | Secondary |
| ASAP 2003 | Healthy individuals (serum cholesterol >5 mmol/L)          | Progression of carotid atherosclerosis                | Primary   |
| ATBC 2003 | Male cigarette smokers                                    | Lung cancer and other major cancers, all-cause and cause specific mortality, incidence of other disease | Primary   |
| Allsup 2004| Older institutionalised people                           | Response to influenza vaccine                          | Secondary |
| CAREFT 2004| Cigarette smokers, former smokers and workers exposed to asbestos | Lung cancer, other cancers, mortality                | Primary   |
Table 4. Participants and outcome measures of included trials with a low risk of bias (Continued)

| Study          | Participants                              | Outcome measures                                                                 | Type   |
|----------------|-------------------------------------------|----------------------------------------------------------------------------------|--------|
| DATOR 2004     | Type 1 diabetic patients                  | Impact on lipids and peroxidation during statin treatment                        | Secondary |
| LAST 2004      | Age-related macular degeneration           | Visual function                                                                  | Secondary |
| Meydani 2004   | Elderly individuals                        | Respiratory tract infections, emergency department visits, hospitalisation, and death | Primary |
| Mezey 2004     | Alcoholic hepatitis                        | Clinical and laboratory parameters of liver function and markers of fibrogenesis  | Secondary |
| SUVIMAX 2004   | General population                         | Incidence of cancer and CVD and all-cause mortality                               | Primary |
| VECAT 2004     | Early or no cataract                       | Age related cataract                                                             | Secondary |
| DATATOP 2005   | Early Parkinson’s disease not requiring levodopa | Level of functional disability for initiation of levodopa therapy                 | Secondary |
| Graf 2005      | Probable or definitive amyotrophic lateral sclerosis | Survival                                                                         | Secondary |
| HOPE TOO 2005  | History of CVD or diabetes in the presence of at least one additional cardiovascular risk factor | Cancer incidence, cancer deaths, major cardiovascular events, unstable angina, congestive heart failure, revascularization or amputation, all-cause mortality | Secondary |
| Limburg 2005   | Patients with oesophageal dysplasia        | Change in histological grade of oesophageal dysplasia                            | Secondary |
| MAVIS 2005     | Elderly individuals irrespective of chronic illness | Self reported days of infection, use of health services, quality of life          | Primary |
| Mooney 2005    | Cigarette smokers                          | Level of an intermediate cancer risk marker                                       | Primary |
| Tam 2005       | Systemic lupus erythematosus               | Effects on markers of oxidative stress, antioxidant defence and endothelial function | Secondary |
### Table 4. Participants and outcome measures of included trials with a low risk of bias (Continued)

| Trial            | Population                        | Outcome Measures                                                                 | Risk Type |
|------------------|-----------------------------------|----------------------------------------------------------------------------------|-----------|
| WHS 2005         | Female health professionals       | Invasive cancer, fatal and non-fatal myocardial infarction, stroke, mortality     | Primary   |
| Witte 2005       | Stable chronic heart failure due to Ischaemic heart disease | Left ventricular function, levels of proinflammatory cytokines, quality of life | Secondary |
| Rayman 2006      | General population                | Mood, quality of life, plasma selenium levels                                    | Primary   |

**Abbreviations:**

BBC, basal cell carcinoma.

CVD, cardiovascular disease.

SSCC, squamous cell carcinoma of the skin.

SI conversion: to convert cholesterol values to mg/dL, divide by 0.0259.

### Experimental interventions

Antioxidants were administered either alone, or in combination with antioxidants, minerals, or other interventions (Table 1; Table 2). All antioxidant supplements were administered orally. The dose and regimen of the antioxidant supplements were: beta-carotene 1.2 to 50.0 mg (mean 18 mg), vitamin A 1333 to 200,000 IU (mean 20219 IU), vitamin C 60 to 2000 mg (mean 497 mg), vitamin E 10 to 5000 IU (mean 570 IU), and selenium 20 to 200 µg (mean 99 µg) daily or on alternate days for 28 days to 12 years (mean 2.8 years). In one trial (Murphy 1992Low), antioxidants were applied in a single dose and participants were followed up for three months thereafter. The mean duration of follow-up in all trials was 3.4 years (range, 28 days to 14.1 years) (Table 2; Table 1).

Beta-carotene was tested in 25 trials, vitamin A in 15, vitamin C in 33, vitamin E in 54, and selenium in 21 trials. Beta-carotene was tested singly in 6 trials, vitamin A in 2, vitamin E in 24, vitamin C and selenium in 3 trials each.

The antioxidant supplements were given in the following combinations:

- beta-carotene and vitamin A
- beta-carotene and vitamin C
- beta-carotene and vitamin E
- vitamin A and vitamin C
- vitamin C and vitamin E
- vitamin E and selenium
- selenium and zinc
- beta-carotene, vitamin C, and vitamin E
- beta-carotene, vitamin C, vitamin E, and selenium
- beta-carotene, vitamin C, vitamin E, selenium, and zinc
- vitamin A, vitamin C, vitamin E
- vitamin A, vitamin C, vitamin E, selenium, and zinc
- vitamin A, vitamin C, vitamin E, selenium, methionine, and ubiquinone.

### Control interventions

Sixty-three trials used placebo and four trials used no intervention in the control group (ter Riet 1995; GISSI 1999; PPP 2001; Takagi 2003).

### Concomitant interventions

In 11 trials, participants were supplemented with different mixtures of antioxidants as well as with vitamins and minerals without antioxidant properties (Chandra 1992; NIT1 1993; NIT2 1993Low; Pike 1995Low; Hogarth 1996; AMDS 1996Low; Graat 2002Low; Allsup 2004Low; LAST 2004Low; MAVIS 2005 Low; Witte 2005Low).

In nine trials, the experimental and control groups were supplemented with vitamins and minerals (with or without antioxidant properties) (Gillilan 1977; Murphy 1992Low; Takamatsu 1995; ter Riet 1995; HATS 2001Low; Sasazuki 2003; Meydani 2003; Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases (Review) Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
In six of the trials, the supplementation was with vitamin E 4 IU (Takamatsu 1995; Meydani 2004Low), vitamin A 1000 IU (Murphy 1992Low), vitamin C 20 mg and 50 mg (ter Riet 1995; Sasazuki 2003); riboflavin 10 mg (Gillilan 1977); or niacin 100 mg (HATS 2001Low).

In some of the factorial designed trials, other interventions were administered to some of the participants in the antioxidant experimental arms and in the control arms. In the trials with factorial or parallel-group design, the additional interventions tested were multivitamins and minerals (zinc, copper, chromium); ubiquinone; L-methionine; omega-3 polyunsaturated fatty acids; citrus bioflavonoid complex; quercetin, bilberry extract, rutin (bioflavonoids); taurine; N-acetyl cysteine; L-glutathione; aged garlic; deprenyl-selgeline (selective monoamine oxidase B inhibitor); donepezil (acetylcholinesterase inhibitor); ribulose (modulator of glutamatergic neurotransmission); amoxicillin, metronidazole (antibiotics); bismuth subsalicylate; omeprazole (proton-pump inhibitor); aspirin; simvastatin (cholesterol-lowering drug); celecoxib (inhibitor of cyclooxygenase), and ramipril (angiotensin-converting enzyme inhibitor).

**All-cause mortality**

Fifty-eight of the trials published data on mortality. Mortality data were obtained from authors of a further nine trials (Jacobson 2000Low; de Waart 2001; Desnuelle 2001Low; White 2002Low; Collins 2003Low; Sasazuki 2003; Allsup 2004Low; DATOR 2004Low; Tam 2005Low). These trials represent the 67 included trials.

**Excluded studies**

The reason for exclusion of studies is given in the table 'Characteristics of excluded studies'.

**Risk of bias in included studies**

Forty-seven of the 67 trials (70.1%) had low-bias risk, ie, had adequate generation of the allocation sequence, allocation concealment, blinding, and follow-up. For an overview of the included trials with low risk of bias see Table 1 and Table 4.

Twenty trials had one or more unclear or inadequate methodological components. For an overview of the included trials with high risk of bias (low methodological quality) see Table 2 and Table 3. Sixty-six trials reported losses to follow-up. The exact number of participants lost to follow-up separately for each group was reported in 65 trials. There was not a substantial difference in the losses to follow-up between the intervention group and the control group (2669 out of 108,480 (2.5%) versus 2593 out of 91168 (2.8%))

**Effects of interventions**

**Mortality in all trials**

A total of 17880 of 136,023 participants (13.1%) randomised to antioxidant supplements and 10136 of 96527 participants (10.5%) randomised to placebo or no intervention died. In random-effects meta-analysis, antioxidant supplements had no significant effect on mortality (RR 1.02, 95% CI 0.99 to 1.06). In fixed-effect meta-analysis, antioxidant supplements significantly increased mortality (RR 1.04, 95% CI 1.02 to 1.06). There was no significant intertrial heterogeneity (I² = 13.1%) (Analysis 1.1).

**Sensitivity analyses taking trials with zero events into account**

We included 14 trials with zero mortality in one arm. To account for the potential influence of these trials, we calculated the RR with 0.5, 0.05, and 0.005 as empirical continuity corrections (Sweeting 2004; Bradburn 2007). The random-effects model RR for the three continuity corrections were RR 1.02, RR 1.02, and RR 1.03. All three analyses were insignificant. The fixed-effect models with the same corrections were all showing significantly increased mortality in the antioxidant group and found the RR 1.04 in all three analyses.

Overall, 405 trials had zero mortality in both the experimental and control groups. These trials are excluded from the meta-analyses using RR as association measure. The total number of participants in these trials was about 40000. Therefore we performed exploratory analyses adding an imagined trial with 1 death and 20000 participants in each intervention group. The influence of zero events trials on our final result was not noticeable.

**Analyses of bias risk**

Inspection of the funnel plot in Figure 2 suggests potential bias (asymmetry). The adjusted-rank correlation test (P = 0.41) and regression asymmetry test (P = 0.21) found, however, no significant evidence of bias.
Figure 2. Funnel plot - overall mortality
Meta-regression analyses

Univariate meta-regression analyses revealed that the following covariates were significantly associated with estimated intervention effect on mortality: bias-risk (RR 1.17; 95% CI 1.05 to 1.30, P = 0.004) and dose of beta-carotene (RR 1.004, 95% CI 1.009 to 1.007; P = 0.013), dose of vitamin A (RR 1.000006, 95% CI 1.000002 to 1.000009, P = 0.003), and dose of selenium (RR 0.998, 95% CI 0.997 to 0.999, P = 0.005). None of the other covariates (dose of vitamin C; dose of vitamin E; single or combined experimental antioxidant regimen; duration of supplementation; and primary or secondary prevention) were significantly associated with estimated intervention effect on mortality.

In multivariate meta-regression analysis including all covariates, low bias risk of the trials was associated with significantly higher estimated intervention effect on mortality (RR 1.16, 95% CI 1.04 to 1.29, P = 0.007), and dose of selenium was associated with significantly lower estimated intervention effect on mortality (RR 0.999, 95% CI 0.997 to 1.000, P = 0.013). None of the other covariates was significantly associated with the estimated intervention effect on mortality.

Intervention effects according to bias risk of trials (Analysis 1.1)

In trials with low-bias risk, mortality was significantly increased in the supplemented group (RR 1.05, 95% CI 1.02 to 1.08, P = 0.003) without significant heterogeneity (I^2 = 7.5%). Exploratory analysis adding an imagined trial with 1 death and 20000 participants in each study group had no noticeable effect on the results.

In trials with high-bias risk (low-methodological quality) mortality was significantly decreased in the supplemented group (RR 0.92, 95% CI 0.85 to 0.99, P = 0.03) without heterogeneity (I^2 = 0%). Exploratory analysis adding an imagined trial with 1 death and 20000 participants in each study group had no noticeable effect on the results.

The difference between the estimate of antioxidants on mortality in low- and high-bias risk trials was statistically significant by test of interaction (z = 3.2, P = 0.0014).

Random-effects and fixed-effect model meta-analyses

For an overview of the effect of the different antioxidant supplements on mortality in a random-effects or fixed-effect model see Table 5 and Table 6.

Table 5. Effects of antiox. suppl. vs placebo or no interv. - random-effects model

| Supplement | Number of trials | Participants number | RR (95%CI) | Heterogeneity (%) |
|------------|------------------|---------------------|------------|-------------------|
| Beta-carotene given singly | 6 | 40977 | 1.05, 1.00-1.11 | 11.8 |
| Intervention                                                                 | Trials | Participants | Odds Ratio | 95% CI     | p Value |
|------------------------------------------------------------------------------|--------|--------------|------------|-----------|---------|
| Beta-carotene given in combination with other antioxidant supplements        | 21     | 139516       | 1.02       | 0.95-1.08 | 50.6    |
| Beta-carotene given singly or in combination with other antioxidant supplements | 24     | 172755       | 1.02       | 0.96-1.08 | 47.5    |
| Beta-carotene given singly or in combination with other antioxidant supplements after exclusion of high-bias risk trials | 19     | 150258       | 1.05       | 1.00-1.10 | 38.4    |
| Beta-carotene given singly or in combination with other antioxidant supplements after exclusion of high-bias risk and selenium trials | 12     | 132610       | 1.07       | 1.02-1.11 | 34      |
| Beta-carotene given singly or in combination with other antioxidant supplements - high-bias risk trials | 5      | 22497        | 0.81       | 0.62-1.07 | 31.3    |
| Vitamin A given singly                                                      | 2      | 2406         | 1.18       | 0.84-1.68 | 0       |
| Vitamin A given in combination with other antioxidant supplements            | 14     | 42431        | 1.03       | 0.90-1.19 | 33.9    |
| Vitamin A given singly or in combination with other antioxidant supplements  | 16     | 44837        | 1.05       | 0.93-1.19 | 26.1    |
| Vitamin A given singly or in combination with other antioxidant supplements after exclusion of high-bias risk trials | 11     | 25811        | 1.10       | 0.96-1.26 | 14.8    |
Table 5. Effects of antiox. suppl. vs placebo or no interv. - random-effects model (Continued)

| Vitamin A given singly or in combination with other antioxidant supplements after exclusion of high-bias risk and selenium trials | 5 | 21677 | 1.16, 1.10-1.24 | 0 |
| Vitamin A given singly or in combination with other antioxidant supplements - high-bias risk trials | 5 | 19026 | 0.96, 0.84-1.08 | 0 |
| Vitamin C given singly | 3 | 826 | 0.88, 0.32-2.42 | 0 |
| Vitamin C given in combination with other antioxidant supplements | 32 | 69941 | 0.98, 0.91-1.06 | 10.2 |
| Vitamin C given singly or in combination with other antioxidant supplements | 33 | 70400 | 0.99, 0.92-1.06 | 68 |
| Vitamin C given singly or in combination with other antioxidant supplements after exclusion of high-bias risk trials | 23 | 46935 | 1.02, 0.96-1.08 | 5.9 |
| Vitamin C given singly or in combination with other antioxidant supplements after exclusion of high-bias risk and selenium trials | 13 | 29275 | 1.06, 0.94-1.20 | 10 |
| Vitamin C given singly or in combination with other antioxidant supplements - high-bias risk trials | 10 | 23210 | 0.93, 0.83-1.05 | 0 |
| Vitamin E given singly | 24 | 41341 | 1.02, 0.98-1.05 | 0 |
Table 5. Effects of antiox. suppl. vs placebo or no interv. - random-effects model  (Continued)

| Antioxidant supplement                                      | Studies | Participants | Ratio     | 95% CI      | P value |
|-------------------------------------------------------------|---------|--------------|-----------|-------------|---------|
| Vitamin E given in combination with other antioxidant supplements | 35      | 128681       | 1.02, 0.98-1.07 | 4.3      |
| Vitamin E given singly or in combination with other antioxidant supplements | 54      | 163454       | 1.02, 1.00-1.05 | 0        |
| Vitamin E given singly or in combination with other antioxidant supplements after exclusion of high-bias risk trials | 37      | 123761       | 1.04, 1.01-1.06 | 0        |
| Vitamin E given singly or in combination with other antioxidant supplements after exclusion of high-bias risk and selenium trials | 26      | 105065       | 1.04, 1.01-1.07 | 0        |
| Vitamin E given singly or in combination with other antioxidant supplements - high-bias risk trials | 17      | 39693        | 0.92, 0.85-0.99 | 0        |
| Selenium given singly                                       | 3       | 1993         | 0.85, 0.68-1.07 | 0        |
| Selenium given in combination with other antioxidant supplements | 17      | 40924        | 0.91, 0.83-0.99 | 0        |
| Selenium given singly or in combination with other antioxidant supplements | 20      | 42916        | 0.90, 0.82-0.98 | 0        |
| Selenium given singly or in combination with other antioxidant supplements after exclusion of high-bias risk trials | 14      | 22446        | 0.90, 0.80-1.01 | 0        |
Table 5. Effects of antiox. suppl. vs placebo or no interv. - random-effects model  (Continued)

| Supplement                                                                 | Number of trials | Participants number | RR (95%CI)          | Heterogeneity (%) |
|---------------------------------------------------------------------------|------------------|---------------------|---------------------|-------------------|
| Selenium given singly or in combination with other antioxidant supplements - high-bias risk trials | 6                | 22390               | 0.90, 0.80-1.01    | 0                 |
| All antioxidant supplements given singly or in combination with other antioxidant supplements | 67               | 232,550             | 1.02, 0.99-1.06    | 13.1              |

Table 6. Effects of antiox. suppl. vs placebo or no interv. - fixed-effect model

| Supplement                                                                 | Number of trials | Participants number | RR (95%CI)          | Heterogeneity (%) |
|---------------------------------------------------------------------------|------------------|---------------------|---------------------|-------------------|
| Beta-carotene given singly                                                | 6                | 40977               | 1.06, 1.02-1.10    | 11.8              |
| Beta-carotene given in combination with other antioxidant supplements     | 21               | 139516              | 1.06, 1.03-1.09    | 50.6              |
| Beta-carotene given singly or in combination with other antioxidant supplements | 24               | 172755              | 1.05, 1.03-1.08    | 47.5              |
| Beta-carotene given singly or in combination with other antioxidant supplements after exclusion of high-bias risk trials | 19               | 150258              | 1.06, 1.04-1.09    | 38.4              |
| Beta-carotene given singly or in combination with other antioxidant supplements after exclusion of high-bias risk and selenium trials | 12               | 132610              | 1.07, 1.04-1.10    | 34.4              |
| Beta-carotene given singly or in combination with other antioxidant supplements - high-bias risk trials | 5                | 22497               | 0.88, 0.78-0.99    | 31.3              |
### Table 6. Effects of antiox. suppl. vs placebo or no interv. - fixed-effect model  
(Continued)

| Description                                                                 | N  | Events | RR (95% CI)  | P  |
|----------------------------------------------------------------------------|----|--------|--------------|----|
| Vitamin A given singly                                                      | 2  | 2406   | 1.19, 0.84-1.68 | 0  |
| Vitamin A given in combination with other antioxidant supplements          | 14 | 42431  | 1.10, 1.04-1.16 | 33.9|
| Vitamin A given singly or in combination with other antioxidant supplements| 16 | 44837  | 1.10, 1.04-1.16 | 26.1|
| Vitamin A given singly or in combination with other antioxidant supplements after exclusion of high-bias risk trials | 11 | 25811  | 1.14, 1.07-1.20 | 14.8|
| Vitamin A given singly or in combination with other antioxidant supplements after exclusion of high-bias risk and selenium trials | 5  | 21677  | 1.16, 1.10-1.24 | 0  |
| Vitamin A given singly or in combination with other antioxidant supplements - high-bias risk trials | 5  | 19026  | 0.96, 0.84-1.08 | 0  |
| Vitamin C given singly                                                      | 3  | 826    | 0.89, 0.33-2.40 | 0  |
| Vitamin C given in combination with other antioxidant supplements          | 32 | 69941  | 1.00, 0.95-1.06 | 10.2|
| Vitamin C given singly or in combination with other antioxidant supplements | 33 | 70400  | 1.00, 0.95-1.05 | 68  |
| Vitamin C given singly or in combination with other antioxidant supplements after exclusion of high-bias risk trials | 23 | 46935  | 1.02, 0.96-1.08 | 5.9 |
Table 6. Effects of antiox. suppl. vs placebo or no interv. - fixed-effect model (Continued)

| Supplement                        | Participants | Events | Risk Ratio | 95% CI       | p-value |
|-----------------------------------|--------------|--------|------------|--------------|---------|
| Vitamin C given singly or in combination with other antioxidant supplements after exclusion of high-bias risk and selenium trials | 13           | 29275  | 1.05       | 0.99-1.12   | 10.3    |
| Vitamin C given singly or in combination with other antioxidant supplements - high-bias risk trials | 10           | 23210  | 0.93       | 0.82-1.04   | 0       |
| Vitamin E given singly            | 24           | 41341  | 1.02       | 0.98-1.05   | 0       |
| Vitamin E given in combination with other antioxidant supplements | 35           | 128681 | 1.03       | 1.00-1.06   | 4.3     |
| Vitamin E given singly or in combination with other antioxidant supplements | 54           | 163454 | 1.02       | 0.99-1.05   | 0       |
| Vitamin E given singly or in combination with other antioxidant supplements after exclusion of high-bias risk trials | 37           | 123761 | 1.03       | 1.01-1.06   | 0       |
| Vitamin E given singly or in combination with other antioxidant supplements after exclusion of high-bias risk and selenium trials | 26           | 105065 | 1.04       | 1.01-1.07   | 0       |
| Vitamin E given singly or in combination with other antioxidant supplements - high-bias risk trials | 17           | 39693  | 0.92       | 0.85-0.99   | 0       |
| Selenium given singly             | 3            | 1993   | 0.85       | 0.68-1.07   | 0       |
| Selenium given in combination with other antioxidant supplements | 17           | 40924  | 0.90       | 0.82-0.98   | 0       |
| Selenium given singly or in combination with other antioxidant supplements | 20 | 42916 | 0.89, 0.82-0.97 | 0 |
| Selenium given singly or in combination with other antioxidant supplements after exclusion of high-bias risk trials | 14 | 20707 | 0.89, 0.79-1.00 | 0 |
| Selenium given singly or in combination with other antioxidant supplements - high-bias risk trials | 6 | 22390 | 0.90, 0.80-1.01 | 0 |
| All antioxidant supplements given singly or in combination with other antioxidant supplements | 67 | 232,550 | 1.04, 1.02-1.06 | 13.1 |

**Primary and secondary prevention (Analysis 1.2)**

In primary prevention trials with low-bias risk, mortality was not significantly increased in the supplemented group in random-effects analysis (RR 1.05, 95% CI 0.98 to 1.12, P = 0.18), but significantly increased in a fixed-effect analysis (RR 1.06, 95% CI 1.04 to 1.10, P < 0.0001) with significant heterogeneity ($I^2 = 46.9\%$).

In primary prevention trials with high-bias risk, mortality was not significantly influenced by supplements (RR 0.95, 95% CI 0.85 to 1.06, P = 0.33, $I^2 = 0\%$).

In secondary prevention trials with low-bias risk, mortality tended to be increased in the supplemented group (RR 1.03, 95% CI 0.98 to 1.08, P = 0.20, $I^2 = 0\%$).

In secondary prevention trials with high-bias risk, mortality was significantly reduced by supplements (RR 0.89, 95% CI 0.80 to 1.00, P = 0.04) without significant heterogeneity ($I^2 = 25.5\%$).

As stated above, meta-regression analysis did not find significant difference in the estimated intervention effects in primary and secondary prevention trials.

**Sensitivity analyses excluding trials with co-administration of additional antioxidant supplements to both the experimental and control groups (Analysis 1.4)**

Sensitivity analyses excluding nine trials that used co-interventions in the form of extra vitamins in both the experimental and control groups did not noticeably change our results. In the 43 low-bias risk trials antioxidant supplements significantly increased mortality (RR 1.05, 95% CI 1.01 to 1.08, P = 0.01) without significant heterogeneity ($I^2 = 12.6\%$).

**Sensitivity analysis excluding factorial trials testing collateral interventions (Analysis 1.5)**

Sensitivity analysis excluding factorial trials testing collateral interventions which could lead to potential confounding did not noticeably change our results. In the 34 trials with low-bias risk, mortality was significantly increased in the supplemented group (RR 1.11, 95% CI 1.05 to 1.17, P < 0.0001, $I^2 = 0\%$).

**Sensitivity analysis excluding trials with co-administration of additional supplements to experimental and control groups, and factorial trials testing collateral interventions (Analysis 1.6)**

Sensitivity analysis excluding trials with co-administration of additional supplements to the experimental and control groups, and factorial trials testing collateral interventions did not noticeably...
change our results. In the 24 trials with low-bias risk, mortality was significantly increased in the supplemented group (RR 1.12, 95% CI 1.07 to 1.19, P < 0.0001, I² = 0%). These trials explored the influence of beta-carotene, vitamin A, vitamin C, vitamin E, and selenium.

The estimate of mortality risk in the 24 low-bias risk trials without potential confounding interventions (1.12, 95% CI 1.07 to 1.19) compared to the estimate of mortality risk in the 48 low-bias risk trials with potential confounding (1.05, 95% CI 1.02 to 1.08) was significantly increased (z = -2.09; P = 0.036).

**Sensitivity analysis excluding trials with co-administration of additional supplements to the experimental and control groups, factorial trials testing collateral interventions, and selenium trials (Analysis 1.7)**

Sensitivity analysis excluding trials with co-administration of additional supplements to the experimental and control groups, factorial trials testing collateral interventions, and selenium trials did not noticeably change our results. In the 19 trials with low-bias risk, mortality was significantly increased in the supplemented group (RR 1.16, 95% CI 1.09 to 1.23, P < 0.00001, I² = 0%).

The estimate of mortality risk in the 19 low-bias risk trials without any potential confounding interventions (1.16, 95% CI 1.09 to 1.23) compared to the estimate of mortality risk in the 48 low-bias risk trials with potential confounding (1.05, 95% CI 1.02 to 1.08) was significantly increased (z = -2.92; P = 0.0035).

**Sensitivity analyses according to type of antioxidant supplement**

**Beta-carotene**

Beta-carotene used singly or in combination with other antioxidants had no significant effect on mortality when including all 25 trials (RR 1.02, 95% CI 0.97 to 1.08, I² = 45%), 20 low-bias risk trials (RR 1.05, 95% CI 1.00 to 1.10, I² = 35%), or 5 high-bias risk trials (RR 0.81, 95% CI 0.62 to 1.07, I² = 31%) (Analysis 1.8). After exclusion of high-bias risk and selenium trials, however, beta-carotene singly or combined significantly increased mortality in 12 trials (RR 1.07, 95% CI 1.02 to 1.11, I² = 34%) (Analysis 1.13; Table 5).

A fixed-effect model analysis found a significant harmful effect of beta-carotene when including all 25 trials (RR 1.05, 95% CI 1.03 to 1.08) or 20 low-bias risk trials (RR 1.06, 95% CI 1.04 to 1.09), but a significant beneficial effect in 5 high-bias risk trials (0.88, 95% CI 0.78 to 0.99) (Table 6).

**Vitamin A**

Vitamin A used singly or in combination with other antioxidants had no significant effect on mortality when including all 15 trials (RR 1.05, 95% CI 0.93 to 1.19, I² = 31%), 11 low-bias risk trials, (RR 1.09, 95% CI 0.93 to 1.28, I² = 23%), or 5 high-bias risk trials (RR 0.96, 95% CI 0.84 to 1.08, I² = 0%) (Analysis 1.9). After exclusion of high-bias risk and selenium trials, however, vitamin A singly or combined significantly increased mortality in 5 trials (RR 1.16, 95% CI 1.10 to 1.24, I² = 0%) (Analysis 1.14; Table 5).

A fixed-effect model analysis found a significant harmful effect of vitamin A when including all 15 trials (RR 1.10, 95% CI 1.04 to 1.16) or 11 low-bias risk trials (RR 1.14, 95% CI 1.07 to 1.20) (Table 6).

**Vitamin C**

Vitamin C used singly or in combination with other antioxidants had no significant effect on mortality when including all 33 trials (RR 0.99, 95% CI 0.92 to 1.06, I² = 4.7%), 23 low-bias risk trials (RR 1.01, 95% CI 0.93 to 1.10, I² = 5.9%), or 10 high-bias risk trials (RR 0.93, 95% CI 0.83 to 1.05, I² = 0%) (Analysis 1.10). After the exclusion of high-bias risk trials and selenium trials vitamin C given singly or combined had no significant effect on mortality in 13 trials (RR 1.06, 95% CI 0.94 to 1.20, I² = 10%) (Analysis 1.15; Table 5).

**Vitamin E**

Vitamin E used singly or in combination with other antioxidants had no significant effect on mortality when including all 54 trials (RR 1.02, 95% CI 1.00 to 1.05, I² = 0%). In 37 low-bias risk trials, vitamin E significantly increased mortality (RR 1.04, 95% CI 1.01 to 1.06, I² = 0%). In 17 high-bias risk trials, vitamin E significantly reduced mortality (RR 0.92, 95% CI 0.85 to 0.99, I² = 0%) (Analysis 1.11). Vitamin E given singly in high (more or equal to 1000 IU) or low dose (less than 1000 IU) did not significantly affect mortality (RR 1.07, 95% CI 0.91 to 1.25, I² = 0% and RR 1.01, 95% CI 0.98 to 1.05, I² = 0%, respectively).

After exclusion of high-bias risk and selenium trials, vitamin E given singly or combined significantly increased mortality in 26 trials (RR 1.04, 95% CI 1.01 to 1.07, I² = 0%) (Analysis 1.16; Table 5).

**Selenium**

Selenium used singly or in combination with other antioxidants significantly decreased mortality when including all 20 trials (RR 0.90, 95% CI 0.83 to 0.98, I² = 0%). Selenium had no significant effect on mortality in 14 low-bias risk trials (RR 0.90 95% CI 0.80 to 1.01, I² = 0%), or 6 high-bias risk trials (RR 0.90, 95% CI 0.80 to 1.01, I² = 0%) (Analysis 1.12; Table 5). Inspection of funnel plot suggested asymmetry (Figure 3).
Figure 3. Funnel plot of 14 selenium trials with low risk of bias

Review: Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases
Comparison: 01 Antioxidants versus placebo/no intervention
Outcome: 17 Mortality in 14 selenium trials with low risk of bias
Our systematic review contains a number of findings. Betacarotene, vitamin A, and vitamin E given singly or combined with other antioxidant supplements significantly increase mortality. There is no evidence that vitamin C may increase longevity. We lack evidence to refute a potential negative effect of vitamin C on survival. Selenium tended to reduce mortality but only when high-bias risk trials were considered. Accordingly, we need more research on vitamin C and selenium. We confirmed that trials with inadequate bias control significantly overestimate intervention effects (Schulz 1995; Moher 1998; Kjaergard 2001; Bjelakovic 2004; Bjelakovic 2006). The detrimental effect of antioxidant supplements became significantly more pronounced when we excluded all trials with potential confounding. Our findings support and extend our previous findings regarding antioxidant supplements and increased mortality (Bjelakovic 2004).

**Fixed-effect model and random-effects model meta-analyses**

The fixed-effect model meta-analysis assumes that the true intervention effect is the same in every randomised trial, ie, the effect is fixed across trials. The random-effects model assumes that the effects being estimated based on the different randomised trials differ, but follow some general distribution. When there is no heterogeneity ($I^2 = 0$%), then fixed- and random-effects meta-analyses tend to give the same result. With increasing heterogeneity, the estimated intervention effect as well as the corresponding 95% confidence interval will differ between the two models.

The meta-analyses we conducted included a heterogenous set of randomised trials, eg, healthy participants or patients, single antioxidant supplement or combination, short duration of follow-up or long duration. These aspects could argue for only employing the random-effects model. We were requested to do so in our sister publication of the present review in JAMA (Bjelakovic 2007a). The standard random-effect model used in RevMan Analysis (RevMan 2003) is the DerSimonian and Laird method, which models the known differences between trials by incorporating a variance parameter $\tau^2$ to account for across-trial variation (DerSimonian 1986). Adoption of the random-effects model in meta-analysis permits extension of inferences to a broader population of studies than the fixed-effect model does, which excludes the parameter $\tau^2$ from the model.

The use of the random-effects model may come at a price. If there is between trial heterogeneity, then the weight of the large trials (usually providing more realistic estimates of intervention effects) becomes less. At the same time, the weight of small trials (usually providing more unrealistic estimates of intervention effects due to ‘bias’ (systematic errors) and ‘chance’ (random errors)) increases. We, therefore, also analysed our meta-analyses with the fixed-effect method. In all meta-analyses the pooled estimate of increased mortality in the antioxidant-supplemented group became more pronounced (Table 6). More of the meta-analyses became more significant or changed from non-significant to significant detrimental effects of vitamin A, betacarotene, and vitamin E or borderline effects of selenium (Table 6).

The choice of statistical model for performing meta-analysis of sparse data is important (Sweeting 2004; Bradburn 2007). Because many methods are based on large sample approximations, they may be unsuitable when events are rare. Bradburn et al found that no method gives completely unbiased estimates (Bradburn 2007).

At event rates below 1%, the Peto odds-ratio method appears to be the least biased and most powerful method when there is no substantial imbalance in treatment and control group sizes within trials, and treatment effects are not exceptionally large. Bradburn 2007 also demonstrated that the Peto odds ratio works well up to event rates around 10%. The calculation avoids addition of 0.5-event adjustments or any other adjustment. When we applied Peto odds ratio (a fixed-effect model analysis), we found even stronger support for detrimental effects of the supplements (for all 67 trials: 1.05; 95% CI 1.02 to 1.10; for the 47 low-bias risk trials: 1.07; 95% CI 1.04 to 1.10; for exclusion of high-bias risk trials and selenium trials, for beta-carotene: 1.09; 95% CI 1.06 to 1.13; for vitamin A: 1.20; 95% CI 1.12 to 1.29; for vitamin C: 1.06; 95% CI 0.99 to 1.14; and for vitamin E: 1.06; 95% CI 1.02 to 1.10). Again, our random-effects model analyses are supported and extended by the fixed-effect model analyses.

**Strengths**

Our review offers a number of strengths. It follows the overall plans of a published, peer-reviewed Cochrane protocol (Bjelakovic 2003), taking into consideration our previous findings in a systematic review on antioxidant supplements for preventing gastrointestinal cancers (Bjelakovic 2004) and requests of having all preventive trials assessed (Forman 2004). Our review represents a comprehensive review of the topic, including 67 randomised trials with almost a quarter of a million participants. This increases the precision and power of our analyses (Higgins 2006).

Previous meta-analyses of preventive trials of antioxidant supplements have included less information (lung cancer, 4 trials with 109,394 participants (Caraballoslo 2003); cardiovascular diseases, 8 trials with 138,113 participants (Vivekananthan 2003); gastrointestinal cancers, 14 trials with 170,525 participants (Bjelakovic 2004); colorectal adenoma, 8 trials with 17620 participants (Bjelakovic 2006); cancer or preinvasive lesions, 7 trials with 5112 participants (Davies 2006); mortality, 19 trials with 355,967 participants (Miller 2005); as well as their efficacy and safety, 5 trials with 47289 participants (Huang 2006). Previous meta-analyses either found no beneficial effect or no harmful effect of the supplements (Caraballoslo 2003; Vivekananthan 2003; Bjelakovic 2006;
Davies 2006; Huang 2006) or reported a significantly increased mortality (Caraballoso 2003; Vivekananthan 2003; Bjelakovic 2004; Miller 2005).

We conducted a thorough review with methodology following the recommendations of The Cochrane Collaboration (Higgins 2006) and findings of methodological studies (Schulz 1995; Moher 1998; Kjaergard 2001). More than two thirds of the included trials with more than 180,000 participants fall in the group of low-risk trials. This highlights the validity of our results (Schulz 1995; Moher 1998; Kjaergard 2001). Antioxidant supplements not only seem to be one of the most researched topics in the world, they also seem to be one of the most adequately researched questions. Usually, only a small proportion of trials use adequate methodologies (Gluud 2006a; Gluud 2006b).

Our meta-analyses had little trial heterogeneity. This increases the trustworthiness of our findings. Our analyses were robust to sensitivity analyses involving different imputations of mortality in the zero-event study groups. We gave full account of all 405 identified trials assessing the supplements having zero events in both intervention groups. These trials were mostly assessing short-term supplement administration and surrogate outcome measures. Our results were robust to exploratory analyses adding an imagined trial with 20000 participants and one death in each intervention group. Accordingly, the increased mortality does not seem to be an artefact created by exclusion of trials with zero events in both intervention groups (Sweeting 2004; Bradburn 2007). Furthermore, all-cause mortality should generally be connected with unbiased estimates (Wood 2008).

Our estimates of increased mortality in low-bias risk trials increased significantly when we excluded factorial trials as well as other trials with collateral interventions. These trials may all suffer from potential confounding from the collateral interventions. This highlights the potential dramatic public health consequences of our results.

A large number of unpublished trials on supplements may exist. Their results are more likely to have been either neutral or negative than to have shown beneficial effects (Dickersin 2003). Accordingly, our estimates of increased mortality are likely to be conservative.

Limitations

Our systematic review has several limitations. As with all systematic reviews, our findings and interpretations are limited by the quality and quantity of available evidence on the effects of specific supplements on mortality. The examined populations varied. The effects of supplements were assessed in the general population or in patients with gastrointestinal, cardiovascular, neurological, skin, ocular, renal, endocrinological, rheumatoid, and undefined diseases. These populations mostly came from countries without overt deficiencies of specific supplements. Accordingly, we are unable to assess how antioxidant supplements affect mortality in populations with specific needs.

We have compared antioxidants with different properties, given at different doses and duration, singly or combined. We are aware of the potential risks in assessing the effects of different types of antioxidants together with different mechanisms of action, bio-transformation, and bioavailability. There are pros (Palace 1999; Vertuani 2004; Kawanishi 2005) and cons (Maxwell 1999) in the literature about vitamin A being antioxidant. We fully acknowledge this. Most trials assessed combinations of different supplements, which reflects the way supplements are marketed, sold, and taken by people (Balluz 2000; Millen 2004; Radimer 2004; Nichter 2006).

All available non-enzymatic antioxidants work differently in the human body, and most of them exert effects that are non-antioxidant. We are not able to point to the specific biochemical mechanisms behind the detrimental effects. We found that trials examining the individual supplements singly were rare. It has been suggested that antioxidant supplements may show interdependency and may have effects only if given in combination (Hercberg 1998).

Most trials investigated the effects of supplements administered at higher doses than those commonly found in a balanced diet, and some of the trials used doses well above the recommended allowances and even above the tolerable upper intake levels (Anonymous 2000a; Anonymous 2000b) (see Figure 4 for overview of recommended dietary allowance, tolerable upper intake level, and experimental doses and regimen used). Our meta-regression analyses revealed significant effects of dose of beta-carotene, vitamin A, and selenium on mortality. The duration of supplementation and follow-up differed among the trials. However, we found no significant effect of treatment duration on our results.
Figure 4. Recommended dietary allowance, tolerable upper intake level, experimental doses, and regimen used in antioxidant supplements

| Antioxidant supplements | RDA<sup>+</sup> | TUILL<sup>**</sup> | Experimental doses | Median doses | Regimen |
|-------------------------|----------------|----------------|-------------------|--------------|---------|
|                         | Man | Woman | Man | Woman | 1.2 to 50 mg | 15.6 mg | Daily or on alternate days |
| Beta-carotene            | ND  | ND    | ND  | ND    | 400 to 7,500 pg | 1,500 pg | Daily |
| Vitamin A                | 900 µg | 700 µg | 3,000 µg | 400 to 7,500 µg<sup>†</sup> | 1,500 µg | Daily |
| Vitamin C                | 90 mg | 70 mg | 2,000 mg | 60 to 2,000 mg | 250 mg | Daily |
| Vitamin E                | 15 mg | 15 mg | 1,000 mg<sup>†</sup> | 10 to 500 mg<sup>†</sup> | 400 mg | Daily or on alternate days |
| Selenium                | 55 µg | 55 µg | 400 µg | 20 to 200 µg | 97.6 µg | Daily |

ND = not determined

**RDA** The Recommended Dietary Allowance is the average daily dietary intake level that is sufficient to meet the nutrient requirement of nearly all (97 to 98 percent) healthy individuals in a particular life stage and gender group. The RDA is intended to be used as a goal for daily intake by individuals. RDA for vitamin A from Anonymous 2000a, and RDA for the other antioxidants from Anonymous 2000b.

**TUILL** Tolerable Upper Intake Level is the highest level of daily nutrient intake that is likely to pose no risk of adverse health effects in almost all individuals. TUILL for vitamin A from Anonymous 2000a, and TUILL for the other antioxidants from Anonymous 2000b.

<sup>†</sup> The European Commission Scientific Committee on Food published its opinion on the tolerable upper intake level of vitamin E (SCF 2003). The TUILL was established as 270 mg for adults, rounded to 300 mg.

<sup>†</sup> One trial (Murphy 1992) was excluded here as it only administered vitamin A once in a dose of 200,000 IU (600,000 µg).
We only assessed all-cause mortality. We are not able to determine the cause of the increased mortality. It is likely that increased cancer and cardiovascular mortality are the main reasons for the increased all-cause mortality (Caraballoso 2003; Vivekananthan 2003; Bjelakovic 2004; Lawson 2007). Further study of causes of mortality is needed. Our results extend previous reviews (Caraballoso 2003; Vivekananthan 2003; Bjelakovic 2004; Miller 2005; Bjelakovic 2006; Davies 2006; Huang 2006; Bjelakovic 2007a) and guidelines (Ritenbaugh 1999; Atkins 2002; McKeith 2003) suggesting that antioxidant supplements may not be beneficial.

Our overall analyses should be evaluated with care as they include data from trials in which bias is likely as well as data from trials in which bias is less likely. Furthermore, our review include several trials, in which we cannot exclude confounding by other interventions examined in these trials. By excluding data from such trials our relative mortality risk rose from 1.05 to 1.16 in low-bias risk trials.

Beta-carotene, administered singly or in combination with other antioxidants had no significant effect on mortality. After exclusion of high-bias risk and selenium trials, beta-carotene singly or combined significantly increased mortality. Recent studies have suggested that beta-carotene may act as a co-carcinogen (Lee 2003; Paolini 2003).

Vitamin A used singly or in combination with other antioxidants had no significant effect on mortality. After exclusion of high-bias risk and selenium trials, vitamin A singly or combined significantly increased mortality. Recent research has suggested that vitamin A can cause oxidative damage to deoxyribonucleic acid (Murata 2000).

We found that vitamin E given singly or combined with four other antioxidants had no significant effect on mortality. However, after exclusion of high-bias risk trials, vitamin E given singly or combined significantly increased mortality. This is in agreement with a recent meta-analysis (Miller 2005). The dose of vitamin E was without significant effect on mortality in our analysis. The chance that vitamin E may benefit seems low (Brown 2005; Devaraj 2005; Guallar 2005).

The trials in which vitamin C was applied singly or in different combinations with beta-carotene, vitamin A, vitamin E, and selenium found no significant effect on mortality. According to the confidence intervals, small beneficial or large harmful effects cannot be excluded. We calculated the proportion of participants who died in the trials in which participants took vitamin C alone. In the control group it was 0.019 and in the vitamin C group it was 0.017. With alpha set to 0.05 and power to 0.90, and a minimal relevant difference of 2% the required sample size would be 186,000 participants. We are still far from having examined a sufficient sample. Studies have demonstrated that vitamin C may act as both a pro-oxidant and as an antioxidant in vivo (Podmore 1998; Duarte 2005), current and future trials should be monitored closely for harm.

Selenium given singly or in combination with other supplements seemed to significantly decrease mortality; but after exclusion of high-bias risk trials, the effect disappeared. Inspection of the funnel plot of the low-bias risk trials on selenium suggested asymmetry. Results of ongoing randomised trials with selenium will likely increase our understanding of the effects of selenium (Klein 2003). Recently, a randomised trial and an observational study have shown that selenium may carry health risks (Bleys 2007a; Bleys 2007b; Stranges 2007). Therefore, current and any future trials should be monitored closely for harm.

Our findings contradict the findings of observational studies, claiming that antioxidants improve health (Machlin 1987; Diplock 1994; van Poppel 1997; Diplock 1998). Considering that more than 10% to 20% of the adult population (80 million to 160 million people) in North America and Europe may consume the assessed supplements (Balluz 2000; Millen 2004; Radimer 2004; Nichter 2006) the public health consequences may be substantial. We are exposed to intense marketing. This is also reflected by the high number of publications per included randomised trial found in the present review.

There are several possible explanations for the increased mortality induced by antioxidant supplements. Although oxidative stress has a hypothesised role in the pathogenesis of many chronic diseases, it may be the consequence of pathological conditions (Halliwell 2000). By eliminating free radicals from our organism, we interfere with some essential defensive mechanisms like apoptosis, phagocytosis, and detoxification (Simon 2000; Salganik 2001; Kimura 2005). Recent evidence suggest that inhibition of reactive oxygen species formation in cells decrease the life span of nematodes (Schulz 2007). Antioxidant supplements are not subjected to the same rigorous toxicity studies as other pharmaceutical agents ( Bast 2002). Better understanding of mechanisms and actions of antioxidants in relation to a potential disease is needed (Ratnam 2006).

The methodological quality of some of the trials was assessed using the published reports, which may not reflect the actual design and bias risk of the trials. Only some authors responded to our requests for further information.

Because we examined only the influence of antioxidant supplements, our findings should not be translated to potential effects of fruits and vegetables. Furthermore, we did not examine the treatment effect of antioxidant supplements (tertiary prevention) in specific patient groups or the preventive effects of antioxidant supplements for patient groups with verified specific need for antioxidant supplements. Other systematic reviews should address these issues.

**AUTHORS’ CONCLUSIONS**

**Implications for practice**

We found no convincing evidence that antioxidant supplements decrease mortality. Even more, beta-carotene, vitamin A, and vitamin E seem to increase mortality. Therefore, we cannot recom-
mend the use of antioxidant supplements as a primary and secondary preventive measure in the population groups studied in the present review.

Implications for research

More randomised trials seem to be needed to more firmly establish the potential effects of vitamin C and selenium. Due to the risks that such antioxidant supplements may harm, such trials should have independent data monitoring and safety committees that should regularly review the accumulating data and incorporate these data with the data of our present review as well as other emerging evidence.

Our review highlights the necessity that national and international laws and regulations require that anything sold to the public claiming health benefits should be subjected to adequate assessment of benefits and harms before market release.

The significant association between unclear or inadequate methodological quality and overestimation of intervention effects has again focused on the need for more objective assessment of preventive and therapeutic interventions.

The published trials included in the systematic review lacked important information. We suggest that researchers in future trials should seriously consider adopting the CONSORT Statement (CONSORT - Consolidated Standards of Reporting Trials: www.consort-statement.org).

We thank the participants who entered the trials and the investigators who conducted them. We thank authors who kindly responded to our requests for further information on the trials they were involved in. We thank Yan Gong, MD, MIH, Ph.D., Copenhagen Trial Unit, Centre for Clinical Intervention Research, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, for assistance with statistical analyses and Sarah Louise Klingenberg, Cochrane Hepato-Biliary Group, Copenhagen Trial Unit, Centre for Clinical Intervention Research, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, for help with paper copies of articles. We thank the Editors and peer reviewers of JAMA for helpful suggestions for improvements for the sister JAMA version of our review. We also thank JAMA for having pointed out a data extraction error, which led us to re-examine all data extraction. Errors identified during this process have been corrected in the present review. We thank Ronald L. Koretz, Contact Editor of The CHBG, Kurinchi Gurusamy, Editor of the CHBG, as well as other CHBG Editors and Consumer Representatives of The CHBG for very helpful comments on the review. This benefited the clarity of our review. The Copenhagen Trial Unit, Centre for Clinical Intervention Research, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark provided monetary support for the review.

ACKNOWLEDGEMENTS

REFERENCES

References to studies included in this review

ADCS 1 1997 [published data only]

Drachman DA, Leber P. Treatment of Alzheimer’s disease - searching for a breakthrough, settling for less. New England Journal of Medicine 1997;336(17):1245–7. [MEDLINE: 9110915]

Klindaran L, Ohrvall M. Alpha-tocopherol and Alzheimer’s disease. New England Journal of Medicine 1997;337(8):572–3. [MEDLINE: 9265107]

Pincus MM. Alpha-tocopherol and Alzheimer’s disease. New England Journal of Medicine 1997;337(8):572. [MEDLINE: 9265106]

Sano M, Ernesto C, Klauber MR, Schafer K, Woodbury P, Thomas R, et al. Rationale and design of a multicenter study of selegiline and alpha-tocopherol in the treatment of Alzheimer disease using novel clinical outcomes. Alzheimer’s Disease Cooperative Study. Alzheimer Disease and Associated Disorders 1996;10(3):132–40. [MEDLINE: 8876776]

* Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer’s disease. The Alzheimer’s Disease Cooperative Study. New England Journal of Medicine 1997;336(17):1216–22. [MEDLINE: 9110909]

ADCS 2 2005 [published data only]

Barnes DE, Yaffe K. Vitamin E and donepezil for the treatment of mild cognitive impairment. New England Journal of Medicine 2005;353(9):951–2. [MEDLINE: 16135844]

Blacker D. Mild cognitive impairment - no benefit from vitamin E, little from donepezil. New England Journal of Medicine 2005;352(23):2439–41. [MEDLINE: 15829528]

* Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. New England Journal of Medicine 2005;352(23):2379–88. [MEDLINE: 15829527]

Allup 2004 Low [published data only]

Allup SJ, Shenkin A, Gouey MA, Taylor S, Taylor W, Hammond M, et al. Can a short period of micronutrient supplementation in older institutionalized people improve response to influenza vaccine? A randomized, controlled trial. Journal of the American Geriatrics Society 2004;52(1):20–4. [MEDLINE: 14687310]

AMDS 1996 Low [published data only]

* Age Related Macular Degeneration Study Group. Multicenter ophthalmic and nutritional age-related macular degeneration study - part 2: antioxidant intervention and conclusions. Journal of the American Optometric Association 1996;67(1):30–49. [MEDLINE: 8825017]

Age-related Macular Degeneration Study Group. Multicenter ophthalmic and nutritional age-related macular degeneration study - part...
Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases (Review)

1: design, subjects and procedures. *Journal of the American Optometric Association* 1996;67(1):12–29. [MEDLINE: 8825016]

AREDS 2001 LOW (published data only)

Age-Related Eye Disease Research Group. The Age-Related Eye Disease Study (AREDS) system for classifying age-related macular degeneration from stereoscopic color fundus photographs. AREDS Report No. 6. *American Journal of Ophthalmology* 2001;132:668–81.

Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. *Archives of Ophthalmology* 2001;119(10):1417–36. [MEDLINE: 11594942]

Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E and beta carotene for age-related cataract and vision loss: AREDS report no. 9. *Archives of Ophthalmology* 2001;119(10):1439–52. [MEDLINE: 11594943]

Age-Related Eye Disease Study Research Group. Impact of antioxidants, zinc, and copper on cognition in the elderly: a randomized, controlled trial. AREDS Report No. 12. *Neurology* 2004;63(9):1705–7.

Age-Related Eye Disease Study Research Group. Risk factors associated with age-related macular degeneration. A case-control study in the age-related eye disease study: age-related eye disease study report number 3. *Ophthalmology* 1999;96(5):1378–43. [MEDLINE: 11470690]

Age-Related Eye Disease Study Research Group. Risk factors associated with age-related nuclear and cortical cataract: a case-control study in the Age-Related Eye Disease Study, AREDS Report No. 5. *Archives of Ophthalmology* 2001;108(8):1400–8. [MEDLINE: 11470690]

Age-Related Eye Disease Study Research Group. The Age-Related Eye Disease Study (AREDS): design implications AREDS Report No. 1. *Controlled Clinical Trials* 1999;20(6):573–600.

Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS) system for classifying cataracts from photographs: AREDS report no. 4. *American Journal of Ophthalmology* 2001;131(2):167–75. [MEDLINE: 11228291]

Age-Related Eye Disease Study Research Group. The effect of five-year zinc supplementation on serum zinc, serum cholesterol and hematocrit in persons randomly assigned to treatment group in the age-related eye disease study: AREDS Report No. 7. *Journal of Nutrition* 2002;132(4):607–702. [MEDLINE: 11925463]

Age-Related Macular Degeneration Study Group. Multicenter ophthalmic and nutritional age-related macular degeneration study - Part 1: design, subjects and procedures. *Journal of the American Optometric Association* 1996;67(1):12–29.

Asensio-Sanchez VM. AREDS and age-related macular degeneration [Estudio AREDS y degeneración macular asociada a la edad]. *Archivos de la Sociedad Espanola de Oftalmologia* 1999;91(20):1738–43. [MEDLINE: 12221538]

Bartlett H, Eperjesi F. Age-related macular degeneration and nutritional supplementation: a review of randomised controlled trials. *Ophthalmic & Physiological Optics* 2003;23(5):383–99. [MEDLINE: 12950868]

Bressler NM, Bressler SB, Congdon NG, Ferris Fl, 3rd, Friedman DS, Klein R, et al. Potential public health impact of Age-Related Eye Disease Study results: AREDS Report No. 11. *Archives of Ophthalmology* 2003;121(11):1621–4. [MEDLINE: 14609922]

Chew EY, Clemons T. Vitamin E and the age-related eye disease study supplementation for age-related macular degeneration. *Archives of Ophthalmology* 2005;123(3):395–6. [MEDLINE: 15767485]

Clemons TE, Chew EY, Bressler SB, McBee WL. National Eye Institute Visual Function Questionnaire in the Age-Related Eye Disease Study (AREDS): AREDS Report No. 10. *Archives of Ophthalmology* 2003;121(2):211–7. [MEDLINE: 12583787]

Clemons TE, Kurinji N, Sperduto RD, AREDS Research Group. Associations of mortality with ocular disorders and an intervention of high-dose antioxidants and zinc in the Age-Related Eye Disease Study: AREDS Report No. 15. *Archives of Ophthalmology* 2004;122(5):716–26. [MEDLINE: 15136520]

Clemons TE, Milton RC, Klein R, Seddon JM, Ferris Fl, 3rd. Age-Related Eye Disease Study Research Group. Risk factors for the incidence of Advanced Age-Related Macular Degeneration in the Age-Related Eye Disease Study (AREDS) AREDS Report no. 19. *Ophthalmology* 2005;112(4):533–9. [MEDLINE: 15808240]

Lindblad AS, Clemons TE. Responsiveness of the National Eye Institute Visual Function Questionnaire to progression to advanced age-related macular degeneration, vision loss, and lens opacity: AREDS Report No. 14. *Archives of Ophthalmology* 2005;123(9):1207–14. [MEDLINE: 16157800]

Rankin MW, Clemons TE, McBee WL. Correlation analysis of the in-clinic and telephone batteries from the AREDS cognitive function ancillary study. AREDS Report No. 15. *Ophthalmic Epidemiology* 2009;12(4):271–7. [MEDLINE: 16033748]

Sackett CS, Schenning S. The age-related eye disease study: the results of the clinical trial. *Insight* 2002;27(1):5–7. [MEDLINE: 11962062]

ASAP 2003 LOW (published data only)

Bruunsgaard H, Poulsen HE, Pedersen BK, Nyynsson K, Kaikkonen J, Salonen JT. Long-term combined supplementations with alpha-tocopherol and vitamin C have no detectable anti-inflammatory effects in healthy men. *Journal of Nutrition* 2003;133(4):1170–3. [MEDLINE: 12672938]

Jialal I, Devaraj S. Antioxidants and atherosclerosis: don’t throw out the baby with the bath water. *Circulation* 2003;107(7):926–8. [MEDLINE: 12609900]

Kaikkonen J, Porkkala-Sarataho E, Morrow JD, Roberts LJ 2nd, Nyynsson K, Salonen R, et al. Supplementation with vitamin E but not with vitamin C lowers lipid peroxidation in vivo in mildly hypercholesterolemic men. *Free Radical Research* 2001;35(6):967–78. [MEDLINE: 11811547]

Porkkala-Sarataho E, Salonen JT, Nyynsson K, Kaikkonen J, Salonen R, Ristonmaa U, et al. Long-term effects of vitamin E, vitamin C, and combined supplementation on urinary 7-hydro-8-oxo-2′-deoxyguanosine, serum cholesterol oxidation products, and oxidation resistance of lipids in nondepleted men. *Arteriosclerosis, Thrombosis, and Vascular Biology* 2000;20(9):2087–93. [MEDLINE: 10978253]

Salonen JT, Nyynsson K, Salonen R, Lakka HM, Kaikkonen J, Porkkala-Sarataho E, et al. Antioxidant Supplementation in Atherosclerosis Prevention (ASAP) Study: a randomized trial of the effect of vitamins E and C on 3-year progression of carotid atherosclerosis. *Journal of Internal Medicine* 2000;248(5):377–86. [MEDLINE: 11123502]

* Salonen RM, Nyynsson K, Kaikkonen J, Porkkala-Sarataho E,
Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases (Review)

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Voutilainen S, Rissanen TH, et al. Six-year effect of combined vitamin C and E supplementation on atherosclerotic progression: the Antioxidant Supplementation in Atherosclerosis Prevention (ASAP) Study. *Circulation* 2003;107(7):947–53. [MEDLINE: 12600905]

**ATBC 2003 Low (published data only)**

Albanes D, Heinonen OP, Huttunen JK, Taylor PR, Virtamo J, Edwards BK, et al. Effects of supplemental alpha-tocopherol and beta-carotene supplementation on cancer incidence in the Alpha-Tocopherol Beta-Carotene Cancer Prevention Study. *American Journal of Clinical Nutrition* 1995;62(6 Suppl):1427s–1430s. [MEDLINE: 7495243]

Albanes D, Heinonen OP, Taylor PR, Virtamo J, Edwards BK, Rautalahti M, et al. Alpha-tocopherol and beta-carotene supplements and lung cancer incidence in the alpha-tocopherol, beta-carotene cancer prevention study: effects of baseline characteristics and study compliance. *Journal of the National Cancer Institute* 1996;88(21):1560–70. [MEDLINE: 8901854]

Albanes D, Malila N, Taylor PR, Huttunen JK, Virtamo J, Edwards BK, et al. Effects of supplemental alpha-tocopherol and beta-carotene on colorectal cancer risk: findings from a controlled trial. *Cancer Causes & Control* 2000;11(3):197–205. [MEDLINE: 10782653]

Blumberg J. The Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study in Finland. *Nutrition Reviews* 1994;52(7):242–50. [MEDLINE: 8090376]

Freedman DM, Tangrea JA, Virtamo J, Albanes D. The effect of beta-carotene supplementation on serum vitamin D metabolite concentrations. *Cancer Epidemiology, Biomarkers & Prevention* 1999;8(12):1115–6. [MEDLINE: 10613346]

Hartman TJ, Dorgan JF, Woodson K, Virtamo J, Tangrea JA, Heinonen OP, et al. Effects of long-term alpha-tocopherol supplementation on serum hormones in older men. *Prostate* 2001;46(1):33–8. [MEDLINE: 11170129]

Leppala JM, Virtamo J, Fogelholm R, Huttunen JK, Albanes D, Taylor PR, et al. Controlled trial of alpha-tocopherol and beta-carotene supplements on stroke incidence and mortality in male smokers. *Arterioscler Thromb Vascular Biology* 2000;20(1):230–5. [MEDLINE: 10634823]

Liede KE, Haukka JK, Saxen LM, Heinonen OP. Increased tendency towards gingival bleeding caused by joint effect of alpha-tocopherol supplementation and acetylsalicylic acid. *Annals of Medicine* 1998;30(6):542–6. [MEDLINE: 9928356]

Malila N, Taylor PR, Virtamo MJ, Korhonen P, Huttunen JK, Albanes D, et al. Effects of alpha-tocopherol and beta-carotene supplementation on gastric cancer incidence in male smokers (ATBC Study, Finland). *Cancer Causes & Control* 2002;13(7):617–23. [MEDLINE: 12296509]

Malila N, Virtamo J, Virtanen M, Albanes D, Tangrea JK, Huttunen J. The effect of alpha-tocopherol and beta-carotene supplementation on colorectal adenomas in middle-aged male smokers. *Cancer Epidemiology, Biomarkers & Prevention* 1999;8(6):489–93. [MEDLINE: 10385137]

Malila N, Virtamo J, Virtanen M, Pietinen P, Albanes D, Teppo L. Dietary and serum alpha-tocopherol, beta-carotene and retinol, and risk for colorectal cancer in male smokers. *European Journal of Clinical Nutrition* 2002;56(7):615–21. [MEDLINE: 12080400]

Michaud DS, Pietinen P, Taylor PR, Virtamo M, Virtanen M, Virtamo J, Albanes D. Intakes of fruits and vegetables, carotenoids and vitamins A, E, C in relation to the risk of bladder cancer in the ATBC cohort study. *British Journal of Cancer* 2002;87(9):960–5. [MEDLINE: 12434284]

Rautalahti MT, Virtamo JR, Taylor PR, Heinonen OP, Albanes D, Haukka JK, et al. The effects of supplementation with alpha-tocopherol and beta-carotene on the incidence and mortality of carcinoma of the pancreas in a randomized, controlled trial. *Cancer* 1999;86(1):37–42. [MEDLINE: 10391561]

Stolzenberg-Solomon RZ, Blaser MJ, Limburg PJ, Perez-Perez G, Taylor PR, Virtamo J, et al. Helicobacter pylori seropositivity as a risk factor for pancreatic cancer. *Journal of the National Cancer Institute* 2001;93(12):937–41. [MEDLINE: 11416115]

Teikari JM, Laatikainen L, Rapola JM, Virtamo J, Haukka J, Liesto K, et al. Retinal vascular changes following supplementation with alpha-tocopherol or beta-carotene. *Acta Ophthalmologica Scandinavica* 1998;76(1):68–73. [MEDLINE: 9541437]

Teikari JM, Laatikainen L, Virtamo J, Haukka J, Rautalahti M, Liesto K, et al. Six-year supplementation with alpha-tocopherol and beta-carotene and age-related maculopathy. *Acta Ophthalmologica Scandinavica* 1998;76(2):224–9. [MEDLINE: 9591958]

Teikari JM, Rautalahti M, Haukka J, Jarvinen P, Hartman AM, Virtamo J, et al. Incidence of cataract operations in Finnish male smokers unaffected by alpha tocopherol or beta carotene supplements. *Journal of Epidemiology and Community Health* 1998;52(7):468–72. [MEDLINE: 9799882]

The ATBC Cancer Prevention Study Group. The Alpha-Tocopherol, Beta-Carotene Lung Cancer Prevention Study: design, methods, participant characteristics, and compliance. *Annals of Epidemiology* 1994;4(1):1–10. [MEDLINE: 8205268]

The ATBC Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. *New England Journal of Medicine* 1994;330(15):1029–35. [MEDLINE: 8127529]

Tornwall ME, Virtamo J, Haukka JK, Albanes D, Huttunen JK. Alpha-tocopherol (vitamin E) and beta-carotene supplementation does not affect the risk for large abdominal aortic aneurysm in a controlled trial. *Atherosclerosis* 2001;157(1):167–73. [MEDLINE: 11427217]

Tornwall ME, Virtamo J, Haukka JK, Aro A, Albanes D, Huttunen JK. The effect of alpha-tocopherol and beta-carotene supplementation on symptoms and progression of intermittent claudication in a controlled trial. *Atherosclerosis* 1999;147(1):193–7. [MEDLINE: 10525141]

Tornwall ME, Virtamo J, Korhonen PA, Virtanen MJ, Albanes D, Huttunen JK. Postintervention effect of alpha-tocopherol and beta carotene on different strokes: a 6-year follow-up of the Alpha Tocopherol, Beta Carotene Cancer Prevention Study. *Stroke* 2004;35(8):2008–13. [MEDLINE: 15205487]

Varis K, Sipponen P, Laxen F, Samloff IM, Huttunen JK, Taylor PR, et al. Implications of serum pepsinogen I in early endoscopic diagnosis of gastric cancer and dysplasia. *Helsinki Gastritis Study Group. Scandinavian Journal of Gastroenterology* 2000;35(9):950–6. [MEDLINE: 11063155]

Varis K, Taylor PR, Sipponen P, Samloff IM, Heinonen OP, Albanes D, et al. Gastric cancer and premalignant lesions in atrophic gastritis: a controlled trial on the effect of supplementation with alpha-tocopherol and beta-carotene. The Helsinki Gastritis Study Group. *Scandinavian Journal of Gastroenterology* 1998;33(3):294–300. [MEDLINE: 18904210]
Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases (Review)

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases (Review)

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases (Review)

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases (Review)

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases (Review)

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases (Review)

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases (Review)

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases (Review)

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases (Review)

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases (Review)

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases (Review)

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases (Review)

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases (Review)

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases (Review)

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases (Review)

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases (Review)

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases (Review)

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases (Review)

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases (Review)

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases (Review)

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases (Review)

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases (Review)

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases (Review)

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases (Review)

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases (Review)

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases (Review)

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases (Review)

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases (Review)

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases (Review)

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases (Review)

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases (Review)

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases (Review)

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases (Review)

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases (Review)

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases (Review)

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases (Review)

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases (Review)

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases (Review)

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases (Review)

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases (Review)

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases (Review)

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases (Review)

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Antioxidant supplements for preven...
Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases (Review)

Chandra 1992 [published data only]

Carpenter KJ, Roberts S, Sternberg S. Nutrition and immune function: a 1992 report. *Lancet* 2003;361(9376):2247–8. [MEDLINE: 12842391]

* Chandra RK. Effect of vitamin and trace-element supplementation on immune responses and infection in elderly subjects. *Lancet* 1992; 340(8828):1124–7. [MEDLINE: 1359211]

Schorah CJ. Micronutrient provision in elderly subjects. *Lancet* 1993;341(8840):306–7. [MEDLINE: 8093941]

CHAOS 1996 [published data only]

Davey PJ, Schulz M, Gilsenan M, Dobson M, Aristides M, Stephens NG. Cost-effectiveness of vitamin E therapy in the treatment of patients with angiographically proven coronary narrowing (CHAOS trial). *Cambridge Heart Antioxidant Study* [American Journal of Cardiology 1998;82(4):414–7. [MEDLINE: 9723625]

Mitchinson MJ, Stephens NG, Parsons A, Bligh E, Schofield PM, Brown MJ. Mortality in the CHAOS trial. *Lancer* 1999;353(9150): 381–2. [MEDLINE: 9950454]

Morite EM. Vitamin E treatment of patients with coronary disease (Cambridge Heart Antioxidant Study - CHAOS). *Deutsche Medizinische Wochenschrift* 1996;121(21):A9. [MEDLINE: 8646975]

Niki E, Noguchi N. CHAOS (Cambridge Heart Antioxidant Study). *Nippon Rinsho* 2001;59(Suppl 3):448–51. [MEDLINE: 11347112]

* Stephens NG, Parsons A, Schofield PM, Kelly F, Chesseman K, Mitchinson MJ. Randomised controlled trial of vitamin E in patients with coronary disease. *Cambridge Heart Antioxidant Study (CHAOS).* Lancet 1996;347(9004):781-6. [MEDLINE: 8622332]

Collins 2003 [published data only]

Collins EG, Edwin Langbein W, Orebrough C, Bammert C, Hanson K, Reda D, et al. PoleStriding exercise and vitamin E for management of peripheral vascular disease. *Medicine & Science in Sports & Exercise* 2003;35(3):384–93.

Correa 2000 [published data only]

* Correa P, Fontham ET, Bravo JC, Bravo LE, Ruiz B, Zarama G, etc. Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-Helicobacter pylori therapy. *Journal of the National Cancer Institute* 2000;92(23):1881–8. [MEDLINE: 11066679]

Correa P, Fontham ETH, Bravo JC, Bravo LE, Ruiz B, Zarama G, etc. Re: Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-Helicobacter pylori therapy. *Journal of the National Cancer Institute* 2001;93(7):559.

Gail MH, Brown LM, You WC. Re: Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-Helicobacter pylori therapy. *Journal of the National Cancer Institute* 2001;93(7):559–60. [MEDLINE: 11287457]

Mera R, Fontham ET, Bravo LE, Bravo JC, Piazuelo MB, Camargo MC, et al. Long-term follow up of patients treated for Helicobacter pylori infection. *Gut* 2005;54(11):1536–40. [MEDLINE: 15985559]

Ruiz B, Gazay J, Correa P, Fontham ET, Bravo JC, Bravo LE, et al. Morphometric evaluation of gastric antral atrophy: improvement after cure of Helicobacter pylori infection. *American Journal of Gastroenterology* 2001;96(12):3281–7.
Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases (Review)

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

DATATOP 2005Low (published data only)

Ben-Shlomo Y, Head J, Lees A. Mortality in DATATOP. Annals of Neurology 1999;45(1):138–9. [MEDLINE: 9894892]

Heikkila R, Terleckyj I,Sieber BA. Monoamine oxidase and the bioactivation of MPTP and related neurotoxins: relevance to DATATOP. Journal of Neural Transmission. Supplementum 1999;32:217–27. [MEDLINE: 2128498]

Jankovic J, McDermott M, Carter J, Gauthier S, Goetz C, Golbe L,et al.Variable expression of Parkinson's disease: a base-line analysis of the DATATOP cohort. The Parkinson Study Group. Neurology 1990;40(10):1529–34.

Landau WM. Clinical neurosyromathy IX. Pyramid sale in the bucket shop: DATATOP bottoms out. Neurology 1990;40(9):1337–9. [MEDLINE: 2118239]

LeWitt PA. Deprenyl's effect at slowing progression of parkinsonian disability: the DATATOP study. The Parkinson Study Group. Acta Neurologica Scandinavica. Supplementum 1991;136:79–86. [MEDLINE: 1801542]

Maki-Ikola O, Heinonen E. Study design problems of DATATOP study analysis. Annals of Neurology 1996;40(6):946–8. [MEDLINE: 9097106]

* Marras C, McDermott MP, Rochon PA, Tanner CM, Naglie G, Rudolph A. Survival in Parkinson disease: thirteen-year follow-up of the DATATOP cohort. Neurology 2005;64(1):87–93. [MEDLINE: 15642909]

Miklya I, Knoll B, Knoll J. A pharmacological analysis elucidating why, in contrast to (-)-depenyl (selegiline), alpha-tocopherol was ineffective in the DATATOP study. Life Sciences 2003;72(23):2641–8. [MEDLINE: 12672509]

Oakes DP. Antiparkinson efficacy of deprenyl. DATATOP Steering Committee of Parkinson Study Group. Annals of Neurology 1993;34(4):634. [MEDLINE: 8215256]

Parkinson Study Group. Cerebrospinal fluid homovanillic acid in the DATATOP study on Parkinson's disease. Archives of Neurology 1995;52(3):237–45. [MEDLINE: 7872875]

Parkinson Study Group. DATATOP: a multicenter controlled clinical trial in early Parkinson's disease. Archives of Neurology 1989;46(10):1052–60. [MEDLINE: 2508608]

Parkinson Study Group. DATATOP and clinical neurosyromathy IX. Neurology 1991;41(6):771–7. [MEDLINE: 1904562]

Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Annals of Neurology 1996;39(1):37–45. [MEDLINE: 8572664]

Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopa. Annals of Neurology 1996;39(1):29–36. [MEDLINE: 8572665]

Parkinson Study Group. Mortality in DATATOP: a multicenter trial in early Parkinson's disease. Annals of Neurology 1998;43(3):318–25. [MEDLINE: 9506548]

Parkinson Study Group. Neurosyromathy IX and DATATOP. Neurology 1991;41(10):1703–4. [MEDLINE: 1922831]

Schneider E. DATATOP study: significance of its results in the treatment of Parkinson's disease. Journal of Neural Transmission. Supplementum 1995;46:391–7. [MEDLINE: 8821074]

Shoulson I. DATATOP: a decade of neuroprotective inquiry. Parkinson Study Group. Deprenyl and tocopherol antioxidant therapy of parkinsonism. Annals of Neurology 1998;44(3 Suppl 1):S160–S166.

Shoulson I. Deprenyl and tocopherol antioxidant therapy of parkinsonism (DATATOP). Parkinson Study Group. Acta Neurologica Scandinavica. Supplementum 1989;126:171–5. [MEDLINE: 2515723]

Varaserry GT, Fahn S, Kuskowski MA. Alpha tocopherol in CSF of subjects taking high-dose vitamin E in the DATATOP study. Parkinson Study Group. Neurology 1998;50(6):1900–2. [MEDLINE: 9633757]

Ward CD. Does selegiline delay progression of Parkinson's disease? A critical re-evaluation of the DATATOP study. Journal of Neurology, Neurosurgery, and Psychiatry 1994;57(2):217–20. [MEDLINE: 8126510]

DATATOR 2004Low (published data only)

Manuel-Y-Keesnoy B, Vinckx M, Vertommen J, Van Gaal L, De Leeuw I. Impact of vitamin E supplementation on lipoprotein per-oxidation and composition in type 1 diabetic patients treated with atorvastatin. Atherosclerosis 2004;175(2):569–76.

de la Maza 1995 (published data only)
de la Maza MP, Petermann M, Bunout D, Hirsch S. Effects of long-term vitamin E supplementation in alcoholic cirrhotics. Journal of the American College of Nutrition 1995;14(2):192–6. [MEDLINE: 7790695]

de Waart 2001 (published data only)
de Waart FG, Kok FJ, Smilde TJ, Hjimam A, Wollersheim H, Stalenhoef AF. Effect of glutathione S-transferase M1 genotype on progression of atherosclerosis in lifelong male smokers. Atherosclerosis 2001;158(1):227–31. [MEDLINE: 11500195]

Desnuelle 2001Low (published data only)

Desnuelle C, Dib M, Garcel C, Favier A. A double-blind, placebo-controlled randomized clinical trial of alpha-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. ALS Riluzole-Tocopherol Study Group. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders 2001;2(1):9–18. [MEDLINE: 11465936]

Gillilan 1977 (published data only)

Gillilan RE, Mondell B, Warbasse JR. Quantitative evaluation of vitamin E in the treatment of angina pectoris. American Heart Journal 1977;93(4):444–9. [MEDLINE: 320856]

Girodon 1997 (published data only)

Girodon F, Lombard M, Galan P, Brunet-Lecomte P, Monget AL, Arnaud J, et al. Effect of micronutrient supplementation on infection in institutionalized elderly subjects: a controlled trial. Annals of Nutrition & Metabolism 1997;41(2):98–107. [MEDLINE: 9267584]

GISSI 1999 (published data only)

Barzi F, Woodward M, Marfisi RM, Tavazzi L, Valagussa F, Marchioli R, et al. Mediterranean diet and all-causes mortality after myocardial infarction: results from the GISSI-Prevenzione trial. Euro-
Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases (Review)

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases (Review)

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

events and cancer: a randomized controlled trial. JAMA 2005;293(11):1358-47. [MEDLINE: 15760967]
Lonn E, Mathow J, Pogue J, Johnstone D, Danisa K, Bosch J, et al. Relationship of electrocardiographic left ventricular hypertrophy to mortality and cardiovascular morbidity in high-risk patients. European Journal of Cardiovascular Prevention and Rehabilitation 2003;10(6):420-8. [MEDLINE: 14671464]
Lonn E, Roccaforte R, Yi Q, Dagenais G, Sleight P, Bosch J, et al. Effect of long-term therapy with ramipril in high-risk women. Journal of the American College of Cardiology 2002;40(4):693-702. [MEDLINE: 12204499]
Lonn E, Yusuf S, Hoogwerf B, Pogue J, Yi Q, Zinnman B, et al. Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: results of the HOPE study and MICRO-HOPE substudy. Diabetes Care 2002;25(11):1919-27. [MEDLINE: 12401753]
Lonn E, Yusuf S, Hoogwerf B, Pogue J, Yi Q, Zinnman B, et al. Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: results of the HOPE study and MICRO-HOPE substudy. Diabetetes Care 2002;25(11):1919-27.
Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Annals of Internal Medicine 2001;134(8):629-36. [MEDLINE: 11304102]
Mann JF, Gerstein HC, Yi QL, Franke J, Lonn EM, Hoogwerf BJ, et al. Progression of renal insufficiency in type 2 diabetes with and without microalbuminuria: results of the Heart Failure and Prevention Evaluation (HOPE) randomized study. American Journal of Kidney Disease 2003;42(5):936-42. [MEDLINE: 14582037]
Mann JF, Gerstein HC, Yi QL, Lonn EM, Hoogwerf BJ, Rashkow A, et al. Development of renal disease in people at high cardiovascular risk: results of the HOPE randomized study. Journal of the American Society of Nephrology 2003;14(3):641-7. [MEDLINE: 12595499]
Mann JF, Lonn EM, Yi Q, Gerstein HC, Hoogwerf BJ, Pogue J, et al. Effects of vitamin E on cardiovascular outcomes in people with mild-to-moderate renal insufficiency: results of the HOPE study. Kidney International 2004;65(4):1375-80. [MEDLINE: 15086477]
Mann JF, Yi QL, Sleight P, Dagenais GR, Gerstein HC, Lonn EM, et al. Serum potassium, cardiovascular risk, and effects of an ACE inhibitor: results of the HOPE study. Clinical Nephrology 2005;63(8):181-7. [MEDLINE: 15766818]
McQueen MJ, Lonn E, Gerstein HC, Bosch J, Yusuf S. The HOPE (Heart Outcomes Prevention Evaluation) Study and its consequences. Scandinavian Journal of Clinical and Laboratory Investigation. Supplmentum 2005;240:143-56. [MEDLINE: 16112972]
Ostergren J, Sleight P, Dagenais G, Danisa K, Bosch J, Qilong Y, et al. Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease. European Heart Journal 2004;25(1):17-24. [MEDLINE: 14683738]
Sharpe N. The HOPE TIPS: The HOPE Study translated into practices. Cardiovascular Drugs and Therapy 2005;19(3):197-201. [MEDLINE: 16142597]
Teo KK, Mitchell LB, Pogue J, Bosch J, Dagenais G, Yusuf S, et al. Effect of ramipril in reducing sudden deaths and nonfatal cardiac arrests in high-risk individuals without heart failure or left ventricular dysfunction. Circulation 2004;110(11):1413-7. [MEDLINE: 15355497]
Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. New England Journal of Medicine 2000;342(3):154-60. [MEDLINE: 10639540]
Yusuf S, Gerstein H, Hoogwerf B, Pogue J, Bosch J, Wolfenhuttel BH, et al. Ramipril and the development of diabetes. JAMA 2001;286(15):1882-5. [MEDLINE: 11597291]
Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effect of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. New England Journal of Medicine 2000;342(3):145-53. [MEDLINE: 10695595]

HPS 2002Low [published data only]
Armitage J, Collins R. Need for large scale randomised evidence about lowering LDL cholesterol in people with diabetes mellitus: MRC/BHF Heart Protection Study and other major trials. Heart 2000;84(4):357-60. [MEDLINE: 10995396]
Bates CJ. MRC/BHF Heart Protection Study. Lancet 2002;360(9347):1781-2. [MEDLINE: 12480450]
Brown MJ. MRC/BHF Heart Protection Study. Lancet 2002;360(9347):1782. [MEDLINE: 12480451]
Collins R, Armitage J, Parish S, Sleight P, Peto R. MRC/BHF Heart Protection Study. Lancet 2002;360(9347):1783-4. [MEDLINE: 12480453]
Collins R, Peto R, Armitage J. The MRC/BHF Heart Protection Study: preliminary results. International Journal of Clinical Practice 2002;56(1):53-6. [MEDLINE: 11831837]
Durrington PN, MRC/BHF Heart Protection Study. Lancet 2002;360(9347):1781. [MEDLINE: 12480449]
Farmer JA. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised, placebo-controlled trial. Current Atherosclerosis Reports 2003;5(2):93-4. [MEDLINE: 12575191]
Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience. European Heart Journal 1999;20(10):725-41. [MEDLINE: 10329064]
Kris-Etherton PM. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Current Atherosclerosis Reports 2002;4(6):411-2. [MEDLINE: 12361485]
Kulbertus H, Scheen AJ. Clinical study of the month. The MRC/BHF Heart Protection Study. ACP Journal Club 2003;138(2):A15. [MEDLINE: 12614142]
* MRC/BHF Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; Vol. 360, issue 9326:33-33.
MRC/BHF Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering therapy
and of antioxidant vitamin supplementation in a wide range of pa-
tients at increased risk of coronary heart disease death: early safety
and efficacy experience. *European Heart Journal* 1999;20:725–41.

MRC/BHF Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 20,536 high-risk individu-
als: a randomized placebo controlled trial. *Lancet* 2002;360(9320):
7–22.

Robins SJ, Despres JP. MRC/BHF Heart Protection Study. *Lancet*
2002;360(9347):1780. [MEDLINE: 12480447]

Vaughn CJ, Buckley BM. MRC/BHF Heart Protection Study. *Lancet*
2002;360(9347):1780–1. [MEDLINE: 12480446]

Violi F, Miceli F, Juliano L. MRC/BHF Heart Protection Study. *Lancet*
2002;360(9347):1782–3. [MEDLINE: 12480452]

Wald N, Law M. MRC/BHF Heart Protection Study. *Lancet* 2002;
360(9347):1781. [MEDLINE: 12480448]

Jacobson 2000 {published data only}

Jacobson JS, Beg MD, Wang LW, Wang Q, Agarwal M, Norkus E.
Effects of a 6-month vitamin intervention on DNA damage in heavy
smokers. *Cancer Epidemiology, Biomarkers & Prevention* 2000;9(12):
1303–11. [MEDLINE: 11142415]

LAST 2004 {published data only}

Richer S, Stiles W, Statkute L, Pulido J, Frankowski J, Rudy D,
et al.Double-masked, placebo-controlled, randomized trial of lutein and
antioxidant supplementation in the intervention of atrophic age-
related macular degeneration: the Veterans LAST study (Lutein Antiox-
didant Supplementation Trial). *Optometry* 2004;75(4):216–30.
[MEDLINE: 15117055]

Limburg 2005 {published data only}

Limburg PJ, Wei W, Ahnén DJ, Qiao Y, Hawk ET, Wang G, et
al.Randomized, placebo-controlled, esophageal squamous cell cancer
chemoprevention trial of selenomethionine and celecoxib. *Gastroen-
terology* 2005;129(3):863–73. [MEDLINE: 16143126]

MAVIS 2005 {published data only}

Avenell A, Campbell MK, Cook JA, Hannaford PC, Kilono MM,
McNeill G, et al.Effect of multivitamin and multimineral supple-
ments on morbidity from infections in older people (MAVIS trial):
pragmatic, randomised, double blind, placebo controlled trial. *BMJ*
2005;331(7512):324–9. [MEDLINE: 16081445]

McKeown-Eyssen 1988 {published data only}

McKeown-Eyssen G, Holloway C, Jazmaji V, Bright-See E, Dion P,
Bruce WR. A randomized trial of vitamins C and E in the prevention
of recurrence of colorectal polyps. *Cancer Research* 1988;48(16):
4701–5. [MEDLINE: 3297777]

Meydani 2004 {published data only}

Meydani SN, Leka LS, Fine BC, Dallal GE, Keusch GT, Singh
MF, et al.Vitamin E and respiratory tract infections in elderly nursing
home residents: a randomized controlled trial. *JAMA* 2004;292(7):
828–36. [MEDLINE: 15315997]

Mezey 2004 {published data only}

Mezey E, Potter JJ, Rennie-Tankersley LS, Calabellita J, Pares A. A ran-
domized placebo controlled trial of vitamin E for alcoholic hepatitis.
*Journal of Hepatology* 2004;40:40–6.

MINVITAOX 1999 {published data only}

Gioodon F, Galan P, Monget AL, Bourrut-Rault MC, Brunet-
Lecompte P, Precioso P, et al.Impact of trace elements and vitamin sup-
plementation on immunity and infections in institutionalized elderly
patients: a randomized controlled trial. *MIN, VIT, AOX. Geri-
atric Network. Archives of Internal Medicine* 1999;159(7):748–54.
[MEDLINE: 10218756]

Mooney 2005 {published data only}

Mooney LA, Madsen AM, Tang D, Orjuela MA, Tsai WY, Gar-
duno ER, et al.Antioxidant vitamin supplementation reduces benzo
(a)pyrene-DNA adducts and potential cancer risk in female smokers.
*Cancer Epidemiology, Biomarkers & Prevention* 2005;14(1):237–42.
[MEDLINE: 15668500]

Murphy 1992 {published data only}

Murphy S, West KP Jr, Greenough WB 3rd, Cherot E, Katz J,
Clement L. Impact of vitamin A supplementation on the incidence of
infection in elderly nursing-home residents: a randomized controlled
trial. *Age and Ageing* 1992;21(6):435–9. [MEDLINE: 1471582]

NIT1 1993 {published data only}

Blot WJ, Li JY. Some considerations in the design of a Nutritional
Intervention Trial in Linxian, People’s Republic of China. *National
Cancer Institute Monograph* 1984;69:29–54.

* Blot WJ, Li JY, Taylor PR, Guo W, Dawsey S, Wang GQ, et al.Nutrition intervention trials in Linxian, China: supplementation
with specific vitamin/mineral combinations, cancer incidence, and
disease-specific mortality in the general population. *Journal of the*
National Cancer Institute* 1993;85(18):1483–92.

Blot WJ, Li JY, Taylor PR, Guo W, Dawsey SM, Li B. The Linxian
trials: mortality rates by vitamin-mineral intervention group. Amer-
ican Journal of Clinical Nutrition* 1995;62(suppl):1424s–1426s.

Li B, Taylor PR, Li JY, Dawsey SM, Wang W, Tangrea JA, et al.Linxian Nutrition Intervention Trials. Design, methods, partici-
pant characteristics, and compliance. *Annals of Epidemiology* 1993;
3(6):577–85. [MEDLINE: 7921303]

Li JY. Vitamins and minerals in cancer: The Nutrition Intervention
Trials in Linxian, China. *Medicine Biologie Environnement* 1998;26:
(2):187–209.

Mark SD, Qiao YL, Dawsey SM, Wu YP, Katki H, Gunter EW, et al.Prospective study of serum selenium levels and incident esophageal
and gastric cancers. *Journal of the National Cancer Institute* 2000;92
(21):1753–63.

Taylor PR, Li B, Dawsey SM, Li JY, Yang CS, Guo W, et al.Prevention
of esophageal cancer: the Nutrition Intervention Trials in Linxian,
China. Linxian Nutrition Intervention Trials Study Group. *Cancer
Research* 1999;54(7 Suppl):2029s–2031s.

Wang GQ, Dawsey SM, Li JY, Taylor PR, Li B, Blot WJ, et al.Effects of
vitamin/mineral supplementation on the prevalence of histological
dysplasia and early cancer of the esophagus and stomach: results from
the General Population Trial in Linxian, China. *Cancer Epidemiology,
Biomarkers & Prevention* 1999;8(2):161–6.

NIT2 1993 {published data only}

Li JY, Li B, Blot WJ. Taylor PR. Preliminary report on the results of
Nutrition Prevention Trials of cancer and other common diseases
among residents in Lintoxin, China. (Zhonghua Zhong Liu Za Zhi)
*Chinese Journal of Oncology* 1993;15(5):165–81.

* Li JY, Taylor PR, Li B, Dawsey S, Wang GQ, Ershow AG, et al.Nutrition Intervention Trials in Linxian, China: multiple vita-

Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases (Review)
mineral supplementation, cancer incidence, and disease-specific mortality among adults with esophageal dysplasia. *Journal of the National Cancer Institute* 1993;85(18):1492–8. [MEDLINE: 8360932] Mark SD, Lin SF, Li JY, Guil MH, Shen Q, Dawsey SM, et al. The effect of oral vitamin and mineral supplementation on esophageal cytology: results from the Linxian Dysplasia Trial. *International Journal of Cancer* 1994;57(2):162–6.

Taylor PR, Wang GQ, Dawsey SM, Guo W, Mark SD, Li JY, et al. Effect of nutrition Intervention on intermediate endpoints in esophageal and gastric carcinogenesis. *American Journal of Clinical Nutrition* 1995;62(Suppl):1420s–1423s.

**NPCT 1996 Low [published data only]**

* Clark LC, Combs GF Jr, Turnbull BW, Slate EH, Chalker DK, Chow J, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. *Journal of American Medical Association* 1996;276(24):1957–63.

Clark LC, Dalkin B, Krongrad A, Combs GF Jr, Turnbull BW, Slate EH, et al. Decreased incidence of prostate cancer with selenium supplementation: results of a double-blind cancer prevention trial. *British Journal of Urology* 1998;81(5):730–4. [MEDLINE: 9634050]

Combs GF, Clark LC, Turnbull BW. Reduction of cancer risk with an oral supplement of selenium. *Biomedical and Environmental Sciences* 1997;10(2–3):227–34.

Combs GF Jr. Impact of selenium and cancer-prevention findings on the nutrition-health paradigm. *Nutrition and Cancer* 2001;40(1):6–11. [MEDLINE: 11799925]

Combs GF Jr, Clark LC, Turnbull BW. Reduction of cancer mortality and incidence by selenium supplementation. *Medizinische Klinik* 1997;92(Suppl 3):42–5.

Duffield-Lillico AJ, Reid ME, Turnbull BW, Combs Jr GF, Slate EH, Fischbach LA. Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. *Cancer Epidemiology, Biomarkers & Prevention* 2002;11(7):630–9.

Redman C, Xu MJ, Peng YM, Scott JA, Payne C, Clark LC, et al. Involvement of polyamines in selenium-deficient induced apoptosis and mitotic alterations in human tumor cells. *Carcinogenesis* 1997;18(6):1195–202. [MEDLINE: 9214603]

Reid ME, Duffield-Lillico AJ, Garland L, Turnbull BW, Clark LC, Marshall JR. Selenium supplementation and lung cancer incidence: an update of the Nutritional Prevention of Cancer Trial. *Cancer Epidemiology, Biomarkers & Prevention* 2002;11(11):1285–91. [MEDLINE: 12435704]

**NSCPT 1999 Low [published data only]**

Darlington S, Williams G, Neale R, Frost C, Green A. A randomized controlled trial to assess sunscreen application and beta carotene supplementation in the prevention of solar keratoses. *Archives of Dermatology* 2003;139(4):451–5. [MEDLINE: 12707092]

Green A, Barrittutta D, Hart V, Leslie D, Marks G, Williams G, et al. The Nambour Skin Cancer and Actinic Eye Disease Prevention Trial: design and baseline characteristics of participants. *Controlled Clinical Trials* 1994;15(6):512–22. [MEDLINE: 7851112]

* Green A, Williams G, Neale R, Hart V, Leslie D, Parsons P, et al. Daily sunscreen application and betacarotene supplementation in prevention of basal-cell and squamous-cell carcinomas of the skin: a randomized controlled trial. *Lancet* 1999;354(9180):723–9. [MEDLINE: 10475183]

**Penn 1991 [published data only]**

Penn ND, Purkins L, Kelleher J, Healey RV, Mascie-Taylor BH, Belfield PW. The effect of dietary supplementation with vitamins A, C and E on cell-mediated immune function in elderly long-stay patients: a randomized controlled trial. *Age and Ageing* 1991;20(3):169–74. [MEDLINE: 1853789]

**PHS 1996 Low [published data only]**

Albert CM, Gaziano JM, Willett WC, Manson JE. Nut consumption and decreased risk of sudden cardiac death in the Physicians’ Health Study. *Archives of Internal Medicine* 2002;162(12):1382–7. [MEDLINE: 12076237]

Andronini F, Burzotta F, de Stefano F, Masieri A, Iacoviello L. The G20210A prothrombin mutation and the Physicians’ Health Study. *Circulation* 2000;101(21):E207–E208. [MEDLINE: 10831536]

Berger K, Kase CS, Buring JE. Interobserver agreement in the classification of stroke in the Physicians’ Health Study. *Stroke* 1996;27(2):238–42. [MEDLINE: 8571416]

Buring JE, Hebert P, Romero J, Kittross A, Cook N, Manson J, et al. Migraine and subsequent risk of stroke in the Physicians’ Health Study. *Archives of Neurology* 1995;52(2):129–34. [MEDLINE: 7848119]

Buring JE, Hennekens CH. Cost and efficiency in clinical trials: the U.S. Physicians’ Health Study. *Statistics in Medicine* 1990;9(1–2):29–33. [MEDLINE: 2345836]

Chan JM, Stampfer MJ, Ma J, Gann PH, Gaziano JM, Giovannucci EL. Dairy products, calcium, and prostate cancer risk in the Physicians’ Health Study. *American Journal of Clinical Nutrition* 2001;74(4):549–54. [MEDLINE: 11566656]

Christen WG, Glynn RJ, Ajani UA, Schauberg DA, Manson JE, Buring JE, et al. Baseline self-reported carotar and subsequent mortality in Physicians’ Health Study. *Archives of Internal Medicine* 1994;154(2):115–25. [MEDLINE: 10934662]

Cook NR, Le IM, Manson JE, Buring JE, Hennekens CH. Confirmation of self-reported carotar in the Physicians’ Health Study. *Ophthalmologic Epidemiology* 1994;1(2):85–91. [MEDLINE: 8799615]

Cook NR, Le IM, Manson JE, Buring JE, Hennekens CH, Effects of beta-carotene supplementation on cancer incidence by baseline characteristics in the Physicians Health Study. *Cancer Causes & Control* 2000;11(7):617–26. [MEDLINE: 10977106]

Friedel UM, Schauberg DA, Kupper TS, Muntylner J, Hennekens CH. A randomized, 12-year primary-prevention trial of beta carotene supplementation for nonmelanoma skin cancer in the Physicians’ Health Study. *Archives of Dermatology* 2000;136(2):179–84. [MEDLINE: 10677093]

Gaziano JM, Gaziano TA, Glynn RJ, Sesso HD, Ajani UA, Stampfer MJ, et al. Light-to-moderate alcohol consumption and mortality in the Physicians’ Health Study enrollment cohort. *Journal of the American College of Cardiology* 2000;35(1):96–105. [MEDLINE: 10636266]

Hennekens CH, Buring JE. Methodologic considerations in the design and conduct of randomized trials: the U.S. Physicians’ Health Study. *Controlled Clinical Trials* 1989;10(4 Suppl):1425–150S. [MEDLINE: 2605963]

* Hennekens CH, Buring JE, Manson JE, Stampfer M, Rosner B,
Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases (Review)

Cook NR, et al. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. *New England Journal of Medicine* 1996;334:1145–9.

Hennekens CH, Eberlein K. A randomized trial of aspirin and beta-carotene among U.S. physicians. *Preventive Medicine* 1985;14(2):165–8.

Jonas S. The Physician’s Health Study. A neurologist’s concern. *Archives of Neurology* 1990;47(12):1352–3. [MEDLINE: 2252454]

Lang JM, Buring JE, Rosner B, Cook N, Hennekens CH. Estimating the effect of the run-in on the power of the Physician’s Health Study. *Statistics In Medicine* 1991;10(10):1585–93. [MEDLINE: 1947514]

Lee IM, Manson JE, Ajani U, Paffenbarger RS Jr, Hennekens CH, Buring JE. Physical activity and risk of colon cancer: the Physicians’ Health Study (United States). *Cancer Causes & Control* 1997;8(4):568–74. [MEDLINE: 9242472]

Liu S, Lee IM, Ajani U, Cole SR, Buring JE, Manson JE. Intake of vegetables rich in carotenoids and risk of coronary heart disease in men: The Physicians’ Health Study. *International Journal of Epidemiology* 2001;30(1):130–5. [MEDLINE: 11171873]

Lotufo PA, Chae CU, Ajani UA, Hennekens CH, Manson JE. Male pattern baldness and coronary heart disease: the Physician’s Health Study. *Archives of Internal Medicine* 2000;160(2):165–71. [MEDLINE: 10647754]

Lotufo PA, Lee IM, Ajani UA, Hennekens CH, Manson JE. Cigarette smoking and risk of prostate cancer in the Physicians’ Health Study (United States). *International Journal of Cancer* 2000;87(1):141–4. [MEDLINE: 10861465]

Ma J, Hennekens CH, Ridker PM, Stampfer MJ. A prospective study of fibrinogen and risk of myocardial infarction in the Physicians’ Health Study. *Journal of the American College of Cardiology* 1999;33(5):1347–52. [MEDLINE: 10193737]

Morris MC, Manson JE, Rosner B, Buring JE, Willett WC, Hennekens CH. Fish consumption and cardiovascular disease in the physicians’ health study: a prospective study. *American Journal of Epidemiology* 1995;142(2):166–75. [MEDLINE: 7598116]

Perera FP, Mooney LA, Stampfer M, Phillips DH, Bell DA, Rundle A, et al. Associations between carcinogen-DNA damage, glutathione S-transferase genotypes, and risk of lung cancer in the prospective Physicians’ Health Cohort Study. *Carcinogenesis* 2002;23(10):1641–6. [MEDLINE: 12376472]

Physicians’ Health Study Research Group. Preliminary report: findings from the aspirin component of the ongoing Physicians’ Health Study. *New England Journal of Medicine* 1988;318(4):262–4.

Satterfield S, Greco PJ, Goldhaber SZ, Stampfer MJ, Swartz SL, Stein EA, et al. Biochemical markers of compliance in the Physicians’ Health Study. *American Journal of Preventive Medicine* 1990;6(5):290–4. [MEDLINE: 2268496]

Sesso HD, Gaziano JM, VanDenburgh M, Hennekens CH, Glynn RJ, Buring JE. Comparison of baseline characteristics and mortality experience of participants and nonparticipants in a randomized clinical trial: the Physicians’ Health Study. *Controlled Clinical Trials* 2002;23(6):686–702. [MEDLINE: 12505246]

Steering Committee of the Physicians’ Health Study Research Group. Final report on the aspirin component of the ongoing Physicians’ Health Study. *New England Journal of Medicine* 1989;321(3):129–35.

Strumser T, Glynn RJ, Lee IM, Christen WG, Hennekens CH. Life-time cigarette smoking and colorectal cancer incidence in the Physicians’ Health Study I. *Journal of the National Cancer Institute* 2000;92(14):1178–81. [MEDLINE: 10904092]

Tang D, Phillips DH, Stampfer M, Mooney LA, Hsu Y, Cho S, et al. Association between carcinogen-DNA adducts in white blood cells and lung cancer risk in the Physicians Health Study. *Cancer Research* 2001;61(18):6708–12. [MEDLINE: 11559540]

Viehr R. Dairy products, calcium, and prostate cancer risk in the Physicians’ Health Study. *American Journal of Clinical Nutrition* 2002;76(2):490–1. [MEDLINE: 12145029]

Pike 1995Low (published data only)

Pike J, Chandra RK. Effect of vitamin and trace element supplementation on immune indices in healthy elderly. *International Journal for Vitamin and Nutrition Research* 1995;65(2):117–21. [MEDLINE: 7591530]

PPP 2001 (published data only)

* Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project. *Lancet* 2001;357(9250):89–95. [MEDLINE: 11197445]

Elwood P, Stillings M. Antioxidant strategy for cardiovascular disease. *Lancet* 2001;357(9269):1705–6. [MEDLINE: 11548768]

Gensini GF, Conti AA. Antioxidant strategy for cardiovascular diseases. *Lancet* 2001;357(9269):1704. [MEDLINE: 11428362]

Rosser WW. Aspirin for primary prevention of cardiovascular events. *Lancet* 2002;357(9250):84–5. [MEDLINE: 11197440]

Violi F, Micheletta F, Luliano L. Antioxidant strategy for cardiovascular disease. *Lancet* 2001;357(9269):1704. [MEDLINE: 11428361]

PPS 1994Low (published data only)

Baron JA, Cole BF, Mott L, Haile R, Grau M, Church TR, et al. Neoplastic and antineoplastic effects of beta-carotene on colorectal adenoma recurrence: results of a multicentre, randomised controlled trial. *British Medical Journal* 2004;328(7437):54. [MEDLINE: 12759389]

Elwood P, Roncosi L, Wroth TH, Greenberg ER, Baron JA, et al. Antioxidant vitamins and colorectal adenoma. *New England Journal of Medicine* 1994;331(25):1720–21. [MEDLINE: 7796373]

Greenberg ER, Baron JA, Tosteson TD, Freeman DH, Beck GJ, Bond JH, et al. A clinical trial of antioxidant vitamins to prevent colorectal adenoma. Polyp Prevention Study Group. *New England Journal of Medicine* 1994;331(3):141–7. [MEDLINE: 8008027]

Prince 2003Low (published data only)

Prince MJ, Mitchison HC, Ashley D, Burke DA, Edwards N, Bramble MG, et al. Oral antioxidant supplementation for fatigue associated with primary biliary cirrhosis: results of a multicentre, randomised, placebo-controlled, cross-over trial. *Alimentary Pharmacology & Therapeutics* 2003;17(1):137–43. [MEDLINE: 12492743]

Rayman 2006Low (published data only)

Rayman M, Thompson A, Warren-Perry M, Galassini R, Carterick J, Hall E, et al. Impact of selenium on mood and quality of life: a randomized, controlled trial. *Biological Psychiatry* 2006;59(2):147–54. [MEDLINE: 16181615]
Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases (Review)

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

SCPS 1990Low [published data only]

* Chylack LT Jr, Brown NP, Bron A, Hartz M, Kopcke W, Thien U, et al. The Roche European American Cataract Trial (REACT): a randomized clinical trial to investigate the efficacy of an oral antioxidant micronutrient mixture to slow progression of age-related cataract. *Ophthalmic Epidemiology* 2002;9(1):49–80. [MEDLINE: 11815895]

Schalch W, Chylack LT. Antioxidant micronutrients and cataract. Review and comparison of the AREDS and REACT cataract studies. *Dev Ophthalmology* 2003;100(3):181–9. [MEDLINE: 12640546]

Sasazuki 2003 [published data only]

Kim MK, Sasaki S, Sasazuki S, Okubo S, Hayashi M, Tsugane S. Lack of vitamin supplement on blood pressure. *Hypertension* 2002;40(6):797–803. [MEDLINE: 12648560]

Kim MK, Sasazuki S, Okubo S, Hayashi M, Tsugane S. Long-term vitamin C supplementation has no markedly favourable effect on serum lipids in middle-aged Japanese subjects. *The British Journal of Nutrition* 2004;91(1):81–90. [MEDLINE: 14748940]

Kim MK, Sasazuki S, Sasaki S, Okubo S, Hayashi M, Tsugane S. Effect of five-year supplementation of vitamin C on serum vitamin C concentration and consumption of vegetables and fruits in middle-aged Japanese: a randomized controlled trial. *Journal of the American College of Nutrition* 2003;22(3):208–16. [MEDLINE: 12805247]

Sasaki S, Tsunobo Y, Okubo S, Hayashi M, Kakizoe T, Tsugane S. Effects of three-month oral supplementation of beta-carotene and vitamin C on serum concentrations of carotenoids and vitamins in middle-aged subjects: a pilot study for a randomized controlled trial to prevent gastric cancer in high-risk Japanese population. *Japanese Journal of Cancer Research* 2000;91(5):464–70.

* Sasazuki S, Sasaki S, Tsunobo Y, Okubo S, Hayashi M, Kakizoe T, et al. The effect of 5-year vitamin C supplementation on serum pepsinogen level and *Helicobacter pylori* infection. *Cancer Science* 2003;94(4):378–82. [MEDLINE: 12824908]

Tsunobo Y, Okubo S, Hayashi M, Kakizoe T, Tsugane S. A randomized controlled trial for chemoprevention of gastric cancer in high-risk Japanese population: study design, feasibility and protocol modification. *Japanese Journal of Cancer Research* 1997;88(4):344–9. [MEDLINE: 9197524]

Tsunogae S, Tsunobo Y, Okubo S, Hayashi M, Kakizoe T. A pilot study for a randomized controlled trial to prevent gastric cancer in high-risk Japanese population: study design and feasibility evaluation. *Japanese Journal of Cancer Research* 1996;87(7):676–9.

SCPS 1990Low [published data only]

Greenberg ER. Carotenoids, cigarette smoking, and mortality risk. *Annals of the New York Academy of Sciences* 1993;691:120–6. [MEDLINE: 8129281]

Greenberg ER, Baron JA, Karagas MR, Stukel TA, Nierenberg DW, Stevens MM, et al. Mortality associated with low plasma concentration of beta carotene and the effect of oral supplementation. *JAMA* 1996;275(9):699–703. [MEDLINE: 8594267]

Greenberg ER, Baron JA, Stevens MM, Stukel TA, Mandel JS, Spencer SK, et al. The Skin Cancer Prevention Study: design of a clinical trial of beta-carotene among persons at high risk for non-melanoma skin cancer. *Controlled Clinical Trials* 1989;10(2):153–66. [MEDLINE: 2666024]

* Greenberg ER, Baron JA, Stukel TA, Stevens MM, Mandel JS, Spencer SK, et al. A clinical trial of beta carotene to prevent basal-cell and squamous-cell cancers of the skin. The Skin Cancer Prevention Study Group. *New England Journal of Medicine* 1990;323(12):789–95. [MEDLINE: 2202901]

Meyxens FL Jr. Coming of age-the chemoprevention of cancer. *New England Journal of Medicine* 1990;323(112):825–7. [MEDLINE: 2202903]

SIT 2001 [published data only]

Gail MH, You WC, Chang YS, Zhang L, Blor WJ, Brown LM, et al. Factorial trial of three interventions to reduce the progression of precancerous gastric lesions in Shandong, China: design issues and initial data. *Controlled Clinical Trials* 1998;19(4):352–69. [MEDLINE: 9683311]

* You WC, Chang YS, Heinrich J, Ma JL, Liu WD, Zhang L, et al. An intervention trial to inhibit the progression of precancerous gastric lesions: compliance, serum micronutrients and S-allyl cystine levels, and toxicity. *European Journal of Cancer Prevention* 2001;10(5):257–63. [MEDLINE: 11432715]

SKICAP AK 1997 [published data only]

Cartmel B, Moon TE, Levine N. Effects of long-term intake of retinol on selected clinical and laboratory indexes. *American Journal of Clinical Nutrition* 1999;69(5):937–43. [MEDLINE: 10326364]

Moon TE, Levine N, Cartmel B, Bangert J, Rodney S, Schreiber M, et al. Design and recruitment for retinoid skin cancer prevention (SKICAP) trials. The Southwest Skin Cancer Prevention Study Group. *Cancer Epidemiology, Biomarkers & Prevention* 1995;4(6):661–6. [MEDLINE: 8547834]

Moon TE, Levine N, Cartmel B, Bangert JL. Retinoids in prevention of skin cancer. *Cancer Letters* 1997;114(1-2):203–5. [MEDLINE: 9103292]

* Moon TE, Levine N, Cartmel B, Bangert JL, Rodney S, Dong Q, et al. Effect of retinol in preventing squamous cell skin cancer in moderate-risk subjects: a randomized, double-blind, controlled trial. Southwest Skin Cancer Prevention Study Group. *Cancer Epidemiology, Biomarkers & Prevention* 1997;6(11):949–56. [MEDLINE: 9367069]

SPAC E 2000Low [published data only]

* Boaz M, Smetana S, Weinstein T, Matas Z, Gaifer U, Laina A, et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. *Lancet* 2000;356(9257):1213–8. [MEDLINE: 11072938]

Gazis A, Fogarty A. Vitamin E supplementation. *Lancet* 2001;357(9256):631–2. [MEDLINE: 11558503]

Violi F, Micheletta F, Iuliano L. Vitamin E supplementation. *Lancet* 2001;357(9256):632–3. [MEDLINE: 11558505]

Stovie 2001 [published data only]

Stovie Z, Nicolai A, Blagjevic D, Saicia ZS, Kocev N, Apostolski S, et al. A controlled trial of combination of methionine and antioxidants in A.I.S. patients. *Jugoslovenska Medicinska Biohemija* 2001;20(4):223–8.

SUVIMAX 2004Low [published data only]

Astorg F, Arnault N, Czernichow S, Noisette N, Galan P, Hercberg S. Dietary intakes and food sources of n-6 and n-3 PUFA in French adult men and women. *Lipids* 2004;39(6):527–35. [MEDLINE: 15554151]

Barrere X, Valeix P, Preziosi P, Beniston M, Pellerier B, Galan P, et al. Determinants of thyroid volume in healthy French adults partic-
Clinical Endocrinology 2006;52 (3):273–8. [MEDLINE: 10718824]

Bellefeuille F, Altenburg-de Assis MA, Feux B, Preziosi P, Galan P, Guy-Grand B, et al.Use of ‘light’ foods and drinks in French adults: biological, anthropometric and nutritional correlates. Journal of Human Nutrition and Dietetics 2001;14(3):191–206. [MEDLINE: 11424511]

Bertrais S, Galan P, Renault N, Zarebska M, Preziosi P, Hercberg S. Consumption of soup and nutritional intake in French adults: consequences for nutritional status. Journal of Human Nutrition and Dietetics 2001;14(2):121–8. [MEDLINE: 11330261]

Bertrais S, Polo Luque ML, Preziosi P, Feux B, Torra De Flot M, Galan P, et al.Contribution of ready-to-eat cereals to nutrition intakes in French adults and relations with corpulence. Annals of Nutrition & Metabolism 2000;44(5–6):249–55. [MEDLINE: 11146332]

Bertrais S, Preziosi P, Mennen L, Galan P, Hercberg, S, Oppert JM. Sociodemographic and geographic correlates of meeting current recommendations for physical activity in middle-aged French adults: the Supplementation en Vitamines et Minéraux Antioxydants (SU.VI.MAX) Study. American Journal of Public Health 2004;94(9): 1560–6. [MEDLINE: 15333315]

Boini S, Briançon S, Guillemin F, Galan P, Hercberg S. Impact of cancer occurrence on health-related quality of life: a longitudinal pre-post assessment. Health and Quality of Life Outcomes 2004;2(1):4. [MEDLINE: 14715085]

Buckscher E, Czernichow S, Bertrais S, Paillard F, Tichet J, Galan P, et al.Blood lipid and lipoprotein levels: relationships with educational level and region of residence in the French SU.VI.MAX study. Preventive Medicine 2005;40(6):803–11. [MEDLINE: 15850882]

Caillol J, Czernichow S, Mennen L, Bourtou-Ruault MC, Zarebska M, Franchisseur C, et al.Participation and medical follow-up in screening of colorectal cancer in France within the SU.VI.MAX study [Dépistage du cancer colorectal par test Hémoccult : taux de participation et prise en charge médicale des sujets à test positif au sein de l’étude SU.VI.MAX]. Revue d’Épidémiologie et de Santé Publique 2002;50(3):321–3. [MEDLINE: 12122348]

Chango A, Potier De Courcy G, Boisson F, Guillard JC, Barbe F, Perrin MO, et al.5,10-methylenetetrahydrofolate reductase common mutations, folate status and plasma homocysteine in healthy French adults of the Supplementation en Vitamines et Minéraux Antioxydants (SU.VI.MAX) cohort. The British Journal of Nutrition 2000; 84(6):891–6. [MEDLINE: 11772086]

Czernichow S, Bertrais S, Oppert JM, Galan P, Blacher J, Ducimetiere P, et al.Body composition and fat repartition in relation to structure and function of large arteries in middle-aged adults (the SU.VI.MAX study). International Journal of Obesity and Related Metabolic Disorders 2005;29(7):826–32. [MEDLINE: 15917850]

Czernichow S, Bertrais S, Preziosi P, Galan P, Hercberg, S, Oppert JM, et al.Indicators of abdominal adiposity in middle-aged participants of the SU.VI.MAX study: relationships with educational level, smoking status and physical inactivity. Diabetes & Metabolism 2004;30(2):153–9. [MEDLINE: 15223987]

Czernichow S, Mennen L, Bertrais S, Preziosi P, Hercberg, S, Oppert JM. Relationships between changes in weight and changes in cardiovascular risk factors in middle-aged French subjects: effect of dieting. International Journal of Obesity 2002;26(8):1138–43. [MEDLINE: 12119581]

Derumeaux H, Valeyre P, Castetbon K, Bensimon M, Bourtou-Ruault MC, Arnaud J, et al.Association of selenium with thyroid volume and echostucture in 35- to 60-year-old French adults. European Journal of Endocrinology 2003;148(3):309–15. [MEDLINE: 12611611]

Dupont N, Preziosi P, Bourtou-Ruault MC, Bertrais S, Galan P, Favier A, et al.Consequences of iron depletion on health in menstruating women. European Journal of Clinical Nutrition 2003;57(9):1169–75. [MEDLINE: 12947438]

Galan P, Arnaud MJ, Czernichow S, Delabrose AM, Preziosi P, Bertrais S, et al.Contribution of mineral waters to dietary calcium and magnesium intake in a French adult population. Journal of the American Dietetic Association 2002;102(11):1658–62. [MEDLINE: 12449291]

Galan P, Briançon S, Favier A, Bertrais S, Preziosi P, Faire H, et al.Antioxidant status and risk of cancer in the SU.VI.MAX study: is the effect of supplementation dependent on baseline levels? British Journal of Nutrition 2005;94(1):125–32. [MEDLINE: 12484233]

Galan P, Favier A, Preziosi P, Bertrais S, Arnaud N, Hercberg S. The bank of biological material in the SU.VI.MAX study [La biothèque de l’étude SU.VI.MAX]. Revue d’Épidémiologie et de Santé Publique 2003;51(1 Pt 2):147–50. [MEDLINE: 12684572]

Galan P, Preziosi P, Durlach V, Valeix P, Ribas L, Bouzid D, et al.Dietary magnesium intake in a French adult population. Magnesium Research 1997;10(4):321–8. [MEDLINE: 9513928]

Galan P, Renaud N, Aissa M, Adad HA, Rahim B, Potier De Courcy G, et al.Relationship between soup consumption, folate, beta-carotene, and vitamin C status in a French adult population. International Journal for Vitamin and Nutrition Research 2003;73(5):315–21. [MEDLINE: 14699794]

Galan P, Viteri FE, Bertrais S, Czernichow S, Faure H, Arnaud J, et al.Serum concentrations of beta-carotene, vitamins C and E, zinc and selenium are influenced by sex, age, diet, smoking status, alcohol consumption and corpulence in a general French adult population. European Journal of Clinical Nutrition 2005;59(10):1181–90. [MEDLINE: 16034362]

Galan P, Yoon HC, Preziosi P, Viteri F, Valeix P, Feux B, et al.Determining factors in the iron status of adult women in the SU.VI.MAX study. SUpplementation en Vitamines et Minéraux Antioxydants. European Journal of Clinical Nutrition 1998;52(6):583–8. [MEDLINE: 9683388]

Gauthier-Chelle K, Mennen L, Arnaud J, Rigalleau V, Hercberg S, Gin H. Comparison of the diet of self-declared diabetics with non-diabetic patients in the SU.VI.MAX study: did the diabetics modify their nutritional behavior?. Diabetes & Metabolism 2004;30(6):535–42. [MEDLINE: 15671923]

Guinot C, Latreille J, Malvy D, Preziosi P, Galan P, Hercberg S, et al.Use of multiple correspondence analysis and cluster analysis to study dietary behaviour: food consumption questionnaire in the SU.VI.MAX cohort. European Journal of Epidemiology 2001;17(6): 505–16. [MEDLINE: 11949721]

Guinot C, Malvy DJ, Latreille J, Ezedine K, Galan P, Tennenhaus M, et al.Sun-reactive skin type in 4912 French adults participating in the SU.VI.MAX study paragraph sign. Photochemistry and Photobiology 2005;81(4):394–40. [MEDLINE: 15850423]

Hercberg S. Antioxidant micronutrients and chronic degenerative pathology: the role of complementary nutritional doses. Bulletin et
Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases (Review)
Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases (Review)

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases (Review)
level. *British Journal of Cancer* 2002; 86:698–701.

Lee I-M, Cook NR, Manson JE, Buring JE, Hennekens CH. Randomised beta-carotene supplementation and incidence of cancer and cardiovascular disease in women: the Women’s Health Study. *Journal of the National Cancer Institute* 1999; 91:2102–6. [MEDLINE: 11875728]

Liu S, Manson JE, Lee I-M, Cole SR, Hennekens CH, Willett WC, et al. Fruit and vegetable intake and risk of cardiovascular disease: the Women’s Health Study. *American Journal of Clinical Nutrition* 2000; 72(4):922–8. [MEDLINE: 11010932]

Rexrode KM, Lee I-M, Cook NR, Manson JE, Buring JE. Baseline characteristics of participants in the Women’s Health Study. *Journal of Women’s Health and Gender Based Medicine* 2000; 9(1): 19–27. [MEDLINE: 10718501]

Ridker PM, Cook NR, Lee I-M, Gordon D, Gazziano JM, Manson JE, et al. A randomized, dose–response trial of vitamin E in the primary prevention of cardiovascular disease in women. *New England Journal of Medicine* 2005; 352(13):1293–304. [MEDLINE: 15753114]

Witte 2005;*low* published data only

Witte KK, Nikitin NP, Parker AC, von Haehling S, Volk HD, Anker SD, et al. The effect of micronutrient supplementation on quality-of-life and left ventricular function in elderly patients with chronic heart failure. *European Heart Journal* 2005; 26(21):2238–44. [MEDLINE: 16081469]

Wluka 2002;*low* published data only

Wluka AE, Stuckey S, Brand C, Cicuttini FM. Abstract Supplementation of vitamin E does not affect the loss of carotid volume in knee osteoarthritis: a 2-year double blind randomized placebo controlled study. *The Journal of Rheumatology* 2002; 29(12):2585–91. [MEDLINE: 12465157]

References to studies excluded from this review

Abbey 1993;*published data only*

Abbey M, Nestel PJ, Baghurst PA. Antioxidant vitamins and low-density-lipoprotein oxidation. *American Journal of Clinical Nutrition* 1993; 58:525–32.

Adler 1993;*published data only*

Adler LA, Peelor E, Retrosen J, Duncan E, Lee M, Rosenthal M, et al. Vitamin E treatment of tardive dyskinesia. *American Journal of Psychiatry* 1993; 150:1405–7.

Aghdassi 1999;*published data only*

Aghdassi E, Royall D, Allard JP. Oxidative stress in smokers supplemented with vitamin C. *International Journal for Vitamin and Nutrition Research* 1999; 69:45–51.

Aghdassi 2003;*published data only*

Aghdassi E, Wendland BE, Steinhart AH, Wolman SL, Jeejeebhoy K, Allard JP. Antioxidant vitamin supplementation in Crohn’s disease decreases oxidative stress. A randomized controlled trial. *American Journal of Gastroenterology* 2003; 98(2):348–53. [MEDLINE: 12591053]

Aguiolo 2004;*published data only*

Aguiolo A, Tauler P, Fuentespina E, Villa G, Cordova A, Tur JA, et al. Antioxidant diet supplementation influences blood iron status in endurance athletes. *International Journal of Sport Nutrition and Exercise Metabolism* 2004; 14:147–60.

Akova 2001;*published data only*

Akova B, Sarmen-Gur E, Gur H, Dirican M, Sarandol E, Kucukoglu S. Exercise-induced oxidative stress and muscle performance in healthy women: role of vitamin E supplementation and endogenous oestrodial. *European Journal of Applied Physiology* 2001; 84:141–7.

Al-Taei 2003;*published data only*

Al-Taei OH, Seufert J, Karvar S, Adolph C, Mork H, Scheurlem M, et al. Selenium supplementation enhances low selenium levels and stimulates glutathione peroxidase activity in peripheral blood and distal colon mucosa in past and present carriers of colon adenomas. *Nutrition and Cancer* 2003; 46:125–30.

Albanes 1992;*published data only*

Albanes D, Virtamo J, Rautalhti M, Haudka J, Palmgren J, Gref CG, et al. Serum beta-carotene before and after beta-carotene supplementation. *European Journal of Clinical Nutrition* 1992; 46:15–24.

Albers 2004;*published data only*

Albers D, Ranger-Moore J, Einspahr J, Saboda K, Bozzo P, Liu Y, et al. Safety and efficacy of dose-intensive oral vitamin A in subjects with sun-damaged skin. *Clinical Cancer Research* 2004; 10(6):1875–80. [MEDLINE: 15041701]

Allard 1994;*published data only*

Allard JP, Royall D, Kurian R, Muggli R, Jeejeebhoy KN. Effects of beta-carotene supplementation on lipid peroxidation in humans. *American Journal of Clinical Nutrition* 1994; 59:884–90.

Allard 1997;*published data only*

Allard JP, Kurian R, Aghdassi E, Muggli R, Royall D. Lipid peroxidation during n-3 fatty acid and vitamin E supplementation in humans. *Lipids* 1997; 32:535–41.

Anah 1980;*published data only*

Anah CO, Jarike LN, Baig HA. High dose ascorbic acid in Nigerian asthmatics. *Tropical and Geographical Medicine* 1980; 32:132–7.

Anderson 1994;*published data only*

Anderson TW, Reid DB. A double-blind trial of vitamin E in angina pectoris. *American Journal of Clinical Nutrition* 1974; 27(10):1174–8. [MEDLINE: 4214473]

Anderson 1975;*published data only*

Anderson TW, Beaton GH, Corry P, Spero L. Winter illness and vitamin C: the effect of relatively low doses. *Canadian Medical Association Journal* 1975; 112:823–6.

Anderson 1997;*published data only*

Anderson D, Phillips BJ, Yu TW, Edwards AJ, Ayesh R, Butterworth KR. The effects of vitamin C supplementation on biomarkers of oxygen radical generated damage in human volunteers with “low” or “high” cholesterol levels. *Environmental and Molecular Mutagenesis* 1997; 30:161–74.

Anderson 1999;*published data only*

Anderson JW, Gowri MS, Turner J, Nichols L, Dwojakar VA, Chow CK, et al. Antioxidant supplementation effects on low-density lipoprotein oxidation for individuals with type 2 diabetes mellitus. *Journal of the American College of Nutrition* 1999; 18:451–61.

Andreone 2001;*published data only*

Andreone P, Fiorino S, Carsaro C, Gramenzi A, Margotti M, Di Giammarino L, et al. Vitamin E as treatment for chronic hepatitis...
Angstwurm 1999 [published data only]
Angstwurm MW, Schottdorf J, Schopohl J, Gaertner R. Selenium replacement in patients with severe systemic inflammatory response syndrome improves clinical outcome. *Critical Care Medicine* 1999; 27(9):1807–13. [MEDLINE: 10507602]

Arad 2005 [published data only]
Arad Y, Newstein D, Roth M, Guerci AD. Rationale and design of the St. Francis Heart Study: a randomized clinical trial of atorvastatin plus antioxidants in asymptomatic persons with elevated coronary calcification. *Controlled Clinical Trials* 2001;22(5):553–72. [MEDLINE: 11578788]

Astley 1999 [published data only]
Astley S, Langrish-Smith A, Souton S, Sampson M. Vitamin E supplementation and oxidative damage to DNA and plasma LDL in type 1 diabetes. *Diabetes Care* 1999;22:1626–31.

Avery 2003 [published data only]
Avery NG, Kaiser JL, Sharman MJ, Schertz TP, Barnes DM, Gomez AL, et al. Effects of vitamin E supplementation on recovery from repeated bouts of resistance exercise. *Journal of Strength and Conditioning Research / National Strength & Conditioning Association* 2003;17:801–9.

Bacic Vrca 2004 [published data only]
Bacic Vrca V, Cepelak I, Mayer L. Supplementation with antioxidants in the treatment of Graves' disease: the effect on the extracellular antioxidative parameters. *Acta Pharmacologica* 2004;54:79–89.

Baumann 1999 [published data only]
Baumann D, Henrotin KG. Effect of sodium selenite and vitamin E treatment in myotonic dystrophy. *Journal of Internal Medicine* 1990; 228(6):577–81. [MEDLINE: 2177668]

Barany 2001 [published data only]
Barany P, Stevink T, Ottosson-Seegerber A, Alvestrand A, Morrow J, Roberts JJ 2nd, et al. Effect of 6 weeks of vitamin E administration on renal haemodynamic alterations following a single dose of neoral in healthy volunteers. *Nephrology Dialysis, Transplantation* 2001;16:580–4.

Barbagallo 1999 [published data only]
Barbagallo M, Dominguez IJ, Tagliamonte MR, Renwick LM, Paulido G. Effects of vitamin E and glutathione on glucose metabolism: role of magnesium. *Hypertension* 1999;34:1002–6.

Barbarich 2004 [published data only]
Barbarich NC, McConaha CW, Halmi KA, Gentell K, Sunday SR, Gaskill J, et al. Use of nutritional supplements to increase the efficacy of fluoxetine in the treatment of anorexia nervosa. *The International Journal of Eating Disorders* 2004;35:10–5.

Barringer 2003 [published data only]
Barringer TA, Kirk JK, Santaniello AC, Foley KL, Michielute R. Effect of a multivitamin and mineral supplement on infection and quality of life. A randomized, double-blind, placebo-controlled trial. *Annals of Internal Medicine* 2003;138(5):365–71. [MEDLINE: 12614088]

Bansayake 1983 [published data only]
Bansayake S, de Silva SV, Miller PC, Rogers S. A comparison of Norinyl and Breviscon in three sites in Sri Lanka. *Contraception* 1983;27:453–64.

Bassenge 1998 [published data only]
Bassenge E, Fink N, Skachkov M, Fink B. Dietary supplement with vitamin C prevents nitrate tolerance. *The Journal of Clinical Investigation* 1998;102:67–71.

Bates 1998 [published data only]
Bates CJ, Walmsey CM, Prentice A, Finch S. Does vitamin C reduce blood pressure? Results of a large study of people aged 65 or older. *Journal of Hypertension* 1998;16(7):925–32. [MEDLINE: 9794732]

Beaton 2002 [published data only]
Beaton LJ, Allan DA, Tarnopolsky MA, Creager MA. Oral antioxidant therapy improves endothelial function in type 1 but not type 2 diabetes mellitus. *American Journal of Physiology. Heart and Circulatory Physiology* 2003;285:H2392–H2398.

Beckman 2003 [published data only]
Beckman JA, Goldfine AB, Gordon MB, Garrett LA, Keaney JF Jr, Creager MA. Oral antioxidant therapy improves endothelial function in type 1 but not type 2 diabetes mellitus. *American Journal of Physiology. Heart and Circulatory Physiology* 2003;285:H2392–H2398.

Benton 1991 [published data only]
Benton D, Cook R. Selenium supplementation improves mood in a double-blind crossover trial. *Psychopharmacology* 1990;102(4):549–50.

Berger 1998 [published data only]
Berger MM, Spertini F, Shenkin A, Wardle C, Wiesner L, Schindler C, et al. Trace element supplementation modulates pulmonary infection rates after major burns: a double-blind, placebo-controlled trial. *American Journal of Clinical Nutrition* 1998;68(2):365–71. [MEDLINE: 9701195]

Bernard 2003 [published data only]
Bernard D, Christophe A, Delanghe J, Langlois M, De Buyzere M, Comhaire F. The effect of supplementation with an antioxidant preparation on LDL-oxidation is determined by haptoglobin polymorphism. *Redox Report: Communications in Free Radical Research* 2003;8:41–6.
Butcher 1989  [published data only]  
Butcher C, Rolla G, Carta E, Arossa W, Bugiani M. Effects of vitamin C on airway responsiveness to inhaled histamine in heavy smokers. *The European Respiratory Journal* 1989;2:229–33.

Butch 1999  [published data only]  
Buchman AL, Killip D, Ou CN, Rognered CL, Pownall H, Dennis K, et al. Short-term vitamin E supplementation before marathon running: a placebo-controlled trial. *Nutrition* 1999;15:278–85.

Bugianesi 2005  [published data only]  
Bugianesi E, Gentilcore E, Manini R, Natale S, Vanni E, Villanova N, et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. *American Journal of Gastroenterology* 2005;100(5):1082–90. [MEDLINE: 15842582]

Bukin 1997  [published data only]  
Bukin YV, Zanidze DG, Draudin-Krylenko VA, Orlov EN, Kuvshinov YP, Podubny BK, Vorobyeva OV, et al. Effect of prolonged beta-carotene or DL-alpha-tocopheryl acetate supplementation on ornithine decarboxylase activity in stomach mucosa of patients with chronic atrophic gastritis. *European Journal of Cancer Prevention* 1995;2(1):61–8. [MEDLINE: 8428179]

Bukin 1995  [published data only]  
Bukin YV, Draudin-Krylenko VA, Orlov EN, Kuvshinov YP, Podubny BK, Vorobyeva OV, et al. Effect of beta-carotene supplementation on the activity of ornithine decarboxylase (ODC) in stomach mucosa of patients with chronic atrophic gastritis. *European Journal of Cancer Prevention* 1995;2(1):61–8. [MEDLINE: 8428179]

Bukin 1995  [published data only]  
Bukin YV, Draudin-Krylenko VA, Orlov EN, Kuvshinov YP, Podubny BK, Shahanova MA. Decrease of ornithine decarboxylase activity in pre-malignant gastric mucosa and regression of small intestinal metaplasia in patients supplemented with high doses of vitamin E. *Cancer Epidemiology, Biomarkers & Prevention* 1997;6:365–70.

Bukin 1997  [published data only]  
Bukin YV, Draudin-Krylenko VA, Kuvushin YP, Podubnii BK, Shahanov MA. Decrease of ornithine decarboxylase activity in pre-malignant gastric mucosa and regression of small intestinal metaplasia in patients supplemented with high doses of vitamin E. *Cancer Epidemiology, Biomarkers & Prevention* 1997;6:543–6.

Bunker 1994  [published data only]  
Bunker VW, Stansfield MF, Peacon-Smith R, Marzil RA, Hounslow A, Clayton BE. Dietary supplementation and immunocompetence in housebound elderly subjects. *British Journal of Biomedical Science* 1994;51(2):128–35. [MEDLINE: 8049610]

Bunout 2000  [published data only]  
Bunout D, Garrido A, Suazo M, Kauffman R, Venegas P, de la Maza P, et al. Effects of supplementation with folic acid and antioxidant vitamins on homocysteine levels and LDL oxidation in coronary patients. *Nutrition* 2000;16:107–10.

Bursell 1999  [published data only]  
Bursell SE, Clermont AC, Aiello LP, Aiello LM, Schlossman DK, Feener EP, et al. High-dose vitamin E supplementation normalizes retinal blood flow and creatinine clearance in patients with type 1 diabetes. *Diabetes Care* 1999;22:1245–51.

Bussey 1982  [published data only]  
* Bussey HJ, DeCosse JJ, Deschner EE, Eyers AA, Lesser ML, Morson BC, et al. A randomized trial of ascorbic acid in polypsis coli. *Cancer* 1982;50(7):1434–9. [MEDLINE: 7049351]

DeCosse JJ, Adams MB, Kuzma JF, LeGerto P, Condon RE. Effect of ascorbic acid on rectal polyps of patients with familial polyposis. *Surgery* 1975;78(5):608–12.

Butcher 1993  [published data only]  
Butcher GP, Rhodes JM, Walker R, Kramer N, Jackson MJ. The effect of antioxidant supplementation on a serum marker of free radical activity and abnormal serum biochemistry in alcoholic patients admitted for detoxification. *Journal of Hepatology* 1993;19:105–9.

Caderes 1996  [published data only]  
Cadenas S, Rojas C, Mendez J, Herrero A, Barja G. Vitamin E decreases urine lipid peroxidation products in young healthy human volunteers under normal conditions. *Pharmacology & Toxicology* 1996;79:247–53.

Cafolla 2002  [published data only]  
Cafolla A, Dragoni F, Girelli G, Tosti ME, Costante A, De Luca AM, et al. Effect of folic acid and vitamin C supplementation on folate status and homocysteine level: a randomised controlled trial in Italian smoker-blood donors. *Atherosclerosis* 2002;163:105–11.

Calabrese 1987  [published data only]  
Calabrese EJ, Stoddard A, Leonard DA, Dinardi SR. The effects of vitamin C supplementation on blood and hair levels of cadmium, lead, and mercury. *Annals of the New York Academy of Sciences* 1987;498:547–55.

Calzada 1997  [published data only]  
Calzada A, Bruckdorfer KR, Rice-Evans CA. The influence of antioxidant nutrients on platter function in healthy volunteers. *Atherosclerosis* 1997;128:97–105.

Candan 1997  [published data only]  
Candan F, Guhrken F, Candan F. Effect of vitamin C and zinc on osmotic fragility and lipid peroxidation in zinc-deficient haemodialysis patients. *Cell Biochemistry and Function* 2002;20:95–8.

Carpenter 2003  [published data only]  
Carpenter KL, Kirkpatrick PJ, Weissberg PL, Challs IR, Dennis IF, Freeman MA, et al. Oral alpha-tocopherol supplementation inhibits lipid oxidation in established human atherosclerotic lesions. *Free Radical Research* 2003;37:1235–44.

Carty 2000  [published data only]  
Carty JL, Bevan R, Waller H, Mistry N, Cooke M, Lunej J, et al. The effects of vitamin C supplementation on protein oxidation in healthy volunteers. *Biochemical and Biophysical Research Communications* 2000;273:729–35.

Cases 2005  [published data only]  
Cases N, Aguilo A, Tauler P, Sureda A, Llompart I, Pons A, et al. Differential response of plasma and immune cells' vitamin E levels to physical activity and antioxidant vitamin supplementation. *European Journal of Clinical Nutrition* 2005;59:781–8.

Ceriello 1991  [published data only]  
Ceriello A, Guigliano D, Quattraro A, Donzella C, Dipalo G, Lefebvre PJ. Vitamin E reduction of protein glycosylation in diabetes. New prospect for prevention of diabetic complications? *Diabetes Care* 1991;14:68–72.

Chan 2005  [published data only]  
Chan D, Irish A, Dogra G. Efficacy and safety of oral versus intravenous ascorbic acid for anaemia in haemodialysis patients. *Nephrology* 2005;10:336–40.

Chandra 2001  [published data only]  
Chandra RK. Effect of vitamin and trace-element supplementation on cognitive function in elderly subjects. *Nutrition* 2001;17(9):709–12. [MEDLINE: 11527656]
Chandra 2002  [published data only]
Chandra RK. Influence of multinutrient supplement on immune responses and infection-related illness in 50–65 year old individuals. Nutrition Research 2002;22:5–11.

Chavance 1993  [published data only]
Chavance M, Herbeih B, Lemoine A, Zhu BP. Does multivitamin supplementation prevent infections in healthy elderly subjects? A controlled trial. International Journal for Vitamin and Nutrition Research 1993;63(1):11–6. [MEDLINE: 8320052]

Chesney 2000  [published data only]
* Chesney CM, Elam MB, Herd JA, Davis KB, Garg R, Hunninghake D, et al. Effect of niacin, warfarin, and antioxidant therapy on coagulation parameters in patients with peripheral arterial disease in the Arterial Disease Multiple Intervention Trial (ADMIT), American Heart Journal 2000;140(4):631–6. [MEDLINE: 11011338]
Egan DA, Garg R, Wilt TJ, Pettinger MB, Davis KB, Crouse J, et al. Rationale and design of the Arterial Disease Multiple Intervention Trial (ADMIT) pilot study. American Journal of Cardiology 1999;83(4):569–75. [MEDLINE: 10073863]
Elam MB, Hunninghake DB, Davis KB, Garg R, Johnson C, Egan D, et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study. A randomized trial. Arterial Disease Multiple Intervention Trial, JAMA 2000;284(10):1265–70. [MEDLINE: 10979113]
Garg R, Elam MB, Crouse JR 3rd, Davis KB, Kennedy JW, Egan D, et al. Effective and safe modification of multiple atherosclerotic risk factors in patients with peripheral arterial disease. American Heart Journal 2000;140(5):792–803. [MEDLINE: 11054628]

Cheung 2001  [published data only]
Cheung MC, Zhao XQ, Chait A, Albers JJ, Brown BG. Antioxidant supplements block the response of HDL to simvastatin-niacin therapy in patients with coronary artery disease and low HDL, Arteriosclerosis, Thrombosis, and Vascular Biology 2001;21:1320–6.

Chuang 2002  [published data only]
Chuang CH, Sheu BS, Huang AH, Yang HB, Wu JJ, Vitamin C and E supplements to lansoprazole-amoxicillin-metronidazole triple therapy may reduce the eradication rate of metronidazole-susceptible Helicobacter pylori infection. Helicobacter 2002;7:310–6.

Clarke 2003  [published data only]
Clarke R, Harrison G, Richards S. Vital Trial Collaborative Group. Effect of vitamins and aspirin on markers of platelet activation, oxidative stress and homocysteine in people at high risk of dementia. Journal of Internal Medicine 2003;254:67–75.

Clausen 1989  [published data only]
Clausen J, Nielsen SA, Kristensen M. Biochemical and clinical effects of an antioxidative supplementation of geriatric patients. A double blind study. Biological Trace Element Research 1989;20(1–2):135–51. [MEDLINE: 2484393]

Colette 1988  [published data only]
Colette C, Pares-Herbute N, Monnier LH, Cartry E. Platelet function in type 1 diabetes: effects of supplementation with large doses of vitamin E. American Journal of Clinical Nutrition 1988;47:256–61.

Corridan 2001  [published data only]
Corridan BM, O’Donoghue M, Hughes DA, Morrissey PA. Low-dose supplementation with lycopene or beta-carotene does not enhance cell-mediated immunity in healthy free-living elderly humans. European Journal of Clinical Nutrition 2001;55:627–35.

Cox 1975  [published data only]
Cox BD, Butterfield WJ. Vitamin C supplements and diabetic cutaneous capillary fragility. British Medical Journal 1975;3:205.

Crary 1987  [published data only]
Crary EJ. Antioxidant treatment of macular degeneration of the aging and macular edema in diabetic retinopathy. Southern Medical Journal 1987;80(9):38.

Crimi 2004  [published data only]
Crimi E, Liguori A, Condorelli M, Cioffi M, Astuto M, Bontempo P, et al. The beneficial effects of antioxidant supplementation in enteral feeding in critically ill patients: a prospective, randomized, double-blind, placebo-controlled trial. Anesthesia and Analgesia 2004;99(3):857–63. [MEDLINE: 15533422]

Crogan 2005  [published data only]
Crogan NL, Vélasquez D, Gagan MJ. Testing the feasibility and initial effects of iron and vitamin C to enhance nursing home residents’ immune status following an influenza vaccine. Geriatric Nursing 2005;26:188–94.

Dahiri 1994  [published data only]
Dahiri LM, Pasta D, Darby JK, Mosbacher D. Effectiveness of vitamin E for treatment of long-term tardive dyskinesia. American Journal of Psychiatry 1994;151:925–6.

Daga 2003  [published data only]
Daga MK, Chhabra R, Sharma B, Mishra TK. Effects of exogenous vitamin E supplementation on the levels of oxidants and antioxidants in chronic obstructive pulmonary disease. Journal of Biosciences 2003;28:7–11.

Dakhale 2005  [published data only]
Dakhale GN, Khanzode SD, Khanzode SS, Saoji A. Supplementation of vitamin C with atypical antipsychotics reduces oxidative stress and improves the outcome of schizophrenia. Psychopharmacology 2005;182:494–8.

Darko 2002  [published data only]
Darko D, Dornhorst A, Kelly FJ, Ritter JM, Chowienczyk PJ. Lack of effect of oral vitamin C on blood pressure, oxidative stress and endothelial function in type II diabetes. Clinical Science 2002;103:349–44.

Davison 2005  [published data only]
Davison GW, Hughes CM, Bell RA. Exercise and mononuclear cell DNA damage: the effects of antioxidant supplementation. International Journal of Sport Nutrition and Exercise Metabolism 2005;15:480–92.

Dawson 1999  [published data only]
Dawson EB, Evans DR, Harris WA, McGanity WJ. The effect of ascorbic acid supplementation on the nicotine metabolism of smokers. Preventive Medicine 1999;29:451–4.

De las Heras 2000  [published data only]
De las Heras Castano G, Garcia de la Paz A, Fernandez MD, Fernandez Forcelledo JL. Use of antioxidants to treat pain in chronic pancreatitis [Utilizacion de antioxidantes en el tratamiento del dolor de la pancreatitis cronica]. Revista Española de Enfermedades Digestivas 2000;92(6):375–80. [MEDLINE: 10985097]

Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases (Review)
Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases (Review)

Duffy SJ, Goke C, Holbrook M, Huang A, Frei B, Keaney JF Jr, et al. Treatment of hypertension with ascorbic acid. *Lancet* 1999;354:2048–9.

Duffy 2001 [published data only] Duffy SJ, O’Brien RC, New G, Harper RW, Meredith IT. Effect of anti-oxidant treatment and cholesterol lowering on resting arterial tone, metabolic vasodilation and endothelial function in the human forearm: a randomized, placebo-controlled study. *Clinical and Experimental Pharmacology & Physiology* 2001;28:409–18.

Dutschie 1996 [published data only] Dutschie SJ, Ma A, Ross MA, Collins AR. Antioxidant supplementation decreases oxidative DNA damage in human lymphocytes. *Cancer Research* 1996;56:1291–5.

Economides 2005 [published data only] Economides PA, Khaothirai L, Caselli A, Caballero AE, Keenan H, Bursell SE, et al. The effect of vitamin E on endothelial function of micro- and macrocirculation and left ventricular function in type 1 and type 2 diabetic patients. *Diabetes* 2005;54:204–11.

Edmonds 1997 [published data only] Edmonds SE, Winyard PG, Guo R, Kidd B, Merry P, Langrish-Smith A, et al. Putative analgesic activity of repeated oral doses of vitamin E in the treatment of rheumatoid arthritis. Results of a prospective placebo controlled double blind trial. *Annals of the Rheumatic Diseases* 1997;56(11):649–55. [MEDLINE: 9462166]

Egan 1992 [published data only] Egan MF, Hyde TM, Albers GW, Elkashef A, Alexander RC, Reeve A, et al. Treatment of tardive dyskinesia with vitamin E. The *American Journal of Psychiatry* 1992;149:773–7.

Eisele 2001 [published data only] Eisele J, Racek J, Treff L, Opatrný K Jr. Effects of a vitamin E-modified dialysis membrane and vitamin C infusion on oxidative stress in hemodialysis patients. *Artificial Organs* 2001;25:430–6.

El-Bayomy 2002 [published data only] El-Bayomy K, Richette JP, Boyini T, Konminou D, Prokopczyk B, Trushin N, et al. Influence of selenium-enriched yeast supplementation on biomarkers of oxidative damage and hormone status in healthy adult males: a clinical pilot study. *Cancer Epidemiology, Biomarkers & Prevention* 2002;11:1459–65.

Dietrich 2003 [published data only] Dietrich M, Block G, Benowitz NL, Morrow JD, Hudes M, Jacob P 3rd, et al. Vitamin C supplementation decreases oxidative stress biomarker F(2)-isoprostanes in plasma of nonsmokers exposed to environmental tobacco smoke. *Nutrition and Cancer* 2003;45:376–84.

Dorfman-Etrog 1999 [published data only] Dorfman-Etrog P, Hermesh H, Pilipko L, Weizman A, Muniz H. The effect of vitamin E addition to acute neuroleptic treatment on the emergence of extrapyramidal side effects in schizophrenic patients: an open label study. *European Neuropsychopharmacology* 1999;9:475–7.

Duffy 1999 [published data only] Duffy SJ, Goke C, Holbrook M, Huang A, Frei B, Keaney JF Jr, et al. Treatment of hypertension with ascorbic acid. *Lancet* 1999;354:2048–9.

Duffy 2001 [published data only] Duffy SJ, O’Brien RC, New G, Harper RW, Meredith IT. Effect of anti-oxidant treatment and cholesterol lowering on resting arterial tone, metabolic vasodilation and endothelial function in the human forearm: a randomized, placebo-controlled study. *Clinical and Experimental Pharmacology & Physiology* 2001;28:409–18.

Dutschie 1996 [published data only] Dutschie SJ, Ma A, Ross MA, Collins AR. Antioxidant supplementation decreases oxidative DNA damage in human lymphocytes. *Cancer Research* 1996;56:1291–5.

Earnest 2003 [published data only] Earnest CP, Wood KA, Church TS. Complex multivitamin supplementation improves homocysteine and resistance to LDL-C oxidation. *Journal of the American College of Nutrition* 2003;22:400–7.

Economides 2005 [published data only] Economides PA, Khaothirai L, Caselli A, Caballero AE, Keenan H, Bursell SE, et al. The effect of vitamin E on endothelial function of micro- and macrocirculation and left ventricular function in type 1 and type 2 diabetic patients. *Diabetes* 2005;54:204–11.

Edmonds 1997 [published data only] Edmonds SE, Winyard PG, Guo R, Kidd B, Merry P, Langrish-Smith A, et al. Putative analgesic activity of repeated oral doses of vitamin E in the treatment of rheumatoid arthritis. Results of a prospective placebo controlled double blind trial. *Annals of the Rheumatic Diseases* 1997;56(11):649–55. [MEDLINE: 9462166]

Egan 1992 [published data only] Egan MF, Hyde TM, Albers GW, Elkashef A, Alexander RC, Reeve A, et al. Treatment of tardive dyskinesia with vitamin E. *The American Journal of Psychiatry* 1992;149:773–7.

Eisele 2001 [published data only] Eisele J, Racek J, Treff L, Opatrný K Jr. Effects of a vitamin E-modified dialysis membrane and vitamin C infusion on oxidative stress in hemodialysis patients. *Artificial Organs* 2001;25:430–6.

El-Bayomy 2002 [published data only] El-Bayomy K, Richette JP, Boyini T, Konminou D, Prokopczyk B, Trushin N, et al. Influence of selenium-enriched yeast supplementation on biomarkers of oxidative damage and hormone status in healthy adult males: a clinical pilot study. *Cancer Epidemiology, Biomarkers & Prevention* 2002;11:1459–65.
Elkashef 1990  [published data only]
Elkashef AM, Ruskin PE, Bacher N, Barrett D. Vitamin E in the treatment of tardive dyskinesia. *American Journal of Psychiatry* 1990; 147:505–6.

Ernster 1985  [published data only]
Ernster VL, Goodson WH 3rd, Hunt TK, Petrakis NL, Sickles EA, Miki R, et al. Vitamin E and benign breast "disease": a double-blind, randomized clinical trial. *Surgery* 1985;97(4):490–4. [MEDLINE: 3885456]

Everett 2002  [published data only]
Everett SM, Drake IM, White KL, Mapstone NP, Chalmers DM, Schohar CJ, et al. Antioxidant vitamin supplements do not reduce reactive oxygen species activity in Helicobacter pylori gastritis in the short term. *British Journal of Nutrition* 2002;87:3–11.

Fairley 1996  [published data only]
Fairley CK, Tabrizi SN, Chen S, Baghurst P, Young H, Quinn M, et al. A randomised clinical trial of beta carotene versus placebo for the treatment of cervical HPV infection. *International Journal of Gynaecol Cancer* 1996;6:225–30.

Fairris 1989  [published data only]
Fairris GM, Lloyd B, Hinks L, Perkins PJ, Clayton BE. The effect of supplementation with selenium and vitamin E in psoriasis. *Annals of Clinical Biochemistry* 1989;26(Pt 1):83–8. [MEDLINE: 2735752]

Falsini 2003  [published data only]
Falsini B, Piccardi M, Iarossi G, Fadda A, Merendino E, Valentini P. Influence of short-term antioxidant supplementation on macular function in age-related maculopathy: a pilot study including electrophysiologic assessment. *Ophthalmology* 2003;110(1):51–60. [MEDLINE: 12511345]

Fang 2002  [published data only]
Fang JC, Kinlay S, Beltrame J, Hikiti H, Wainstein M, Behrendt D, et al. Effect of vitamins C and E on progression of transplant-associated arteriosclerosis: a randomised trial. *Lancet* 2002;359(9312):1108–13. [MEDLINE: 11943259]

Farvid 2005  [published data only]
Farvid MS, Jalali M, Sissai F, Hosseini M. Comparison of the effects of vitamins and/or mineral supplementation on glomerular and tubular dysfunction in type 2 diabetes. *Diabetes Care* 2005;28(10):2458–64. [MEDLINE: 16186280]

Faure 2004  [published data only]
Faure P, Ramon O, Favier A, Halimi S. Selenium supplementation decreases nuclear factor-kappa B activity in peripheral blood mononuclear cells from type 2 diabetic patients. *European Journal of Clinical Investigation* 2004;34:475–81.

Fawzi 2004  [published data only]
Fawzi WW, Maamanga GJ, Spiegelman D, Wei R, Kapiga S, Villamor E, et al. A randomized trial of multivitamin supplements and HIV disease progression and mortality. *New England Journal of Medicine* 2004;351(1):23–32. [MEDLINE: 15229304]

Fenech 1997  [published data only]
Fenech M, Dresti I, Aitken C. Vitamin-E supplements and their effect on vitamin-E status in blood and genetic damage rate in peripheral blood lymphocytes. *Carcinogenesis* 1997;18:359–64.

Finley 1998  [published data only]
Finley JW, Penland JG. Adequacy or deprivation of dietary selenium in healthy men: clinical or psychological findings. *Selenium in Healthy Men: Clinical and Ps. The Journal of Trace Elements in Experimental Medicine* 1998;11:1–27.

Fischer 2004  [published data only]
Fischer CP, Hiscock NJ, Penkowa M, Basu S, Vesby B, Kallner A, et al. Supplementation with vitamins C and E inhibits the release of interleukin-6 from contracting human skeletal muscle. *The Journal of Physiology* 2004;558:633–45.

Florencio 1981  [published data only]
Florencio CA. Effects of iron and ascorbic acid supplementation on hemoglobin level and work efficiency of anemic women. *Journal of Occupational Medicine* 1981;23:699–704.

Fogarty 2003  [published data only]
Fogarty A, Lewis SA, Scrivener SL, Antoniak M, Pacey S, Pringle M, et al. Oral magnesium and vitamin C supplements in asthma: a parallel group randomized placebo-controlled trial. *Clinical and Experimental Allergy* 2003;33(10):1355–9. [MEDLINE: 14519140]

Fortes 1998  [published data only]
Fortes C, Forastiere F, Agabiti N, Fano V, Pacifici R, Virgili F, et al. The effect of zinc and vitamin A supplementation on immune response in an older population. *Journal of the American Geriatrics Society* 1998;46:19–26.

Fotherby 2000  [published data only]
Fotherby MD, Williams JC, Forster LA, Craner P, Ferns GA. Effect of vitamin C on ambulatory blood pressure and plasma lipids in older persons. *Journal of Hypertension* 2000;18:411–5.

Frank 2004  [published data only]
Frank DH, Roe DJ, Chow HH, Guillen JM, Choquette K, Gracie D, et al. Effects of a high-selenium yeast supplement on celecoxib plasma levels: a randomized phase II trial. *Cancer Epidemiology, Biomarkers & Prevention* 2004;13:299–303.

Fuchs 1998  [published data only]
Fuchs J, Kern H. Modulation of UV-light-induced skin inflammation by D-alpha-tocopherol and L-ascorbic acid: a clinical study using solar simulated radiation. *Free Radical Biology & Medicine* 1998;25:1006–12.

Fuller 1996  [published data only]
Fuller CJ, Chandalia M, Garg A, Grundy SM, Jalal I. RRR-alpha-tocopheryl acetate supplementation at pharmacologic doses decreases low-density-lipoprotein oxidative susceptibility but not protein glycation in patients with diabetes mellitus. *American Journal of Clinical Nutrition* 1996;63:753–9.

Fuller 2000  [published data only]
Fuller CJ, May MA, Martin KJ. The effect of vitamin E and vitamin C supplementation on LDL oxidizability and neutrophil respiratory burst in young smokers. *Journal of the American College of Nutrition* 2000;19:361–9.

Fumeron 2005  [published data only]
Fumeron C, Nguyen-Khoa T, Saltiel C, Kebede M, Buissin C, Druke TB, et al. Effects of oral vitamin C supplementation on oxidative stress and inflammation status in haemodialysis patients. *Nephrology, Dialysis, Transplantation* 2005;20(9):1874–9. [MEDLINE: 15972322]
Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases (Review)

Gaede 2001 (published data only)
Gaede P, Poulsen HE, Parving HH, Pedersen O. Double-blind, randomised study of the effect of combined treatment with vitamin C and E on albuminuria in type 2 diabetic patients. Diabetic Medicine 2001;18(9):756–60. [MEDLINE: 11606175]

Gal 1996 (published data only)
Gal M, le Carreher P, Strzeby K. Pharmacokinetics of the treatment of functional fatigue: a double-blind study versus placebo evaluated by a new methodology. Physiotherapy Research 1996;10:49–53.

Galley 1997 (published data only)
Galley HF, Thornton J, Howdle PD, Walker BE, Webster NR. Combination oral antioxidant supplementation reduces blood pressure. Clinical Science 1997;92:361–5.

Garewal 1999 (published data only)
Garewal HS, Ketz RV, Meykens F, Pitcock J, Morse D, Friedman S, et al. Beta-carotene produces sustained remissions in patients with oral leukoplakia: results of a multicenter prospective trial. Archives of Otolaryngology - Head & Neck Surgery 1999;125:1305–10.

Garmyn 1995 (published data only)
Garmyn M, Ribaya-Mercado JD, Russel RM, Bhawan J, Gilchrest BA. Effect of beta-carotene supplementation on the human sunburn reaction. Experimental Dermatology 1995;4:104–11.

Gartner 2001 (published data only)
Gartner R, Albrecht W, Angstwurm MW. The effect of a selenium supplementation on the outcome of patients with severe systemic inflammation, burn and trauma. Biofactors 2001;14(1–4):139–204. [MEDLINE: 11568457]

Gartner 2002 (published data only)
Gartner R, Gazier BC, Dietrich JW, Krebs B, Angstwurm MW. Selenium supplementation in patients with autoimmune thyroiditis decreases thyroid peroxidase antibodies concentrations. The Journal of Clinical Endocrinology and Metabolism 2002;87:1687–91.

Gazia 1999 (published data only)
Gazia A, White DJ, Page SR, Cockcroft JR. Effect of oral vitamin E (alpha-tocopherol) supplementation on vascular endothelial function in type 2 diabetes mellitus. Diabetic Medicine 1999;16:304–11.

Gerta 1990 (published data only)
Gerta MA, Kyle RA. Phase II trial of alpha-tocopherol (vitamin E) in the treatment of primary systemic amyloidosis. American Journal of Hematology 1990;34(1):55–8. [MEDLINE: 2327405]

Gesch 2002 (published data only)
Gesch CB, Hammond SM, Hampson SE, Eves A, Crowder MJ. Influence of supplementary vitamins, minerals and essential fatty acids on the antioxidant behaviour of young adult prisoners. Randomised, placebo-controlled trial. The British Journal of Psychiatry 2002;181:22–8.

Ghatak 1996 (published data only)
Ghatak A, Brar MJ, Agarwal A, Goel N, Rastogi AK, Vaid AK, et al. Oxy free radical system in heart failure and therapeutic role of oral vitamin E. International Journal of Cardiology 1996;57:119–27.

Ghosh 1994 (published data only)
Ghosh SK, Ekpo EB, Shakh IU, Girling AJ, Jenkins C, Sinclair AJ. A double-blind, placebo-controlled parallel trial of vitamin C treatment in elderly patients with hypertension. Gerontology 1994;40:268–72.

Gianduzzo 2003 (published data only)
Gianduzzo TR, Holmes EG, Tinggi U, Shahin M, Macaggart P, Nicol D. Prostatic and peripheral blood selenium levels after oral supplementation. The Journal of Urology 2003;170:870–3.

Gokce 1999 (published data only)
Gokce N, Keaney JF Jr, Frei B, Holbrook M, Olesiak M, Zachariah BJ, et al. Long-term ascorbic acid administration reverses endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation 1999;99:3234–40.

Goldfarb 2005 (published data only)
Goldfarb AH, Bloomer RJ, McKenzie MJ. Combined antioxidant treatment effects on blood oxidative stress after eccentric exercise. Medicine and Science in Sports and Exercise 2005;37:234–9.

Goldfarb 2005a (published data only)
Goldfarb AH, Patrick SW, Byer S, You T. Vitamin C supplementation affects oxidative-stress blood markers in response to a 30-minute run at 75% VO2max. International Journal of Sport Nutrition and Exercise Metabolism 2005;15:279–90.

Gollnick 2002 (published data only)
Gollnick H. Photoprotection of UV-irradiated human skin: an antioxidative combination of vitamins E and C, carotenoids, selenium and prostacyclin. Skin Pharmacology and Applied Skin Physiology 2002;15:307–15.

Gomez-Perez 1996 (published data only)
Gomez-Perez FJ, Valles-Sanchez VE, Lopez-Alvarenga JC, Chosza-Romero R, Ibarra Pascuali JJ, Gonzalez Orellana R, et al. Vitamin E modifies neither fructosamine nor HbA1c levels in poorly controlled diabetes. Revista de Investigacion Clinica 1996;48(6):421–4. [MEDLINE: 9028151]

Goodman 1998 (published data only)
Goodman MT, Hernandez B, Wilkens LR, Lee J, Le Marchand L, Liu LQ, et al. Effects of beta-carotene and alpha-tocopherol on bloomycin-induced chromosomal damage. Cancer Epidemiology, Biomarkers & Prevention 1998;7:113–7.

Goudiev 2000 (published data only)
Goudiev S, Kuzyatkiev S, Gorgova Y, Karshlova E, Georgiev D, Ater D, et al. Reduced concentrations of soluble adhesion molecules after antioxidant supplementation in postmenopausal women with high cardiovascular risk profiles - a randomized double-blind study. Cardioology 2000;94:227–32.

Green 1995 (published data only)
Green D, O’Driscoll G, Blanksby B, Taylor R. Lack of effect of vitamin E administration on basal nitric oxide function in male smokers and non-smokers. Clinical Science 1995;89:343–8.

Greas 2002 (published data only)
Greas AK, Grundmann JU, Heinrich F, Pitzner I, Bernhardt J, Ambach B, et al. Photoprotection of UV-irradiated human skin: an antioxidative combination of vitamins E and C, carotenoids, selenium and prostacyclin. Skin Pharmacology and Applied Skin Physiology 2002;15:307–15.

Griesinger 2002 (published data only)
Griesinger C, Frazke K, Kinaat C, Kurzelniig A, Riedinger S, Kulun S, et al. Ascorbic acid supplement during luteal phase in IVF. Journal of Assisted Reproduction and Genetics 2002;19:164–8.
Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases (Review)

Grievink 1998  [published data only]
Grievink L, Jansen SM, van't Veer P, Brunekreef B. Acute effects of ozone on pulmonary function of cyclists receiving antioxidant supplements. *Occupational and Environmental Medicine* 1998;55:13–7.

Grievink 1999  [published data only]
Grievink L, Zijlstra AG, Ke X, Brunekreef B. Double-blind intervention trial on modulation of ozone effects on pulmonary function by antioxidant supplements. *American Journal of Epidemiology* 1999;149:306–14.

Gueguen 2003  [published data only]
Gueguen S, Prollot P, Leroy P, Guillard JC, Arnaud J, Paille F, et al. Changes in serum retinol, alpha-tocopherol, vitamin C, carotenoids, xic and selenium after micronutrient supplementation during alcohol rehabilitation. *Journal of the American College of Nutrition* 2003;22:303–10.

Gupta 2001  [published data only]
Gupta R, Singhal S, Goye A, Sharma VN. Antioxidant and hypcholesterolaemic effects of Terminalia arjuna tree-bark powder: a randomised placebo-controlled trial. *The Journal of the Association of Physicians of India* 2001;47:231–5.

Hajjar 2002  [published data only]
Hajjar IM, George V, Sasse EA, Kochar MS. A randomized, double-blind, controlled trial of vitamin C in the management of hypertension and lipids. *American Journal of Therapeutics* 2002;9(4):289–93. [MEDLINE: 12115017]

Hamiton 2000  [published data only]
Hamiton IM, Gilmore WS, Benzie IF, Mulholland CW, Strain JJ. Interactions between vitamins C and E in human subjects. *The British Journal of Nutrition* 2000;84:261–7.

Harman 1986  [published data only]
Harman D, White Miller R. Effect of vitamin E on the immune response to influenza virus vaccine and the incidence of infectious disease in man. *Age* 1986;9:21–3.

Harrison 2003  [published data only]
Harrison SA, Torgerson S, Hayashi P, Ward J, Schenker S. Vitamin E and vitamin C treatment improves fibrosis in patients with non-alcoholic steatohepatitis. *American Journal of Gastroenterology* 2003;98(11):2485–90. [MEDLINE: 14638353]

Hasselmaw 1993  [published data only]
Hasselmaw L, Malmgren R, Zetterstrom O, Unge G. Selenium supplementation in intrinsic asthma. *Allergy* 1993;48(1):30–6. [MEDLINE: 8457023]

Hata 1994  [published data only]
Hata T, Terasi A, Matsuaki T, Ohtomo E, Goto Y. A prevention trial on cerebral infarction with dl-alpha-tocopheryl nicotinate - rationales for trial. *The Alpha-Tocopherol Nicotinate Prevention Study Group, Journal of Nutritional Science and Vitaminology* 1992; Spec No:204–7. [MEDLINE: 1297741]

Hawkes 1996  [published data only]
Hawkes WC, Hornbost L. Effects of dietary selenium on mood in healthy men living in a metabolic research unit. *Biological Psychiatry* 1996;39(2):121–8. [MEDLINE: 8717610]

Heinle 1997  [published data only]
Heinle K, Adam A, Grall M, Wiseman M, Adam O. Selenium concentration in erythrocytes of patients with rheumatoid arthritis. Clinical and laboratory chemistry infection markers during administration of selenium. *Medizinische Klinik* 1997;92 Suppl 3:29–31.

Heinrich 2003  [published data only]
Heinrich U, Gartner C, Wiebusch M, Eichler O, Sies H, Tronnier H, et al. Supplementation with beta-carotene or a similar amount of mixed carotenoids protects humans from UV-induced erythema. *Journal of Nutrition* 2003;133:98–101.

Heitzer 1999  [published data only]
Heitzer T, Yla Hertruala S, Wild E, Luoma J, Drexler H. Effect of vitamin E on endothelial vasodilator function in patients with hypercholesterolemia, chronic smoking or both. *Journal of the American College of Cardiology* 1999;33:499–505.

Hernandez 2005  [published data only]
Hernandez J, Syed S, Weiss G, Fernandes G, von Merveldt D, Troyer DA, et al. The modulation of prostate cancer risk with alpha-tocoopherol: a pilot randomized, controlled clinical trial. *The Journal of Urology* 2005;174(2):519–22. [MEDLINE: 16006884]

Herrazai 1998  [published data only]
Herrazai LA, Hsieh WC, Parker RS, Swanson JE, Bendich A, Roe DA. Effect of UV exposure and beta-carotene supplementation on delayed-type hypersensitivity response in healthy older men. *Journal of the American College of Nutrition* 1998;17:617–24.

Herrick 2000  [published data only]
Herrick AL, Hollis S, Schofield D, Rieley F, Blann A, Griffin K, et al. A double-blind placebo-controlled trial of antioxidant therapy in limited cutaneous systemic sclerosis. *Clinical and Experimental Rheumatology* 2000;18(3):349–56. [MEDLINE: 10895372]

Hillert 2001  [published data only]
Hillert L, Kolmodin-Hedman B, Eneroth P, Arnetz BB. The effect of supplementary antioxidant therapy in patients who report hypersensitivity to electricity: a randomized controlled trial. *Medecine General Medicin* 2001;3:11.

Hininger 2001  [published data only]
Hininger IA, Meyer-Wenger A, Moser U, Wright A, Southon S, Thornburn D, et al. No significant effects of lutein, lycopene or beta-carotene supplementation on biological markers of oxidative stress and LDL oxidizability in healthy adult subjects. *Journal of the American College of Nutrition* 2001;20:232–8.

Hodis 1995  [published data only]
Hodis HN, Mack WJ, LaBree L, Cashin-Hemphill L, Sevanian A, Johnson R, et al. Serial coronary angiographic evidence that antioxidant vitamin intake reduces progression of coronary artery atherosclerosis. *JAMA* 1995;273(23):1849–54. [MEDLINE: 7776501]

Hoffmann 1999  [published data only]
Hoffmann RM, Garwelal HS. Alpha-tocopherol supplementation for men with existing coronary artery disease: a feasibility study. *Preventive Medicine* 1999;29:112–8.

Hofstad 1998  [published data only]
Almendingen K, Hofstad B, Vam MH. Dietary habits and growth and recurrance of colorectal adenomas: results from a three-year
Hofstad B, Vatn M, Hoff G, Larsen S, Osnes M. Growth and recurrence of colorectal polyps: a double-blind 3-year intervention with calcium and antioxidants. *Digestion* 1998; Vol. 59, issue 2:148–56. [MEDLINE: 11467659]

Hofstad B, Vatn M, Larsen S, Osnes M. Growth of colorectal polyps: design of a prospective, randomized, placebo-controlled intervention study in patients with colorectal polyps. *European Journal of Cancer Prevention* 1992:1:415–22.

Hofstad B, Vatn M, Larsen S, Osnes M. Growth of colorectal polyps: recovery and evaluation of unresected polyps of less than 10 mm, 1 year after detection. *Scandinavian Journal of Gastroenterology* 1994; 29(7):640–5. [MEDLINE: 7939401]

Hofstad B, Vatn MH, Andersen SN, Huitfeldt HS, Rognum T, Larsen S, et al. Growth of colorectal polyps: redetection and evaluation of unresected polyps for a period of three years. *Gut* 1996;39(3):449–56. [MEDLINE: 8940653]

Hofstad B, Vatn MH, Andersen SN, Owen RW, Larsen S, Osnes M. The relationship between faecal bile acid profile with or without supplementation with calcium and antioxidants on recurrence and growth of colorectal polyps. *European Journal of Cancer Prevention* 1998;7(4):287–94. [MEDLINE: 9806117]

Hornig 1998 [published data only]

Hornig B, Arakawa N, Kohler C, Drexler H. Vitamin C improves endothelial function of conduit arteries in patients with chronic heart failure. *Circulation* 1998;97:363–8.

Huang 2005 [published data only]

Huang HY, Appel LJ, Choi MJ, Gelber AC, Charleston J, Norkus EP, et al. The effects of vitamin C supplementation on serum concentrations of uric acid: results of a randomized controlled trial. *Arthritis and Rheumatism* 2005;52(6):1843–7. [MEDLINE: 15934094]

Hughes 1997 [published data only]

Hughes DA, Wright AJ, Finglas PM, Peerless AC, Bailey AL, Astley SB, et al. The effect of beta-carotene supplementation on the immune function of blood monocytes from healthy male nonsmokers. *The Journal of Laboratory and Clinical Medicine* 1997;129:309–17.

Huijuan 1989 [published data only]

Huijuan W, Luo X, Li X, Xing J, Dong J. Influence of selenium supplement on cadmium metabolism in human. *Acta Academica Medicinae Sinicae* 1989;11:185–9.

Iino 1977 [published data only]

Iino K, Abe K, Kariya S, Kimura H, Kusaba T. A controlled, double-blind study of dl-alpha-tocopheryl nicotinate (Javela-Nicotinate) for treatment of symptoms in hypertension and cerebral arteriosclerosis. *Japanese Heart Journal* 1977;18(3):277–83. [MEDLINE: 881743]

Inagaki 1978 [published data only]

Inagaki Y, Kinoshita MO, Nakamura Y, Masuda VA. Tocopherol, oxygen and biomembranes. In: C DeDuve, O Hayashi editor(s). *Double-blind controlled study of the efficacy of DL-A-Tocopherylnicotinate in patients with vascular disease*. Amsterdam and New York: Elsevier- North Holland Biomedical Press, 1978:339–49.

Itoh 2000 [published data only]

Itoh H, Otkawa T, Yamazaki Y, Shimoda T, Wakayama A, Tamura S, et al. Vitamin E supplementation attenuates leakage of enzymes following 6 successive days of running training. *International Journal of Sports Medicine* 2000;21:360–74.

Iwanier 1995 [published data only]

Iwanier K, Zachara BA. Selenium supplementation enhances the element concentration in blood and seminal fluid but does not change the spermatozoal quality characteristics in subfertile men. *Journal of Andrology* 1995;16(5):441–7. [MEDLINE: 8575984]

Jacob 2003 [published data only]

Jacob RA, Aiello GM, Stephensen CB, Blumberg JB, Milbury PE, Wallock LM, et al. Moderate antioxidant supplementation has no effect on biomarkers of oxidant damage in healthy men with low fruit and vegetable intakes. *Journal of Nutrition* 2003;133:740–3.

Jacques 1995 [published data only]

Jacques PF, Sulsky SI, Petrone GE, Jenner J, Schaefer EJ. Effect of vitamin C supplementation on lipoprotein cholesterol, apolipoprotein, and triglyceride concentrations. *Annals of Epidemiology* 1995; 5:52–9.

Jain 2002 [published data only]

Jain AL. Influence of vitamins and trace-elements on the incidence of respiratory infection in the elderly. *Nutrition Research* 2002;22: 85–7.

Jantti 1991 [published data only]

Jantti J, Nikkari T, Solakivi T, Vapaatalo H-M, Isomaki H, Jantti J, et al. Treatment of rheumatoid arthritis with fish oil, selenium, vitamins A and E, and placebo. *Scandinavian Journal of Rheumatology* 1991; 20:225.

Jawwal 2003 [published data only]

Jawwal S, Mehta HC, Sood AK, Kaur J. Antioxidant status in rheumatoid arthritis and role of antioxidant therapy. *Clinica Chimica Acta* 2003;338:123–9.

Jeng 1996 [published data only]

Jeng KC, Yang CS, Sun WY, Tsai YS, Liao WJ, Kuo JS. Supplementation with vitamins C and E enhances cytokine production by peripheral blood mononuclear cells in healthy adults. *American Journal of Clinical Nutrition* 1996;64:960–5.

Jensen 2002 [published data only]

Jensen C, Holloway L, Block G, Spiller G, Gildengorin G, Gunderson E, et al. Long-term effects of nutrient intervention on markers of bone remodeling and calcitropic hormones in late-postmenopausal women. *American Journal of Clinical Nutrition* 2002;75:1114–20.

Jesup 2003 [published data only]

Jesup JV, Horne C, Yaradi H, Quindry J. The effects of endurance exercise and vitamin E on oxidative stress in the elderly. *Nutrition Research* 2003;23:47–55.

Jialal 1992 [published data only]

Jialal I, Grundy SM. Effect of dietary supplementation with alphatocopherol on the oxidative modification of low density lipoprotein. *Journal of Lipid Research* 1992;33:899–906.

Jialal 1993 [published data only]

Jialal I, Grundy SM. Effect of combined supplementation with alphatocopherol, ascorbate, and beta carotene on low-density lipoprotein oxidation. *Circulation* 1993;88:2780–6.
Jialal 1995  [published data only]
Jialal I, Fuller CJ, Huet BA. The effect of alpha-tocopherol supplement-
ondation on LDL oxidation. A dose-response study. Arteriosclerosis, Thrombosis, and Vascular Biology 1995;15:390–8.

Johnsson 1995  [published data only]
Johnsson EJ, Suter PM, Sabyoun N, Ribaya-Mercado JD, Russell
RM. Relation between beta-carotene intake and plasma and adipose
issue concentrations of carotenoids and retinoids. American Journal of Clinical Nutrition 1995;62:598–603.

Kahler 1993  [published data only]
Kahler W, Kuikkinski B, Ruhlmann C, Ploetz C. Diabetes mellitus
- a free radical-associated disease. Results of adjuvant antioxidant
supplementation. Zeitschrift für die Gesamte Innere Medizin und Ihre Grenzgebiete 1993;48:223–32.

Kaikkonen 1998  [published data only]
Kaikkonen J, Kosoten L, Nyssonen K, Pörkkä-Sarataho E, Salonen R, Korpela H, et al. Effect of combined coenzyme Q10 and d-
alpha-tocopheryl acetate supplementation on exercise-induced lipid
peroxidation and muscular damage: a placebo-controlled double-
blind study in marathon runners. Free Radical Research 1998;29:85–92.

Kaikkonen 2000  [published data only]
Kaikkonen J, Nyssonen K, Tomasi A, Iannone A, Tuomainen TP, Pörkkä-Sarataho E, et al. Antioxidative efficacy of parallel and com-
bined supplementation with coenzyme Q10 and d-alpha-tocopherol in
mildly hypercholesterolemic subjects: a randomized placebo-con-
trolled clinical study. Free Radical Research 2000;33(3):329–40. [MEDLINE: 10993487]

Kaiser 1995  [published data only]
Kaiser HJ, Flammer J, Stumpf D, Hendrickson P. Visaline in
the treatment of age-related macular degeneration: a pilot study. Ophthalmo-
logia 1995;209(6):302–5. [MEDLINE: 8751336]

Kanter 1993  [published data only]
Kanter MM, Nolte LA, Holloszy JO. Effects of an antioxidant vita-
min mixture on lipid peroxidation at rest and postexercise. Journal of Applied Physiology 1993;74:965–9.

Karlowski 1975  [published data only]
Karlowski TR, Chalmers TC, Frenkel LD, Kapikian AZ, Lewis TL, Lynch JM. Ascorbic acid for the common cold. A prophylactic and
therapeutic trial. Cancer Epidemiology, Biomarkers & Prevention 1995;4:1448–51.

Kim HS, Lee BM. Protective effects of antioxidant supplementation
on plasma lipid peroxidation in smokers. Journal of Toxicology and Environmental Health. Part A 2001;63:583–98.

King 1997  [published data only]
King TM, Irizuna Z, Wu X, Amos CI, Fueger RH, Fueger JJ, et al. Clinical trial to evaluate the effect of vitamin C supplementation
on intratumor mutagen sensitivity. The University of Texas M. D. Anderson Clinical Community Oncology Program Network. Cancer Epidemiology, Biomarkers & Prevention 1997;6:537–42.

Kinlay 2004  [published data only]
Kinlay S, Behendt D, Fang JC, Delagrange D, Morrow J, Witztum
et al. Long-term effect of combined vitamins E and C on coronary
and peripheral endothelial function. Journal of the American College of Cardiology 2004;43:629–34.

Kitagawa 1989  [published data only]
Kitagawa M, Mino M. Effects of elevated d-alpha(RRR)-tocopherol
dosage in man. Journal of Nutritional Science and Vitaminology 1989;35(2):133–42. [MEDLINE: 2732807]

Keith 2001  [published data only]
Keith ME, Jesseeboh KN, Langer A, Kurian R, Barr A, O’Kelly B, Sole MJ. A controlled clinical trial of vitamin E supplementation
in patients with congestive heart failure. The American Journal of Clinical Nutrition 2001;73:219–24.

Keskus-Ammar 2003  [published data only]
Keskus-Ammar L, Fekl-Chakroun N, Rebai T, Sahnoun Z, Ghooz
H, Hammami S, et al. Sperm oxidative stress and the effect of an oral vitamin E and selenium supplement on semen quality in
infertile men. Archives of Andrology 2003;49(2):83–94. [MEDLINE: 12623744]

Kessopoulou 1995  [published data only]
Kessopoulou E, Powers HJ, Sharma KK, Pearson MJ, Russell JM, Cooke ID, et al. A double-blind randomized placebo cross-over con-
trolled trial using the antioxidant vitamin E to treat reactive oxy-
gen species associated male infertility. Fertility and Sterility 1995;64:825–31.

Khajedehi 2000  [published data only]
Khajedehi P. Effect of vitamins on the lipid profile of patients on
regular hemodialysis. Scandinavian Journal of Urology and Nephrology 2000;34:62–6.

Khajedehi 2001  [published data only]
Khajedehi P, Mojerezlou M, Behzadi S, Rais-Jalali GA. A randomized,
double-blind, placebo-controlled trial of supplementary vitamins E,
and their combination for treatment of haemodialysis cramps. Nephrology, Dialysis, Transplantation 2001;16:448–51.

Khasaaf 2003  [published data only]
Khasaaf M, McArell A, Esanu C, Vasilaki A, McAndle F, Griffiths
RD, et al. Effect of vitamin C supplements on antioxidant defence
and stress proteins in human lymphocytes and skeletal muscle. The Journal of Physiology 2003;549:645–52.

Kim 2001  [published data only]
Kim HS, Lee BM. Protective effects of antioxidant supplementation
on plasma lipid peroxidation in smokers. Journal of Toxicology and Environmental Health. Part A 2001;63:583–98.

Kirsemdjian-S 1994  [published data only]
Kirsemdjian-Schumacher L, Roy M, Wishe HI, Cohen MW, Stotzky
G. Supplementation with selenium and human immune cell func-
tion. Journal of Toxicology and Environmental Health. Part A 1994;43:629–34.

Kiremidjian-S 1999  [published data only]
Kiremidjian-Schumacher L, Roy M, Wishe HI, Cohen MW, Stotzky
G. Supplementation with selenium and human immune cell func-
tion. II. Effect on cytotoxic lymphocytes and natural killer cells. Biological Trace Element Research 1994;41:115–27.
Korpela 1989 [published data only]

Koh 1999 [published data only]

Kugiyama 1999 [published data only]

Konen 2000 [published data only]

Korpela 1989 [published data only]

Kugiyama 1999 [published data only]

la Ruche 1991 [published data only]

Koh 1999 [published data only]

London 1983 [published data only]

Li 2004 [published data only]

Lofts 2004 [published data only]

Lovat 1993 [published data only]

Lykkesfeldt 2000 [published data only]

Mackerras 1999 [published data only]

MacLennan 1995 [published data only]

MacPherson 1995 [published data only]

Mader 1988 [published data only]

Malo 1986 [published data only]

Mann 1987 [published data only]

Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases (Review)
Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases (Review)

Mancella D, Barbieri M, Ragno E, Paolino G. Chronic administration of pharmacologic doses of vitamin E improves the cardiac autonomic nervous system in patients with type 2 diabetes. *American Journal of Clinical Nutrition* 2001;73(6):1052–7. [MEDLINE: 8480861]

Margaritis I, Palazzetti S, Rotaseau AS, Richard MJ, Favier A. Antioxidant supplementation and tapering exercise improve exercise-induced antioxidant response. *Journal of the American College of Nutrition* 2003;22:147–56.

Marotta F, Barreto R, Tajiri H, Bertuccelli J, Safran P, Yoshiida C, et al. The aging/precancerous gastric mucosa: a pilot nautical trial. *Annals of the New York Academy of Sciences* 2004;1019:395–9.

Marotta F, Barreto R, Tajiri H, Bertuccelli J, Safran P, Bobadilla J, et al. Atrophic/metaplastic changes of gastric mucosa: a preliminary interventional trial comparing different antioxidant supplements. *International Congress Series* 2003;1255:291–4.

Martinez-Abun 2001 [published data only]

Martinez-Abundis E, Barreto R, Tajiri H, Bertiuccelli J, Safran P, Yoshiida C, et al. The aging/precancerous gastric mucosa: a pilot nautical trial. *Annals of the New York Academy of Sciences* 2004;1019:395–9.

Marotte 2003 [published data only]

Mathews-Roth MM, Pathak MA, Parrish J, Fitzpatrick TB, Sass KR. Antioxidant supplementation and exercise-induced oxidative stress in the 60-year-old as measured by antipyrine hydroxylates. *The British Journal of Nutrition* 2001;86:569–75.

McGavin 2000 [published data only]

McGavin JK, Mann JI, Skeaff CM, Chisholm A. Comparison of a vitamin E-rich diet and supplemental vitamin E on measures of vitamin E status and lipoprotein profile. *European Journal of Clinical Nutrition* 2001;55:555–61.

Meydani 1990 [published data only]

Meydani SN, Parklund MF, Liu S, Meydani M, Miller RA, Cannon JG, et al. Vitamin E supplementation enhances cell-mediated immunity in healthy elderly subjects. *American Journal of Clinical Nutrition* 1990;52(5):557–63. [MEDLINE: 2203257]

Meydani 1994 [published data only]

Meydani SN, Mollay M, Rall LC, Morrow F, Blumberg JB. Assessment of the safety of high-dose, short-term supplementation with vitamin E in healthy elderly adults. *American Journal of Clinical Nutrition* 1994;60(5):704–9. [MEDLINE: 7942576]

Meydani 1997 [published data only]

Meydani SN, Meydani M, Blumberg JB, Leka LS, Biber G, Loszewski R, et al. Vitamin E supplementation and in vivo immune response in healthy elderly subjects. A randomized controlled trial. *JAMA* 1997;277(17):1380–6. [MEDLINE: 9134944]

Meyer 1999 [published data only]

Meyer EC, Sommers DK, Reitz CJ, Mensis H. Vitamin E and benign breast disease. *Surgery* 1990;107(5):549–51. [MEDLINE: 2185569]

Micheletta 2004 [published data only]

Micheletta E, Nutoli S, Mistraci M, Sharigia E, Dicafalay U, Juliano L. Vitamin E supplementation in patients with carotid atherosclerotic reversal of altered oxidative stress status in plasma but not in plaque. *Arteriosclerosis, Thrombosis, and Vascular Biology* 2004;24:136–40.

Micozzi 1992 [published data only]

Micozzi MS, Brown ED, Edwards BK, Bieri JG, Taylor PR, Khachik F, et al. Plasma carotenoid response to chronic intake of selected foods and beta-carotene supplements in men. *American Journal of Clinical Nutrition* 1992;55:1120–5.
Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases (Review)

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Muller 1997 [published data only]
Muller ER 3rd, Appel LJ, Levander OA, Levine DM. The effect of antioxidant vitamin supplementation on traditional cardiovascular risk factors. *Journal of Cardiovascular Risk* 1997;4:19–24.

MIVIT 2005 [published data only]
Jara-Chamiec T, Redzart B, Dzadowska D, Gresiek J, Gnior J, Jank K, et al. Antioxidant effects of combined vitamins C and E in acute myocardial infarction. The randomized, double-blind, placebo-controlled, multicenter pilot Myocardial Infarction and Vitamins (MIVIT) trial. *Kardiologia Polska* 2005;62(4):344–50. [MEDLINE: 16059992]

Mohsenin 1987 [published data only]
Mohsenin V. Effect of vitamin C on NO2-induced airway hyperresponsiveness in normal subjects. A randomized double-blind experiment. *The American Review of Respiratory Disease* 1987;136:1408–11.

Moller 2004 [published data only]
Moller P, Viscovich M, Lykkefeldt J, Loft S, Jensen A, Poulsen HE. Antioxidant vitamin supplementation decreases oxidative DNA damage in mononuclear blood cells of smokers. *European Journal of Nutrition* 2004;43:267–74.

Mosca 1997 [published data only]
Mosca L, Rubenfire M, Mandel C, Rock C, Tarsis T, Tsai A, et al. Antioxidant nutrient supplementation reduces the susceptibility of low density lipoprotein to oxidation in patients with coronary artery disease. *Journal of the American College of Cardiology* 1997;30(2):392–9. [MEDLINE: 9247510]

Mottram 1999 [published data only]
Mottram P, Shige H, Nestel P. Vitamin E improves arterial compliance in middle-aged men and women. *Atherosclerosis* 1999;145:399–404.

Mulholland 1993 [published data only]
Mulholland CW, Strain J. Total radical-trapping antioxidant potential (TRAP) of plasma: effects of supplementation of young healthy volunteers with large doses of alpha-tocopherol and ascorbic acid. *International Journal for Vitamin and Nutrition Research* 1993;63:27–30.

Mulholland 1996 [published data only]
Mulholland CW, Strain J, Trinick TR. Serum antioxidant potential, and lipoprotein oxidation in female smokers following vitamin C supplementation. *International Journal of Food Sciences and Nutrition* 1996;47:227–31.

Mullan 2002 [published data only]
Mullan BA, Young IS, Fee H, McCance DR. Ascorbic acid reduces blood pressure and arterial stiffness in type 2 diabetes. *Hypertension* 2002;40:804–9.

Munoz 1985 [published data only]
Munoz N, Wahrenford J, Bang LJ, Crespi M, Thurnham DI, Day NE, et al. No effect of riboflavin, retinol, and zinc on prevalence of precancerous lesions of oesophagus. Randomised double-blind intervention study in high-risk population of China. *Lancet* 1985;2(8447):111–4. [MEDLINE: 2862315]

Munoz 2001 [published data only]
Munoz CA, Kiger RD, Stephens JA, Kim J, Wilson AC. Effects of a nutritional supplement on periodontal status. *The Compendium of Continuing Education in Dentistry* 2001;22:425–8.

Mustad 2002 [published data only]
Mustad VA, Smith CA, Reus PP, Eleno NK, DeMichele SJ. Supplementation with 3 compositionally different tocotrienol supplements does not improve cardiovascular disease risk factors in men and women with hypercholesterolemia. *American Journal of Clinical Nutrition* 2002;76:1237–43.

Nelson 2003 [published data only]
Nelson JL, Bernstein PS, Schmidt MC, Von Tress MS, Askew EW. Dietary modification and moderate antioxidant supplementation differentially affect serum carotenoids, antioxidant levels and markers of oxidative stress in older persons. *Journal of Nutrition* 2003;133:3117–23.

Nenster 1995 [published data only]
Nenster MS, Volden V, Berg T, Drevon CA, Ose L, Tonstad S. No effect of beta-carotene supplementation on the susceptibility of low density lipoprotein to in vitro oxidation among hypercholesterolemic, postmenopausal women. *Scandinavian Journal of Clinical and Laboratory Investigation* 1995;55:477–85.

Neunteufl 2000 [published data only]
Neunteufl T, Priglinger U, Heher S, Zehetguber M, Soregi G, Lehr S, et al. Effects of vitamin E on chronic and acute endothelial dysfunction in smokers. *Journal of the American College of Cardiology* 2000;35:277–83.

Nieman 1997 [published data only]
Nieman DC, Henson DA, Butterworth DE, Warren BJ, Davis JM, Fagoua OR, et al. Vitamin C supplementation does not alter the immune response to 2.5 hours of running. *International Journal of Sport Nutrition* 1997;7:173–84.

Nieman 2002 [published data only]
Nieman DC, Henson DA, McAnulty SR, McAnulty L, Swick NS, Utter AC, et al. Influence of vitamin C supplementation on oxidative and immune changes after an ultramarathon. *Journal of Applied Physiology* 2002;92:1970–7.

Nimmagadda 1998 [published data only]
Nimmagadda AP, Burri BJ, Neidlinger T, O'Brien WA, Goetz MB. Effect of oral beta-carotene supplementation on plasma human immunodeficiency virus (HIV) RNA levels and CD4+ cell counts in HIV-infected patients. *Clinical Infectious Diseases* 1998;27(5):1311–3. [MEDLINE: 9827288]

Nysssson 1994 [published data only]
Nysssson K, Porrkkala E, Salonen R, Korpela H, Salonen JT. Increase in oxidation resistance of atherogenic serum lipoproteins following antioxidant supplementation: a randomized double-blind placebo-controlled clinical trial. *European Journal of Clinical Nutrition* 1994;48:633–42.

O'Byrne 2000 [published data only]
O'Byrne D, Grundy S, Packer I, Devaraj S, Buldenius K, Hoppe PP, et al. Studies of LDL oxidation following alpha-, gamma-, or delta-tocotrienyl acetate supplementation of hypercholesterolemic humans. *Free Radical Biology & Medicine* 2000;29:834–45.

Olmedilla 2002 [published data only]
Olmedilla B, Granado E, Sowthor S, Wright AJ, Blanco I, Gil-Martinez E, et al. European multicentre, placebo-controlled supplementation study with alpha-tocopherol, carotene-rich palm oil, lutein or lycopene: analysis of serum responses. *Clinical Science* 2002;102:447–56.
Olmedilla 2003  [published data only]
Olmedilla B, Granado F, Blanco I, Vaquero M, Lutein, but not alpha-tocopherol, supplementation improves visual function in patients with age-related cataracts: a 2-y double-blind, placebo-controlled pilot study. Nutrition 2003;19(1):21–4. [MEDLINE: 12507634]

Ono 1985  [published data only]
Ono K, Effects of large dose vitamin E supplementation on anemia in hemodialysis patients. Nephron 1985;40:440–5.

Onofrj 2002  [published data only]
Onofrj M, Thomas A, Luciano AL, Iacono D, Di Rollo A, D’Andreamatteo G, et al. Donepezil versus vitamin E in Alzheimer’s disease: Part 2: mild versus moderate-severe Alzheimer’s disease. Clinical Neuropharmacology 2002;25(4):207–15. [MEDLINE: 12151908]

Orndahl 1994  [published data only]
Orndahl G, Grimby G, Grimby A, Johansson G, Wilhelmson L. Functional deterioration and selenium-vitamin E treatment in myotonic dystrophy. A placebo-controlled study. Journal of Internal Medicine 1994;235(3):205–10. [MEDLINE: 8120515]

Osilesi 1991  [published data only]
Osilesi O, Trout DL, Ogunwole JO, Glover E. Blood pressure and plasma lipid during ascorbic acid. Supplementation on borderline hypertensive and normotensive adults. Nutrition Research 1991;11:405–12.

Paganelli 1998  [published data only]
Paganelli GM, Biasco G, Brandi G, Santucci R, Gizzi G, Villani V, et al. Effect of vitamin A, C, and E supplementation on rectal cell proliferation in patients with colorectal adenomas. Journal of the National Cancer Institute 1998;90:47–51.

Pallast 1999  [published data only]
Pallast EG, Schouten EG, de Waart FG, Fokk HC, Doekes G, von Blomberg BM, et al. Effect of 50- and 100-mg vitamin E supplements on cellular immune function in noninstitutionalized elderly persons. American Journal of Clinical Nutrition 1999;69(6):1273–81. [MEDLINE: 10577750]

Paolisso 1993  [published data only]
Paolisso G, D’Amore A, Giugliano D, Ceriello A, Varricchio M, D’Onofrio F. Pharmacologic doses of vitamin E improve insulin action in healthy subjects and non-insulin-dependent diabetic patients. American Journal of Clinical Nutrition 1993;57(5):650–6. [MEDLINE: 8480681]

Paolisso 1993a  [published data only]
Paolisso G, D’Amore A, Galznera D, Balbi V, Giugliano D, Varricchio M, et al. Daily vitamin E supplements improve metabolic control but not insulin secretion in elderly type II diabetic patients. Diabetes Care 1993;16:1433–7.

Paolisso 1994  [published data only]
Paolisso G, Di Maro G, Galznera D, Cacciapuoti F, Varricchio G, Varricchio M, et al. Pharmacological doses of vitamin E and insulin action in elderly subjects. American Journal of Clinical Nutrition 1994;59:1291–6.

Paolisso 1995  [published data only]
Paolisso G, Gambardella A, Giugliano D, Galznera D, Amaro L, Volpe C, et al. Chronic intake of pharmacological doses of vitamin E might be useful in the therapy of elderly patients with coronary heart disease. American Journal of Clinical Nutrition 1995;61:848–52.

Paolisso 1995a  [published data only]
Paolisso G, Balbi V, Volpe C, Varricchio G, Gambardella A, Saccaman F, et al. Metabolic benefits deriving from chronic vitamin C supplementation in aged non-insulin dependent diabetics. Journal of the American College of Nutrition 1995;14:387–92.

Paolisso 2000  [published data only]
Paolisso G, Tagliamonte MR, Barbieri M, Zito GA, Gambardella A, Varricchio G, et al. Chronic vitamin E administration improves brachial reactivity and increases intracellular magnesium concentration in type II diabetic patients. The Journal of Clinical Endocrinology and Metabolism 2000;85:109–15.

Park 2002  [published data only]
Park S, Choi SB. Effects of alpha-tocopherol supplementation and continuous subcutaneous insulin infusion on oxidative stress in Korean patients with type 2 diabetes. American Journal of Clinical Nutrition 2002;75:728–33.

Pasantes-Morales 2002  [published data only]
Pasantes-Morales H, Quiroz H, Quesada O. Treatment with taurine, dilituzam, and vitamin E retards the progressive visual field reduction in retinitis pigmentosa: a 3-year follow-up study. Metabolic Brain Disease 2002;17(3):183–97. [MEDLINE: 12322788]

Patrignani 2000  [published data only]
Patrignani P, Panara MR, Tacconelli S, Seta F, Bucciarelli T, Ciabattini G, et al. Effects of vitamin E supplementation on F(2)-isoprostane and thromboxane biosynthesis in healthy cigarette smokers. Circulation 2000;102:439–45.

Pearson 2004  [published data only]
Pearson PJ, Lewis SA, Britton J, Fogarty A. Vitamin E supplements in patients with chronic kidney disease. The Journal of Clinical Endocrinology and Metabolism 2004;89:537–43.

Peretz 2001  [published data only]
Peretz A, Neve J, Duchateau J, Famaey JP. Adjuvant treatment of recent onset rheumatoid arthritis by selenium supplementation: preliminary observations. British Journal of Rheumatology 1992;31(4):281–2. [MEDLINE: 1555045]

Pereira 2003  [published data only]
Pereira EM, Goetzsch JJ, Grobbelaar B, Noakes TD. Vitamin C supplementation reduces the incidence of postrace symptoms of upper-respiratory-tract infection in ultramarathon runners. American Journal of Clinical Nutrition 1993;57(2):170–4. [MEDLINE: 8185726]

Peters 2001  [published data only]
Peters EM, Anderson R, Nieman DC, Field H, Jogessar V. Vitamin C supplementation attenuates the increases in circulating cortisol, adrenaline and anti-inflammatory polypeptides following ultramartial running. International Journal of Sports Medicine 2001;22:537–43.
Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases (Review)

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

- Petersen CE, Folstein M, Chase GA, Starkstein S, Brandt J, Cockrell JR. Effect of vitamin E supplementation on cytokine response and on muscle damage after strenuous exercise. *American Journal of Physiology. Cell Physiology* 2001;280(6):C1570–5. [MEDLINE: 11350752]
- Peyser CE, Folsom AR, Chase GA, Starkstein S, Brandt J, Cockrell JR. Trial of d-alpha-tocopherol in Huntington’s disease. *American Journal of Psychiatry* 1995;152(12):1771–5. [MEDLINE: 8526244]
- Ponz de Leon M, Roncucci L. Chemoprevention of colorectal tumors: role of lactulose and of other agents. *Scandinavian Journal of Gastroenterology* 1997; Vol. 32, issue Suppl 222:72–5. [MEDLINE: 993–9].
- Ponz de Leon M, Roncucci L. Chemoprevention of colorectal tumors: role of lactulose and of other agents. *Scandinavian Journal of Gastroenterology* 1997; Vol. 32, issue Suppl 222:72–5. [MEDLINE: 993–9].
- Pinkney JH, Downs L, Hopton M, Mackness MI, Bolton CH. Endothelial dysfunction in type 1 diabetes mellitus: relationship with LDL oxidation and the effect of vitamin E. *Diabetic Medicine* 1999; 16:993–9.
- Ponz de Leon M, Roncucci L. Chemoprevention of colorectal tumors: role of lactulose and of other agents. *Scandinavian Journal of Gastroenterology* 1997; Vol. 32, issue Suppl 222:72–5. [MEDLINE: 993–9].
- Ponz de Leon M, Roncucci L. Chemoprevention of colorectal tumors: role of lactulose and of other agents. *Scandinavian Journal of Gastroenterology* 1997; Vol. 32, issue Suppl 222:72–5. [MEDLINE: 993–9].
- Ponz de Leon M, Roncucci L. Chemoprevention of colorectal tumors: role of lactulose and of other agents. *Scandinavian Journal of Gastroenterology* 1997; Vol. 32, issue Suppl 222:72–5. [MEDLINE: 993–9].
- Preziosi P, Galan P, Herberth B, Valeix P, Roussel AM, Malvy D, et al. Effect of supplementation with a combination of antioxidant vitamins and trace elements, at nutritional doses, on biochemical indicators and markers of the antioxidant system in adult subjects. *Journal of the American College of Nutrition* 1998;17:244–9.
- Prieme H. Effect of supplementation of smoking men with vitamins C supplementation in normal subjects reduces constitutive ICAM-1 expression. *Biochemical and Biophysical Research Communications* 2003;308:339–45.
- Reaven PD, Fergusson E, Navab M, Powell FL. Susceptibility of human LDL to oxidative modification. Effects of variations in beta-carotene concentration and oxygen tension. *Arteriosclerosis and Thrombosis* 1994;14:1162–9.
- Reaven PD, Fergusson E, Navab M, Powell FL. Susceptibility of human LDL to oxidative modification. Effects of variations in beta-carotene concentration and oxygen tension. *Arteriosclerosis and Thrombosis* 1994;14:1162–9.
- Reaven PD, Herold DA, Bartnett J, Edelman S. Effects of Vitamin E on susceptibility of low-density lipoprotein and low-density lipoprotein subfractions to oxidation and on protein glycation in NIDDM. *Diabetes Care* 1995;18(6):807–16. [MEDLINE: 7555507]
- Remans PH, Sont JK, Wagenaar LW, Wouters-Wesseling W, Zuiderduin WM, Jongma A, et al. Nutrient supplementation with polyunsaturated fatty acids and micronutrients in rheumatoid arthritis: clinical and biochemical effects. *European Journal of Clinical Nutrition* 2004;58(6):839–45. [MEDLINE: 15164103]
- Richards GA, Theron AJ, Van Rensburg CE, Van Rensburg AJ, Van der Merwe CA, Kayil JM, et al. Investigation of the effects of oral administration of vitamin E and beta-carotene on the chemiluminescence responses and the frequency of sister chromatid exchanges in pulmonary tuberculosis. *Tropical Medicine & International Health* 2005;10(9):826–32. [MEDLINE: 16135188]
circular leukocytes from cigarette smokers. The American Review of Respiratory Disease 1990;142:648–54.

Rinzler 1950 [published data only]
Rinzler SH, Bakst H, Benjamin ZH, Bobb AL, Travell J. Failure of alpha tocopherol to influence chest pain in patients with heart disease. Circulation 1950;2(2):288–93. [MEDLINE: 15403032]

Robinson 1997 [published data only]
Robinson MF, Thomson CD, Jenkinson CP, Luizhen G, Whanger PD. Long-term supplementation with selenium and selenomethionine: urinary excretion by New Zealand women. The British Journal of Nutrition 1997;77:551–63.

Robson 2003 [published data only]
Robson P, Rosic PJ, Myburgh KH. Antioxidant supplementation enhances neutrophil oxidative burst in trained runners following prolonged exercise. International Journal of Sport Nutrition and Exercise Metabolism 2003;13:369–81.

Rokitzki 1994a [published data only]
Rokitzki L, Logemann E, Huber G, Keck E, Keul J. Alpha-Tocopherol supplementation in racing cyclists during extreme endurance training. International Journal of Sport Nutrition 1994;4:253–64.

Rokitzki 1994b [published data only]
Rokitzki L, Logemann E, Sagredo AN, Murphy M, Wetzel-Roth W, Keul J. Lipid peroxidation and antioxidative vitamins under extreme endurance stress. Acta Physiologica Scandinavica 1994:151:149–58.

Romieu 1998 [published data only]
Romieu I, Meneses F, Ramirez M, Ruiz S, Perez Padilla R, Siena J, et al. Antioxidant supplementation and respiratory functions among workers exposed to high levels of ozone. American Journal of Respiratory and Critical Care Medicine 1998;158(1):226–32. [MEDLINE: 9655734]

Romney 1997 [published data only]
Romney SL, Ho GY, Palan PR, Basu J, Kadish AS, Klein S, et al. Effects of beta-carotene and other factors on outcome of cervical dysplasia and human papillomavirus infection. Gynecologic Oncology 1997;65(3):483–92. [MEDLINE: 9190980]

Roncucci 1993 [published data only]
Roncucci L, Di Donato P, Carati L, Ferrari A, Perini M, Bertoni G, et al. Antioxidant vitamins or lactulose for the prevention of the recurrence of colorectal adenomas. Colorectal Cancer Study Group of the University of Modena and the Health Care District 16. Diseases of the Colon and Rectum 1993;36(3):227–34.

Roedengaen 2000 [published data only]
Roedengaen AJ, Leenen R, van het Hof KH, Weststrate JA, Tijburg LB. Amount of fat in the diet affects bioavailability of lutein esters but not of alpha-carotene, beta-carotene, and vitamin E in humans. American Journal of Clinical Nutrition 2000;71:1187–93.

Rossig 2001 [published data only]
Rossig L, Hoffmann J, Hubel B, Mallat Z, Haase A, Freysinet JM, et al. Vitamin C inhibits endothelial cell apoptosis in congestive heart failure. Circulation 2001;104:2182–7.

Sachek 2003 [published data only]
Sachek JM, Milbury PE, Canton JJ, Roubenoff R, Blumberg JB. Effect of vitamin E and eccentric exercise on selected biomarkers of oxidative stress in young and elderly men. Free Radical Biology & Medicine 2003;34:1575–88.

Salonen 1991 [published data only]
Salonen JT, Salonen R, Seppanen K, Rinta-Kiikka S, Knucca M, Korpela H, et al. Effects of antioxidant supplementation on platelet function: a randomized pair-matched, placebo-controlled, double-blind trial in men with low antioxidant status. American Journal of Clinical Nutrition 1991;53:1222–9.

Samet 2001 [published data only]
Samet JM, Hatch GE, Horstman D, Steck-Scott S, Arab L, Bormberg PA, et al. Effect of antioxidant supplementation on ozone-induced lung injury in human subjects. American Journal of Respiratory and Critical Care Medicine 2001;164:819–25.

Samman 1997 [published data only]
Samman S, Brown AJ, Beltran C, Singh S. The effect of ascorbic acid on plasma lipids and oxidisability of LDL in male smokers. European Journal of Clinical Nutrition 1997;51:472–7.

Sampson 2001 [published data only]
Sampson MJ, Arledge S, Richardson T, Willis G, Davies IR, Hughes DA, et al. Increased DNA oxidative susceptibility without increased plasma LDL oxidizability in type II diabetes: effects of alpha-tocopherol supplementation. Clinical Science 2001;101:235–41.

Sankaranarayanan 1997 [published data only]
Sankaranarayanan R, Mathew B, Varghese C, Sudhakaran PR, Menon V, Jayadeep A, et al. Chemoprevention of oral leukoplakia with vitamin A and beta-carotene: an assessment. Oral Oncology 1997;33(4):231–6. [MEDLINE: 9307711]

Schachter 1982 [published data only]
Schachter EN, Schlesinger A. The attenuation of exercise-induced bronchoconstriction by ascorbic acid. Annals of Allergy 1982;49:146–51.

Schlebusch 2000 [published data only]
Schlebusch L, Bosch BA, Polglase G, Kleinenschmidt I, Pillay BJ, Cassimjee MH. A double-blind, placebo-controlled, double-centre study of the effects of an oral multivitamin-mineral combination on stress. South African Medical Journal 2000;90:1216–23.

Schneider 2003 [published data only]
Schneider M, Niess AM, Rozario F, Angres C, Tschirnix K, Golly L, et al. Vitamin E supplementation does not increase the vitamin C radical concentration at rest and after exhaustive exercise in healthy male subjects. European Journal of Nutrition 2003;42:195–200.

Schorah 1981 [published data only]
Schorah CJ, Tormey WP, Brooks GH, Rubershaw AM, Young GA, Talukder R, et al. The effect of vitamin C supplements on body weight, serum proteins, and general health of an elderly population. American Journal of Clinical Nutrition 1981;34:871–6.

Schrader 2001 [published data only]
Schrader H, Navarro E, Mora J, Galiano D, Trumalaza A. Effects of alpha-tocopherol, beta-carotene and ascorbic acid on oxidative, hormonal and enzymatic exercise stress markers in habitual training activity of professional basketball players. European Journal of Nutrition 2001;40:178–84.

Schutte 2004 [published data only]
Schutte AE, Huisman HW, Oosthuizen W, van Rooyen JM, Jerling JC. Cardiovascular effects of oral Supplementation of vitamin C, E and folic acid in young healthy males. International Journal for Vitamin and Nutrition Research 2004;74:285–93.
Scott 1998  {published data only}
Scott R, MacPherson A, Yates RW, Housain B, Dixon J. The effect of oral selenium supplementation on human sperm motility. British Journal of Urology 1998;82(1):76–80. [MEDLINE: 9698665]

Scott 2005  {published data only}
Scott DA, Poston RN, Wilson RF, Coward PY, Palmer RM. The influence of vitamin C on systemic markers of endothelial and inflammatory cell activation in smokers and non-smokers. Inflammation Research 2005;54:138–44.

SECURE 2001  {published data only}
* Lonn E, Yusuf S, Dravik V, Doris C, Yi Q, Smith S, et al. Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation 2001;103(7):919–25. [MEDLINE: 11181464]
Lonn EM, Yusuf S, Doris CI, Sahbine MJ, Dravik V, Hutchison K, et al. Study design and baseline characteristics of the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E: SECURE. American Journal of Cardiology 1996;78(8):914–9. [MEDLINE: 8888665]

Seppanen 2000  {published data only}
Seppanen K, Kantola M, Laatikainen R, Nyyssonen K, Valkonen VP, Kaarlopp V, et al. Effect of supplementation with organic selenium on mercury status as measured by mercury in pubic hair. Journal of Trace Elements in Medicine and Biology 2000;14:84–7.

Serwin 2003  {published data only}
Serwin AB, Mysliwiec H, Hukalowicz K, Potrebki P, Borawska M, Chodynicka B. Soluble tumor necrosis factor-alpha receptor type 1 during selenium supplementation in psoriasis patients. Nutrition 2003;19:847–50.

Shafat 2004  {published data only}
Shafat A, Butler P, Jensen RL, Donnelly AE. Effects of dietary supplementation with vitamins C and E on muscle function during and after eccentric contractions in humans. European Journal of Applied Physiology 2004;93:196–202.

Shahar 2004  {published data only}
Shahar E, Hassoun G, Pollack S. Effect of vitamin E supplementation on the regular treatment of seasonal allergic rhinitis. Annals of Allergy, Asthma & Immunology 2004;92:654–8.

Shriqui 1992  {published data only}
Shriqui CL, Bradwejn J, Annable L, Jones BD. Vitamin E in the treatment of tardive dyskinesia: a double-blind placebo-controlled study. American Journal of Psychiatry 1992;149:391–3.

Simon-Schnass 1999  {published data only}
Simon-Schnass I, Korniszewski L. The influence of vitamin E on rheological parameters in high altitude mountaineers. International Journal for Vitamin and Nutrition Research 1999;69:26–34.

Simons 1999  {published data only}
Simons LA, von Konigsmark M, Simons J, Stocker R, Celermajer DS. Vitamin E ingestion does not improve arterial endothelial dysfunction in older adults. Atherosclerosis 1999;143:193–9.

Singh 1992  {published data only}
Singh A, Moses FM, Deuster PA. Vitamin and mineral status in physically active men: effects of a high-potency supplement. American Journal of Clinical Nutrition 1992;55:1–7.

Singh 2002  {published data only}
Singh N, Graves J, Taylor PD, MacAllister RJ, Singer DR. Effects of a ‘healthy’ diet and of acute and long-term vitamin C on vascular function in healthy older subjects. Cardiovascular Research 2002;56:118–25.

Sisto 1995  {published data only}
Sisto T, Paajanen H, Metsa-Ketela T, Harmoinen A, Nordbeck I, Tarkka M. Pretreatment with antioxidants and allopurinol diminishes cardiac onset events in coronary artery bypass grafting. The Annals of Thoracic Surgery 1995;59(6):1519–23. [MEDLINE: 7771834]

SKICAP S/B 1997  {published data only}
Levine N, Moon TE, Carter B, Bangert JL, Rodney S, Dong Q, et al. Trial of retinol and isoretinoin in skin cancer prevention: a randomized, double-blind, controlled trial. Southwest Skin Cancer Prevention Study Group. Cancer Epidemiology, Biomarkers & Prevention 1997;6(11):957–61. [MEDLINE: 9367070]

Skyrme-Jones 2000  {published data only}
Skyrme-Jones RA, O’Brien RC, Berry KL, Meredith JT. Vitamin E supplementation improves endothelial function in type I diabetes mellitus: a randomized, placebo-controlled study. Journal of the American College of Cardiology 2000;36:94–102.

Spiller 1985  {published data only}
Spiller GA, Pattison TS, Jensen CD, Wong LG, Whitam JH, Scala J. Multivitamin-mineral supplementation: effects on blood chemistries of college-age women. Acta Vitaminologica et Enzymologica 1985:7217–22.

Stamper 1988  {published data only}
Stamper MJ, Jakubowski JA, Faigl D, Vaillancourt R, Deykin D. Vitamin E supplementation effect on human platelet function, arachidonic acid metabolism, and plasma prostacyclin levels. American Journal of Clinical Nutrition 1988;47:700–6.

Stark 1985  {published data only}
Stark H. Long-term treatment of senile macular degeneration with Cosodental A+E [Langzeitbehandlung der senilen Makuladegeneration mit Cosodental A + E]. Klinische Monatsblatter für Augenheilkunde 1985;187(4):296–302. [MEDLINE: 3934458]

Steck-Scott 2004  {published data only}
Steck-Scott S, Arab L, Craft NE, Sumer MJ. Plasma and lung macrophage responsiveness to carotenoid supplementation and ozone exposure in humans. European Journal of Clinical Nutrition 2004;58:1571–9.
Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases (Review)

Steinberg 1998 (published data only)
Steinberg FM, Chait A. Antioxidant vitamin supplementation and lipid peroxidation in smokers. The American Journal of Clinical Nutrition 1998;68:319–27.

Steiner 1995 (published data only)
Steiner M, Glantz M, Lekos A. Vitamin E plus aspirin compared with aspirin alone in patients with transient ischemic attacks. American Journal of Clinical Nutrition 1995;62(6 Suppl):1381S–1384S. [MEDLINE: 7495235]

Stich 1986 (published data only)
Stich HF, Hornby AP, Dunn BP. Beta-carotene levels in exfoliated human mucosa cells following its oral administration. Cancer Letters 1986;30:133–41.

Stich 1988 (published data only)
Stich HF, Hornby AP, Mathew B, Sankaranarayanan R, Nair MK. Response of oral leukoplakias to the administration of vitamin A. Cancer Letters 1988;40(1):93–101. [MEDLINE: 3370632]

Stone 2005 (published data only)
Stone PH, Lloyd-Jones DM, Kinlay S, Frei B, Carlson W, Rubenstein J, et al. Evaluating cardiovascular pathophysiology and anatomy in atherosclerosis. The American Heart Journal 2005;150(3):688–695. [MEDLINE: 16086935]

Subakir 2000 (published data only)
Subakir SB, Setiadi E, Affandi B, Pringgoutomo S, Freisleben HJ. Benefits of vitamin E supplementation to Neoplant users - in vitro and in vivo studies. Toxicology 2000;148:173–8.

Subudhi 2004 (published data only)
Subudhi AW, Jacobs KA, Hagobian TA, Fattor JA, Fulco CS, Muza SR, et al. Antioxidant supplementation does not attenuate oxidative stress at high altitude. Aviation, Space, and Environmental Medicine 2004;75:881–8.

Sumida 1997 (published data only)
Sumida S, Doi T, Sakurai M, Yoshioka Y, Okamura K. Effect of a single bout of exercise and beta-carotene supplementation on the urinary excretion of 8-hydroxy-2′-deoxyguanosine in humans. Free Radical Research 1997;27:607–18.

Taher 2005 (published data only)
Tahir M, Foley B, Pate G, Crean P, Moore D, McCarron N, et al. Impact of vitamin E and C supplementation on serum adhesion molecules in chronic degenerative aortic stenosis: a randomized controlled trial. American Heart Journal 2005;150(2):302–6. [MEDLINE: 16086935]

Tardif 1997 (published data only)
Cote G. Prevention de la restenose post-angioplastie par la therapie antioxidante. Annales de Cardiologie et D’Angiologie 1997;4:223–4.

Title 2000 (published data only)
Title LM, Cummings PM, Giddens K, Nassar BA. Oral glucose loading acutely attenuates endothelium-dependent vasodilation in healthy adults without diabetes: an effect prevented by vitamins C and E. Journal of the American College of Cardiology 2000;36:2185–91.

Tollefson 2000 (published data only)
Tollefson GH, Suec JJ, Szuhbe I, Beadle J, Feng D, Lipinska I, et al. The effect of vitamin C supplementation on coagulability and lipid levels in healthy male subjects. Thrombosis Research 2000;100:35–41.

Tolonen 1985 (published data only)
Tolonen M, Hallmalm M, Sarna S, Vitamin E and selenium supplementation in geriatric patients A double blind preliminary clinical trial. Biological Trace Element Research 1985;7:161–8.

Tooulios 2003 (published data only)
Tooulios D, Antoniades C, Tentolouris C, Tsoufis C, Tzouroua M, Tzourouza R, et al. Effects of combined administration of vitamins C and
and E on reactive hyperemia and inflammatory process in chronic smokers. *Atherosclerosis* 2003;170:261–7.

**Trebble 2005 (published data only)**
Trebble T, Arden NK, Stroud MA, Wootton SA, Burdge GC, Miles EA, et al. Inhibition of tumour necrosis factor-alpha and interleukin 6 production by mononuclear cells following dietary fish-oil supplementation in healthy men and response to antioxidant co-supplementation. *The British Journal of Nutrition* 2005;94:405–12.

**Trebble 2005 (published data only)**
Trebble TM, Stroud MA, Wootton SA, Calder PC, Fine DR, Mullee MA, et al. High-dose fish oil and antioxidants in Crohn's disease and the response of bone turnover: a randomised controlled trial. *The British Journal of Nutrition* 2005;94:253–61.

**Trente 2001 (published data only)**
Trente CA, Koenig JQ, Williams PV. Dietary antioxidants and ozone-induced bronchial hyperresponsiveness in adults with asthma. *Archives of Environmental Health* 2001;56:242–9.

**Tsai 1978 (published data only)**
Tsai AC, Kelley JJ, Peng B, Cook N. Study on the effect of megavi-mineral E supplementation in man.

**Tsai 1998 (published data only)**
Tsai AC, Kelley JJ, Peng B, Cook N. Study on the effect of megavi-mineral E supplementation in man. *American Journal of Clinical Nutrition* 1978;31(5):831–7. [MEDLINE: 347918]

**Tutuncu 1998 (published data only)**
Tutuncu NB, Bayraktar M, Varli K. Reversal of defective nerve conduction with vitamin E supplementation in type 2 diabetes: a preliminary study. *Diabetes Care* 1998;21:1915–8.

**Uden 1990 (published data only)**
Uden S, Bilton D, Nathan L, Hunt LP, Main C, Braganza JM. Antioxidant therapy for recurrent pancreatitis: placebo-controlled trial. *Alimentary Pharmacology & Therapeutics* 1990;4(4):357–71. [MEDLINE: 2103755]

**Uden 1993 (published data only)**
Uden S, Schofield D, Miller PF, Day JP, Bortiglier T, Braganza JM. Antioxidant therapy for recurrent pancreatitis: biochemical profiles in a placebo-controlled trial. *Alimentary Pharmacology & Therapeutics* 1992;6(2):229–40. [MEDLINE: 1600043]

**Uprichard 2000 (published data only)**
Uprichard JE, Sutherland WH, Mann JI. Effect of supplementation with tomato juice, vitamin E, and vitamin C on LDL oxidation and products of inflammatory activity in type 2 diabetes. *Diabetes Care* 2000;23:733–8.

**Uprichard 2003 (published data only)**
Uprichard JE, Schuurman CR, Wiersma A, Tijburg LB, Coolen SA, Rijken PJ, et al. Spread supplemented with moderate doses of vitamin E and carotenoids reduces lipid peroxidation in healthy, nonsmoking adults. *American Journal of Clinical Nutrition* 2003;78:985–92.

**van Amsterdam 2005 (published data only)**
van Amsterdam J, van der Horst-Graat J, Bischoff E, Steenenberg P, Opperhuizen A, Schouten E. The effect of vitamin E supplementation on serum DHEA and neopterin levels in elderly subjects. *International Journal for Vitamin and Nutrition Research* 2005;75:327–31.

**Van Gossum 1995 (published data only)**
Van Gossum A, Neve J. Low selenium status in alcoholic cirrhosis is correlated with aminopyrine breath test. Preliminary effects of selenium supplementation. *Biological Trace Element Research* 1995;47:201–7.

**Van Hoydonck 2004 (published data only)**
Van Hoydonck PG, Schouten EG, Manuel Y, Keenoy B, van Campenhout A, Hoppenbrouwers KP, Temme EH. Does vitamin C supplementation influence the levels of circulating oxidized LDL, sCAM-1, sVCAM-1 and vWF-antigen in healthy male smokers? *European Journal of Clinical Nutrition* 2004;58:1587–93.

**van Poppel 1994 (published data only)**
Van Poppel G, Hespers J, Buytenhek R, Princen HM. No effect of beta-carotene supplementation on plasma lipoproteins in healthy smokers. *American Journal of Clinical Nutrition* 1994;60:730–4.

**van Rhijn 1990 (published data only)**
van Rhijn AG, Prior AC, Corrigan FM. Dietary Supplementation with Zinc Sulphate, Sodium Selenite and Fatty Acids in early dementia of Alzheimer's type. *Journal of Nutritional Medicine* 1990;1:259–66.

**Van Straten 2002 (published data only)**
Van Straten M, Joling P. Preventing the common cold with a vitamin C supplement: a double-blind, placebo-controlled survey. *Advances in Therapy* 2002;19:151–9.

**van Tits 2003 (published data only)**
van Tits Lj, de Waart F, Hak-Lemmers HL, de Graaf J, Demacker PN, Stalenhoof AF. Neutrophil superoxide-anion generating capacity in chronic smoking: effect of long-term alpha-tocopherol therapy. *Journal of Biociences* 2003;28:23–7.

**Vannas 1958 (published data only)**
Vannas S, Orma H. On the treatment of arteriosclerotic chorioteroinopathy. *Acta Ophthalmologica* 1958;36(3):601–12. [MEDLINE: 13594370]

**Vasankari 1997 (published data only)**
Vasankari TJ, Kujala UM, Vasankari TM, Vuorimaa T, Ahotupa M. Increased serum and low-density-lipoprotein antioxidant potential after antioxidant supplementation in endurance athletes. *American Journal of Clinical Nutrition* 1997;65:1052–6.

**Vasankari 1998 (published data only)**
Vasankari T, Kujala U, Sarna S, Ahotupa M. Effects of ascorbic acid and carbohydrate ingestion on exercise induced oxidative stress. *The Journal of Sports Medicine and Physical Fitness* 1998;38:281–5.

**Vega-Lopez 2003 (published data only)**
Vega-Lopez S, Kaul N, Devaraj S, Cai RY, German B, Jialal I. Supplementation with omega3 polyunsaturated fatty acids and all-rac alpha-tocopherol alone and in combination failed to exert an anti-inflammatory effect in human volunteers. *Metabolism* 2004;53:236–40.

**Vela 2000 (published data only)**
Vela C, Cristol JP, Ribstein J, Mitzman A, Descomps B, Mourad G. Antioxidant supplementation and chronic renal transplant dysfunction. *Transplantation Proceedings* 2000;32:427–8.

**Venn 2003 (published data only)**
Venn BJ, Grant AM, Thomson CD, Green TJ. Selenium supplements do not increase plasma total homocysteine concentrations in men and women. *The Journal of Nutrition* 2003;133:418–20.

**Verret 2005 (published data only)**
Verret WJ, Chen Y, Ahmed A, Islam T, Parvez F, Kibriya MG, et al. A randomized, double-blind placebo-controlled trial evaluating the effects of vitamin E and selenium on arsenic-induced skin lesions.
Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases (Review)

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

in Bangladesh. *Journal of Occupational and Environmental Medicine* 2005;47(10):1026–35. [MEDLINE: 16217243]

Vertrugno 2001 *published data only*

Vertrugno M, Maino A, Cardia G, Quaranta GM, Cardia L. A randomised, double masked, clinical trial of high dose vitamin A and vitamin E supplementation after photorefractive keratectomy. *The British Journal of Ophthalmology* 2001;85(5):537–9. [MEDLINE: 11361710]

Viscovich 2004 *published data only*

Viscovich M, Lykkesfeldt J, Poulsen HE. Vitamin C pharmacokinetics of plain and slow release formulations in smokers. *Clinical Nutrition* 2004;23:1043–50.

Volkova 2005 *published data only*

Volkova K, Barancokova M, Kazimirova A, Collins A, Raslova K, Smolkova B, et al. Antioxidant supplementation reduces inter-individual variation in markers of oxidative damage. *Free Radical Research* 2005;39:659–66.

von Herbay 1997 *published data only*

von Herbay A, Stahl W, Niederer C, Sies H. Vitamin E improves the aminotransferase status of patients suffering from viral hepatitis C: a randomized, double-blind, placebo-controlled study. *Free Radical Research* 1997;27(6):599–605. [MEDLINE: 9455695]

Wander 1996 *published data only*

Wändner RC, Du SH, Ketchum SO, Rowe KE. Effects of interaction of RRR-alpha-tocopheryl acetate and fish oil on low-density-lipoprotein oxidation in postmenopausal women with and without hormone-replacement therapy. *The American Journal of Clinical Nutrition* 1996;63:184–93.

Watanabe 1997 *published data only*

Watanabe H, Kakeihana M, Ohrnska S, Sugishita Y. Randomized, double-blind, placebo-controlled study of supplemental vitamin E on attenuation of the development of nitrate tolerance. *Circulation* 1997;96:2545–50.

Watanabe 1998 *published data only*

Watanabe H, Kakeihana M, Ohrnska S, Sugishita Y. Randomized, double-blind, placebo-controlled study of the preventive effect of supplemental oral vitamin C on attenuation of development of nitrate tolerance. *Journal of the American College of Cardiology* 1998;31:1323–9.

Watson 1991 *published data only*

Watson RR, Prabhala RH, Plezia PM, Alberts DS. Effect of beta-carotene on lymphocyte subpopulations in elderly humans: evidence for a dose-response relationship. *American Journal of Clinical Nutrition* 1991;53(1):90–4. [MEDLINE: 1824583]

Welch 1999 *published data only*

Welch RW, Turley E, Sweetman SF, Kennedy G, Collins AR, Dunne A, et al. Dietary antioxidant supplementation and DNA damage in smokers and nonsmokers. *Nutrition and Cancer* 1999;34:167–72.

Wen 1997 *published data only*

Wen Y, Cooke T, Feedy J. The effect of pharmacological supplementation with vitamin C on low-density lipoprotein oxidation. *British Journal of Clinical Pharmacology* 1997;44(1):94–7. [MEDLINE: 9241103]

Wen 1999 *published data only*

Wen Y, Killala S, Norris LA, Cooke T, Feedy J. Vitamin E supplementation in hyperlipidaemic patients: effect of increasing doses on in vitro and in vivo low-density lipoprotein oxidation. *European Journal of Clinical Investigation* 1999;29:1027–34.

Wenzel 1993 *published data only*

Wenzel G, Kuklinska B, Ruhlmann C, Ehhardt D. Alcohol-induced toxic hepatitis - a 'free radical' associated disease. Lowering fatality by adjuvant antioxidant therapy [Alkoholotóxische hepatis – eine freie radikale – assoziierte Erschwerung der Leberzellschaden durch adjuvante antioxidantientherapie]. *Zeitschrift für die gesamte innere Medizin und ihre Grenzgebiete* 1993;48:490–6.

Werninghaus 1994 *published data only*

Werninghaus K, Meydani M, Bhawan J, Margolis R, Blumberg JBM, Gilchrest BA. Evaluation of the photoprotective effect of oral vitamin E supplementation. *Archives of Dermatology* 1994;130:1257–61.

Wesnes 2003 *published data only*

Wesnes K, Luthringer R, Ambrosiatti L, Edgar C, Petrini O. The effects of a combination of Panax ginseng, vitamins and minerals on mental performance, mood and physical fatigue in nurses working night shifts: a double-blind, placebo controlled trial. *Current Topics in Nutraceutical Research* 2003;1:169–74.

Wijnen 2002 *published data only*

Wijnen MH, Roumen RM, Vader HL, Goris RJ. A multiantioxidant supplementation reduces damage from ischaemia reperfusion in patients after lower torso ischaemia. A randomised trial. *European Journal of Vascular and Endovascular Surgery* 2002;23(6):486–90. [MEDLINE: 12093062]

Willett 1983 *published data only*

Willett WC, Stampfer MJ, Underwood BA, Taylor JO, Hennekens CH. Vitamins A, E, and carotene: effects of supplementation on their plasma levels. *The American Journal of Clinical Nutrition* 1983;38:59–66.

Willett 1984 *published data only*

Willett WC, Stampfer MJ, Underwood BA, Sampson LA, Hennekens CH, Wallingford JC, et al. Vitamin A supplementation and plasma retinol levels: a randomized trial among women. *Journal of the National Cancer Institute* 1984;73:1445–8.

Williams 2001 *published data only*

Williams MJ, Sutherland WH, McCormick MP, de Jong SA, McDonald JR, Walker RJ. Vitamin C improves endothelial dysfunction in renal allograft recipients. *Nephrology, Dialysis, Transplantation* 2001;16:1251–5.

Winkler 2005 *published data only*

Winkler P, de Vrese M, Laue Ch, Schrezenmeir J. Effect of a dietary supplement containing probiotic bacteria plus vitamins and minerals on common cold infections and cellular immune parameters. *International Journal of Clinical Pharmacology & Therapeutics* 2005;43:318–26.

Wittenborg 1998 *published data only*

Wittenborg A, Petersen G, Lorkowski G, Brabant T. Effectiveness of vitamin E in comparison with diclofenac sodium in treatment of patients with chronic polyarthritis [Wirksamkeit von vitamin E im vergleich zu Diclofenac–Natrium in der behandlung von patienten mit chronischer polyarthritis]. *Zeitschrift für Rheumatologie* 1998;57(4):215–21. [MEDLINE: 9782602]

Wolters 2005 *published data only*

Wolters M, Hickstein M, Flintermann A, Tewes U, Hahn A. Cognitive performance in relation to vitamin status in healthy elderly Ger-
man women—the effect of 6-month multivitamin supplementation. Preventive Medicine 2005;41:253–9.

Wood 1999 [published data only]
Wood SM, Beckham C, Yoshioka A, Darban H, Watson RR. Beta-caro
tene and selenium supplementation enhances immune response in aged humans. Integrative Medicine 2000;2(2):85–92. [MEDLINE: 10882881]

Woodside 1999 [published data only]
Woodside JV, Young IS, Yarnell JW, Roxborough HE, McMaster D, McCrum EE, et al. Antioxidants, but not B-group vitamins increase the resistance of low-density lipoprotein to oxidation: a randomized, factorial design, placebo-controlled trial. Atherosclerosis 1999;144: 419–27.

Wu 2004 [published data only]
Wu D, Han SN, Meydani M, Meydani SN. Effect of concomitant consumption of fish oil and vitamin E on production of inflammatory cytokines in healthy elderly humans. Annals of the New York Academy of Sciences 2004;1031:422–4.

Wu 2001 [published data only]
Wu Yi, Li B, Li J, Ma J, Tian T, Wang N. Prevention of endemic arsenicism with selenium. Current Science 2001;81:1215–8.

Xia 2005 [published data only]
Xia Y, Hill KE, Byrne DW, Xu J, Bark RE. Effectiveness of selenium supplements in a low-selenium area of China. American Journal of Clinical Nutrition 2005;81(4):829–34. [MEDLINE: 15817859]

Xu 1992 [published data only]
Xu MJ, Plezia PM, Albert D, Emerson SS, Yager PM, Yager SM, et al. Reduction in plasma or skin alpha-tocopherol concentration with long-term oral administration of beta-carotene in humans and mice. Journal of the National Cancer Institute 1992;84:1559–65.

Yu 1990 [published data only]
Yu SY, Mao BL, Xiao P, Yu WP, Wang YL, Huang CZ, et al. Intervention trial with selenium for prevention of lung cancer among tin miners in Yunnan, China. A pilot study. Biological Trace Element Research 1990;24:105–8.

Yu 1991 [published data only]
Yu SY, Zhu YJ, Li WG, Huang QS, Huang CZ, Zhang QN, et al. A preliminary report on the intervention trials of primary liver cancer in high-risk populations with nutritional supplementation of selenium in China. Biological Trace Element Research 1991;29(3):289–94.

Yu 1997 [published data only]
Yu SY, Zhu YJ, Li WG. Protective role of selenium against hepatitis B virus and primary liver cancer in Qidong. Biological Trace Element Research 1997;56:117–24. [MEDLINE: 97297046]

Zaridze 2002 [published data only]
Zaridze D, Evstifeeva T, Boyle P. Abstract Chemoprevention of oral leukoplakia and chronic esophagitis in an area of high incidence of oral and esophageal cancer. Annals of Epidemiology 1993;3(3):225–34. [MEDLINE: 8275193]

Zhu 2002 [published data only]
Zhu S, Mason J, Shi Y, Hu Y, Li R, Wang M, et al. The effect of folic acid on the development of stomach and other gastrointestinal cancers. Chinese Medical Journal 2003;116(1):15–9. [MEDLINE: 12667580]

References to ongoing studies

APPOSE 2001 [published data only]
Costello AJ. A randomized, controlled chemoprevention trial of sele
nium in familial prostate cancer: Rationale, recruitment, and design issues. Urology 2001;57(4):182–4. [MEDLINE: 11295622]

PHS II 2000 [published data only]
Christen WG, Gaziano JM, Hennekens CH. Design of Physicians’ Health Study II a randomized trial of beta-carotene, vitamins E and C, and multivitamins, in prevention of cancer, cardiovascular disease, and eye disease, and review of results of completed trials. Annals of Epidemiology 2000;10(2):125–34. [MEDLINE: 10691066]

SELECT 2003 [published data only]
Klein EA. Selenium and vitamin E cancer prevention trial. Annals of the New York Academy of Sciences 2004;1031:254–41. [MEDLINE: 15753149]

WACS 1995 [published data only]
Bassuk SS, Albert CM, Cook NR, Zaharris E, MacFadyen JG, Danielson E, et al. The Women’s Antioxidant Cardiovascular Study: design and baseline characteristics of participants. Journal of Women’S Health 2004;13(1):99–117. [MEDLINE: 15006283]

* Manson JE, Gaziano JM, Spelsberg A, Ricker PM, Cook NR, Bur
ing JE, et al. A secondary prevention trial of antioxidant vitamins and cardiovascular disease in women. Rationale, design, and methods. The WACS Research Group. Annals of Epidemiology 1995;5(4):261–9. [MEDLINE: 8520707]

Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases (Review) 71

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Zielinski 1978 [published data only]
Zielinski HW. On the treatment of arteriosclerotic retinopathy with Cosdalon A+ E [Zur behandlung der arteriosklerotischen Chori
tenopathie mit Cosdalon R A + E]. Klinische Monatsblatter fur Augenheilkunde 1978;175(6):857–64. [MEDLINE: 752204]

Zimmermann 1997 [published data only]
Zimmermann T, Albrecht S, Kühne H, Vogelsang U, Grützner R, Koppraud S. Selenium administration in patients with sep sis syndrome. A prospective randomized study [Selenubstirbution bei Sep
sipatienten. Eine prospektiv randomisierte Studie]. Medizinische Klinik 1997;92(Suppl III):3–4.

Zollinger 1999 [published data only]
Zollinger PE, Tünheim WE, Kreis RW, Bredervedd RS. Effect of vitamin C on frequency of reflex sympathetic dystrophy in wrist fractures: a randomised trial. Lancet 1999;354:2025–8.

gastrointestinal cancers - Clinical trial and follow-up for seven years. Chinese Journal of Gastroenterology 2002; Vol. 7, issue 2:73–8.

Zollinger 1999 [published data only]
Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases (Review) 72

Additional references

Altmann 2003
Altmann DG, Bland JM. Interaction revisited: the difference between two estimates. BMJ 2003;326(7382):219. [MEDLINE: 12543843]

Ames 1993
Ames BN, Shigenaga MK, Hagen TM. Oxidants, antioxidants, and the degenerative diseases of aging. Proceedings of the National Academy of Sciences of the United States of America 1993;90:7915–22.

Anonymous 2000a
Panel on Micronutrients, Subcommittees on Upper Reference Levels of Nutrients and of Interpretation and Use of Dietary Reference Intakes, and the Standing Committee on the Scientific Evaluation of Dietary Reference Intakes. Institute of Medicine, Food and Nutrition Board. Dietary reference intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc. National Academy Press, Washington DC 2000:1–800.

Anonymous 2000b
Panel on Dietary Antioxidants and Related Compounds, Subcommittees on Upper Reference Levels of Nutrients and Interpretation and Uses of DRI, Standing Committee on the Scientific Evaluation of Dietary Reference Intakes, Food and Nutrition Board. Institute of Medicine. Dietary reference intakes for Vitamin C, Vitamin E, Selenium, and Carotenoids. National Academy Press, Washington, DC 2000:1–529.

Atkins 2002
Atkins D, Sherry P. Update of the evidence from randomized controlled trials, 1999-2002. Routine vitamin supplementation to prevent cancer. http://www.ahrq.gov/clinic/3rduspstf/vitamins/vitupdate.htm. Agency for Healthcare Research and Quality, Rockville, MD., (accessed 24 May 2007).

Balluz 2000
Balluz LS, Kieszak SM, Philen RM, Mulinare J. Vitamin and minerals supplement use in the United States. Results from the third National Health and Nutrition Examination Survey. Archives of Family Medicine 2000;9:258–62.

Bast 2002
Bast A, Haenen GR. The toxicity of antioxidants and their metabolites. Environmental Toxicology and Pharmacology 2002;11:251–8.

Begg 1994
Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088–101.

Berger 2005
Berger MM. Can oxidative damage be treated nutritionally. Clinical Nutrition 2005;24(2):172–83. [MEDLINE: 15784476]

Bjelakovic 2003
Bjelakovic G, Nikolova D, Simonetti R. Antioxidants for preventing gastrointestinal cancers. Cochrane Database of Systematic Reviews 2003, Issue 2. [DOI: 10.1002/14651858.CD004183]

Bjelakovic 2004
Bjelakovic G, Nikolova D, Simonetti RG, Gluud C. Antioxidant supplements for preventing gastrointestinal cancers. Cochrane Database of Systematic Reviews 2004, Issue 4. [DOI: 10.1002/14651858.CD004183.pub2]

Bjelakovic 2006
Bjelakovic G, Nagorni A, Nikolova D, Simonetti RG, Bjelakovic M, Gluud C. Meta-analysis: antioxidant supplements for primary and secondary prevention of colorectal adenoma. Alimentary Pharmacology & Therapeutics 2006;24:281–91.

Bjelakovic 2007b
Bjelakovic G, Gluud C. Surviving antioxidant supplements. Journal of the National Cancer Institute 2007;99:742–3.

Bleys 2007a
Bleys J, Navas-Acien A, Guallar E. Serum selenium and diabetes in U.S. adults. Diabetes Care 2007;30(4):829–34.

Bleys 2007b
Bleys J, Navas-Acien A, Guallar E. Selenium and diabetes: more bad news for supplements. Annals of Internal Medicine 2007;147(4):271–2.

Block 1992
Block G, Patterson B, Subar A. Fruit, vegetables, and cancer prevention: a review of the epidemiological evidence. Nutrition and Cancer, 1992;18:1–29.

Bradburn 2007
Bradburn MJ, Deeks JJ, Berlin JA, Russell Localio A. Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Statistics in Medicine 2007;26:53–77.

Brown 2005
Brown BG, Crowley J. Is there any hope for vitamin E. JAMA 2005;293(11):1387–90. [MEDLINE: 15769974]

Caraballoso 2003
Caraballoso M, Sacristan M, Serra C, Bonfill X. Drugs for preventing lung cancer in healthy people. Cochrane Database of Systematic Reviews 2003, Issue 2. Art. No.: CD002141. DOI: 10.1002/14651858.CD002141.

Davies 2006
Davies AA, Davey Smith G, Harbord R, Bekkering GE, Sterne JA, Beynon R, et al. Nutritional interventions and outcome in patients with cancer or preinvasive lesions: systematic review. Journal of the National Cancer Institute 2006;98(14):961–73. [MEDLINE: 16849679]

DeMets 1987
DeMets DL. Methods for combining randomized clinical trials: strengths and limitations. Statistics in Medicine 1987;6(3):341–50.

DeSimonian 1986
DeSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7(3):177–88.

Devraj 2005
Devraj S, Jialal I. Failure of vitamin E in clinical trials: is gammatoopherol the answer. Nutrition Reviews 2005;63:290–3.

Dickersin 2003
Dickersin K, Rennie D. Registering clinical trials. Journal of the American Medical Association 2003;290:516–23.

Diplock 1994
Diplock AT. Antioxidants and disease prevention. Molecular Aspects of Medicine 1994;15:293–376.

Diplock 1998
Diplock AT, Charleux JL, Crozier-Willi G, Kok FJ, Rice-Evans C, Roberfroid M, et al. Functional food science and defence against re-
Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases (Review)

Huang 2006
Huang HY, Caballero B, Zhang S, Alberg AJ, Semba RD, Schneyer CR, et al. The efficacy and safety of multivitamin and mineral supplement use to prevent cancer and chronic disease in adults: a systematic review for a National Institutes of Health state-of-the-science conference. *Annals of Internal Medicine* 2006;145(5):372–85. [MEDLINE: 16880453]

Kawanishi 2005
Kawanishi S, Oikawa S, Murata M. Evaluation for safety of antioxidant chemopreventive agents. *Antioxidants & Redox Signaling* 2005;7:1728–39.

Klein 2003
Klein EA, Thompson IM, Lippman SM, Goodman PJ, Albames D, Taylor PR, et al. SELECT: the selenium and vitamin E cancer prevention trial. *Urologic Oncology* 2003;21:59–65.

Lawson 2007
Lawson KA, Wright ME, Subar A, Mouch T, Hollenbeck A, Scharzhklin A, et al. Multivitamin use and risk of prostate cancer in the National Institutes of Health - AARP diet and health study. *Journal of the National Cancer Institute* 2007;99(10):754–64.

Lee 2003
Lee BM, Park KK. Beneficial and adverse effects of chemopreventive agents. *Mutation Research* 2003;523-4:265–78.

Machlin 1987
Machlin LJ, Bendich A. Free radical tissue damage: protective role of antioxidant nutrients. *The FASEB Journal* 1987;1:441–5.

Maxwell 1999
Maxwell SR. Antioxidant vitamin supplements: update of their potential benefits and possible risks. *Drug Safety* 1999;21(4):253–66. [MEDLINE: 10514018]

McAlister 2003
McAlister AL, Strauss SE, Sackett DL, Altman DG. Analysis and reporting of factorial trials - A systematic review. *Journal of the American Medical Association* 2003;289:2545–53.

McKeith 2003
McKeith B, Kelly C, Stanner S, Hughes J, Buttriss J. The Food Standards Agency's antioxidants in food programme - a summary. *Journal of Human Nutrition and Dietetics* 2003;16:257–63.

Muller 2004
Mullen AE, Dodd KW, Subar AF. Use of vitamin, mineral, nonvita-

min, and nonmineral supplements in the United States: The 1987, 1992, and 2000 National Health Interview Survey results. *Journal of the American Dietetic Association* 2004;104:942–50.

Muller 2005
Miller ER 3rd, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high-dose vitamin E supplementation
Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases (Review)

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

may increase all-cause mortality. *Annals of Internal Medicine* 2005; 142:37–46.

**Moher 1998**
Moher D, Plam B, Jones A, Cook D, Jadad A, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analysis. *Lancet* 1998;352:609–13.

**Murata 2000**
Murata M, Kawanishi S. Oxidative DNA damage by vitamin A and its derivative via superoxide generation. *The Journal of Biological Chemistry* 2000;275(3):2003–8. [MEDLINE: 10636903]

**Nichter 2006**
Nichter M, Thompson JJ. For my wellness, not just my illness. North Americans’ use of dietary supplements. *Culture, Medicine and Psychiatry* 2006;30:175–222.

**Palace 1999**
Palace VP, Khaspey N, Qin Q, Singal PK. Antioxidant potentials of vitamin A and carotenoids and their relevance to heart disease. *Free Radical Biology & Medicine* 1999;26:746–61.

**Paolini 2003**
Paolini M, Abdel-Rahman SZ, Sapone A, Pedulli GF, Perocco P, Cantrell-Forti G, et al. Beta-carotene: a cancer chemopreventive agent or a co-carcinogen?. *Mutation Research* 2003;543(3):195–200.

**Pocock 2004**
Pocock SJ. *Clinical Trials: A Practical Approach*. John Wiley & Sons, 2004.

**Podmore 1998**
Podmore ID, Griffiths HR, Herbert KE, Mistry N, Mistry P, Lunec J. Vitamin C exhibits pro-oxidant properties. *Nature* 1998;392(6670):559.

**Radimer 2004**
Radimer K, Binnewald B, Hughes J, Ervin B, Swanson C, Picciano MF. Dietary supplement use by US adults: data from the National Health and Nutrition Examination Survey, 1999–2000. *American Journal of Epidemiology* 2004;160:339–49.

**Ratnam 2006**
Ratnam DV, Ankola DD, Bhardwaj V, Sahana DK, Kumar MN. Role of antioxidants in prophylaxis and therapy: a pharmaceutical perspective. *Journal of Controlled Release* 2006;113:189–207.

**RevMan 2003**
Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 4.2 for Windows. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2003.

**Ritenbaugh 1999**
Ritenbaugh C, Streit K, Helfand M. Routine vitamin supplementation to prevent cancer: Summary of evidence from randomized controlled trials. http://www.ahrq.gov/clinic/3rduspst/vitamins/vitasum.htm. Agency for Healthcare Research and Quality, Rockville, MD, (accessed 24 May 2007).

**Royle 2003**
Royle P, Milne R. Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches. *International Journal of Technology Assessment in Health Care* 2003;19:591–603.

**Salganik 2001**
Salganik RI. The benefits and hazards of antioxidants: controlling apoptosis and other protective mechanisms in cancer patients and the human population. *Journal of the American College of Nutrition* 2001;20(5 Suppl):4645–472S. [MEDLINE: 11603657]

**SCF 2003**
European Commission Scientific Committee on Food. Opinion of the Scientific Committee on Food on the Tolerable Upper Intake Level of Vitamin E. 2003.

**Schulz 1995**
Schulz KE, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. *Journal of the American Medical Association* 1995;273:608–12.

**Schulz 2007**
Schulz TJ, Zarse K, Voigt A, Urban N, Birringer M, Ristow M. Glucose restriction extends *Caenorhabditis elegans* life span by inducing mitochondrial respiration and Increasing oxidative stress. *Cell Metabolism* 2007;6(4):280–293. [MEDLINE: 17908557]

**Sies 1985**
Sies H. Introductory remarks. In: Sies H editor(s). *Oxidative Stress*. Orlando, Fla: Academic Press, 1985:1–7.

**Simon 2000**
Simon HU, Haj-Yehia A, Levi-Schaffer F. Role of reactive oxygen species (ROS) in apoptosis induction. *Apoptosis* 2000;5(5):415–8. [MEDLINE: 11256882]

**Stanner 2004**
Stanner SA, Hughes J, Kelly CN, Buttriss J. A review of the epidemiological evidence for the ‘antioxidant hypothesis’. *Public Health Nutrition* 2004;7:407–22.

**Stranges 2007**
Stranges S, Marshall JR, Narazajan R, Donahue RP, Trevisan M, Combs GF, et al. Effects of long-term selenium supplementation on the incidence of type 2 diabetes: a randomized trial. *Annals of Internal Medicine* 2007;147(4):217–23.

**Sweeting 2004**
Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of continuity corrections in meta-analyses of sparse data. *Statistics in Medicine* 2004;23:1351–75.

**van Poppel 1997**
van Poppel G, van den Berg H. Vitamins and cancer. *Cancer Letters* 1997;114:195–202.

**Vertuani 2004**
Vertuani S, Angusti A, Manfredini S. The antioxidants and pro-antioxidants network: an overview. *Current Pharmaceutical Design* 2004;10:1677–94.

**Vivekananthan 2003**
Vivekananthan DP, Penn MS, Sapp SK, Hsu A, Topol EJ. Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials. *Lancet* 2003;361(9374):2017–23.
References to other published versions of this review

Bjelakovic 2007a

Bjelakovic G, Nikolova D, Gluud LL, Simoneti RG, Gluud C. Mortality in randomized trials on antioxidant supplements for primary and secondary prevention. Systematic review and meta-analysis. JAMA 2007;297(8):842–57.

* Indicates the major publication for the study
### Characteristics of included studies  
**[ordered by study ID]**

**ADCS 1 1997**

| Methods | Alzheimer’s Disease Cooperative Study (ADCS 1)  
Randomised, double-blind, placebo-controlled trial with two-by-two factorial design.  
Generation of the allocation sequence: unclear, not reported.  
Allocation concealment: unclear, not reported.  
Blinding: adequate, identical placebo pills.  
Follow-up: adequate. The losses to follow-up were 7% in the placebo group, 5% in the selegiline group, 9% in the alpha-tocopherol group, and 6% in the selegiline and alpha-tocopherol group.  
Intention-to-treat analysis: yes.  
Sample-size calculation: yes. |
|---|---|
| Participants | Country: United States of America.  
Number of participants randomised: 341, older than 18 years, mean age 73 years, 65% females from 23 centres participating in the Alzheimer’s Disease Co-operative Study  
Inclusion criteria: patients with probable Alzheimer’s disease of moderate severity, as measured by a Clinical Dementia Rating of 2, free of other central nervous system diseases, were not taking psychoactive medications, and were residing either at home or in a supervised setting with a care giver but not in a skilled-nursing facility.  
Exclusion criteria: none stated. |
| Interventions | The patients were randomly assigned to receive:  
group 1: selegiline 5 mg (n = 87),  
group 2: alpha-tocopherol 1000 IU (n = 85),  
group 3: selegiline and alpha-tocopherol (n = 85),  
group 4: placebo (n = 84).  
Selegiline was given in a dose of 5 mg twice a day, and a racemic mixture of dl-alpha-tocopherol was given in a dose of 1000 IU twice a day. Both agents were given in the morning and in the afternoon for two years. |
| Outcomes | The primary outcome measure was: the time to the occurrence of any one of the following outcomes: death; institutionalisation; loss of the ability to perform at least two of three basic activities of daily living (ie, eating, grooming, using the toilet), as measured by part 2 of the Blessed Dementia Scale; and severe dementia, defined as a Clinical Dementia Rating of 3.  
Secondary outcome measures were: measures of cognition, function, behaviour, and the presence or absence of extrapyramidal signs. |
| Notes | Compliance was monitored in two ways. At each visit, unused medication was returned and the pills were counted. Measures to counter poor compliance included additional phone contact or review of the correct medication dosing schedule with the appropriate caregivers. Compliance was also monitored with surveillance of serum tocopherol concentrations, and the level of selegiline was monitored by measuring amphetamine, its major metabolite, in the urine.  
Compliance with treatment was good. Urine samples were available from 318 patients for analysis of amphetamine levels. The proportion of patients with positive tests for selegiline was 93% in the combined... |
group, 98% in the selegiline group, 11% in the alpha-tocopherol group, and 13% in the placebo group. Serum samples were available from 332 patients. The proportion of patients with positive tests for alphatocopherol was 91% in the combined group, 93% in the alpha-tocopherol group, 9% in the selegiline group, and 12% in the placebo group. Follow-up was conducted one month after enrolment and at three-month intervals for the remainder of the two-year trial period. At each interval, every effort was made to assess primary and secondary outcomes, regardless of whether an outcome measure had been reached or the medication had been discontinued. Study agents were supplied by Somerset Pharmaceuticals, Tampa, Fla. (Selegiline) and Hoffmann-LaRoche, Nutley, N.J. (alpha tocopherol).

### Risk of bias

| Item                  | Authors' judgement | Description |
|-----------------------|--------------------|-------------|
| Allocation concealment?| Unclear            | B - Unclear |

### ADCS 2 2005

#### Methods

Alzheimer’s Disease Cooperative Study (ADCS 2). Randomised, double-blind, placebo-controlled trial with parallel group design. Generation of the allocation sequence: unclear, not reported. Allocation concealment: unclear, not reported. Blinding: adequate, identical placebo pills. Follow-up: adequate. A total of 230 (29.9%) participants discontinued treatment during the double-blind phase; 92 in the donepezil group, 72 in the vitamin E group, and 66 in the placebo group. Intention-to-treat analysis: yes. Sample-size calculation: no.

#### Participants

Country: United States and Canada. Number of participants randomised: 769, 417 (54%) men and 352 (46%) women, aged 55-90 years, mean age 72.9 years. Inclusion criteria: amnestic mild cognitive impairment (MCI), age 55-90 years, inclusive, study informant available, mini-mental state examination (MMSE) 24-30, adequate vision and hearing for neuropsychological testing, normal vitamin B12 level and thyroid function studies and non-reactive rapid plasma reagin, electrocardiogram normal or no clinically significant abnormalities, a clinical dementia rating (CDR) of 0.5, all participants and study informants signed written consent. Exclusion criteria: significant cerebral vascular disease, depression, central nervous system infarct, infection or focal lesions of clinical significance on computed tomography or magnetic resonance Imaging, medical diseases or psychiatric disorders that could interfere with study participation, pregnant, lactating or of child bearing potential, taking vitamin supplements, other supplements or a multi-vitamin, restrictions on concomitant medication usage, including those with significant cholinergic or anticholinergic effects or potential adverse effects on cognition.
Participants were randomly assigned to receive:
group 1: 2000 IU of vitamin E, placebo donepezil, and a multivitamin daily (n = 257);
group 2: 10 mg of donepezil, placebo vitamin E, and a multivitamin daily (n = 253);
group 3: placebo vitamin E, placebo donepezil, and a multivitamin daily (n = 259);
over a period of 3 years.

The multivitamin contained 15 IU of vitamin E.
The initial dose of donepezil was 5 mg daily, and the dose was increased to 10 mg after six weeks.
The initial dose of vitamin E was 1000 IU daily, and the dose was increased to 2000 IU (1000 IU twice daily) after six weeks. If a participant had difficulty tolerating the higher dose of vitamin E or donepezil, the investigator could reduce the dose of either medication temporarily and then rechallenge with the higher dose.

On verification by a central review committee that a participant met clinical criteria for Alzheimer’s disease, the participant stopped taking donepezil or matching placebo in a blinded fashion and was offered open-label donepezil until he or she completed the study at month 36.

The primary outcome measure was: the time to the development of possible or probable Alzheimer's disease.
The secondary outcome measures were: the scores for the mini-mental state examination (MMSE); the Alzheimer’s Disease Assessment Scale, cognitive subscale (ADAS-Cog); the global CDR (Clinical Dementia Rating); the CDR sum of boxes (the sum of individual CDR domain scores); the ADCS Mild Cognitive Impairment Activities of Daily Living Scale; the Global Deterioration Scale; and a neuropsychological battery of tests.

Compliance with treatment is not described.
Supported by a grant from Pfizer and Eisai. DSM Nutritional Products donated the vitamin E.

### Risk of bias

| Item                  | Authors’ judgement | Description   |
|-----------------------|--------------------|---------------|
| Allocation concealment? | Unclear            | B - Unclear   |
Allsup 2004

### Methods
Randomised, double-blind, placebo-controlled trial with parallel group design.

- **Generation of the allocation sequence:** adequate, using a computer generated list of random numbers in the order in which consent was obtained.
- **Allocation concealment:** adequate, the identities of placebo and supplement were kept with the manufacturer (Recip AB, Arsta, Sweden) and were not revealed to the researchers until all data had been analysed.
- **Blinding:** adequate, active intervention and placebo had identical appearance.
- **Follow-up:** adequate. Analysed for primary outcome were 61 (75.3%) participants in the active and 57 (68.7%) participants in the placebo group. Overall, 20 participants in the active and 26 participants in the placebo group were lost to follow-up.

Intention-to-treat analysis: yes.
Sample size calculations: yes.

### Participants
- **Country:** Great Britain
- **Number of participants randomised:** 164, mean age 83 (37% males).
- **Inclusion criteria:** older people (60 or older) living in nursing and residential homes able to give informed consent (abbreviated mental test score \(> 7\)), not having neoplastic disease, and not prescribed immunosuppressant medication at the time of recruitment.

- **Exclusion criteria:** taking multivitamin supplements, vitamin C, or vitamin B, previous adverse reaction to influenza vaccine.

### Interventions
Participants were randomly assigned to receive:
- **Group 1:** multivitamin and trace element supplement (vitamin A 2666 IU, vitamin D3 400 IU, vitamin E 60 mg, vitamin B1 1.2 mg, vitamin B2 1.4 mg, vitamin B6 3.0 mg, nicotinamide 14 mg, folic acid 0.6 mg, vitamin B12 200 µg, biotin 30 mg, calcium pantothenate 5 mg, vitamin C 120 mg, iron 12 mg, zinc 14 mg, copper 2 mg, iodine 150 µg, manganese 1 mg, chromium 50 µg, selenium 60 µg, molybdenum 100 µg, calcium 240 mg, and magnesium 100 mg, \(n = 81\));
- **Group 2:** placebo, \(n = 83\).

Tablets were taken over an 8-week period.
Influenza vaccine was administered 4 weeks after tablet commencement.

### Outcomes
The primary outcome was: response to influenza vaccine.

### Notes
The nursing staff at each home were responsible for the administration of tablets.

### Risk of bias

| Item                           | Authors’ judgement | Description |
|-------------------------------|--------------------|-------------|
| Allocation concealment?       | Yes                | A - Adequate |

Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases (Review)  
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
**Methods**

Age Related Macular Degeneration Study (AMDS)
Randomised, double-blind placebo-controlled trial with parallel group design.
Generation of the allocation sequence: adequate, on a computer. Group one and group two patients were randomised between capsule number 1601 (starch placebo) and capsule number 1602 (Ocugard) at each centre by the optometrist co-investigator.
Allocation concealment: adequate, coded bottles. Both the capsule for the placebo and antioxidant group (Ocuguard) were formulated by independent laboratories, and an intermediary company was responsible for assigning and maintaining the identity of codes, labelling and distributing masked bottles of capsules to each Medical Centre pharmacy service, informing the Medical Centre of capsule identity in case of adverse reaction, and breaking the code. None of the optometrist and the registered dietician co-investigators and the participants knew of the identity of the capsules.
Blinding: adequate, identical looking capsules.
Follow-up: adequate. Attrition data were as follows: 71 patients at baseline, 61 patients at 6 months, 59 patients at 12 months, and 59 patients at 18 months. Overall 2 participants from active intervention arm and 1 participant from placebo arm were lost to follow-up.
Intention-to-treat analysis: no.
Sample size calculations: no.

**Participants**

Country: United States.
Number of participants randomised: 71, 66 men (93%) and 5 women (7%), mean age 72 years.
Inclusion criteria: monocular one line drop of acuity, not attributable to cataract, amblyopia, systemic or ophthalmic disease, loss of macular reflex, Retinal Pigment Epithelium disruption and drusen observable by 90 degrees lens stereoscopic evaluation.
Exclusion criteria: greater than 1 year prior use of vitamins, veterans who were former prisoners of war and veterans who were chronic alcoholics with tobacco/nutritional amblyopia or gastrointestinal absorption disorders.

**Interventions**

Patients were randomly assigned to receive:
group 1: antioxidants (beta-carotene 20,000 IU; vitamin E 200 IU; vitamin C 750 mg; citrus bioflavonoid complex 125 mg; quercitin 50 mg; bilberry extract 5 mg; rutin 50 mg; zinc picolinate 12.5 mg; selenium 50 μg; taurine 100 mg; n-acetyl cysteine 100 mg; l-glutathione 5 mg; vitamin B2 25 mg; chromium 100 μg (n = 39);
group 2: starch placebo (n = 32);
for a period of 18 months.

**Outcomes**

The primary outcome was: non-exudative age-related macular degeneration.

**Notes**

Compliance with treatment was not described.
Trial agents were provided by Twin Laboratories, Inc., Ronkonkoma, NY.

**Risk of bias**

| Item                  | Authors' judgement | Description |
|-----------------------|--------------------|-------------|
| Allocation concealment? | Yes                | A - Adequate |
### Methods
Age Related Eye Disease Study (AREDS). Randomised, double-blind, placebo-controlled trial.

Generation of the allocation sequence: adequate, centrally by the Co-ordinating Centre using the on-site computers, with procedures to protect the integrity of randomisation. Multiple levels of data encryption ensured the integrity of the treatment assignment files.

Allocation concealment: adequate. Each centre had two treatment assignment databases: one for patients without age-related macular degeneration (AMD); (category 1) containing approximately 100 records consisting of bottle numbers for placebo (five bottle numbers) or antioxidants (five bottle numbers), and one for patients with some AMD (categories 2, 3, or 4) containing approximately 420 records consisting of a different sequence of bottle numbers for placebo and antioxidants (ten bottle numbers each) as well as for zinc and antioxidant and zinc formulations ten bottle numbers each). Each treatment assignment database residing on the hard drives at each Clinical Center is encrypted and includes check numbers to insure tamper-free operation and proper sequential treatment assignments. The computerised randomisation system identified which of the two randomisation tables (category 1 compared to categories 2, 3, or 4) should be used for assigning a treatment, and the participant was randomly assigned a bottle number from the appropriate list.

Blinding: adequate, identical placebo tablets.

Follow-up: adequate. About 2.3% of participants were lost to follow-up. The rate of participants withdrawal from the trial medication was 14% by 60 months and 15% by the end of trial. This rates include participants lost to follow-up and current smokers, 24% of whom withdrew from the trial medication after the results from the clinical trials of beta-carotene and lung cancer were announced. Overall, the vital status was known for 4753 out of 4757 participants.

Intention-to-treat analysis: yes.

Sample-size calculation: yes.

### Participants
Country: United States of America.

Number of participants randomised: 4757; 56% female, aged 55 to 80 years, median age 68 years.

Inclusion criteria: participants free of any illness or condition that would make long-term follow-up or compliance with study medications unlikely or difficult. On the basis of fundus photographs graded by a central reading centre, best corrected visual acuity, and ophthalmologic evaluations, participants were enrolled in one of several AMD categories. At least one eye of each participant was free from eye disease that could complicate assessment of AMD, lens opacity progression, or visual acuity, and that eye could not have had previous ocular surgery (other than cataract surgery).

Exclusion criteria: illness or disorders (eg, history of cancer with a poor 7-year prognosis, major cardiovascular or cerebrovascular event within the last year, haemachromatosis) that would make long term follow-up or compliance with the study protocol unlikely or difficult. Persons bilaterally aphakic or pseudophakic were ineligible for AMD category one.

### Interventions
Participants were divided into two clinical trials:

| Trial                  | Number of Participants |
|------------------------|------------------------|
| AMD Trial (n = 128)    |                        |
| Cataract Trial (n = 4629) |                        |

In the Cataract Trial participants were randomly assigned to receive:

- group 1: placebo (n = 1456);
- group 2: zinc 80 mg (as zinc oxide) (n = 869);
- group 3: beta-carotene 15 mg, vitamin C 500 mg, vitamin E 400 IU, (n = 1451);
- group 4: beta-carotene 15 mg, vitamin C 500 mg, vitamin E 400 IU and zinc (n = 853).
AREDS 2001Low  (Continued)

Two study medication tablets were to be taken each morning and two each evening, to meet the total daily
dose requirement. Tablets were to be taken with food to avoid potential irritation of an empty stomach
by zinc.
Participants were followed up for an average of 6.3 years.

| Outcomes | Primary outcome measures were: an increase from baseline in nuclear, cortical, or posterior subcapsular
opacity grades or cataract surgery, and at least moderate visual acuity loss from baseline (> 15 letters). |
| Notes | Compliance with treatment was checked by random serum assessments. Compliance with treatment was
excellent. Overall adherence was estimated to be 75% or greater (participants took > 75% of their study
tables) for 70% of participants at five years. At 60 months, 20% of participants (20% both for current
smokers and former or non-smokers) reported taking some multivitamin supplement containing at least
one of the study medication. In 1994 and 1996, AREDS participants were informed of the results of the
Alpha-Tocopherol, Beta Carotene Cancer Prevention Study and the Beta-Carotene and Retinol Efficacy
Trial suggesting potential harmful effects of beta-carotene among smokers.
The trial was supported from Bausch & Lomb Inc, Rochester, NY.
Additional information received through personal communication with the authors. |

Risk of bias

| Item | Authors’ judgement | Description |
| Allocation concealment? | Yes | A - Adequate |

ASAP 2003Low

Methods

The Antioxidant Supplementation in Atherosclerosis Prevention (ASAP) Study. Randomised, partially
double-blind, placebo-controlled trial with two-by-two factorial design. Generation of the allocation
sequence: adequate, computer generated randomisation lists. Participants were randomised separately
in four strata of approximately equal size. Allocation concealment: adequate, the masking was carried
out by the provider of the supplements and delivered to the data centre of the Field Centre, Research
Institute of Public Health, University of Kuopio. Blinding: adequate, tablets were identical in appearance,
size, and colour. Follow-up: adequate. Of the 520 participants randomised, 440 (84.6%) completed the
study and underwent the 6-year re-examination. overall, 55 participants in the three vitamin groups and
25 participants in the placebo group were lost to follow-up. Intention-to-treat analysis: yes. Sample-size
calculation: yes.

Participants

Country: Finland. Number of participants randomised: 520, 256 men and 264 postmenopausal women,
smoking and non smoking, aged 45 to 69 years with serum cholesterol > 5 mmol/L (193 mg/dL).
Inclusion criteria: participants with hypercholesterolemia defined as serum cholesterol levels > 5 mmol/L
(193 mg/dL). Exclusion criteria: regular intake of antioxidants, acetasalicylate, or any other drug with
antioxidative properties, severe obesity (body mass index >32 kg/m2), type 1 diabetes, uncontrolled
hypertension (sitting diastolic blood pressure >105 mm Hg), any condition limiting mobility, or severe
disease shortening life expectancy. Premenopausal women and those taking oral oestrogen therapy were
also excluded.
### Interventions

The study consisted of 8-week dietary counselling and placebo lead-in phase, a 3-year double-masked treatment period, and a 3-year open treatment period. The participants were randomly allocated to receive twice daily with meal:

- **Group 1:** d-alpha tocopherol 91 mg (corresponding to 100 mg of d-alpha-tocopheryl acetate and 136 IU of vitamin E) (n = 130);
- **Group 2:** 250 mg slow-release vitamin C (n = 130);
- **Group 3:** both d-alpha-tocopherol and slow-release ascorbic acid in a single tablet (CellaVie), (n = 130);
- **Group 4:** placebo only (n = 130);

for a period of 6 years.

### Outcomes

The primary outcome measure was: progression of carotid atherosclerosis.

### Notes

Compliance with treatment was checked by random serum assessments. Of the 390 participants randomised to supplementation, 335 continued the study after 3 years and 256 (76.4%) took the supplements as instructed for 6 years, whereas 62 participants stopped the supplements during the first 3 study years and additional 18 participants during the last 3 study years. The mean plasma alpha-tocopherol and ascorbate concentration increased in 6 years in the group randomised to supplementation, and in the unsupplemented group decrease. Ferrosan A/S, Denmark, provided the vitamin supplements.

### Risk of bias

| Item                  | Authors' judgement | Description |
|-----------------------|--------------------|-------------|
| Allocation concealment? | Yes                | A - Adequate|

### ATBC 2003Low

#### Methods

Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study (ATBC). Randomised, double-blind, placebo-controlled trial with two-by-two factorial design. Generation of the allocation sequence: adequate, centrally by computer. Randomisation performed in blocks of eight within each of the study areas. Allocation concealment: adequate, coded capsule packs maintained centrally. Blinding: adequate, identical placebo capsules. Follow-up: adequate, no losses to follow-up. Intention-to-treat analysis: yes. Sample size calculations: yes.

#### Participants

Country: Finland. Number of participants randomised: 29,133 males. Inclusion criteria: male smokers (five or more cigarettes daily), aged 50 to 69 years, averaged 57.2 years of age at study entry, who lived in south-western Finland. Exclusion criteria: men with a prior cancer or with other serious illness, or who used vitamin E, vitamin A, or beta-carotene supplements in excess of predefined doses (> 20 mg, > 20000 IU, or > 6 mg, respectively), or anticoagulants.

#### Interventions

Participants were randomly assigned in four groups to receive:

- **Group 1:** alpha-tocopherol 50 mg (n = 7286);
- **Group 2:** beta-carotene 20 mg (n = 7282);
- **Group 3:** alpha-tocopherol and beta-carotene, (n = 7278);
group 4: placebo (n = 7287); daily for five to eight years (median 6.1 years).
All participants took a single capsule daily. The four trial intervention groups were well balanced for all baseline characteristics evaluated. The two-by-two factorial design allowed assessment of the two intervention agents independently, with one-half of participants receiving alpha-tocopherol (n = 14,564) and the other half not (n = 14,569); similarly, half of the participants received beta-carotene (n = 14,560) and half did not (n = 14,573).

The study was conducted between 1985 and 1993 (mean 6.1 years). The active intervention continued through April 30, 1993 and postintervention follow-up until April 30, 2001. Mean follow-up time regarding incident cancers and cause-specific deaths was 12.1 years and overall mortality 14.1 years.

**Outcomes**
The primary outcome measure was: incidence of lung cancer. Secondary outcome measures were: incidence of other major cancers, overall and cause specific mortality and incidence of other diseases.

**Notes**
Compliance with treatment was assessed by counts of the remaining capsules at each visit, by measurement of serum alpha-tocopherol and beta-carotene levels after three years of supplementation, and by measurements in random serum samples throughout the study. Compliance with treatment was excellent with four out of five active participants taking more than 95% of the scheduled capsules. Dropout rate and compliance were similar between all four groups. All capsules were supplied by Hoffmann-La Roche, Basel, Switzerland. Additional information received through personal communication with the authors.

**Risk of bias**

| Item                        | Authors' judgement | Description |
|-----------------------------|--------------------|-------------|
| Allocation concealment?     | Yes                | A - Adequate|

**Bonelli 1998**

**Methods**
Randomised, double-blind, placebo-controlled trial with parallel group design.
Generation of the allocation sequence: unclear, not reported.
Allocation concealment: unclear, not reported.
Blinding: adequate, active intervention and placebo had identical appearance.
Follow-up: adequate. Of 304 patients randomised, 233 (76.6%) underwent at least one endoscopic follow-up examination. Overall, 30 participants in the active treatment group and 41 participant in the placebo group were lost to follow-up.
Intention-to-treat analysis: yes.
Sample size calculations: yes.

**Participants**
Country: Italy.
Number of patients randomised: 304, patients who had histologically confirmed adenomatous polyps removed from the colon, aged 25 to 75 years.
Inclusion criteria: age 25 to 75 years, at least one histologically confirmed colorectal adenoma endoscopically removed with a clean colon as a result of the work up.
Exclusion criteria: Familial adenomatous polyposis, inflammatory bowel diseases, polypectomy performed more than six months before randomisation, adenoma with invasive carcinoma, previous colorectal resection, invasive cancer at any site, life-threatening chronic heart, liver or kidney diseases, current use of vitamin or calcium supplements, mental disability precluding informed consent to participate and adherence to the treatment, patients with 10 adenomas or more and those with large sessile adenomas (3 cm or more in diameter). The clean colon after polypectomy was assessed by means of total colonoscopy. When a total colonoscopy was not feasible a double contrast barium enema was performed. Colonoscopy was scheduled on years one, three and five after randomisation.

### Interventions
Patients were randomly assigned to receive:
- group 1: selenium 200 µg (l-selenemethionine), zinc 30 mg, vitamin A 6000 IU, vitamin C 180 mg, vitamin E 30 mg (n = 147);
- group 2: placebo (n = 157);

daily for 5 years.

### Outcomes
The primary outcome measure was: occurrence of metachronous adenomas detected at follow-up endoscopic examinations.

### Notes
The overall 5 year actuarial compliance to the treatment was 51%. Of the 304 randomised patients, 233 (76.6%) underwent at least one endoscopic follow up examination: 117 in the active compound group and 116 in the placebo group.
Active intervention and placebo were provided by Pharma Nord.
Additional information obtained through personal communication with authors.

## Risk of bias

| Item               | Authors’ judgement | Description |
|--------------------|--------------------|-------------|
| Allocation concealment? | Unclear            | B - Unclear |

---

Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases (Review)  
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
### CARET 2004Low

#### Methods

The Beta-Carotene and Retinol Efficacy Trial (CARET). Randomised, double-blind, placebo-controlled trial with two-by-two factorial design in a pilot phase and then one-by-one. Generation of the allocation sequence: adequate, permuted block design with random block size chosen uniformly among 8, 10, 12, 14, and 16. Allocation concealment: adequate, locked central database with the link between study identifier and intervention assignment; all data analyses were performed centrally; the analyses that involved intervention assignment were performed only by the Co-ordinating Center's statisticians using coded intervention assignment unknown to the statisticians; analyses involving the coded intervention assignments were seen only by CARET's Data and Safety Monitoring Board, Co-ordinating Center statisticians, and a single CARET investigator who saw no participants. Blinding: adequate, identical placebo capsules provided by a sponsor. Follow-up: adequate. The losses to follow-up were less than 2% at the end of treatment. Intention-to-treat analysis: yes. Sample size calculations: yes.

#### Participants

Country: United States of America. Number of participants randomised: 18314; 12025 males and 6289 females. Inclusion criteria: smokers, former smokers, and workers exposed to asbestos at high risk of developing lung cancer. A total of 4060 male workers, mean age 57 years, exposed to asbestos and 14254 heavy smokers (44% of whom were women), mean age 58 years, were randomised. The participants agreed to limit their supplemental intake of vitamin A to less than 5500 IU per day and to take no supplemental beta-carotene.

#### Interventions

CARET builds on the experience of two pilot studies performed in Seattle (1985-1988). The first pilot study initiated a phase III trial of the safety and efficacy of the study vitamins in 816 asbestos-exposed participants randomised to a daily combination of 15 mg 13-carotene and 25,000 IU retinol or a placebo medication. Participants were eligible up to age 74 and were not required to have a history of cigarette smoking; otherwise, the eligibility criteria were the same as for the asbestos-exposed population in CARET. The second pilot study was a phase II trial of the comparative safety of the study vitamins in heavy smokers. The eligibility criteria were identical to those for heavy smokers in CARET. Overall 539 men and 490 women were randomised to one of four intervention groups: group 1: a daily combination of 30 mg 13-carotene and 25,000 IU retinol; group 2: 30 mg 13-carotene only; group 3: 25,000 IU retinol only; group 4: placebo medication. All 1845 participants in the two pilot studies continue to be followed for outcomes in CARET, together with approximately 16,000 additional participants. Participants of CARET trial were randomly assigned to receive: group 1: combination of 30 mg beta-carotene and 25,000 IU vitamin A (n = 9420); group 2: placebo, (n = 8894). Both formulations were given as capsules. Beta-carotene beadlets were combined with retinyl palmitate in a single capsule and dispensed in bottles, which were weighed and their content checked. The design projected active intervention until late 1997. The CARET active intervention was stopped 21 months earlier because of clear evidence of no benefit and substantial evidence of possible harm. The average duration of follow-up was 10.0 years.

#### Outcomes

The primary outcome measure was: the incidence of lung cancer. Other outcomes reported are: mortality rates, and incidence of other cancers.

#### Notes

Compliance was assessed by weighing the returned bottles to estimate the number of capsules remaining (in 85% of the assessments), or by relying on the participants own estimates (in 15% of the assessments). Compliance with treatment was excellent. Among the active participants, the mean rate of capsule consumption was 93% through five years of follow-up, with no significant differences between the treatment groups. Participants who stopped receiving study vitamins for any reason other than death were defined as inactive participants and were still followed for outcomes and counted in the analysis. As of December 15, 1995 ascertainment of vital status for more than 98% was complete. Active agents and placebos were
purchased from Hoffmann-La Roche and formulated by Tischon Corporation. Data were extracted from the primary publication, but additional information was received through personal communication with the authors.

### Risk of bias

| Item                | Authors' judgement | Description   |
|---------------------|--------------------|---------------|
| Allocation concealment? | Yes               | A - Adequate  |

### Chandra 1992

#### Methods

Randomised, double-blind, placebo-controlled trial.
- Generation of the allocation sequence: adequate, four blocks of 24 random numbers.
- Allocation concealment: unclear, not reported.
- Blinding: adequate, the supplement and the placebo appeared identical and were prepared specifically for this study.
- Follow-up: adequate. Five participants on placebo and 3 participants from the supplemented group withdrew from the trial for personal reasons.
- Intention-to-treat analysis: yes.
- Sample-size calculation: no.

#### Participants

Country: Canada.
- Number of participants randomised: 96 independently living, healthy elderly individuals aged 66 to 86 years, mean age 74 years, 41 men and 55 women.
- Inclusion criteria: independently living, healthy elderly individuals over 65 years of age.
- Exclusion criteria: none stated.

#### Interventions

Participants were randomly assigned to receive:
- group 1: vitamin A 400 µg retinol equivalents, beta-carotene 16 mg, thiamin 2.2 mg, riboflavin 1.5 mg, niacin 16 mg, vitamin B6 3.0 mg, folate 400 µg, vitamin B12 4.0 µg, vitamin C 80 mg, vitamin D 4 µg, vitamin E 44 mg, iron 16 mg, zinc 14 mg, copper 1.4 mg, selenium 20 µg, iodine 0.2 mg, calcium 200 mg, and magnesium 100 mg (n = 48);
- group 2: placebo, calcium 200 mg and magnesium 100 mg (n = 48) for one year.
- Influenza vaccine was given four weeks before the end of the study. Participants with infection were treated appropriately with antimicrobial agents and supportive measures.

#### Outcomes

The primary outcome measures were: immunocompetence and occurrence of infection related illness.

#### Notes

Compliance was verified by interview at fortnightly visits and counting of leftover medication. There was no report about the compliance.
Risk of bias

| Item                | Authors’ judgement | Description |
|---------------------|--------------------|-------------|
| Allocation concealment? | Unclear           | B - Unclear |

**CHAOS 1996**

**Methods**
- Cambridge Heart Antioxidant Study (CHAOS).
- Randomised, double-blind, placebo-controlled trial.
- Generation of the allocation sequence: adequate, computer-generated lists.
- Allocation concealment: adequate, computer programme that used a random-number database to allocate treatment by blocks of two after clinical data had been entered.
- Blinding: adequate, identical placebo capsules.
- Follow-up: adequate, complete follow-up data were available in 98% of participants. There were no differences between the groups in completeness of follow-up (98% placebo, 97.8% active treatment).
- Overall 23 participants in the active and 19 participants in the placebo group were lost to follow-up.
- Intention-to-treat analysis: yes.
- Sample-size calculation: yes.

**Participants**
- Country: United Kingdom.
- Number of participants randomised: 2002; 1690 men and 312 women, mean age 61.8 years.
- Inclusion criteria: angiographically proven coronary atherosclerosis.
- Exclusion criteria: prior use of vitamin supplements containing vitamin E.

**Interventions**
- Participants were randomly assigned to receive:
  - group 1: vitamin E 800 IU, and then 400 IU (free 2R,4'R,8'R-alpha-tocopherol from natural sources in soya oil) (n = 1035): 546 patients received 800 IU daily for a median of 731 days (range 3 to 981), and 489 newly recruited patients received 400 IU daily for a median of 366 days (8 to 961). These two groups are not distinguished in the analysis.
  - group 2: matching placebo (oil only), (n = 967).
- Median follow-up was 510 days (range 3 to 981).

**Outcomes**
- The primary outcome measures were: non-fatal myocardial infarction alone and combination of non-fatal myocardial infarction and cardiovascular death.

**Notes**
- Compliance with treatment was measured as the ratio of days that study medication was requested to per-protocol days prescribed. 73.2% of all prescribed alpha-tocopherol or placebo were requested as follow-up medications. There was no difference between treatment groups in the proportion of participants who were 100% compliant with the trial medication (48% placebo, 49% alpha-tocopherol).
- Study agents were supplied by Henkel Corporation (La Grange, Illinois, USA)
- Data were extracted from Mitchinson MJ, Stephens NG, Parsons A, Bligh E, Schofield PM, Brown MJ. Mortality in the CHAOS trial.
- Lancet 1999;353:381-2.
CHAOS 1996Low  (Continued)

### Risk of bias

| Item                  | Authors' judgement | Description  |
|-----------------------|--------------------|--------------|
| Allocation concealment? | Yes                | A - Adequate |

#### Collins 2003Low

**Methods**
- Randomised, double-blind, placebo-controlled trial with two-by-two factorial design.
- Generation of the allocation sequence: adequate, using computer generated permuted blocks.
- Allocation concealment: adequate, for the vitamin E randomisation sequence was given to research pharmacist and the prescription bottles were coded. Experimental and control assignments were in sealed envelopes.
- Blinding: adequate, identical placebo capsules.
- Follow-up: adequate. Six randomised participants did not complete the study; 1 participant from the exercise and vitamin E group, 3 participants from exercise plus placebo group, and 2 participants from the placebo group.
- Intention-to-treat analysis: yes.
- Sample size calculations: yes.

**Participants**
- Country: United States of America. Number of participants randomised: 52, mean age 67, 98% males.
- Inclusion criteria: current diagnosis of peripheral arterial disease, a history of intermittent claudication, and an ankle-brachial index < 0.95 at rest and/or < 0.85 after exercise.
- Exclusion criteria: taking any of the following drugs, vitamin E, Coumadin, or pentoxifylline.

**Interventions**
- Participants were randomly assigned in four groups to receive:
  - group 1: PoleStriding exercise with vitamin E (n = 13);
  - group 2: PoleStriding exercise with placebo (n = 14);
  - group 3: vitamin E without PoleStriding exercise (n = 13);
  - group 4: placebo without exercise (n = 12).
- The dose of vitamin E was 400 IU daily. Participants were supplemented 0.5 year, and followed 2.5 years.
- PoleStriding is a form of walking that uses muscles of the upper and lower body in a continuous movement similar to cross country skiing.

**Outcomes**
- The primary outcome was: walking ability and perceived quality of life.

**Notes**
- Compliance with the study drug treatment was monitored in two ways: patient self-report and measured vitamin E levels. Vitamin E levels were obtained at baseline and 3 and 6 months. Investigators did not receive the measured vitamin E levels until the trial ended.
- For the first 3 months drug compliance was assessed biweekly by the study staff and monthly thereafter.
- Vitamin E and placebo capsules were provided by the Henkel Corporation, La-Grange, IL.
- Additional information received through personal communication with the authors.

---

**Risk of bias**
### Allocation concealment?

| Item                        | Authors’ judgement | Description |
|-----------------------------|--------------------|-------------|
| Allocation concealment?     | Yes                | A - Adequate|

### Correa 2000Low

#### Methods

Randomised, controlled, partially double-blind, chemoprevention trial with two-by-two-by-two factorial design.

Generation of the allocation sequence: adequate, computer-generated lists. Participants were randomly assigned in a single step, using a permuted block design, to one of eight different treatment regimens. Allocation concealment: adequate, coded capsules.

Blinding: adequate, using identical placebo capsules.

Follow-up: adequate, the average rate of loss was 4.3% per year over the six-year trial. Two hundred twenty-one participants withdrew from the study before their 72-month evaluation: 102 quitted treatment, 59 were lost to follow-up, 34 dropped out of the study because of pregnancy and other medical conditions, 18 died of causes unrelated to gastric cancer, and eight developed cancer other than gastric cancer. In one participant, the 72-month biopsy specimen was inadequate for histologic evaluation and determination of outcome. A total of 684 participants came to the 36-month biopsy; of those, 92% (631) came for the 72-month biopsy, there was a dropout rate of 2.6% per year for the last three years of the trial. Overall 24 participants from the placebo group, 25 from anti-Helicobacter pylori (anti-HP), 34 from the beta carotene (BC), 23 from the ascorbic acid (AA), 20 from the anti-HP + BC, 23 from anti-HP + AA, 17 from BC + AA, and 37 from anti-HP + BC + AA were lost to follow-up.

Intention-to-treat analysis: no.

Sample size calculations: no.

#### Participants

Country: Colombia.

Number of participants randomised: 976; 46% males, aged 29 to 69 years, mean age 51.1 years.

Inclusion criteria: preliminary histologic diagnosis of multifocal atrophic gastritis with or without intestinal metaplasia and dysplasia, good health.

Exclusion criteria: normal histology, non-atrophic gastritis, gastric cancer.

Before randomisation, participants were classified into one of three strata: atrophy (without metaplasia), intestinal metaplasia, or dysplasia, according to baseline histologic diagnosis.

#### Interventions

Participants were assigned to a dietary supplement of beta-carotene (30 mg once per day) and/or ascorbic acid (1 g twice a day) or their corresponding placebos, for a six-year period. The prevalence of Helicobacter pylori infection among all gastric biopsy specimens was 97%. Anti-Helicobacter pylori treatment consisting of amoxicillin (500 mg three times per day), metronidazole (375 mg three times per day), and bismuth subsalicylate (262 mg three times per day) was given for 14 days to half of the study participants assigned randomly. This treatment was not blinded or placebo controlled because an appropriate placebo was not available for bismuth subsalicylate.

Participants were divided in eight treatment groups to receive:

- group 1: placebo (n = 117);
- group 2: anti-Helicobacter pylori treatment, which consisted of amoxicillin, metronidazole, and bismuth subsalicylate (n = 120);
- group 3: beta-carotene (n = 117);
Correa 2000

(Continued)

| Group | Description |
|-------|-------------|
| 4     | Ascorbic acid (n = 130); |
| 5     | Helicobacter pylori treatment, which consisted of amoxicillin, metronidazole, and bismuth subsalicylate, and additionally beta-carotene (n = 126); |
| 6     | Helicobacter pylori treatment, which consisted of amoxicillin, metronidazole, and bismuth subsalicylate, and additionally ascorbic acid (n = 111); |
| 7     | Beta-carotene and ascorbic acid (n = 121); |
| 8     | Helicobacter pylori treatment, which consisted of amoxicillin, metronidazole, and bismuth subsalicylate, and additionally beta-carotene and ascorbic acid (n = 134). |

Gastric biopsy specimens taken at baseline were compared with those taken at 72 months.

### Outcomes

The primary outcome measures were: progression, no change or regression of gastric precancerous lesions (preliminary histologic diagnosis of multifocal atrophic gastritis with or without intestinal metaplasia and dysplasia). For our purposes we extracted data about the incidence of gastric cancer. We have also extracted data on overall mortality for all antioxidants as well as for beta-carotene and vitamin C.

### Notes

Compliance with treatment was constantly encouraged and monitored by a social worker who interviewed the participants and recorded pill counts every three months. In addition, blood levels of beta-carotene and ascorbic acid were measured every three months in a 20% random sample of the participants.

Compliance with treatment among participants who completed the study was high for all intervention modalities (mean compliance for ascorbic acid, 91.8%; for beta-carotene, 92.3%; and for anti-Helicobacter pylori treatment, 99.1%).

Active medication and placebos were provided like identical coded tablets by Hoffmann-La Roche Inc. (Nutley, NJ).

Additional information received through personal communication with the authors.

Data were extracted from the article: Correa, et al. Re: Chemoprevention of gastric dysplasia: Randomized trial of antioxidant supplements and anti-Helicobacter pylori therapy. Journal of the National Cancer Institute 2001; 93: 559.

### Risk of bias

| Item                  | Authors’ judgement | Description |
|-----------------------|--------------------|-------------|
| Allocation concealment? | Yes                | A - Adequate |
### Methods

The Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism (DATATOP). Randomised, double-blind, placebo-controlled secondary prevention trial with two-by-two factorial design. Generation of the allocation sequence: adequate, centrally by computer. Allocation concealment: adequate, coded capsule packs maintained centrally. Blinding: adequate, identical placebo capsules. Follow-up: adequate, losses to follow-up almost equal in each treatment group. Intention-to-treat analysis: yes. Sample size calculations: yes.

### Participants

Country: United States and Canada.
Number of patients randomised: 800, 530 men and 270 women, 66% men, mean age 61 years.
Inclusion criteria: early Parkinson's disease not requiring levodopa without severe postural instability (Parkinson's Disease at Hoehn and Yahr stage 1 or 2) within a 5 years of symptom onset and not yet requiring symptomatic therapy.
Exclusion criteria: important comorbid illness, cognitive impairment (Mini Mental State examination score of < 23, or severe tremor (tremor score of >3 on the Unified Parkinson's Disease Rating Scale.

### Interventions

Patients were randomly assigned to receive: group 1: vitamin E (dl-alpha-tocopherol; all-racemic) 1000 IU; group 2: deprenyl 5 mg; group 3: tocopherol and deprenyl; group 4: placebo; twice daily with morning and evening meals. 401 participants were assigned to tocopherol and 399 participants to deprenyl. Participants were instructed to take one tablet and one capsule twice daily with morning and evening meals. A standard multivitamin containing vitamin E (30 IU) was provided to all participants. Median duration of vitamin E exposure during the randomised phase was 2.6 years. Preliminary analysis in the fall of 1989, after an average 1.5 years of follow-up, indicated unexpectedly striking effects of deprenyl in postponing PD disability as measured by the need for levodopa therapy. After this disclosure, all active trial participants, whether or not they required levodopa therapy, were placed on open-label deprenyl, 10 mg/day, for about 3.5 years, from fall 1989 to spring 1993. Blinded tocopherol treatment assignments were maintained for about 3 years after the initial randomisation. Participants began taking levodopa (with carbidopa, a peripheral dopa decarboxylase inhibitor) in addition to their experimental treatments at any point in the trial when they were judged clinically to require therapy for emerging disability. Investigators adjusted levodopa dosage to achieve optimal clinical benefits and avoid dopaminergic adverse effects. Because of concerns about the sustained benefit of deprenyl, a second randomisation was undertaken in spring 1993. Consenting research participants who required levodopa were randomised, independently of their original randomisation, to continue deprenyl (50%) or to switch to deprenyl placebo (50%). Further adjustments of levodopa dosage were permitted after the second randomisation. This additional placebo-controlled phase of deprenyl assignment was continued for 2 years until the last formal (face-to-face) clinical evaluation in spring 1995. The 800 participants have therefore been followed at least annually for an average of 8.2 years. Participants who underwent the second randomisation had a minimum of 3.2 years and a maximum of 7.3 years of exposure to active deprenyl. Participants were followed 13 years.

### Outcomes

The primary outcome in the trial occurred when, in the judgement of the enrolling investigator, a participant reached a level of functional disability sufficient to warrant the initiation of levodopa therapy. Operationally, the primary response variable in the trial was defined as the time from randomisation to the end point. After the outcome, the experimental treatments were withdrawn in blinded fashion, and approximately 30 days later the participants received a final evaluation.
Monitoring of compliance was carried out in follow-up evaluations in which unused doses return by the subject were counted, the serum tocopherol levels measured, and the urinary levels of amphetamine and metamphet mine metabolites of deprenyl determined. The results of the compliance monitoring were not shared with the participants or the investigators. Compliance in taking experimental medications was excellent among all treatment groups. The overall compliance rate, as a percentage of the doses dispensed that were actually taken, ranged from 97.9 to 99.5 percent for both tocopherol and deprenyl. Tablets of L-deprenyl and matching placebos were provided by Someret Pharmaceuticals, Denville; N.J. Capsules of d-L-alpha tocopherol and matching placebos were provided by Hoffman-LaRoche, Nutley, N.J. A standard vitamin (One-A-Day) by Miles Laboratories, Elkhart, Ind.

| Risk of bias |
|-------------|
| Item        | Authors' judgement | Description |
| Allocation concealment? | Yes | A - Adequate |

**DATOR 2004Low**

### Methods
Randomised, single-blind, placebo-controlled trial with parallel group design.
Generation of the allocation sequence: adequate, block randomisation using the Geigy manual randomisation tables.
Allocation concealment: adequate, sealed envelopes.
Blinding: adequate, identical placebo capsules.
Follow-up: adequate. During the course of the trial, 1 participant from each group dropped out - 1 participant due to thyroid dysfunction and 1 participant due to an accident.
Intention-to-treat analysis: no.
Sample size calculations: no.

### Participants
Country: Belgium.
Number of participants randomised: 24, mean age 51, 86% males.
Inclusion criteria: type 1 diabetic patients attending the outpatient diabetes clinic having history of high serum cholesterol, (total cholesterol > 4.9 and LDL cholesterol > 3.0 mmol/L) but triglycerides < 4.5 mmol/L) and normal blood levels of thyroxin (9.7-23.4 pmol/L) and TSH (0.47-4.7µU/mL).
Exclusion criteria: none reported.

### Interventions
Participants were randomly assigned to receive:
group 1: Atorvastatin® 20 mg together with 750 IU (504 mg) d-alpha-tocopherol;
group 2: Atorvastatin® with placebo (280 mg soybean oil containing 0.25 mg tocopherol per capsule), daily.
Participants were supplemented 0.5 years and followed 4.5 years.

### Outcomes
The primary outcome measure was: impact on lipids and peroxidation during statin treatment.
Notes
Omega-Pharma NV is acknowledged for the supply of alpha-tocopherol and placebo. Additional information received through personal communication with the authors. Due to the addition of 0.25 mg tocopherol to the control group, the ‘placebo’ control of the trial can be discussed.

Risk of bias

| Item                      | Authors' judgement | Description     |
|---------------------------|--------------------|-----------------|
| Allocation concealment?   | Yes                | A - Adequate    |

de la Maza 1995

Methods
Randomised, double-blind, placebo-controlled trial with parallel group design. Generation of the allocation sequence: unclear, not reported. Allocation concealment: unclear, not reported. Blinding: adequate, identical placebo tablets. Follow-up: adequate: 7 randomised participants were removed from the trial due to lack of compliance. Intention-to-treat analysis: no. Sample size calculations: no.

Participants
Country: Chile.
Number of participants randomised: 74, mean age 50, 85% males.
Inclusion criteria: clinical evidence of alcoholic liver disease at the time of enrolment (two or more of the following): jaundice, encephalopathy, ascites, oedema, spider nevi, marked collateral circulation, bleeding disorders, esophageal varices on endoscopy; a history of > 5 years of heavy alcohol consumption (daily alcohol intake > 150 g); absence of hepatitis B surface antigen; absence of significant renal, pulmonary or cardiac disease, clinical diabetes or malignant tumours (including hepatoma). Exclusion criteria: none mentioned.

Interventions
Patients were randomly assigned to receive:
group 1: vitamin E 500 mg (in the form of alpha-tocopheryl acetate, n = 37);
group 2: placebo, n = 37.
Participants were supplemented and followed 1 year.

Outcomes
The primary outcome measure was: the liver function, mortality, and hospitalisation rates.

Notes
Patients were seen once a month by a nurse practitioner at the liver disease clinic. Patients were asked about compliance to the treatment, which was assessed by counting the leftover tablets. Blood samples were obtained at the beginning of the study and every 3 months to measure serum levels of vitamin E. Financing was provided by Roche and Saval Laboratories.

Risk of bias
### de la Maza 1995 (Continued)

| Item                      | Authors' judgement | Description |
|---------------------------|--------------------|-------------|
| Allocation concealment?   | Unclear            | B - Unclear |

### de Waart 2001

**Methods**  
Randomised, double-blind, placebo-controlled trial with parallel group design.  
Generation of the allocation sequence: unclear, not reported.  
Allocation concealment: unclear, not reported.  
Blinding: adequate, identical looking capsules.  
Follow-up: adequate, 29 participants (13 in active and 16 in placebo groups) were lost to follow-up.  
Intention-to-treat analysis: no.  
Sample size calculations: no.

**Participants**  
Country: The Netherlands.  
Number of patients randomised: 218 men, aged from 50 to 76 years, mean age 60 years.  
Inclusion criteria: male cigarette smokers aged 50 to 76 years.  
Exclusion criteria: diabetes patients, users of (multi)vitamin-, vitamin E, vitamin C, beta-carotene, garlic, or fish oil supplements, users of vitamin K antagonists (phenprocoumon, acenocoumarol), individuals with current illness interfering with participation, and unwillingness to participate.

**Interventions**  
Participants were randomly assigned to receive:  
group 1: vitamin E (dl-alpha-tocopherol) 400 IU (n = 109);  
group 2: placebo (n = 109)  
for a period of 2 years. Mean follow-up time was 1.8 years.

**Outcomes**  
The primary outcome measure was: progression of atherosclerosis in lifelong male smokers measured by 2-year change of the common carotid intima media thickness as measured by B-mode ultrasonography.

**Notes**  
Compliance with treatment is not reported.  
Vitamin E or placebo capsules were provided by F Hoffman La Roche Ltd, Basel.

### Risk of bias

| Item                      | Authors' judgement | Description |
|---------------------------|--------------------|-------------|
| Allocation concealment?   | Unclear            | B - Unclear |
Desnuelle 2001Low

### Methods

Amyotrophic Lateral Sclerosis riluzole-tocopherol study (ALSRT). Randomised, double-blind, placebo-controlled trial with parallel group design.

Generation of the allocation sequence: adequate, randomisation schedule prepared by laboratory. Randomisation was balanced by centre.

Allocation concealment: adequate, randomisation schedule prepared by laboratory and coded bottles.

Blinding: adequate, identical looking capsules and tablets.

Follow-up: adequate, no losses to follow-up. One hundred and forty-six patients (74 in the placebo group and 72 in the alpha-tocopherol group) did not complete the one-year treatment period.

Intention-to-treat analysis: yes.

Sample-size calculation: yes.

### Participants

Country: France.

Number of participants randomised: 288, 158 men and 130 women, mean age 64 years.

Inclusion criteria: probable or definitive amyotrophic lateral sclerosis (ALS), according to El Escorial criteria, over 18 years of age at recruitment, to be able to fully understand the study information, have been treated with riluzole 950 mg b.i.d. for at least three months without presenting side effects.

Exclusion criteria: signs of dementia and/or major psychiatric disorders, another concomitant serious disease, or handicap likely to interfere with their assessment of survival, forced vital capacity of less than 60%, monoclonal gammopathy, conduction blocks of motor nerves on electromyography, hepatic or renal dysfunction, pregnancy or breast feeding, creatinine plasma concentration above 200 µM, alanine aminotransferase and/or aspartate transaminase activity greater than twice the upper limit of the normal range, known hepatic disease, taking drugs known to be hepatotoxic, enzyme-inducing or enzyme-inhibiting, taking vitamin E.

### Interventions

Participants were randomly assigned to receive:

- group 1: vitamin E 500 mg plus riluzole 50 mg (n = 144);
- group 2: placebo (n = 144) plus riluzole 50 mg;

one capsule (vitamin E) and one tablet (Riluzole) daily for one year.

### Outcomes

The primary outcome measure was: change in functional status of each patient using the modified Norris limb scale.

The secondary outcome measures were: survival (defined as the time to death or tracheostomy), bulbar function assessed with the Norris bulbar scale (total possible score 39) and manual muscle testing.

### Notes

Compliance with treatment was checked by measuring the plasma vitamin E levels.

Compliance with treatment good. In the vitamin E group, a highly significant increase in plasma levels of vitamin E was observed after 3 months of treatment.

Study agents were supplied by: alpha-tocopherol (Toco 500R) Laboratories Rhone-Poulenc Rorer (now trading under the name Laboratories Aventis); riluzole Rhone-Poulenc Rorer.

Additional information received through personal communication with the authors.

### Risk of bias

| Item               | Authors’ judgement | Description |
|--------------------|--------------------|-------------|
| Allocation concealment? | Yes                | A - Adequate |
Gillilan 1977

| Methods | Randomised, double-blind, placebo-controlled cross-over trial.
|         | Generation of the allocation sequence: unclear, not reported.
|         | Allocation concealment: unclear, not reported.
|         | Blinding: identical looking placebo capsule.
|         | Follow-up: adequate, 48 participants (of 52) completed the trial. There were no losses to follow-up.
|         | Intention-to-treat analysis: no.
|         | Sample size calculations: no.

| Participants | Country: United States.  
|             | Number of patients randomised: 52.  
|             | Inclusion criteria: typical, stable, effort-related angina pectoris, and Q wave electrographic evidence of previous myocardial infarction and/or positive coronary arteriograms as defined by 75% obstruction at least one major coronary artery (31 patients).  
|             | Exclusion criteria: none stated.

| Interventions | Participants were randomly assigned to receive:  
|               | group 1: vitamin E (d-alpha-tocopherol succinate) 1600 IU (n = 26);  
|               | group 2: placebo (containing 2.5 mg of riboflavin), (n = 26);  
|               | three capsules of vitamin E (400 IU) or placebo daily for a period of six months, and then cross-over.  
|               | The mean duration of double-blind therapy was 189 days of vitamin E and 192 days of placebo.

| Outcomes | The primary outcome measure was: any improvement of angina pectoris.

| Notes | Drug adherence was followed by capsule count and a urine fluorescence test. Serum vitamin E levels were measured at baseline and at the end of the first and six months of each treatment phase.  
|       | The capsule count data shows a mean consumption of 88% of the prescribed capsules during vitamin E phase, and 84% consumption during placebo therapy. The percent of urine specimens with fluorescence indicate 78% of taking placebo prescribed medication. The serum tocopherol levels were significantly higher during the supplementation.  
|       | Vitamin E and placebo capsules supplied by Wilson and Wolfer Pharmaceutical Manufacturers and Distributors, Detroit, Michigan.

| Risk of bias |  
| Item | Authors' judgement | Description |
|-------|---------------------|-------------|
| Allocation concealment? | Unclear | B - Unclear |
Girodon 1997

Methods
Randomised, double-blind, placebo-controlled trial with parallel group design.
Generation of the allocation sequence: unclear, not reported.
Allocation concealment: unclear, not reported.
Blinding: adequate, identical looking capsules.
Follow-up: adequate. There were no losses to follow-up.
Intention-to-treat analysis: yes.
Sample size calculations: yes.

Participants
Country: France.
Number of participants randomised: 81 elderly participants, 20 males and 61 females, aged 65 to 102 years, with an average age of 84 years.
Inclusion criteria: at least 65 years of age, only age related diseases (osteoarthritis, hypertension, residual stroke etc.), that required chronic care.
Exclusion criteria: history of cancer, taking medication that might interfere with nutritional status, immunocompetence, or vitamin or mineral supplements.

Interventions
Participants were randomly assigned to receive:
group 1: placebo (n = 20);
group 2: trace elements (zinc 20 mg in a form of zinc sulfate; selenium 100 µg in a form of selenite) (n = 20);
group 3: vitamins (vitamin C 120 mg; beta-carotene 6 mg; vitamin E 15 mg) (n = 20);
group 4: combination of trace elements and vitamins at equal doses (n = 21);
daily (one capsule a day) for a period of 2 years.
Mean duration of follow-up was 730 days.

Outcomes
The primary outcome measure was: impact of a trace element and vitamin supplementation on infectious morbidity.

Notes
Compliance with treatment was checked by measuring the plasma vitamin levels and counting of the returned capsules.
Compliance was good. After 6 months of supplementation, a significant increase in vitamin and trace element serum levels was obtained in the corresponding treatment groups: a plateau was then observed for the whole study. No changes appeared in the placebo group.
Study agents were provided by Produits Roche SA.

Risk of bias

| Item               | Authors' judgement | Description |
|--------------------|--------------------|-------------|
| Allocation concealment? | Unclear            | B - Unclear |

Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases (Review)
### GISSI 1999

#### Methods
- **GISSI-Prevenzione trial (Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico).** Randomised clinical secondary prevention trial with two-by-two factorial design.
- Generation of the allocation sequence: adequate, computer programme based on the biased-coin algorithm, stratified by hospital.
- Allocation concealment: adequate, central randomisation over the telephone and by computer network.
- Randomisation data kept at the co-ordinating centre.
- Blinding: inadequate, there is no intervention in the control arm.
- Follow-up: adequate. Information on the vital status of patients at the end of the trial was available for 99.9% of the population.
- Intention-to-treat analysis: yes.
- Sample size calculations: yes.

#### Participants
- **Country:** Italy.
- **Number of participants randomised:** 11324; 9659 males and 1665 females, mean age 59 years.
- **Inclusion criteria:** recent (< 3 months) myocardial infarction, informed written consent. Age limits were not defined.
- **Exclusion criteria:** contraindications to the dietary supplements (ie, known allergy to n-3 PUFA or alpha-tocopherol, or known congenital defects of coagulation), unfavourable short-term outlook (eg, overt congestive heart failure, cancers, etc).

#### Interventions
- **Patients were randomly assigned to four treatment groups to receive:**
  - **group 1:** n-3 PUFA alone (as 1 gelatin capsule containing 850 mg to 882 mg eicosapentaenoic acid and docosahexaenoic acid as ethyl esters in the average ratio of 1:2), 1 g daily (n = 2836);
  - **group 2:** vitamin E alone, 300 mg daily (n = 2830);
  - **group 3:** n-3 PUFA and vitamin E combined (n = 2830);
  - **group 4:** no supplement (n = 2828);
- **for 3.5 years.**

#### Outcomes
- **The primary outcome measures were:** cumulative rate of all-cause death, non-fatal myocardial infarction, and non-fatal stroke; and the cumulative rate of cardiovascular death, non-fatal myocardial infarction, and nonfatal stroke.

#### Notes
- **Compliance with treatment was measured by refilling drug supplies every three months.** Compliance with assigned treatment was excellent. At year one and at the end of the study, 11.6% and 28.5% of patients receiving n-3 PUFA and 7.3% and 26.2% of those receiving vitamin E, respectively, had permanently stopped taking the study drug. Conversely, during the whole course of the study, only two patients not assigned vitamin E and 26 patients not assigned n-3 PUFA were receiving these drugs.
- The trial was supported by grants from Bristol-Myers Squibb, Pharmacia-Upjohn, Società Prodotti Antibiotici, and Pfizer. Pharmacia-Upjohn and Società Prodotti Antibiotici supplied marketed capsules containing 850 to 882 mg EPA/DHA ethyl esters. Vitamin E (acetyl d, l-a-tocopherol) was supplied by Bracco.

### Risk of bias

| Item | Authors’ judgement | Description |
|------|--------------------|-------------|
| Allocation concealment? | No | C - Inadequate |
|-------------------------|----|----------------|

**Gratt 2002Low**

**Methods**
Randomised, double-blind, placebo-controlled trial with two-by-two factorial design.
Generation of the allocation sequence: adequate, a computer-generated, 4-per-block, randomisation list.
Allocation concealment: adequate, randomisation list was created by the pharmacy allocating treatment to participant number. Numbered boxes containing identical looking capsules were transported from the pharmacy to the Wageningen University. At enrolment, boxes were assigned consecutively to participants. Treatment allocation was kept at the pharmacy exclusively in sealed opaque envelopes while participant identity was known exclusively at the Wageningen University. None of the treatment codes was broken during the study period.
Blinding: adequate, identical looking placebo capsules.
Follow-up: adequate. In total, 16% of the participants discontinued the treatment. Overall, 26 participants assigned to receive multivitamin-mineral, 25 to vitamin E, 26 to multivitamin-mineral plus vitamin E, and 20 to placebo were lost to follow-up.
Intention-to-treat analysis: yes.
Sample size calculations: yes.

**Participants**
Country: The Netherlands.
Number of participants randomised: 652, 325 men and 327 women, older than 60 years.
Inclusion criteria: noninstitutionalized elderly persons older than 60 years.
Exclusion criteria: used immunosuppressive treatment, anticoagulants interfering with vitamin K metabolism, or dietary supplements in the previous 2 months or if they had a history of cancer, liver disease, or fat malabsorption during the 5 years before randomisation.

**Interventions**
Participants were randomly assigned to receive:
- group 1: multivitamins and minerals (n = 163);
- group 2: vitamin E 272 IU (n = 164);
- group 3: multivitamins and minerals plus vitamin E (n = 172);
- group 4: placebo (n = 153).
The multivitamin-mineral capsule contained: retinol (600 µg), beta-carotene (1.2 mg), ascorbic acid (60 mg), vitamin E (10 mg), cholecalciferol (5 µg), vitamin K (30 µg), thiamin mononitrate (1.4 mg), riboflavin (1.6 mg), niacin (18 mg), pantothenic acid (6 mg), pyridoxine (2.0 mg), biotin (150 µg), folic acid (200 µg), cyanocobalamin (1 µg), zinc (10 mg), selenium (25 µg), iron (4.0 mg), magnesium (30 mg), copper (1.0 mg), iodine (100 µg), calcium (74 mg), phosphor (49 mg), manganese (1.0 mg), chromium (25 µg), molybdenum (25 µg), and silicium (2 µg). The vitamin E capsule contained 200 mg/dL of alpha-tocopherol. Placebo capsules contained soybean oil. Quality control of the capsules after treatment showed no decrease in the original contents.
Each participant received 2 capsules per day to be ingested with dinner for a maximum of 15 months.

**Outcomes**
The primary outcomes were: incidence and severity of acute respiratory tract infections.
Compliance with treatment was checked by measuring the plasma vitamin levels and counting of the returned capsules. Baseline plasma samples were collected for determination of alpha-tocopherol, ascorbic acid, retinol, and carotenoids. To monitor compliance, these assessments were repeated in a postintervention sample of a subset (n = 300). Returned capsules were counted for all participants. After treatment, ascorbic acid, total carotenoids, alpha-tocopherol, and cholesterol-adjusted alpha-tocopherol levels increased significantly in the multivitamin-mineral and multivitamin-mineral plus vitamin E group, while gamma-tocopherol decreased significantly. In the vitamin E group, alpha-tocopherol and cholesterol-adjusted alpha-tocopherol levels increased significantly, while gamma-tocopherol levels decreased significantly. In the placebo group, none of the measured vitamins changed significantly. 94% of the participants met the compliance criteria of 80% capsule intake.

Trial agents were provided by Roche Vitamins, Europe, Basel, Switzerland.

### Risk of bias

| Item                        | Authors' judgement | Description |
|-----------------------------|--------------------|-------------|
| Allocation concealment?     | Yes                | A- Adequate |

### Graf 2005Low

**Methods**  
Randomised, double-blind, placebo-controlled trial with parallel group design.  
Generation of the allocation sequence: adequate, computer generated.  
Allocation concealment: adequate, central independent unit.  
Blinding: adequate, identical looking capsules.  
Follow-up: adequate, no losses to follow-up.  
Intention-to-treat analysis: yes.  
Sample size calculations: no.

**Participants**  
Country: Germany.  
Number of participants randomised: 160, 104 males and 56 females, mean age 58 years with probable or definite amyotrophic lateral sclerosis (ALS).  
Inclusion criteria: patients with probable or definite amyotrophic lateral sclerosis (ALS) treated with riluzole and disease duration of less than 5 years.  
Exclusion criteria: none stated.

**Interventions**  
Patients were randomly assigned to receive:  
group 1: vitamin E (alpha-tocopherol), 5000 mg (five times daily one capsule of 1000 mg) (n = 83);  
group 2: placebo (n = 77);  
for a period of 18 months.

**Outcomes**  
Primary outcome measure was: survival, calculating time to death, tracheostomy, or permanent assisted ventilation.  
Secondary outcome measures were: the rate of deterioration of function assessed by the modified Norris limb and bulbar scales, manual muscle testing, spasticity scale, ventilatory function and the Sickness Impact Profile.
Compliance with treatment was checked by measuring the plasma vitamin E levels. Vitamin plasma levels were, as expected, significantly higher in the high dose vitamin E group than in the placebo group. Trial agents were provided by Schwarzhaupt, Cologne, Germany. Additional information obtained with personal communication with authors.

### Risk of bias

| Item                     | Authors’ judgement | Description   |
|--------------------------|--------------------|---------------|
| Allocation concealment?  | Yes                | A - Adequate  |

**HATS 2001Low**

**Methods**

The HDL-Atherosclerosis Treatment Study (HATS).
Randomised, double-blind, placebo-controlled trial with two-by-two factorial design.
Generation of the allocation sequence: adequate, random numbers generated by computer.
Allocation concealment: adequate, central independent unit.
Blinding: adequate, identical placebo capsules.
Follow-up: adequate. Vital status was ascertained at 38 months for all 160 patients enrolled. Follow-up information for 159 patients was complete, including records of events from the patient's physicians.
Intention-to-treat analysis: yes.
Sample size calculations: yes.

**Participants**

Country: United States and Canada.
Number of participants randomised: 160, mean age 53 years, 13 % female.
Inclusion criteria: men (younger than 63 years of age) and women (younger than 70 years of age) with clinical coronary disease (defined as previous myocardial infarction, coronary interventions, or confirmed angina) and with at least three stenoses of at least 30 percent of the luminal diameter or one stenosis of at least 50 percent. All had low levels of HDL cholesterol (35 mg per decilitre [0.91 mmol per litre] or lower in men and 40 mg per deciliter [1.03 mmol per litre] in women), LDL cholesterol levels of 145 mg per deciliter (3.75 mmol per litre) or lower, and triglyceride levels below 400 mg per deciliter (4.52 mmol/L). Exclusion criteria: lipid levels outside of the specified ranges, coronary bypass surgery, severe hypertension, recent gout, or liver, thyroid, or kidney disease, or uncontrolled diabetes.

**Interventions**

Patients were randomly assigned to receive:
group 1: simvastatin (10 mg to 20 mg) plus niacin (500 mg to 4 g), (n = 33);
group 2: antioxidant vitamins, 800 IU of vitamin E (as d-alpha-tocopherol), 1000 mg of vitamin C, 25 mg of natural beta-carotene, and 100 µg of selenium;
group 3: simvastatin plus niacin plus antioxidants (n = 40),
group 4: all placebos (n = 34);
for three years.
Simvastatin therapy began at 10 mg per day for patients with an LDL cholesterol level of 110 mg per decilitre (2.84 mmol per litre) or lower on screening and 20 mg per day for those with an LDL cholesterol level higher than 110 mg per decilitre. The dose was increased by 10 mg per day in patients whose LDL cholesterol level was higher than 90 mg per decilitre (2.33 mmol per litre) in any sample during the first year of the study and was reduced by 10 mg per day if the LDL cholesterol level fell below 40 mg per decilitre (1.03 mmol per litre) at any time during the study. During treatment, patients receiving the matching placebo were given 10 mg of simvastatin if their LDL cholesterol level was 140 mg per decilitre (3.62 mmol per litre) or higher; the target level was 130 mg per decilitre (3.37 mmol per litre) or lower. The dose of slow-release niacin was increased linearly from 250 mg twice daily to 1000 mg twice daily at four weeks. Patients whose HDL cholesterol levels had not increased by at least 5 mg per decilitre (0.13 mmol per litre) at 3 months, at least 8 mg per decilitre (0.21 mmol per litre) at 8 months, and at least 10 mg per decilitre at 12 months were switched to crystalline niacin the dose of which was gradually increased to 3 g per day or, at most, 4 g per day in order to meet the target levels. Niacin “placebo” tablets (taken at a dose of 50 mg twice daily) were active, provoking flushing without affecting lipid levels.

| Outcomes | The primary outcome measures were: arteriographic evidence of a change in coronary stenosis and the occurrence of a first cardiovascular event (death, myocardial infarction, stroke, or revascularisation). |
| Notes | Compliance with the trial regimens, measured by means of pill counts, ranged between 80 percent and 95 percent. The mean doses of simvastatin and niacin taken by patients were 13 ± 6 mg per day and 2.4 ± 2.0 g per day, respectively. Plasma vitamin concentrations increased significantly in 75 patients who received active vitamin therapy. The active agents and placebos were provided by: Simvastatin (Zocor, Merck, West Point, Pa.) slow-release niacin (Slo-Niacin, Upsher-Smith, Minneapolis) crystalline niacin (Niacor, Upsher-Smith). |

### Risk of bias

| Item | Authors’ judgement | Description |
| --- | --- | --- |
| Allocation concealment? | Yes | A - Adequate |

### Hogarth 1996

| Methods | Randomised, double-blind, placebo-controlled trial with two-by-two factorial design. Generation of the allocation sequence: unclear, not reported. Allocation concealment: unclear, not reported. Blinding: adequate, identical placebo capsules and solution. Follow-up: adequate, 87 patients completed the trial (13 died, 6 withdrew). Three participants in supplemented group and 3 participants in placebo group withdrew. Intention-to-treat analysis: no. Sample size calculations: yes. |
Participants
Country: UK.
Number of participants randomised: 106, 64 (44%) men and 42 (56%) women, mean age 82.65 years.
Inclusion criteria: elderly medical in-patients.
Exclusion criteria: already taking nutritional supplements, had diabetes mellitus, dysphagia, or a body mass index > 25 or < 15 kg/m².

Interventions
Participants were randomly assigned to receive:
- group 1: active energy and active vitamin supplementation (n = 31);
- group 2: active energy and placebo vitamin supplementation (n = 24);
- group 3: placebo energy and active vitamin supplementation (n = 23);
- group 4: placebo energy and placebo vitamin supplementation (n = 28);
for one month period.
Supplementation was provided as 750 ml glucose drink (2317.5 kJ, 540 kcal) (Lucozade), and capsules containing vitamins A 8000 IU, B1 15 mg, B2 15 mg, B3 50 mg, B6 10 mg, C 500 mg. Matching placebos were Nutrasweet drinks or capsules of maize, starch and lactose.

Outcomes
The primary outcome measures were: weight, serum albumin levels, and activities of daily living, cognitive functioning and length of stay.

Notes
Compliance with the energy supplement (active or placebo) was monitored by measuring unconsumed fluid each day during admission. Following discharge, patients or carers were asked to complete a form estimating the volume of fluid (in quarters) remaining in each bottle each day. Vitamin compliance was monitored by tablet count at the end of the 1-month period at the final assessments.
Compliance was poor with the liquid energy supplement with only one-third of patients consuming > 50% of offered drinks during the study period (17/55 patients, active group; 16/51 patients, placebo group). Vitamin capsule compliance was higher with approximately 90% of patients taking more than 50% of the capsules provided (48/52 patients, active group; 49/54 patients, placebo group).
The energy supplement (Lucozade) and placebo preparation were provided by SmithKline and Beecham.

Risk of bias

| Item                  | Authors' judgement | Description |
|-----------------------|--------------------|-------------|
| Allocation concealment? | Unclear           | B - Unclear |
### Methods
The Heart Outcomes Prevention Evaluation Study (HOPE). Randomised, double-blind, placebo-controlled trial with two-by-two factorial design. Generation of the allocation sequence: adequate, by computer. Allocation concealment: adequate, randomisation is done by a telephone call to a central office. After receipt of appropriate baseline data over the telephone, the patient is randomised. Blinding: adequate, identical placebo capsules. Follow-up: adequate. At the end of the initial HOPE trial, vital status was ascertained for 9535 (99.9%) of 9541 randomized patients. At the end of the HOPE-TOO trial, vital status was ascertained for 4724 (99.8%) of 4732 patients who participated in the extension trial. Intention-to-treat analysis: yes. Sample size calculations: yes.

### Participants
Country: International, North America, South America, Europe (19 countries) Number of participants randomised: 9541; 6996 males and 2545 females, 55 years old or older, mean age 66 years. Inclusion criteria: 55 years or older, had a history of CV disease (coronary artery disease, stroke or peripheral arterial disease) or diabetes in the presence of at least one additional CV risk factor (total cholesterol > 5.2 mmol/l, HDL cholesterol <0.9 mmol/l, hypertension, defined as use of medications to treat high blood pressure, or blood pressure at time of recruitment > 160 mmHg systolic or > 90 mmHg diastolic, known microalbuminuria, or current smoking). Exclusion criteria: Dipstick-positive proteinuria, diabetic nephropathy, serum creatinine > 200 mmol/l, history of congestive heart failure, or known left ventricular ejection fraction (< 40%), hyperkalaemia, uncontrolled hypertension, myocardial infarction, unstable angina or stroke within 1 month before study enrolment, and use of or intolerance to vitamin E or angiotensin-converting-enzyme (ACE) inhibitors.

### Interventions
Patients were randomly assigned to receive either group 1: 400 IU of vitamin E (RRR-a-tocopheryl acetate) daily from natural sources (n = 4761); or group 2: matching placebo (n = 4780); or group 3: an angiotensin-converting-enzyme inhibitor (ramipril 10 mg) (n = 4645); or group 4: matching placebo (n = 4652), once a day for a four to six years, mean 4.5 years. The Heart Outcomes Prevention Evaluation [HOPE] trial is conducted between December 21, 1993, and April 15, 1999. The Heart Outcomes Prevention was extended (HOPE-The Ongoing Outcomes [HOPE-TOO]) between April 16, 1999, and May 26, 2003. Of the initial 267 HOPE centres that had enrolled 9541 patients, 174 centres participated in the HOPE-TOO trial. Of 7030 patients enrolled at these centres, 916 were deceased at the beginning of the extension of the trial, 1382 refused participation, 3994 continued to take the study intervention, and 738 agreed to passive follow-up. The mean follow-up period was 7 years.

### Outcomes
The primary outcome measures were: cancer incidence, cancer deaths, major cardiovascular events (myocardial infarction, stroke, and cardiovascular death). The secondary outcomes were: unstable angina, congestive heart failure, revascularisation or amputation, death from any cause, complications of diabetes, and cancer.

### Notes
Compliance with treatment was checked by measuring the plasma vitamin E levels in randomly selected patients. The rate of compliance with the assigned regimen was high throughout the study. The percentages of patients who were taking vitamin E in the vitamin E and placebo groups, respectively, were 94.2% and 1.0% at 1 year, 93.3% and 1.7% at 2 years, 91.3% and 2.0% at 3 years, 90.2% and 2.7% at 4 years, and 89.2% and 3.4% at the final visit. There was no significant interaction between the study treatments (ramipril and vitamin E) for the primary, secondary, and other study outcomes. At the end of the initial HOPE trial, vital status was ascertained for 9535 (99.9%) of 9541 randomised patients. Funded by the Medical Research Council of Canada, Natural Source Vitamin E Association, Negma, Hoechst-Marion Roussel, AstraZeneca, King Pharmaceuticals, and the Heart and Stroke Foundation of Ontario.
### HPS 2002Low

**Methods**

Heart Protection Study. Randomised, double-blind, placebo-controlled trial with two-by-two factorial design. 
Generation of the allocation sequence: adequate, computer generated random numbers. 
Allocation concealment: adequate, central telephone randomisation system. 
Blinding: adequate, identical placebo capsules. 
Follow-up: adequate. 99.7% of the participants were with complete follow-up for average of 5 years in vitamins allocated group and 99.6% in placebo group. Overall, 25 participants allocated to vitamins group and 35 participants to placebo group were lost to follow-up. 
Intention-to-treat analysis: yes. 
Sample size calculations: yes.

**Participants**

Country: United Kingdom. 
Number of participants randomised: 20,536; 15,454 males and 5082 females at an age 40 to 80 years. 
Inclusion criteria: adults with coronary disease, other occlusive arterial disease, or diabetes, and non-fasting blood total cholesterol concentrations of at least 3.5 mmol/L. 
Exclusion criteria: other life-threatening conditions, such as chronic liver disease, severe renal disease, severe heart failure, severe chronic airways disease, or diagnosed cancer (other than non-melanoma skin cancer). In addition, anyone already taking high-dose vitamin E supplements, or in whom such supplements were considered indicated, was not to be randomised.

**Interventions**

Participants were randomly assigned to receive: 
group 1: 600 mg vitamin E, 250 mg vitamin C, and 20 mg beta-carotene daily (n = 10,269); or 
group 2: matching placebo capsules (n = 10,267), daily during the scheduled 5-year treatment period.

**Outcomes**

The primary outcome measures were: major coronary events (for overall analyses) and fatal or non-fatal vascular events (for subcategory analyses), with subsidiary assessments of cancer and of other major morbidity.

**Notes**

Compliance with treatment was assessed at each follow-up by reviewing the calendar packed tablets remaining and, for those who had stopped, the reasons for doing so were sought. An average of 83% of participants in each treatment group remained compliant during the scheduled five-year treatment period. To assess the effects of the treatment allocation on blood concentrations of the vitamins being studied, assays were performed in non-fasting samples collected from about 5% of participants at the initial screening visit and at an average of about three years of follow-up (the approximate mid-point of the study). 
Vitamins were provided by Roche.

| Item | Authors' judgement | Description |
|------|--------------------|-------------|
| Allocation concealment? | Yes | A - Adequate |

**References**

Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases (Review) Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Data were extracted from the primary publication, but additional information was received through personal communication with the authors.

### Risk of bias

| Item                     | Authors’ judgement | Description       |
|--------------------------|--------------------|-------------------|
| Allocation concealment?  | Yes                | A - Adequate      |

### Jacobson 2000

#### Methods
- Randomised, double-blind, placebo-controlled trial with parallel group design.
- Generation of the allocation sequence: adequate, computer-generated random number sequence.
- Allocation concealment: adequate, a three-letter code was written on the bottles to distinguish treatment from placebo without indicating which was which. The specimens were labelled by study ID and whether it was the first, second, third, etc., specimen. The numbers were scrambled according to a set formula to keep the technicians blind to which specimen it was.
- Blinding: adequate, identical placebo tablets.
- Follow-up: adequate, 73 participants completed the trial. Drop-out rates were high in both groups, but were higher in the placebo (53%) than in the treatment (35%) group.
- Intention-to-treat analysis: no.
- Sample size calculations: no.

#### Participants
- Country: United States of America.
- Number of participants randomised: 121, mean age 42, 58% males.
- Inclusion criteria: adults 18 years of age and older who smoked one or more packs of cigarettes per day and were not currently taking the study vitamins.
- Exclusion criteria: nondetectable polycyclic aromatic hydrocarbon PAH-DNA adduct levels in mononuclear cells and plasma vitamin levels higher than 1.0 mg/dl for vitamin C, 15 mg/dl for beta-carotene, and 1.2 mg/dl for alpha-tocopherol at the first study visit.

#### Interventions
- Participants were randomly assigned to receive:
  - group 1: vitamin C 500 mg, alpha-tocopherol 400 IU, beta-carotene 6 mg, n = 60;
  - group 2: placebo, n = 61.
- Participants were supplemented and followed 0.5 years.

#### Outcomes
- The primary outcome measure was DNA damage.

#### Notes
- Compliance with treatment was not reported.
- Additional information received through personal communication with the authors.
### LAST 2004Low

**Methods**

Lutein Antioxidant Supplementation Trial (LAST).

Randomised, double-blind placebo-controlled trial with parallel group design.

Generation of the allocation sequence: adequate, by consecutive random card-3-choice, allocation sequence.

Allocation concealment: adequate, manufacturer of the capsules maintained and concealed the blinding and four digit allocation codes. Bottles with masked four-digit allocation codes were sent to the assigned research pharmacist at DVA Medical Centre, North Chicago. All personnel at the DVA Medical Centre were unaware of the masked allocation codes during the 12-month clinical study. Participants were provided with opaque capsules of identical appearance in numbered containers.

Blinding: adequate, identical looking capsules.

Follow-up: adequate. During the one year clinical trial, 1, 2, and 1 participants were lost to follow-up from each group.

Intention-to-treat analysis: yes.

Sample size calculations: yes.

**Participants**

Country: United States of America.

Number of participants randomised: 90, 86 men and 4 women, mean age 74.7 years.

Inclusion criteria: diagnosis of atrophic age-related macular degeneration (ARMD) by stereo biomicroscopy and at least one vision-degrading visual-psychophysical abnormality associated with ARMD in one or both eyes; clear non-lenticular ocular media (cornea, aqueous and vitreous), free of advanced glaucoma and diabetes or any other ocular or systemic disease that could affect central or parafoveal macular visual function.

Exclusion criteria: recent (within 6 months) cataract or retinal surgery; taking photosensitizing drugs (such as phenotiazines and chloroquine).

**Interventions**

Patients were randomly assigned to receive:

- group 1: lutein 10 mg (n = 29);
- group 2: lutein 10 mg, and antioxidants/vitamins and minerals broad spectrum supplementation formula (n = 30);
- group 3: placebo (maltodextrin) (n = 31);

taken as three capsules twice per day with food, over a period of 12 months.

The OcuPower supplement consists of: lutein 10 mg; vitamin A 2,500 IU; natural beta-carotene 15,000 IU (Betatene®); vitamin C 1,500 mg (as calcium ascorbate-Ester C R); vitamin D3 400 IU; natural vitamin E (d-alpha tocopherol succinate) 500 IU; vitamin B1 50 mg; vitamin B2 10 mg; vitamin B3 70 mg; vitamin B5 50 mg; vitamin B6 50 mg; vitamin B12 500 mcg; folic acid 800 mcg; biotin 300 mcg; calcium 500 mg; magnesium 300 mg; iodine 75 µg; zinc (as zinc L-methionine-L-Optizinc) R) 25 mg; copper 1 mg; manganese 2 mg; selenium 200 µg; chromium 200 µg; molybdenum 75 µg; lycopene 600 µg; bilberry extract (standardized to 25% anthocyanosides); alpha lipoic acid 150 mg; N-acetyl cysteine 200 mg; quercetin 100 mg; rutin 100 mg; citrus bioflavonoids 250 mg; plant enzymes 50 mg; black
pepper extract (Bioperine R) 5 mg; malic acid 325 mg; taurine 900 mg; L-glycine 100 mg; L-glutathione 10 mg; boron 2 mg.

Outcomes

The primary outcome measures were: visual function and symptoms in atrophic age-related macular degeneration (ARMD).

Notes

Compliance was assessed by telephone at one week, two weeks, four weeks, six weeks, three months, and 12 months. Compliance with treatment was good. During one-year study, 96% of the participants took approximately 92% of their assigned capsules. There was no difference in compliance among the three groups.

Lutein (Floraglo R) was provided by Kemin Foods International, Des Moines, Iowa; lutein in combination with additional antioxidants and nutrients (OcuPower R) and placebo were provided by Nutraceutical Sciences Institute, Boynton Beach, Florida.

Risk of bias

| Item                  | Authors’ judgement | Description |
|-----------------------|--------------------|-------------|
| Allocation concealment? | Yes                | A - Adequate |

Limburg 2005

Methods

Randomised, double-blind, placebo-controlled trial with two-by-two factorial design.
Generation of the allocation sequence: adequate, the random allocation sequences by sex were generated by the US data-coordinating centre before the baseline evaluation by computer.
Allocation concealment: adequate, the masked code linking agent bottles to intervention group assignments was retained by data-coordinating centre staff and concealed from all but the study statisticians until completion of the study analyses.
Blinding: adequate, identical placebo capsules.
Follow-up: adequate. Vital status was ascertained at the trial end in all patients in the vitamin E group and in 99.9% in the placebo group.
Intention-to-treat analysis: yes.
Sample size calculations: yes.

Participants

Country: China.
Number of participants randomised: 360, mean age 47, 42% males.
Inclusion criteria: at least 1 grossly visible oesophageal lesion with biopsy-proven mild or moderate squamous dysplasia, according to histological interpretation by a single pathologist.
Exclusion criteria: history of cancer (except nonmelanoma skin cancer), symptoms suggestive of an upper gastrointestinal tract malignancy, recently treated peptic ulcer disease, or contraindications to the intervention agent(s) or study-related procedures. Subjects were also excluded if a grossly visible lesion could not be confirmed during the baseline EGD or if the worst histological diagnosis at baseline was less than mild or greater than moderate dysplasia.
Limburg 2005Low  (Continued)

**Interventions**

Participants were randomly assigned into four groups to receive:
- group 1: selenium 200 µg and celecoxib 400 mg, n = 90;
- group 2: celecoxib 400 mg, n = 90;
- group 3: selenium 200 µg, n = 90;
- group 4: placebo, n = 90.
Participants were supplemented and followed 10 months.

**Outcomes**

The primary outcome measure was: change in histological grade of squamous dysplasia (determined by comparing the most advanced histological diagnosis for each subject at the baseline and end-of-trial evaluations) and was categorised as regression, stable, or progression.

**Notes**

Compliance was assessed by pill counts and by direct observation by the village doctors who watched all participants take 2 morning pills each day throughout the intervention period. Compliance was further assessed biochemically by comparing baseline and end-of-trial serum selenium concentrations. Compliance with the single daily dose of selenomethionine (or placebo) and 1 of the 2 daily doses of celecoxib (or placebo) was in excess of 99% by both direct observation and pill counts. Pfizer, Incorporated, provided active and placebo celecoxib agent supplies.

**Risk of bias**

| Item                      | Authors' judgement | Description  |
|---------------------------|--------------------|--------------|
| Allocation concealment?   | Yes                | A - Adequate |

**MAVIS 2005 Low**

**Methods**

- Mineral And Vitamin Intervention Study (MAVISI)
- Randomised, double-blind placebo-controlled trial with parallel group design.
- Generation of the allocation sequence: adequate, participants were randomly allocated to intervention or placebo by batch numbers generated by a password protected computer program.
- Allocation concealment: adequate, the computer program used for randomisation could be accessed by only the data programmer, blind to treatment allocation. The identity of the tablets was concealed in a double envelope sent by the manufacturer, which was kept locked in a cabinet during the trial.
- Blinding: adequate, identical placebo tablets.
- Follow-up: adequate, only 13% (n = 121) of the participants were lost to follow-up or reported stopping taking tablets. At least 1 diary was provided by 99% (901) of participants, 6 diaries by 93% (846), and 12 diaries by 89% (808). Losses to follow-up was equal in the active and the placebo (n = 22) groups.
- Intention-to-treat analysis: yes.
- Sample size calculations: yes.

**Participants**

- Country: Scotland
- Number of participants randomised: 910, 479 men and 431 women, aged 65 or over who did not take vitamins or minerals.
### MAVIS 2005 Low (Continued)

| Inclusion criteria: all people aged 65 or over who were registered with the practices were eligible, irrespective of chronic illness, unless their doctors considered them too unwell. Exclusion criteria: use of vitamin, mineral, or fish oil supplements in the previous three months (one month in the case of water soluble vitamins) or vitamin B12 injection in the past three months. |
|---|
| Interventions |
| Participants were randomly assigned to receive: group 1: multivitamin and multimineral supplement (800 µg vitamin A (acetate), 60 mg vitamin C, 5 µg vitamin D3, 10 mg vitamin E (D, L alpha-tocopheryl acetate), 1.4 mg thiamin (mononitrate), 1.6 mg riboflavin, 18 mg niacin (nicotinamide), 6 mg pantothenic acid (calcium D-pantothenate), 2 mg pyridoxine (hydrochloride), 1µg vitamin B12, 200 µg folic acid, 14 mg iron (fumarate), 150 µg iodine (potassium iodide), 0.75 mg copper (gluconate), 15 mg zinc (oxide), and 1 mg manganese (sulphate); or group 2: matched sorbitol placebo, one tablet daily for one year. Tablets were purchased from a commercial supplier. |
| Outcomes |
| The primary outcome measures were: number of contacts with primary care (doctor and other primary care workers, in person or by phone) for infection, number of self reported days of infection, and health related quality of life measured by the EuroQol and SF-12. The secondary outcome measures were: number of antibiotic prescriptions in primary care, number of days that antibiotics were prescribed, number of hospital admissions (including those related to infection), number of days in hospital with infection, number of infection related and all outpatient visits, adverse events reported by participants, and compliance with trial drugs (from diaries submitted monthly in all participants and tablet count at six and 12 months in a random sample of 10% of participants). |
| Notes |
| Compliance with treatment was assessed by self-report and was consistent with tablet counting. There were no differences between the groups for compliance with drug taking. Compliance in participants still taking tablets and returning information in diaries was over 91% throughout the trial. |

### Risk of bias

| Item | Authors' judgement | Description |
|---|---|---|
| Allocation concealment? | Yes | A - Adequate |
**Methods**

Randomised, double-blind, placebo-controlled trial with parallel group design.

Generation of the allocation sequence: unclear, not reported.

Allocation concealment: unclear, not reported.

Blinding: adequate, identical placebo pills.

Follow-up: adequate, the losses to follow-up were 14.1% in the vitamins group and 11.9% in the placebo group. Seventeen participants of 96 assigned to receive vitamins withdrew, and 5 were lost to follow-up. Of 89 participants assigned to placebo, 15 withdrew and 4 were lost to follow-up.

Intention-to-treat analysis: no.

Sample size calculations: no.

**Participants**

Country: Canada.

Number of participants randomised: 200. Fifteen participants had to be excluded after initial randomisation because none of the polyps was adenomatous. Of the 185 participants, 121 were males and 64 females. Mean age was 58 years.

Inclusion criteria: At least one polyp in the colon or rectum identified by colonoscopy and removed at two Toronto hospitals between 1979 and 1984. Patients who used supplements of vitamin C or E agreed to discontinue their use for the duration of the trial.

Of the 185 eligible participants 137 completed the study with a second colonoscopic examination.

**Interventions**

Participants were randomly assigned to receive:

- group 1. vitamin C 400 mg; vitamin E 400 mg (n = 96).
- group 2: lactose placebos (n = 89);

over a period of two years.

Second colonoscopic examination was performed approximately two years after the initial examination, but could be performed earlier if judged clinically necessary. The physician assessed the presence and location of polyps, and any observed were removed.

**Outcomes**

The primary outcome measure was: recurrence of colorectal polyps.

**Notes**

Compliance with treatment was assessed by random urine samples collected at each visit from which urinary vitamin C levels were assessed, using a dipstick, as an index of compliance. The compliance to the vitamin supplements appears to be good. Of the 185 eligible participants, 137 (75%) completed the study with second colonoscopic examination conducted when most participants (81.5% of those on vitamins and 82.3% of those on placebo) had been receiving supplements for 12 to 30 months.

Trial agents were supplied by H. Newmark of Roche, New Jersey and Roche, Canada.

**Risk of bias**

| Item                   | Authors' judgement | Description |
|------------------------|--------------------|-------------|
| Allocation concealment?| Unclear            | B - Unclear |
Methods

Randomised, double-blind placebo-controlled trial with parallel group design.
Generation of the allocation sequence: adequate, in blocks of 4 according to lists generated by the trial's statistician, who used a computer program. Six randomisation lists were constructed.
Allocation concealment: adequate, those enrolling the participants had no access to the randomisation lists. Participants were unknown to the statistician.
Blinding: adequate, identical looking placebo capsules. Capsules were in 2 equal batches, soft gel and identical in colour and taste.
Follow-up: adequate. Of the 617 randomised persons, 37% in the vitamin E and 36% in the placebo groups, respectively, completed the 1-year trial period. Forty-one participants in the vitamin group and 42 participants in the placebo group were lost to follow-up. The losses to follow-up were equal in both groups.
Intention-to-treat analysis: yes.
Sample size calculations: yes.

Participants

Country: United States.
Number of participants randomised: 617, 169 men and 448 women, mean age 84 years.
Inclusion criteria: aged 65 years or older; life expectancy greater than 6 months; no anticipated discharge within 3 months; not room-bound for the past 3 months; absence of active neoplastic disease; no tube feeding, no kidney dialysis; no intravenous or urethral catheters for the last 30 days; no tracheostomy or chronic ventilator; antibiotic-free for more than 2 weeks; no long-term steroid treatment greater than 10 mg/d, no use of immunosuppressive drugs, or greater than the recommended daily allowance (RDA) level of supplements of vitamins E, C, or B6, selenium, zinc, beta-carotene, or fish oil; body mass index of at least 18; serum albumin at least 3.0 g/dL; able to swallow pills; willing to receive influenza vaccine; and willing to provide informed consent (for patients with dementia, family members provided informed consent).

Interventions

Participants were randomly assigned to receive:
group 1: 200 IU of vitamin E (dl-alpha-tocopherol) (n = 311);
group 2: placebo 4 IU of vitamin E (n = 306); both in soybean oil, one capsule daily for a period of one year.
All participants received a capsule containing half the recommended daily allowance of essential vitamins and minerals.
All participants received influenza vaccine.

Outcomes

Primary outcomes of the trial were: incidence of, number of persons with, and number of days with respiratory tract infections (upper and lower), and number of new antibiotic prescriptions for respiratory tract infection. Secondary outcomes included emergency department visits, hospitalisation, and death. A post hoc subgroup analysis was performed to determine the effect of vitamin E on common colds.

Notes

Adherence to trial protocol was verified by nursing home medication records, returned pill count, and quarterly measurement of plasma vitamin E levels. Ninety-eight percent of those completing the trial consumed the capsules for at least 330 days (>90% of the 1-year supplementation period). The number of missed supplements did not differ statistically between the vitamin E and placebo groups.
Capsules were manufactured by Tishcon Corporation (Westbury, NY). The capsules were packed by Pharmasource Healthcare Inc (Marlboro, Mass).
### Risk of bias

| Item                        | Authors' judgement | Description |
|-----------------------------|--------------------|-------------|
| Allocation concealment?     | Yes                | A - Adequate |

### Mezey 2004

**Methods**
- Randomised, double-blind placebo-controlled trial with parallel group design.
- Allocation concealment: adequate. The vitamin E capsules and placebo capsules were prepared and labelled by the hospital pharmacies. For each patient entered into the trial the investigators opened a consecutive sealed container which had a 3-month supply of capsules.
- Blinding: adequate, capsules were identical in looks, smell, and taste.
- Follow-up: adequate. During the initial 3-month period of therapy, one patient in the treatment group withdrew from the trial. Four patients, 2 in each group, died during the initial 3 months. Five patients in the treatment group and 4 patients in the placebo group were lost between 3 and 12 months to follow up.
- Intention-to-treat analysis: yes.
- Sample size calculations: yes.

**Participants**
- Country: United States and Spain.
- Number of participants randomised: 51, 34 men and 17 women, mean age 48 years.
- Inclusion criteria: age (18 years to 70 years), recent history of heavy alcohol ingestion and clinical and laboratory characteristics adopted by the International Informatics Hepatology Group for the diagnosis of alcoholic hepatitis. These criteria included moderate elevation of the serum aspartate aminotransferase AST (< 10 times above normal), an AST/alanine aminotransferase (ALT) ratio greater than 1.0 and no evidence of liver disease due to viral hepatitis, autoimmune disease, haemochromatosis, Wilsons disease or drug-induced hepatitis.
- Exclusion criteria: pregnancy, breast feeding, cardiovascular, pulmonary, kidney disease, pancreatitis, type I diabetes, recent (within 1 month) gastrointestinal bleeding, peptic ulcer disease, concurrent infection, history of thrombophlebitis, HIV positivity and history of ingestion of more than 100 IU vitamin E for the prior month.

**Interventions**
- Participants were randomly assigned to receive:
  - group 1: vitamin E (dl-alpha-tocopheryl acetate) 1000 IU (n = 25)
  - group 2: placebo (n = 26); one capsule daily 3 months.
- The patients were followed for 1 year after entry into the trial.

**Outcomes**
- The primary outcome measures was: clinical and laboratory parameters of liver function and on markers of fibrogenesis.

**Notes**
- Compliance with treatment was checked by serum assessments. Plasma alpha-tocopherol levels increased in patients on vitamin E.
- The authors published results of shorter (3 months) and longer (1-year) follow-up period.
### MINVITAOX 1999

#### Methods

MIN.VIT.AOX geriatric network.
Randomised, double-blind placebo-controlled trial with two-by-two factorial design.
Generation of the allocation sequence: adequate, random numbers generated by computer program.
Allocation concealment: adequate, central independent unit.
Blinding: adequate, identical placebo capsules.
Follow-up: adequate, losses to follow-up were approximately 2.2% in each treatment group. Three participants from the vitamin group, 3 participants from the vitamin and trace elements group, 4 participants from the trace elements group, and 4 participants from the placebo group withdrew before the end of the trial.
Intention-to-treat analysis: yes.
Sample size calculations: yes.

#### Participants

Country: France.
Number of participants randomised: 725 institutionalised elderly patients from 25 geriatric centres, 185 men and 540 women, aged 65 to 103 years, mean age 83.9 years.
Inclusion criteria: no acute illnesses and at least 65 years of age. Age-related diseases were allowed.
Exclusion criteria: patients with a history of cancer or those taking medication that might interfere with nutritional status, immunocompetence, or vitamin or mineral supplementation.

#### Interventions

Participants were randomly assigned to receive:
- group 1: trace elements zinc sulfate and selenium sulfide (providing 20 mg of zinc and 100 µg of selenium), (n = 182);
- group 2: vitamin group - ascorbic acid (120 mg), beta-carotene (6 mg), and alpha-tocopherol (15 mg) (n = 180);
- group 3: trace element and vitamin supplements (n = 181);
- group 4: placebo capsules (n = 182).
Participants received one capsule daily, with their breakfast for two years.

#### Outcomes

The primary outcome measures were: delayed-type hypersensitivity skin response, humoral response to influenza vaccine, and infectious morbidity and mortality.

#### Notes

Compliance with treatment was assessed first by the nursing teams that administered the pills every morning and then at the end of each six months by counting the remaining capsules in the pillboxes, and by random serum assessments. High compliance (> 85%) was observed.
The supplements and placebo were provided by Produits Roche SA, Fontenay-aux-Roses, France.
Additional information received through personal communication with the authors.
Risk of bias

| Item                | Authors’ judgement | Description |
|---------------------|--------------------|-------------|
| Allocation concealment? | Yes                | A - Adequate |

Mooney 2005

Methods
Randomised, double-blind placebo-controlled parallel group trial
Generation of the allocation sequence: adequate, sample IDs were generated sequentially for each patient at each visit, without reference to treatment group by computer.
Allocation concealment: adequate, uniformly coded bottles. Participants, interviewers, and laboratory personnel were blinded to treatment group and did not have access to the randomisation code.
Blinding: adequate, identical placebo pills.
Follow-up: adequate, 83 of 142 (58%) in the treatment group and 93 of 142 (66%) in the placebo group completed 15 months of treatment.
Intention-to-treat analysis: yes.
Sample size calculations: yes.

Participants
Country: United States.
Number of participants randomised: 284, 55% men and 45% women were aged 18 or older, mean age 36.8 years.
Inclusion criteria: men and women ages > 18 years who smoked at least 10 CPD, did not take vitamin supplements or use a nicotine patch in the 3 months before enrolment, had no prior history of cancer or liver disease, lived at a permanent address, owned a home telephone, were willing to comply with the 2-year protocol, and completed a 1-month placebo run-in.
Exclusion criteria: none stated.

Interventions
Participants were randomly assigned to receive:
group 1: vitamin C 500 mg and vitamin E 400 IU (n = 142);
group 2: placebo (n = 142);
for a period of 1.25 years.

Outcomes
The primary outcome measure was: level of benzo(a)pyrene [B(a)P]-DNA adducts as an intermediate cancer risk marker.

Notes
Treatment compliance was assessed by serum vitamin measurements and pill counts. Compliance with treatment did not differ by gender measured by blood levels of [alpha]-tocopherol at 15 months of follow-up or by pill counts. At all time points after randomisation, in all participants, the treatment group had significantly higher levels of vitamin E than the placebo group. However, in women, the blood levels of vitamin E did not plateau until the 9-month time point.
Trial agents were provided by Hoffman-LaRoche.
Mooney 2005

| Item                     | Authors' judgement | Description             |
|--------------------------|--------------------|-------------------------|
| Allocation concealment?  | Yes                | A - Adequate            |

Murphy 1992

**Methods**
Randomised, double-blind, placebo-controlled trial with parallel group design.
Generation of the allocation sequence: unclear, not reported.
Allocation concealment: adequate, participants were given a content of a single capsule by a research assistant who was not involved with outcome ascertainment. Patients, their regular physicians, and study team members remained masked to the capsule contents for the duration of the trial.
Blinding: adequate, identical placebo tablets.
Follow-up: adequate, 2 patients from vitamin A group were lost to follow-up.
Intention-to-treat analysis: yes.
Sample size calculations: no.

**Participants**
Country: United States of America.
Number of participants randomised: 109, 37 men and 72 women, mean age 73 years.
Inclusion criteria: patients on the chronic medical and skilled/intermediate care wards of an academically affiliated nursing home.
Exclusion criteria: patients in the rehabilitation unit.

**Interventions**
Participants were randomly assigned to receive:
group 1: vitamin A 60,000 µg retinol equivalent (200,000 IU) (n = 53);
group 2: placebo (vitamin A 300 retinol equivalents 1000 IU) as retinyl palmitate in arachis oil (n = 56).
All capsules contained 40 IU of vitamin E as an antioxidant.
Patients receiving multivitamin preparations at the onset of the trial continued to receive them. No patient was commenced on vitamin A-containing supplements during the follow-up period.
A content of a single capsule was given to participants by research assistant. Participants were followed-up for 90 days.

**Outcomes**
The primary outcome measure was: incidence of antibiotic treated bacterial infections among elderly nursing-home residents.

**Notes**
Participants were given a content of a single capsule by a research assistant.
Due to the administration of vitamin A in the control group, the 'no intervention' in that group can be discussed.
Trial capsules were provided by Roche, Basel, Switzerland.

**Risk of bias**

| Item                     | Authors' judgement | Description |
|--------------------------|--------------------|-------------|
| Allocation concealment?  | Yes                | A - Adequate|
**Methods**

Nutrition Intervention Trial (NIT); The General Population Trial, in Linxian, China. Randomised, placebo-controlled trial with one-half replicate of a two-by-two-by-two-by-two factorial design.

Generation of the allocation sequence: adequate, random numbers generated by independent data management centre in USA. The randomisation sequence was known only at data management centre until the intervention concluded.

Allocation concealment: adequate, sequentially numbered coded bottles. Pill containers were labelled in the USA at the pill distribution centre.

Blinding: adequate, identical placebo pills.

Follow-up: inadequate, losses to follow-up not reported.

Intention-to-treat analysis: yes.

Sample size calculations: yes.

**Participants**

Country: China, Henan Province of north central China, Linxian County.

Number of participants randomised: 29584; 45% males, aged 40 to 69 years.

Inclusion criteria: residents willing to take part in a multi-year, daily pill-taking regimen.

Exclusion criteria: debilitating disease or prior oesophageal or stomach cancer.

**Interventions**

Participants were randomly assigned to receive one of eight vitamin/mineral supplement combinations in the form of individual oral tablets. The eight intervention groups (each with 3677 to 3709 participants) were derived from a one-half replicate of a two-by-two-by-two-by-two factorial design which allowed to assess four factors (ie, nutrient combinations) in a single experiment. The four factors designated by the letters A, B, C, D were:

A - retinol (as palmitate) 5000 IU, zinc (as zinc oxide) 22.5 mg;

B - riboflavin (vitamin B2) 3.2 mg and niacin (vitamin B3) 40 mg;

C - ascorbic acid 120 mg and molybdenum (as molybdenum yeast complex) 30 µg;

D - beta carotene 15 mg, selenium (as selenium yeast) 50 µg, and alpha-tocopherol 30 mg.

Doses of each nutrient varied from one to two times US Recommended Daily Allowances (RDAs).

The eight intervention groups were defined by the following combinations of supplements: AB, AC, AD, BC, BD, CD, ABCD, or placebo and packed in coded bottles containing a one-month supply. Bottles were distributed monthly beginning in March 1986 and continuing through May 1991, average 5.25 years.

**Outcomes**

The primary outcome measures were: cancer incidence, cancer mortality, and overall mortality.

**Notes**

Compliance with study treatment was assessed by monthly pill counts and biochemical measures. Compliance was excellent throughout the study. The overall pill disappearance rate was 93% for all participants, with no difference by treatment group (range 92% to 93%) and little change during the trial.

All vitamin/mineral supplements and placebos were provided by Hoffmann-La Roche, Basel, Switzerland and Lederle Laboratories, Inc.

Data were extracted from the primary publication.

Additional information received through personal communication with the authors.

**Risk of bias**

| Item | Authors' judgement | Description |
|------|-------------------|-------------|
|      |                   |             |
Methods
The Dysplasia Trial.
Randomised, placebo-controlled trial with parallel group design.
Generation of the allocation sequence: adequate, random numbers generated by independent data management centre in USA.
Allocation concealment: adequate, sequentially numbered coded bottles. Pill containers were labelled in the USA at the pill distribution centre.
Blinding: adequate, identical placebo pills.
Follow-up: adequate, the morbidity and mortality follow-up rates were 99%.
Intention-to-treat analysis: yes.
Sample size calculation: yes.

Participants
Country: China, Henan Province of north central China, Linxiaun County.
Number of participants randomised: 3318; 1461 males and 1857 females at age 40 to 69 years, mean age 54 years.
Inclusion criteria: place of living in one of the three northern Linxian communes (Yaocon, Rencun, or Donggang), provided consent, diagnosis of oesophageal dysplasia on a balloon cytology examination.
Exclusion criteria: taking vitamins of any type regularly, or antitumour B (a traditional Chinese drug consisting of a mixture of six medical herbs), history of malignancy or other debilitating disease.

Interventions
Participants were randomly assigned to receive:
group 1: 14 vitamins and 12 minerals (vitamin A (acetate) 10000 IU; vitamin E (dl-alpha tocopherol acetate) 60 IU; vitamin C (ascorbic acid) 180 mg, vitamin B1 5 mg, vitamin B2 5.2 mg, vitamin B6 6 mg, vitamin B12 18 µg, vitamin D 800 IU; beta-carotene 15 mg, folic acid 800 µg, niacinamide 40 mg, biotin 90 µg, pantothenic acid 20 mg, calcium 324 mg, phosphorus 250 mg, iodine 300 µg, iron 54 mg, magnesium 200 mg, copper 6 mg, manganese 15 mg, potassium 15.4 mg, chloride 14 mg, chromium 30 µg, molybdenum 30 µg, selenium (sodium selenate) 50 µg, and zinc (n = 1657);
group 2: placebo (n = 1661);
for a period of 6 years.
The doses were typically two to three times the US Recommended Daily Allowances (RDAs), but ranged from 0.26 to seven times the RDA depending on the vitamin or mineral. Each participant was given three pills daily, including one capsule beta-carotene or placebos and two tablets of vitamin/mineral supplement, or placebos.

Outcomes
The primary outcome measures were: cancer incidence, cancer mortality, and overall mortality.

Notes
Compliance with treatment was assessed by counting unused pills for all trial participants and by assessing nutrient levels in blood collected from samples of individuals randomly selected without replacement every three months throughout the trial. Compliance with treatment was excellent. The overall pill disappearance rate was 94% in both groups with slight decline (from 96% in year 1 to 92% in year 6 in both groups) over the duration of the trial.
Data were extracted from the primary publication.
Active medications and placebos were provided: beta-carotene as Solatane by Hoffmann-La Roche, Inc., Nutley, N.Y., and vitamin/mineral supplement as Centrum by Lederle Laboratories, Inc., Pearl River, N.Y. Additional information received through personal communication with the authors.

### Risk of bias

| Item                          | Authors’ judgement | Description          |
|-------------------------------|--------------------|----------------------|
| Allocation concealment?       | Yes                | A - Adequate         |

### NPCT 1996

#### Methods

Nutritional Prevention of Cancer Trial (NPCT).
Randomised, double-blind, placebo-controlled trial with parallel group design.
Generation of the allocation sequence: adequate, computer generated random numbers.
Allocation concealment: adequate, treatment group assignment was made centrally. The co-ordinating centre held all treatment information in blinded form. Medications were distributed using sealed pill bottles.
Follow-up: adequate. At the end of the blinded period of treatment no participants were lost to vital follow-up, and only 7 participants (3 in the selenium group and 4 in the placebo group) declined to provide additional information about the illness.
Blinding: adequate, identical placebo tablets.
Intention-to-treat analysis: yes.
Sample size calculations: yes.

#### Participants

Country: United States of America.
Number of participants randomised: 1312; 75% males, aged 18 to 80 years, mean age 63 years.
Inclusion criteria: history of two or more basal cell skin cancers (BCC) or one squamous cell skin cancer (SCC), with one of this occurring within the year prior the randomisation, life expectancy of at least five years and no internal malignancies treated within the previous five years.
Exclusion criteria: history of significant liver or kidney disorders.
Recruitment began on September 15, 1983 and continued each year through 1991.

#### Interventions

Patients were randomly assigned to receive:
group 1: 200 µg of selenium supplied in a 0.5 g high-selenium bakers yeast tablet (n = 653);
group 2: placebo (n = 659);
The end of a blinded period of treatment was on February 1, 1996. Mean length of treatment was 4.5 years and follow-up 7.4 years.

#### Outcomes

The primary outcome measures were: incidences of basal cell and squamous cell carcinoma of the skin. In 1990 secondary outcome measures were identified, which included: total mortality and cancer mortality, as well as the incidence of the lung, colorectal, and prostate cancers.
Notes
Compliance with treatment: excellent, 79.3% of the participants (80.3% in the placebo group and 78.4% in the selenium group) missed taking a pill less than twice a month.
Trial medications were provided by Nutrition 21 (La Jolla, CA), through 1995 and by Cypress Systems (Fresno, CA) thereafter.

Risk of bias

| Item                      | Authors’ judgement | Description |
|---------------------------|--------------------|-------------|
| Allocation concealment?   | Yes                | A - Adequate|

NSCPT 1999
Methods
Nambour Skin Cancer Prevention Trial (NSCPT).
Randomised, double-blind, placebo-controlled trial with two-by-two factorial design.
Generation of the allocation sequence: adequate, randomisation computer program.
Allocation concealment: adequate, the treatment code was known only to the investigator who generated it and the two people who packaged the tablets for distribution. None of these people had contact with participants.
Blinding: adequate, identical looking placebo tablets of beta-carotene.
Follow-up: adequate. At the end of the trial after 5 years, 15% participants had withdrawn without a complete skin examination by a dermatologist in the follow-up period. Fifty participants, assigned to sunscreen and beta carotene, 70 assigned to sunscreen and placebo, 59 assigned to no sunscreen and beta carotene, and 59 assigned no sunscreen and placebo were lost to follow-up.
Intention-to-treat analysis: yes.
Sample size calculations: yes.

Participants
Country: Australia.
Number of participants randomised: 1621, 708 men and 913 women, aged between 20 and 69 years, mean age 48.8 years.
Inclusion criteria: examination by a dermatologist with removal of all diagnosed skin cancers, written informed consent.
Exclusion criteria: taking vitamin supplements containing beta-carotene and those who reported that they were already applying sunscreen on a strict daily basis.

Interventions
Patients were randomly assigned to receive:
- group 1: sunscreen and beta-carotene (30 mg) (n = 404);
- group 2: sunscreen and oral placebo (n = 408);
- group 3: beta-carotene (n = 416);
- group 4: oral placebo (n = 393);
one tablet daily for a period of 4.5 years.
Use of a placebo skin cream is considered unethical from two points of view: an oil-in-water emulsion with no active chemicals may enhance ultraviolet damage after evaporation of the water component; and people in the trial may use the placebo skin cream rather than a protective sunscreen in situations that
lead to sunburn. The treatment protocol involves the self-application of an adequate layer of sunscreen to all exposed sites on the head, neck, and upper limbs every morning, after heavy sweating or bathing.

### Outcomes

The primary outcomes were: incidence of basal-cell and squamous-cell carcinomas both in terms of people treated for newly diagnosed disease and in terms of the numbers of tumours that occurred. Analysis of the effect of sunscreen was based only on skin cancers that developed on sites of daily application.

### Notes

Compliance is assessed on a 3-monthly basis when supplies of sunscreens and tablets are replenished comparing the weight of sunscreen used to an empirical standard usage rate, by counting the remaining tablets, and by determining serum beta-carotene in a random sample of participants at 12 and 54 months. At the end of the trial, 75% of participants who were assigned daily sunscreen use were applying sunscreen to their head, neck, arms, and hands at least 3 or 4 days per week. Of those people not assigned to the sunscreen group, 74% were applying sunscreen to head, neck, and arms either not at all or no more than 1 or 2 days per week. Self-reported frequency of sunscreen application was well correlated with estimated daily weight of sunscreen used (averaged across the entire intervention period) in the sunscreen group. On the basis of counts of returned tablets, 72% of the beta-carotene group and 70% of the placebo group took at least 80% of the prescribed tablet intake over the entire intervention period. The beta-carotene group had significantly greater mean skin reflectance on the palm at follow-up than at baseline and their follow-up values were greater than those of the placebo group. Study agents were supplied by Hoffman-La Roche, Nutley, NJ (beta-carotene), and broad-spectrum, sun protection factor 15+ sunscreen supplied by Woolworths Limited, Sydney, Australia, under the brand Auscreen Ultrablock Lotion SPE 15+ Ross Cosmetics, Melbourne, Australia.

### Risk of bias

| Item                  | Authors' judgement | Description |
|-----------------------|--------------------|-------------|
| Allocation concealment? | Yes                | A - Adequate |

### Methods

Randomised, double-blind, placebo-controlled trial with parallel group design.

Generation of the allocation sequence: unclear, not reported.

Allocation concealment: unclear, not reported.

Blinding: adequate, identical vitamin cocktail.

Follow-up: adequate, 1 patient from each group was lost to follow-up.

Intention-to-treat analysis: no.

Sample size calculations: no.

### Participants

Country: United Kingdom.

Number of participants randomised: 30; 20% males, mean age 83.7 years.

Inclusion criteria: patients who had been in hospital for more than 3 months, requiring nursing care as a consequence of stroke disease, but without active medical problem.
Exclusion criteria: patients who were catheterised, or who had pressure sores, or who were receiving medication known to affect immune function.

Interventions

Participants were randomly assigned to receive:
- group 1: vitamin A 8000 IU, vitamin C 100 mg, and vitamin E 50 IU (n = 15);
- group 2: placebo (n = 15);
for 28 days.

Outcomes
The primary outcome measures were: nutritional status and cell-mediated immune function.

Notes
Compliance with treatment is not described.

Risk of bias

| Item                        | Authors’ judgement | Description |
|-----------------------------|--------------------|-------------|
| Allocation concealment?     | Unclear            | B - Unclear |

PHS 1996Low

Methods

Physicians Health Study (PHS).
Randomised, double-blind, placebo-controlled trial with two-by-two factorial design.
Generation of the allocation sequence: adequate, by computer in blocks.
Allocation concealment: adequate, the shipping department sent out calendar packs (which were identical whether active or placebo) to individual participants depending on this code. All of the calendar packs were in coded boxes, supplied by the drug manufacturer, so that the shippers did not know which drug they were shipping.
Blinding: adequate, identical placebo capsules.
Follow-up: adequate. By December 31, 1995, the scheduled end of the trial, less than 1% of the participants were lost to follow up.
Intention-to-treat analysis: yes.
Sample size calculations: yes.

Participants

Country: United States of America.
Number of participants randomised:
22071 US male physicians at age 40 to 84 years, mean age 53 years.
Inclusion criteria: US male physicians willing to take part in this trial.
Exclusion criteria: chronic liver disease or evidence of abnormal liver function, severe renal disease or evidence of impaired renal function, inflammatory muscle disease or evidence of muscle problems (creatine kinase > 750 IU/L); concurrent treatment with cyclosporin, fibrates, or high-dose niacin; child-bearing potential; severe heart failure; some life-threatening condition other than vascular disease or diabetes (eg, severe chronic Airways disease or any cancer other than non-melanoma skin cancer); or conditions that might limit long-term compliance (eg, severely disabling stroke, dementia, or psychiatric disorder).
Interventions

Physicians were randomly assigned to one of the four groups including:

- group 1: active aspirin 325 mg on alternate days plus beta-carotene placebo;
- group 2: active beta-carotene 50 mg on alternate days plus aspirin placebo;
- group 3: both active agents; or
- group 4: both placebos.

The randomised aspirin component of the study was terminated early, on 25 January 1988. The beta-carotene component continued uninterrupted until its scheduled end in December 1995.

A total of 11036 physicians were assigned at random to receive beta-carotene and 11035 to receive beta-carotene placebo.

Time from randomisation to the end of study averaged 12 years, and time of follow-up 12.9 years.

Outcomes

The primary outcome measures were: overall and within subgroups, incidence of malignant neoplasms (except non-melanoma skin cancer), incidence of cardiovascular disease, and overall mortality.

Notes

Compliance with treatment was checked by random serum assessments obtained at unannounced visits to trial participants. Compliance with treatment excellent, the average per cent of pills taken was 97% in both the active and placebo groups. There was 85% compliance with beta-carotene treatment after five years and 78% after 12 years. The use of vitamin A supplements was reported by only 6% of the placebo group even by the end of trial.

Active trial packs and matching placebos were provided by: aspirin (Bufferin) by Bristol Meyers; beta-carotene (Lurotin), BASF corporation.

Additional information received through personal communication with the authors.

Data were extracted from the article: Cook et al. Effects of beta-carotene supplementation on cancer incidence by baseline characteristics in the Physicians' Health Study (United States). Cancer Causes and Control 2000; 11: 617-26, with extended follow-up of 12.9 years.

**Risk of bias**

| Item             | Authors' judgement | Description |
|------------------|--------------------|-------------|
| Allocation concealment? | Yes                | A - Adequate |

Pike 1995Low

Methods

Randomised, double-blind, placebo-controlled trial with parallel group design.

Generation of the allocation sequence: adequate, blocks of computer generated random numbers.

Allocation concealment: adequate, sealed envelopes.

Blinding: adequate, identical placebo tablets.

Follow-up: adequate. Five participants in the placebo group and 7 in the supplemented group did not complete the trial.

Intention-to-treat analysis: yes.

Sample size calculations: no.
Participants

Country: United States of America.
Number of participants randomised: 47; 13 men and 34 women at age 61 to 79, mean age 69 years.
Inclusion criteria: healthy, noninstitutionalised elderly participants with no known chronic or serious medical illness (eg, cancer, end stage renal disease, chronic liver disease).
Exclusion criteria: taking nutritional supplements 3 months before the trial start.

Interventions

Participants were randomly assigned to receive:
- group 1: micronutrient supplement (Multivitol R) containing vitamin A (retinol acetate) 800 retinol equivalents (RE); vitamin D2 (ergocalciferol) 5.0 µg; vitamin E (alpha-tocopherol acetate) 45 mg; vitamin B1 (thiamin mononitrate) 2.18 mg; vitamin B2 (riboflavin) 2.6 mg; vitamin B6 (pyridoxin hydrochloride) 3.65 mg; vitamin B12 (cyanocobalamin) 9 µg; nicotinamide 30 mg; vitamin C (ascorbic acid) 90 mg; calcium (calcium hydrogen phosphate 2H2O 695 mg) 162 mg; magnesium (magnesium oxyde 165.78 mg) 100 mg; iron (iron (II) fumarate 82.14 mg) 27 mg; copper (copper (II) oxyde 1.87 mg) 1.5 mg; zinc (zinc oxide 28 mg) 22.5 mg; iodine (potassium iodide 0.294 mg) 0.225 mg; (n = 24);
- group 2: placebo: (n = 23);
one tablet daily for a period of one year.

Outcomes

The primary outcome measure was: immune indices in healthy elderly.

Notes

Compliance was verified by interview with the patient during trimonthly visits to the center and through morbidity forms, phone calls, and checking supplement containers when brought back to the center. Trial agents were provided by Hermes Arzneimittel GmbH.

Risk of bias

| Item                                | Authors' judgement | Description |
|-------------------------------------|--------------------|-------------|
| Allocation concealment?             | Yes                | A - Adequate |
### PPP 2001

| Methods | The Primary Prevention Project (PPP)  
Randomised controlled clinical trial with two-by-two factorial design.  
Generation of the allocation sequence: adequate, computer generated randomisation table produced in random permuted blocks of 12, allowing stratification.  
Allocation concealment: adequate, centrally assigned treatments on telephone verification of the correctness of inclusion criteria.  
Blinding: inadequate. There is no intervention in the control arm.  
Follow-up: adequate. At the end of the trial, 4150 (92.3%) patients had clinical follow-up. For 314 (7.0%) participants, information on vital status was obtained through census offices. Overall, vital status information was obtained for 99.3% of the population enrolled. Fourteen participants assigned to vitamin group and 17 assigned to control group were lost to follow-up.  
Intention-to-treat analysis: yes.  
Sample size calculations: yes. |
|---|---|
| Participants | Country: Italy.  
Number of participants randomised: 4495; 1912 males and 2583 females, mean age 64.4 years.  
Inclusion criteria: old age (> 65 years); hypertension (systolic blood pressure > 160 mmHg or diastolic blood pressure > 95 mm Hg on at least three separate occasions); hypercholesterolaemia (total blood cholesterol > 6.4 mmol/L on at least two separate occasions); diabetes mellitus (fasting venous plasma glucose concentration > 7.8 mmol/L on at least two separate occasions (chronic drug treatment for any of the three latter conditions was also a criterion for inclusion); obesity (body mass index > 30 kg/m2); and family history of myocardial infarction before 55 years of age in at least one parent or sibling.  
Exclusion criteria: treatment with antiplatelet drugs (history of vascular events or diseases); chronic use of anti-inflammatory agents or anticoagulants; contraindications to aspirin; diseases with predictable poor short-term prognosis; and predictable psychological or logistical difficulties affecting compliance with the trial requirements. |
| Interventions | Patients were randomly assigned to receive:  
group 1: aspirin, 100 mg (enteric-coated aspirin a day) (n = 2226); or  
group 2: no aspirin (n = 2269); and  
group 3: vitamin E (one capsule of 300 mg synthetic alpha-tocopherol a day), (n = 2231) or;  
group 4: no vitamin E (n = 2264),  
following a two-by-two factorial design.  
The mean follow-up was 3.6 years. |
| Outcomes | The primary outcome measure was: the cumulative rate of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke. Predefined analyses included cardiovascular deaths, total deaths, total cardiovascular events (cardiovascular death, nonfatal myocardial infarction, non-fatal stroke, angina pectoris, transient ischaemic attacks, peripheral artery disease, and revascularisation procedures). |
| Notes | At the beginning, and repeatedly during the trial, all patients received advice on compliance with background treatments. Compliance with treatments: at year 1 and at the end of the study 19.2% and 19.3% of the patients randomised to aspirin and 13.1% and 13.6% of those randomised to vitamin E had stopped taking the treatment. Side effects were the reason for discontinuation for 7.9% of the patients in the aspirin group and 1.1% in the vitamin E group. At the end of the trial, 7.2% of the patients not randomised to aspirin were taking aspirin and 0.2% of those not randomised to vitamin E were taking vitamin E. |
PPP 2001  (Continued)

| Item                        | Authors’ judgement | Description               |
|-----------------------------|--------------------|---------------------------|
| Allocation concealment?     | No                 | C - Inadequate            |

**Risk of bias**

**Methods**
The Polyp Prevention Study (PPS).
Randomised, double-blind, placebo-controlled trial with two-by-two factorial design.
Generation of the allocation sequence: adequate, by computer.
Allocation concealment: adequate, only pharmacy and safety and data monitoring committee had access to the treatment assignments.
Blinding: adequate, identical placebo capsules provided by a sponsor.
Follow-up: adequate. Of 864 patients randomised, 751 (87%) underwent follow-up colonoscopic examinations and provided all subsequent data. Overall, 69 participants were lost to follow-up; 56 in 3 active intervention groups and 13 in placebo group.
Intention-to-treat analysis: no.
Sample size calculations: yes.

**Participants**
Country: United States of America.
Number of participants randomised: 864; 751 participants completed the study, 592 males and 159 females, mean age 61 years.
Inclusion criteria: at least one adenoma diagnosed within the previous three months, patients have undergone colonoscopy with the entire large bowel seen and judged to be free of further polyps, good health, age less than 80 years.
Exclusion criteria: familial polyposis, a history of invasive colorectal cancer, malabsorption syndromes, or any condition (such as a history of renal calculi or thrombophlebitis) that might be worsened by dietary supplementation with vitamin C or E.
Participants agreed not to take supplemental vitamin C or E or beta carotene outside the trial.
The trial protocol called for two follow-up colonoscopic examinations, the first approximately one year after the colonoscopy that qualified the patient for study (year 1), and second 36 months after the first (year 4). A colonoscopy was considered to be satisfactory for study purposes if cecum was reached, the entire mucosa was seen, and all polyps were removed. The endoscopist recorded the size and location of all raised mucosal lesions.

**Interventions**
Patients were randomly assigned to receive:
group 1: beta carotene 25 mg, vitamin C 1000 mg, vitamin E (dl-alpha-tocopherol) 400 mg (n = 208);
group 2: vitamin C 1000 mg, vitamin E 400 mg, and placebo (n = 225);
group 3: beta carotene 25 mg plus placebo (n = 217);
group 4: placebo (n = 214);
daily for 4 years.
The study agents were provided in the form of soft gelatine capsules (containing placebo, beta carotene alone, vitamin E alone, or beta carotene plus vitamin E) and tablets (containing placebo or vitamin C) packaged in calendar packs, with each day’s blister containing one capsule and one pill.

| Outcomes | The primary trial outcome was: the occurrence of new adenomas between the colonoscopic examinations conducted at year 1 and year 4. |
|----------|----------------------------------------------------------------------------------------------------------------------------------|
| Notes    | Compliance was checked by random serum assessments. Compliance with treatment was good, 82% of all patients reported taking the study agents at least six days per week, and further 5% took them three to five days per week. Only five patients stopped taking the medications because of their presumed toxicity. Trial agents were provided at no cost by BASF of of Wiandotte, Michigan. Additional information received through personal communication with the authors. |

**Risk of bias**

| Item             | Authors’ judgement | Description |
|------------------|--------------------|-------------|
| Allocation concealment? | Yes                | A - Adequate |

**Prince 2003 Low**

**Methods**

Randomised, double-blind, placebo-controlled cross-over trial. Generation of the allocation sequence: adequate, computer-generated. Allocation concealment: adequate, therapy was randomly allocated using computer-generated tables by an independent pharmacist (central randomisation). Blinding: adequate, identical looking capsules. Follow-up: adequate, 44 (72%) patients completed the trial per protocol. One patient died from previously undiagnosed ischaemic heart disease during the first (active) treatment period. Eight further patients (5 from the active group) withdrew from the trial during the first treatment period and 8 (4 from the active group) withdrew during the second treatment period. Intention-to-treat analysis: no. Sample size calculations: yes.

**Participants**

Country: United Kingdom. Number of participants randomised: 61 patient with primary biliary cirrhosis, 92% women, mean age 58 years. Inclusion criteria: primary biliary cirrhosis and self-reported fatigue. Exclusion criteria: change in disease (or symptom) altering medication in the 3 months prior to randomisation (e.g. ursodeoxycholic acid, colestyramine, rifampicin), current use or use within the last 3 months of nutritional supplements containing antioxidants, inability to complete symptom severity assessment documents, life-threatening intercurrent disease; presence of other uncontrolled disease with fatigue forming part of its clinical spectrum (e.g. hypothyroidism, anaemia, renal failure, depression); drug dependency or addiction; women of child-bearing potential who were not practising effective contraception.
Participants received 12 weeks each of placebo and antioxidant supplementation (vitamins A, C and E, selenium, methionine and ubiquinone) in random order, separated by a four-week washout period. Active medication consisted of four gelatine-covered capsules daily containing selenium (l-selenomethionine) 75 µg, beta-carotene 3 mg, vitamin E (d-alpha-tocopherol acetate) 50 mg, vitamin C 150 mg, l-methionine 375 mg, and ubiquinone (coenzyme Q10) 25 mg. Placebo consisted of identical-looking capsules containing inactive carrier. Participants were requested not to start any other nutrient supplements or complementary therapies during the trial. Forty-three (70%) patients were co-prescribed ursodeoxycholic acid. The median dose (interquartile range) prescribed was 9.6 mg/kg (8.5-11.3 mg/kg). Fifteen (25%) patients were taking thyroxine for pre-existing hypothyroidism. All patients had normal thyroid stimulating hormone levels and had been on stable thyroxine doses for at least 3 months prior to enrolment. Two patients were taking long-term beta-adrenergic blocking medication (one each propranolol and sotalol). Three patients were long-term users of benzodiazepines.

The primary outcome measure for this study was: the change in patient fatigue. Fatigue was assessed using the Fisk fatigue severity score (FFSS). The FFSS assesses the impact of fatigue-associated impairment in three domains (physical, cognitive and psychosocial) that can be summed to give a total score. Higher scores relate to increased fatigue severity.

Trial medications were provided by Bioquantox, Pharma Nord, Morpeth, UK. Additional information received through personal communication with the authors.

| Item               | Authors’ judgement | Description |
|--------------------|--------------------|-------------|
| Allocation concealment? | Yes                | A - Adequate |
Prevention of Cancer by Intervention with Selenium Pilot Study (PRECISEp).
Randomised, double-blind, placebo-controlled trial with parallel group design.
Generation of the allocation sequence: adequate, computer-generated permuted blocks.
Allocation concealment: adequate, research nurses telephoned the independent randomisation service to obtain an anonymous code for each volunteer, and then gave the volunteer their corresponding pre-coded tablets.
Blinding: adequate, identical intervention and placebo yeast.
Follow-up: adequate, 34 participants (7%) withdrew from treatment within the first 6 months. There was no significant difference in treatment withdrawals between groups (7, 10, 5, and 12 in the placebo and 100, 200, and 300 µg groups respectively).
Intention-to-treat analysis: yes.
Sample size calculations: yes.

Country: United Kingdom.
Number of participants randomised: 501, 53% men at age 60 to 74 years, mean age 67 years.
Inclusion criteria: volunteers from four general practices.
Exclusion criteria: incapable of carrying out light housework or office work, active liver or kidney disease, prior diagnosis of cancer (excluding nonmelanoma skin cancer), diagnosed HIV infection, immunosuppressive therapy, diminished mental capacity, taking > 50 µg/day of selenium supplements in the previous six months (by patient report).

Participants were randomly assigned to receive:
group 1: placebo (n = 121);
group 2: selenium 100 µg (n = 127);
group 3: selenium 200 (n = 127);
group 4: selenium 300 µg (n = 126);
in the form of high-selenium yeast, Seleno PreciseTM per day for two years.

The primary outcome measures were: mood, quality of life, and plasma selenium level.
Compliance with randomised treatment was determined by pill count, with participants considered compliant if they took at least 80% of their allocated tablets. Reasons for participant withdrawal were noted. Four hundred fifty three of the 467 participants (97%) who completed six months were compliant according to pill count.
Trial agents were provided by Pharma Nord, V ejle, Denmark.

| Item                  | Authors’ judgement | Description |
|-----------------------|--------------------|-------------|
| Allocation concealment? | Yes                | Adequate    |
**Methods**

The Roche European American Cataract Trial (REACT). Randomised, double blind, placebo-controlled, trial with parallel groups design. Generation of the allocation sequence: adequate, by Efron’s biased coin method. Allocation concealment: adequate, the generator of the assignment (the individual who generated, using a bias-free method, the listing that identified the intervention assignment for every participant) was located in Munich, Germany. The executor of the assignment (the individual who, having determined a participant’s eligibility, consulted the assignment system for that participant’s intervention designation) was also located in Munich, Germany. The persons who prepared the randomisation scheme were not involved in determining eligibility, administering intervention, or assessing outcomes. Blinding: adequate, identical placebo capsules contained corn oil as the major constituent provided by a sponsor. Follow-up: adequate, the pattern of drop-outs was similar in the groups, and drop-outs created no imbalances between the placebo and treatment groups. There were no differences noted between the vitamin and placebo groups regardless of the length of follow-up. Overall 59 participants in the vitamin group and 68 participants in the placebo group were lost to follow-up. Intention-to-treat analysis: yes. Sample size calculations: yes.

**Participants**

Country: United States and United Kingdom
Number of patients randomised: 297, mean age 68 years, 59 % females.
Inclusion criteria: at least one eye met the following ocular criteria: cataract extraction unlikely within two years, immature idiopathic ‘senile’ cataract present in one or both eyes, (U.S. patients) presence of minimal cataract by Lens Opacities Classification System (U.K. patients) presence of cataract of minimal Oxford grade: cortical and posterior subcapsular grades: grade I; nuclear brunescence: grade II; and white nuclear scatter: grade II. If both eyes met the inclusion criteria, and cataracts were of different types, the cataract type in the eye with the worse visual acuity determined the group for randomisation. If an eye had more than one type of cataract, the morphological type that in the clinicians opinion was the more destructive to visual acuity determined the group for randomisation, no visually significant fundus pathology, no clinical signs of glaucoma and intraocular pressure, no history of amblyopia, eye surgery, argon or YAG laser eye treatment, or major eye trauma, no history of iritis, retinal crystalline deposits, or optic nerve disease, no extended (daily for >3 months) use of ocular corticosteroid or glaucoma therapy, no participation in another clinical trial investigating an anticataract formulation within the last year. Exclusion criteria: pregnancy, insulin dependent diabetes mellitus, severe renal failure or kidney stones, fat malabsorption syndrome, history of major intestinal surgery, chronic diarrhoea, alcoholism, extended use (daily for > 3 months) of systemic corticosteroid treatment, use of anticoagulants, or regular use of any vitamin supplement.

**Interventions**

Patients were randomly assigned to receive:
- group 1: 600 mg vitamin E (all-rac alpha-tocopherol acetate), vitamin C 750 mg, and beta-carotene 18 mg (n = 149);
- group 2: placebo (n = 148);
The actual supplementation period ranged from 2 to 51 months, 231 patients were followed for at least two years, 158 patients for at least three years and 36 patients for at least four years. Patients remained in the study for 34 months.
The primary outcome was: the measure of area, ‘increase % pixels opaque’ cataract severity documented with serial digital retroillumination imagery of the lens; progression was quantified by image analysis assessing increased area of opacity.

Compliance with treatment was checked by serum assessments. The plasma concentrations of vitamin C, vitamin E, and beta-carotene in the treated and placebo groups were maintained at consistent levels throughout the trial indicating excellent compliance with instructions about the use of the trial medication. There appeared to be little if any supplementation of placebo with other vitamins or failure to take the vitamin capsules.

The work was supported by grants from F. Hoffmann-La Roche, Ltd., Basel, Switzerland, and Roche Vitamins, Inc., Parsippany, NJ.

| Item                | Authors’ judgement | Description |
|---------------------|--------------------|-------------|
| Allocation concealment? | Yes               | A - Adequate |

Randomised, double-blind placebo-controlled trial with three-by-three, then two-by-two factorial design and then parallel group design.

Generation of the allocation sequence: unclear, not reported.

Allocation concealment: adequate, the capsules were allocated to each participant in a central control centre.

Blinding: adequate, identical looking capsules.

Follow-up: inadequate, losses to follow-up were high due to modification of the protocol. Out of 439 participants randomised, 134 has dropped out before the trial was altered. Of the 397 remaining participants, 305 (77%) consented to take part in a modified trial and 244 completed the trial. Overall, 98 participants, assigned to receive 500 mg vitamin C and 97 participants, assigned to receive 50 mg vitamin C were lost to follow-up.

Intention-to-treat analysis: yes.

Sample size calculations: yes.

Country: Japan.

Number of participants randomised: 439, 35% men and 65% women, aged 40 to 69 years, mean age 57 years.

Inclusion criteria: men and women living in four municipalities (3 towns and one village of Yokote Public Health Centre District in Akita prefecture, participated in annual screening programmes for circulatory diseases with chronic atrophic gastritis (determined by serum pepsinogen (PG) levels (PG I < 70 ng/ml and PG I/PG II ration < 3.0).

Exclusion criteria: past history of gastric cancer or surgery, liver cancer or cirrhosis, and other cancers within 5 years; abnormal liver function (AST > 100 IU/L, ALT > 100 IU/L, or ALP > 800 IU/L), use of supplements containing beta-carotene or vitamin C, unable to follow-up for at least one year.
### Interventions

Participants were randomly assigned to receive:

- **group 1**: vitamin C 50 mg and beta-carotene placebo;
- **group 2**: vitamin C 500 mg and beta-carotene placebo;
- **group 3**: vitamin C 50 mg and beta-carotene 15 mg;
- **group 4**: vitamin C 500 mg and beta-carotene 15 mg.

217 participants (low-dose group) were assigned to receive 50 mg of vitamin C and 0/15 mg of beta-carotene;

222 participants were assigned to receive 500 mg of vitamin C and 0/15 mg of beta-carotene.

daily for 5 years.

Out of 439 persons initially participating in the study, 134 participants dropped before and on modification of the study protocol based on a National Cancer Institute report that indicated that 2 beta-carotene trials had shown no benefit or potential harm from the supplement. Of the 305 remaining participants, 244 completed this study.

Participants were supplemented with beta-carotene from September 1995 to March 1996, (three to six months). After that study was continued with parallel group design.

Participants were randomly assigned to receive:

- **group 1**: vitamin C 50 mg (n = 144);
- **group 2**: vitamin C 500 mg (n = 161);

for five years.

### Outcomes

The primary outcome measure was: the 10-year cumulative incidence of gastric cancer. The secondary outcome measure was: 5-year change in serum levels of pepsinogens.

After the modification of the protocol the primary outcome measure was 5-year change in serum levels of pepsinogens and other biomarkers.

### Notes

Compliance with treatment was constantly encouraged and monitored by nurses, who interviewed the participants and recorded pill counts every 3 months (compliance rate, 80%). Compliance with treatment was checked by serum assessments. Blood samples were drawn and stored three times (at baseline, and after the first, and the fifth year) in order to measure serum level of ascorbic acid. Compliance in taking the vitamin capsules was 92.9% in men and 95.4% in women.

Additional information about all-cause mortality obtained through personal communication with authors. These data, which are extremely positive, are not published.

### Risk of bias

| Item                  | Authors' judgement | Description |
|-----------------------|--------------------|-------------|
| Allocation concealment| Unclear            | B - Unclear |

---

**Sasazuki 2003 (Continued)**

---

*Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases (Review)*

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
### Methods

Skin Cancer Prevention Study (SCPS).

Randomised, double-blind placebo-controlled trial with parallel group design.

Generation of the allocation sequence: adequate, on a computer in block of 16 without stratification.

Allocation concealment: adequate, central independent unit.

Blinding: adequate, identical looking capsules.

Follow-up: adequate. Of the 1805 patients who have been randomised, 89% completed at least three years of observation, 79% four years, and 46% five years. The patterns of follow-up were similar in the two treatment groups.

Intention-to-treat analysis: no.

Sample size calculations: no.

### Participants

Country: United States of America.

Number of participants randomised: 1805, 1251 (70%) men and 554 (30%) women.

Inclusion criteria: < 85 years old, at least one biopsy-proved basal-cell or squamous-cell carcinoma, could not become pregnant, agreement not to take vitamin supplements containing vitamin A or betacarotene, not a vegan vegetarian (one who eats no animal products, including milk or eggs).

Exclusion criteria: xeroderma pigmentosum, basal-cell nevus syndrome, an active nonskin cancer, known exposure to arsenic, or any other major medical problem that would limit their ability to participate in the planned five years of study.

### Interventions

Patients were randomly assigned to receive:

- group 1: beta-carotene 50 mg (n = 913);
- group 2: placebo (n = 892);

one capsule daily for five years.

Duration of follow-up was five years.

### Outcomes

The primary outcome measures were: the first occurrence of basal-cell or squamous-cell skin cancer.

### Notes

Compliance with the study medication was determined by interviewing the patients and by measurement of plasma beta-carotene levels. At four months interval patients were asked to complete questionnaires concerning compliance in taking the capsules. Reported adherence to treatment did not differ appreciably between the placebo and beta-carotene groups, and during each of the first four years at least 80% of the patients reported taking half or more of their capsules. Plasma beta-carotene levels showed more than eight-fold increase in the group that received beta-carotene and almost no-change in the placebo group.

The trial agents were provided by BASF, Wyendotte, Michigan.

Though a study with a longer follow-up on this same trial was published in JAMA (Mortality associated with low plasma concentration of beta carotene and the effect of oral supplementation. JAMA 1996;275(9):699-703.), we could not use the mortality data from the latter because it does not report on the 85 excluded patients. However, replacing the number of deaths from Greenberg 1990 with the mortality data given in the JAMA publication (146 vs 139 (placebo) does not change the result noticeably.

### Risk of bias

| Item             | Authors' judgement | Description   |
|------------------|--------------------|---------------|
| Allocation concealment? | Yes                | A - Adequate  |
Methods

Shandong Intervention Trial
Randomised, double-blind, placebo controlled, primary prevention trial with stratified, factorial design 2x2x2 versus 2x2.

Generation of the allocation sequence: unclear, not reported.
Allocation concealment: adequate, treatments were randomly assigned at Westar, Inc. and this assignment is used to distribute coded bottles of capsules from the pharmacy in the city of Weifang in Shandong Province.
Blinding: adequate, using identical placebo capsules.
Follow-up: adequate, overall 15 participants from placebo and 19 participants from active intervention group were lost to follow-up.
Intention-to-treat analysis: no.
Sample size calculations: yes.

Participants

Country: China (Linqu County, Shandong Province).
Number of participants randomised: 3411, 1753 men and 1658 women aged 35 to 64 years.
Inclusion criteria: participants aged 35 to 64 years willing to participate in 42-month study, baseline gastroscopy with biopsies, known Helicobacter pylori status.
Exclusion criteria: illness, bleeding disorders, cancers (except nonmelanoma skin cancer), heart failure, emphysema, renal or liver diseases, other life-threatening illnesses, allergy to penicillin or related antibiotics.

Interventions

Participants were first divided on the basis of whether they showed serologic evidence of Helicobacter pylori infection at baseline (2285) or not (1126). Participants with serologic evidence of Helicobacter Pylori at baseline were eligible to receive amoxicillin (1 g twice a day) and omeprazole (20 mg twice a day) in three capsules (two 500 mg amoxicillin and one 20 mg omeprazole) to be taken twice daily (before breakfast and dinner) for 2 weeks. Look-alike placebo capsules containing lactose and starch for amoxicillin and sucrose and starch for omeprazole were given to serologically positive controls and to all seronegative participants. Approximately 3 months after initial treatment for Helicobacter Pylori, supplementation with 100 IU alpha-tocopherol, 250 mg vitamin C, and 37.5 µg selenium twice a day began its 39-month course. Participants receive this mixture in one capsule, to be taken twice daily before or after breakfast and dinner. From December 1995 to May 1996, this mixture also contained beta-carotene (7.5 mg twice a day). Look-alike placebo capsules contained cellulose, lactose, and magnesium stearate.
In the garlic group, participants take two capsules twice a day before or after breakfast and dinner. Each capsule contains 200 mg Kyolic aged garlic extract and 1 mg steam-distilled garlic oil. To prepare the extract, the manufacturer slices garlic cloves and soaks them in aqueous ethanol (about 20%) for over 18 months at room temperature. The extract is then filtered, concentrated, and dried. The look-alike placebo capsules contain cellulose, granulated sugar, caramel, and magnesium stearate. Bottles holding placebo capsules contained minute quantities of garlic oil so they would smell like garlic.
HP-seropositive at baseline (2258) entered 2x2x2 factorial of antibiotics, vitamins, and garlic. HP-seronegative at baseline (1126) entered 2x2 factorial trial of vitamins, and garlic.
Participants were randomised in 12 groups:
- group 1: amoxicillin and omeprazole, garlic, vitamin and selenium (n=286);
- group 2: amoxicillin and omeprazole, garlic, vitamin and selenium placebo (n=285);
- group 3: amoxicillin and omeprazole, garlic placebo, vitamin and selenium (n=286);
- group 4: amoxicillin and omeprazole, garlic placebo, vitamin and selenium placebo (n=285);
- group 5: amoxicillin and omeprazole placebo, garlic, vitamin and selenium (n=285);
- group 6: amoxicillin and omeprazole placebo, garlic, vitamin and selenium placebo (n=286);
- group 7: amoxicillin and omeprazole placebo, garlic placebo, vitamin and selenium (n=286);
group 8: amoxicillin and omeprazole placebo, garlic placebo, vitamin and selenium placebo (n=286);
group 9: amoxicillin and omeprazole placebo, garlic; vitamin and selenium (n=282);
group 10: amoxicillin and omeprazole placebo, garlic, vitamin and selenium placebo (n=281);
group 11: amoxicillin and omeprazole placebo, garlic placebo, vitamin and selenium (n=281);
group 12: amoxicillin and omeprazole placebo, garlic placebo, vitamin and selenium placebo (n=282);

Outcomes

The primary outcome measures were: prevalence of dysplasia or gastric cancer, prevalence of severe chronic atrophic gastritis, intestinal metaplasia, dysplasia or gastric cancer, and average severity score. Secondary outcome measures were: rates of transition from baseline to final histopathologic states and the effects of treatments on these rates of transition; evidence of the effectiveness of amoxicillin and omeprazole in eradicating Helicobacter pylori, based on 13C-urea breath tests 3 months following treatment, on annual serology, and on a final pathologic examination of biopsies to look for Helicobacter pylori; and blood pressure at the time of the final examination.

Notes

Compliance with treatment was checked by measuring the plasma vitamin levels in randomly selected participants every 3 months and counting of the pills. Compliance with treatment was good. The average monthly proportion of participants taking all pills was 92.3%. Serum samples obtained from randomly selected participants demonstrate higher levels of vitamins C and E in participants assigned to vitamins 2 and higher levels of S-allylcysteine in those assigned to garlic preparation. (Wakunaga of America, Co., Ltd, Mission Viejo, CA) provided the garlic preparation, Astra (East Asia Region) provided amoxicillin and omeprazole; and Sino-American Shanghai-Squibb Pharmaceuticals, Ltd. provided vitamin and mineral supplement.

Risk of bias

| Item                | Authors' judgement | Description |
|---------------------|--------------------|-------------|
| Allocation concealment? | Unclear           | B - Unclear |

SKICAP AK 1997Low

Methods

Skin Cancer Prevention Study - actinic keratoses (SKICAP-AK). Randomised, double-blind placebo-controlled trial with parallel group design. Generation of the allocation sequence: adequate, on a computer in permuted blocks of size 4. Allocation concealment: adequate, numbered coded bottles. Blinding: adequate, identical looking capsules. Follow-up: adequate. Overall, 99 participants from the intervention group and 88 from the placebo group were lost to follow-up. Intention-to-treat analysis: no. Sample size calculations: yes.
| Participants | Country: United States.  
Number of participants randomised: 2297, 679 (30%) women and 1618 (70%) men, aged 21 to 84 years, median age 63 years, with a history of more than 10 actinic keratoses and at most 2 squamous cell carcinoma (SCC) or basal cell carcinoma (BCC) skin cancers.  
Inclusion criteria: free living participants aged 21 to 84 years, ambulatory and capable of self care, with no diagnosis of life threatening diseases, an intended continual resident of Arizona for at least five years, willing to return during the five years for semi-annual follow-up clinic visits, and willing to limit non-study vitamin A supplementation to no more than 10,000 IU per day, clinical laboratory values within the 95% normal range for total cholesterol, liver function (AST and ALT), WBC count, haemoglobin and platelet count, and history of more than 10 actinic keratoses and at most 2 squamous cell carcinoma (SCC) or basal cell carcinoma (BCC) skin cancers.  
Exclusion criteria: cancer diagnosis or treatment within the year preceding the trial other than BCC or SCC, history of xeroderma pigmentosum or basal-cell nevus syndrome. |
| Interventions | Patients were randomly assigned to receive:  
group 1: vitamin A (retinol) 25,000 IU (n = 1157);  
group 2: placebo (n = 1140);  
one capsule daily for a period of 5 years (median follow-up time of 3.8 years). |
| Outcomes | The primary outcome measures were: the time to first new occurrence of SCC and time to first new occurrence of BCC pathologically confirmed by the study pathologist. |
| Notes | Compliance with the study medication was determined by counting capsules in the returned medication bottles and by measurement of plasma vitamin A levels. Participants were scheduled for a return clinic visit one month after randomisation and then every six months. They were interviewed to evaluate adherence, motivated to adhere and provided with a six-month supply of capsules. Participants were telephoned and mailed postcards between clinic visits for symptom assessment and adherence monitoring and motivation. Vitamin intake was reported by 73% of the participants, and 30% of participants reported dietary intake near or below the recommended. Calculated adherence to the intervention was almost identical between the placebo and retinol groups. During the 5-year intervention period, at least 85% of participants reported taking at least three-quarters of their capsules, and at least 95% reported taking at least half of their capsules. The results show very similar baseline retinyl palmitate levels and approximately an 8-fold increase in the median serum retinyl palmitate level in the group assigned to receive retinol.  
Hoffmann-LaRoche provided intervention capsules. |
| Risk of bias | Item | Authors’ judgement | Description |
|---|---|---|---|
| Allocation concealment? | Yes | A - Adequate |
Methods

Secondary prevention with antioxidants of cardiovascular disease in end stage renal disease (SPACE). Randomised, double blind, placebo-controlled, secondary prevention intervention trial with parallel group design.

Generation of the allocation sequence: adequate, computer generated coin toss within each stratum.
Allocation concealment: adequate, central independent unit. Randomisation done by an individual not directly involved in the study.
Blinding: adequate, identical placebo capsules provided by a sponsor.
Follow-up: adequate. There were no losses to follow-up.
Intention-to-treat analysis: yes.
Sample size calculations: yes.

Participants

Country: Israel.
Number of patients randomised: 196; 135 males and 61 females, aged 40 to 75 years, mean age 64.6 years.
Inclusion criteria: stable haemodialysis patients between the ages of 40 and 75 years inclusive at baseline with a documented medical history of cardiovascular disease (including hospital records, appropriate electrocardiographic and biochemical supporting indices).
Exclusion criteria: anticoagulant therapy with warfarin sodium; known history of malignant disease (except non-melanoma skin cancer); active liver disease; treatment with hypolipaemic agents for less than eight weeks before the study started; pregnant or planning to become pregnant during duration of the study; any condition the treating physician deemed to preclude the patient on grounds of safety or study evaluation.

Interventions

Patients were randomly assigned to receive:
- group 1: vitamin E 800 IU/day (n = 97);
- group 2: matching placebo (n = 99);
Vitamin E was provided as two capsules of 400 IU each. Patients were instructed to take two capsules nightly.
Median follow-up time was 519 (range 10 to 763) days.

Outcomes

The primary outcome measure was: a composite variable consisting of: acute myocardial infarction (fatal and nonfatal); ischaemic stroke; peripheral vascular disease (excluding the arterio-venous fistula) in a limb not previously affected; and unstable angina.
Secondary outcome measures were: fatal and non-fatal myocardial infarction, cardiovascular disease mortality (fatal myocardial infarction, ischaemic stroke or sudden death), total mortality, ischaemic stroke, peripheral vascular disease, and unstable angina.

Notes

Compliance with treatment was evaluated by measuring serum vitamin E concentrations. Throughout the study, patients continued to receive regular monthly follow-up by their unit dieticians, who instructed them to comply with dietary recommendations for maintenance haemodialysis patients. Additional vitamin supplementation was similar in the two treatment conditions. Folate (5 to 10 mg/day), vitamin B6 (10 to 250 mg/day), and vitamin B12 (250 µg/day) were prescribed to 57 (57.5%) patients in the placebo group and 55 (56.7%) patients in the vitamin E group. Only one patient (in the vitamin E group) received vitamin B12 as a monthly intramuscular injection. Vitamin C (100 to 500 mg/day) was prescribed to 42 (42.5%) of the placebo group and 42 (43.3%) of the vitamin E group.
Vitamin E and placebos were provided by Solgar, Inc, New York, USA, during the first year and Henkel Corp, La Grange, IL, USA, during the second year.
### Risk of bias

| Item                              | Authors’ judgement | Description   |
|-----------------------------------|--------------------|---------------|
| Allocation concealment?           | Yes                | A - Adequate  |

### Stevic 2001

**Methods**
- Randomised, double-blind, placebo-controlled trial with parallel group design.
- Generation of the allocation sequence: unclear, not reported.
- Allocation concealment: unclear, not reported.
- Blinding: adequate, identical placebo pills.
- Follow-up: adequate. There were no losses to follow-up.
- Intention-to-treat analysis: no.
- Sample-size calculation: no.

**Participants**
- Country: Yugoslavia.
- Number of participants randomised: 28, 75% men and 25% women, aged 20 to 70 years, mean age 57 years.
- Inclusion criteria: probable or definite ALS by El Escorial criteria, age 20 to 70 years, disease duration < 3 years, ambulatory.
- Exclusion criteria: significant compromise of bulbar or respiratory function, conduction block, M protein, significant imaging abnormality, dementia, and concurrent systemic disease.

**Interventions**
- Participants were randomly assigned to receive:
  - group 1: alesmert-L-methionine (2 g), vitamin E (400 IU), selenium (3 x 10^-5g) three times daily (n = 16);
  - group 2: placebo (n = 12);
- for a period of one year.

**Outcomes**
- The primary outcome measures were: survival and rate of disease progression as expressed by decline in limb-function, bulbar-function and muscle-testing scores.
- Secondary outcome measures were: activity of antioxidative components, and level of vitamin E in blood.

**Notes**
- Compliance with treatment is not reported.

### Risk of bias

| Item                              | Authors’ judgement | Description   |
|-----------------------------------|--------------------|---------------|
| Allocation concealment?           | Unclear            | B - Unclear   |
Methods

The SUpplementation en VItamines et Mine´ raux AntioXydant s (SU.VI.MAX) Study. Randomised, double-blind, placebo-controlled, primary-prevention trial with parallel group design. Generation of the allocation sequence: adequate, random treatment allocation was performed by block-sequence generation stratified by sex and age group by computer. Allocation concealment: adequate, capsule boxes were labelled with the participant’s number, using partitioned organisation to ensure total security of the blind study. Blinding: adequate, identical placebo capsules. Follow-up: adequate. Losses to follow-up; 5.4 % in the intervention group and 6.2% in the placebo group. Overall, 739 participants in the active and 828 participants in the placebo group were lost to follow-up. Intention-to-treat analysis: yes. Sample size calculations: yes.

Participants

Country: France. Number of participants randomised: 13017 French adults, 5141 men and 7876 women, aged from 35 to 60 years, mean age 48.95 years. Inclusion criteria: lack of disease likely to hinder active participation or threatened 5-year survival; acceptance of possibility to be given placebo and acceptance of the constraints of participation; lack of previous regular supplementation with any of the vitamins and minerals in the supplement provided and absence of extreme beliefs or behaviour regarding diet. Exclusion criteria: none stated.

Interventions

Participants were randomly assigned to receive:
group 1: beta carotene 6 mg; vitamin C 120 mg; vitamin E 30 mg; selenium 100 µg; zinc 20 mg (n = 6481);
group 2: placebo (n = 6536).
All participants took a single daily capsule. Median follow-up time was 7.5 years.

Outcomes

The primary outcome measures were: major fatal and nonfatal ischaemic cardiovascular events and cancer of any kind, except for the basal cell carcinoma of the skin. The secondary outcome measure was: all cause mortality.

Notes

Compliance for the intervention group was confirmed by measuring the biochemical markers of supplementation after 2 years and after 7 years for beta-carotene, vitamin C and selenium. At the end of follow-up, 74% of participants reported having taken at least two thirds of the capsules. There were no differences between the groups mean percentage of capsules taken, ie, 79% in each group). Sponsors of the trial: Fruit d’Or Recherche, Candia, Lipton, Kellogg’s, Centre d’Information sur Canderel, Orangina, Este e Lauder, Cereal, Grands Moulins de Paris, CERIN, L’Ore al, Peugeot, Jet Service, RP Scherer, Sodexho, France Telecom, Santogen, Becton Dickinson, Fould Springer, Boehringer Diagnostic, Seppic Givaudan Lavriote, Le Grand Canal.

Risk of bias

| Item                        | Authors' judgement | Description |
|-----------------------------|--------------------|-------------|
| Allocation concealment?     | Yes                | A - Adequate |
### Takagi 2003

| Methods | Randomised, clinical trial with parallel group design.  
| Allocation concealment: unclear, not reported.  
| Blinding: inadequate, no intervention in the control arm.  
| Follow-up: adequate. Seven patients in the vitamin E group and 3 patients from the control group dropped out from the trial.  
| Intention-to-treat analysis: no.  
| Sample size calculations: no. |

| Participants | Country: Japan.  
| Number of patients randomised: 93, 45% males and 55% females, mean age 62.5 years.  
| Inclusion criteria: liver cirrhosis caused by hepatitis C infection.  
| Exclusion criteria: none stated. |

| Interventions | Patients were randomly assigned to receive:  
| group 1: vitamin E (600 mg) (n = 51);  
| group 2: no treatment (n = 42);  
| for a period of 5 years. |

| Outcomes | The primary outcome measures were: tumor-free survival and cumulative survival rate. |

| Notes | Compliance was not reported. |

### Risk of bias

| Item | Authors’ judgement | Description |
|------|--------------------|-------------|
| Allocation concealment? | No | C - Inadequate |

### Takamatsu 1995

| Methods | Randomised, double-blind, placebo-controlled trial with parallel group design.  
| Generation of the allocation sequence: unclear, not reported.  
| Allocation concealment: adequate, centrally by pharmacy. Capsules required by each participant for a 6-month period were placed in identical bottles labelled with the personal numbers of the volunteers.  
| Blinding: adequate, capsules identical in size, shape, weight and colour.  
| Follow-up: adequate. Losses to follow-up were 4 participants (6.75%) in the active treatment group and 10 participants (13.69%) in the placebo group during the trial.  
| Intention-to-treat analysis: no.  
| Sample-size calculation: no.  

| Participants | Country: Japan.  
| Number of participants randomised: 161, 64 men and 97 women, aged 39 to 56 years.  
| Inclusion criteria: healthy Japanese adults free of acute and chronic illness, including hypertension. |
Takamatsu 1995  (Continued)

| Exclusion criteria: taking oral contraceptives, vitamins or mineral supplements, pregnant or lactating women. |
|---|

**Interventions**

Participants were randomly assigned to receive:
- group 1: vitamin E (d-alpha-tocopheryl acetate) 100 mg (n = 82);
- group 2: placebo (vitamin E 3 mg), (n = 79);
for a period of 6 years.

**Outcomes**

The primary outcome measure was: any illness.

**Notes**

Medication compliance during the trial period was 89.6% in vitamin E group and 91.3% in the placebo group.
Vitamin E (d-alpha tocopheryl acetate capsules) were provided by Eisai Co. Ltd (Tokyo, Japan).

**Risk of bias**

| Item | Authors’ judgement | Description |
|---|---|---|
| Allocation concealment? | Unclear | B - Unclear |

Tam 2005Low

**Methods**

Randomised, double-blind, placebo-controlled trial with parallel group design.
Generation of the allocation sequence: adequate, by computer.
Allocation concealment: adequate, by a central independent unit (the school of pharmacy).
Blinding: adequate, identical placebo tablets.
Follow-up: adequate. There were no losses to follow-up.
Intention-to-treat analysis: no.
Sample size calculations: no.

**Participants**

Country: Hong Kong.
Number of patient’s randomised: 39 females, mean age 46.
Inclusion criteria: female patients with systemic lupus erythematosus.
Exclusion criteria: flare of systemic lupus erythematosus requiring increase in immunosuppressive agents.

**Interventions**

Patients were randomly assigned to receive:
- group 1: vitamin C 500 mg, vitamin E (D-alpha tocopheryl succinate) 800 IU n=20;
- group 2: placebo, n=19; daily, 12 weeks.
Patients were followed 2.67 years.

**Outcomes**

The primary outcome measures were: effects on markers of oxidative stress, antioxidant defence, and endothelial function.

**Notes**

Compliance was assessed by tablet counting, and patients with less than 70% compliance were excluded from the analyses. Overall compliance by pill count was 95%.
### Risk of bias

| Item                        | Authors' judgement | Description       |
|-----------------------------|--------------------|-------------------|
| Allocation concealment?     | Yes                | A - Adequate      |

**ter Riet 1995**

**Methods**

- Randomised, double-blind, placebo-controlled trial with two-by-two factorial design.
- Generation of the allocation sequence: adequate, by computer.
- Allocation concealment: unclear, not reported.
- Blinding: adequate, identical placebo tablets. The 'placebo' tablet was in fact containing 20 mg vitamin C. The dose could eradicate vitamin C deficiency in the control arm. Accordingly, the 'placebo' control of the trial can be discussed.
- Follow-up: adequate, during the course of the study three participants withdrew. Overall 1 participant withdrew from the intervention group and 2 withdrew from the control group.
- Intention-to-treat analysis: yes.
- Sample size calculations: no.

**Participants**

- Country: The Netherlands.
- Number of participants randomised: 88.
- Inclusion criteria: patients with pressure ulcers (partial thickness skin loss or worse).
- Exclusion criteria: difficulties with swallowing or frequent vomiting, osteomyelitis in the ulcer area, idiopathic haemochromatosis, thalassaemia major, sideroblastic anaemia, Cushing's syndrome or disease, pregnancy, radiotherapy in the ulcer area, and the use of antineoplastic agents or systemic glucocorticosteroids, high probability to drop out within the 12 week follow-up period (terminally ill patients, patients for whom surgical treatment of the ulcer-other than debridement), taking vitamin C supplements in excess of 50 mg/day.

**Interventions**

- Participants were randomly assigned in four groups to receive:
  - group 1: vitamin C 1000 mg and ultrasound;
  - group 2: vitamin C 1000 mg and sham ultrasound;
  - group 3: vitamin C 20 mg and ultrasound;
  - group 4: vitamin C 20 mg and sham ultrasound;
- daily for 12 weeks. Overall 43 participants were supplemented with 1000 mg of vitamin C, while 45 participants were in 'placebo' group supplemented with 20 mg of vitamin C.

**Outcomes**

- The primary outcome measures were: wound survival, healing rates of wound surfaces, and clinimetric changes.

**Notes**

- Compliance with prevention is not reported. The trial used 20 mg vitamin C in the placebo pills. Removing this trial from our analyses does not noticeably change our results.
- Hoffmann-La Roche & Co., Ltd., Basel supplied vitamin C tablets.
### Risk of bias

| Item                        | Authors' judgement | Description |
|-----------------------------|-------------------|-------------|
| Allocation concealment?     | Unclear           | B - Unclear |

#### VEAPS 2002Low

**Methods**
The Vitamin E Atherosclerosis Prevention Study (VEAPS). Randomised, double-blind, placebo-controlled, primary-prevention trial with parallel group design. Generation of the allocation sequence: adequate, computer-generated random numbers. Allocation concealment: adequate, central independent unit. Participants, clinical staff, imaging specialists, data monitor, and statistical analysts were blinded to treatment assignment. Blinding: adequate, identical placebo capsules. Follow-up: adequate, 90% of the randomised participants completed the 2-year treatment. Overall, 15 participants in the active group and 6 participants in the placebo group were lost to follow-up. Intention-to-treat analysis: yes. Sample size calculations: yes.

**Participants**
Country: United States of America. Number of participants randomised: 353 men and women, aged from 40 to 82 years, mean age 56 years. Inclusion criteria: age > 40 years, with LDL cholesterol (LDL-C) > 3.37 mmol/L (130 mg/dL) and no clinical signs or symptoms of cardiovascular disease (CVD). Exclusion criteria: fasting triglycerides > 5.64 mmol/L, diabetes mellitus or fasting serum glucose > 3.62 mmol/L, regular vitamin E supplement intake > 1 year, lipid standardised plasma vitamin E > 35 µmol/L, diastolic blood pressure > 100 mm Hg, untreated thyroid disease, serum creatinine > 0.065 mmol/L, life-threatening disease with prognosis < 5 years, or alcohol intake > 5 drinks daily.

**Interventions**
Participants were randomly assigned to receive:
- group 1: vitamin E (DL-alpha-tocopherol) 400 IU (n = 177);
- group 2: placebo (n = 176);
for a period of three years. Participants were instructed to take trial pills with their greatest fat-containing meal of the day. The initial trial design called for a 2-year treatment period. Based on evolving null results from other antioxidant clinical trials, the External Data and Safety Monitoring Board recommended after 2 years of initiation of the study that the treatment period be extended to 3 years. Participants were offered the opportunity to continue another year of their randomised and blinded treatment assignment. The 81% of 2-year completers, 73% of randomised elected to continue for a 3-year treatment period.

**Outcomes**
The primary trial outcome was: rate of change in the right distal common carotid artery intima-media thickness in computer image-processed B-mode ultrasonograms.
Notes

Compliance with treatment was assessed by counting unused pills and measuring plasma vitamin levels. Mean pill compliance was 92% in the placebo-treated group and 91% in the vitamin E group. Pill compliance for the placebo-treated versus the active vitamin E participants was maintained throughout the trial, as follows: 89% versus 87%, 90% versus 89%, 92% versus 92%, 91% versus 93%, 94% versus 91%, and 93% versus 93% at 6, 12, 24, 30, and 36 months, respectively. There was an appropriate rise in the mean plasma vitamin E level in the active vitamin E group from a baseline level. The trial was supported by Hoffmann-La Roche, Inc.

Risk of bias

| Item                                | Authors' judgement | Description |
|-------------------------------------|--------------------|-------------|
| Allocation concealment?             | Yes                | Adequate    |

VECA T 2004Low

Methods

Vitamin E, Cataract and Age-Related Maculopathy Trial (VECAT). Randomised, double blind, placebo-controlled trial with parallel group design. Generation of the allocation sequence: adequate, the randomisation schedule was prepared by a biostatistician using a permuted block allocation scheme. Allocation concealment: adequate, central, independent unit. The allocation list was stored at a remote site. Identification of which patients received vitamin E or placebo was concealed from the outcome assessors and data analysts until the analysis was finalised. Blinding: adequate, the medications were dispensed in identical containers so that neither the trial staff nor the participants were aware of the intervention in any specific patient. Follow-up: adequate. Overall, 60 participants from the placebo group and 58 participants from the vitamin group withdrew from the trial. Intention-to-treat analysis: yes. Sample size calculations: yes.

Participants

Country: Australia. Number of participants randomised: 1193, 44% men and 56% women, aged 55 to 80, mean age 65.7 years. Inclusion criteria: good general health, early or no cataract. Exclusion criteria: prior cataract surgery, advanced cataract in both eyes, glaucoma, known sensitivity to vitamin E, and long-term treatment with steroids or anticoagulants.

Interventions

Participants were randomly assigned to receive:
group 1: vitamin E (natural vitamin E in soybean oil) 500 IU (n = 595),
group 2: placebo (n = 598); for four years.

Outcomes

The primary outcome measures were: major age-related types of cataract: nuclear, cortical cuneiform, and posterior subcapsular.
Compliance with the trial medication was determined by counting capsules in the returned medication bottles and by measurement of plasma vitamin E levels in a random sample of participants. Overall, 77% of the actively treated group and 79% of those participants randomised to placebo were estimated to have consumed 80% or more of their capsules. After 4 years of follow-up, 74% of the vitamin E group and 76% of the placebo group remained on their assigned medication and participated in the annual reviews. Among the remaining 25% of the participants, 12% in each group ceased taking the assigned medication but continued participating to have their eye examined.

The trial was funded by Smith and Nephew, Australia, Henkel, Australia.

### Risk of bias

| Item                  | Authors' judgement | Description        |
|-----------------------|--------------------|--------------------|
| Allocation concealment| Yes                | A - Adequate       |

### WAVE 2002Low

#### Methods

Women's Angiographic Vitamin and Estrogen Trial (WAVE).

Randomised, double blind, placebo-controlled trial with two-by-two factorial design.

Generation of the allocation sequence: adequate, centrally by computer. Randomisation lists were produced for each stratum using a permuted block design with block sizes of two and four being randomly selected.

Allocation concealment: adequate, the clinical centres nurse co-ordinators randomised women by calling the dedicated randomisation computer at the study co-ordinating centre.

Blinding: adequate, identical placebo tablets.

Follow-up: adequate. Twenty-three participants from the placebo group and 29 from the HRT group, 38 from the vitamins, and 27 from the HRT and vitamin group withdrew from the trial.

Intention-to-treat analysis: yes.

Sample size calculations: yes.

#### Participants

Country: United States of America and Canada.

Number of participants randomised: 423 women mean age 65 years.

Inclusion criteria: postmenopausal women as defined by any one of the following criteria: (bilateral oophorectomy at any age or age 45 to 55 with FSH 40 mIU/ml or older than 55 years. Protocol angiogram within four months performed while haemodynamically stable demonstrating at least one vessel segment free of intervention, with 15 to 75% stenosis. If the angiogram was performed within two weeks of a myocardial infarction, the qualifying segment may not be the infarct segment.

Exclusion criteria: oestrogen replacement therapy within the past three months. Estrogen vaginal cream permitted if used no more than 25% of the time. Concurrent use of vitamins C and E exceeding the recommended dietary allowance, history of breast cancer or mammogram suggestive of cancer without subsequent negative biopsy, history of endometrial carcinoma without subsequent hysterectomy, any abnormal uterine bleeding or endometrial hyperplasia at baseline, pap smear with dysplasia of cervical intraepithelial neoplasia grade 1 or greater, uncontrolled diabetes or hypertension, myocardial infarction less than four weeks prior to randomisation, planned or prior coronary artery bypass grafting, fasting triglycerides 500 mg/dl within four months of randomisation, creatinine 2.0 mg/dl, symptomatic gallstones, New York Heart association class IV congestive heart failure or known ejection fraction 25%, history
of haemorrhagic stroke or bleeding diathesis, history of pulmonary embolism or idiopathic deep venous thrombosis, history of osteoporosis unless treated with nonhormonal therapy, anticipated survival three years, concurrent participation in other masked clinical trial, participation in an interventional device trial or short-term postangioplasty antithrombotic trial was permitted so long as follow-up angiography was not a requirement of that trial.

### Interventions

The participants were randomly assigned to receive:

- group 1: vitamins (vitamin E 400 IU and vitamin C 500 mg) and hormone replacement therapy (HRT) placebo (n = 105);
- group 2: HRT (women with a prior hysterectomy took one tablet containing conjugated equine estrogens (0.625 mg of Premarin, while the women who had not had a hysterectomy took one tablet containing conjugated equine estrogens and medroxyprogesterone acetate (0.625 mg/2.5 mg of Prempro) and vitamins placebo daily (n = 103));
- group 3: vitamins C and E and HRT (n = 107);
- group 4: vitamin placebo and HRT placebo (n = 108);

Twice daily for a median of three years.

### Outcomes

The primary outcome measure was: annualised mean change in minimum lumen diameter from baseline to concluding angiogram of all qualifying coronary lesions averaged for each patient. Patients with intercurrent death or myocardial infarction were imputed the worst rank of angiographic outcome.

### Notes

Compliance with treatment was checked by serum assessments. Among the women with angiographic follow-up, those assigned to HRT took 67% of their prescribed medication according to pill counts, and those assigned to HRT placebo took 70%. The corresponding figures were both 84% for antioxidant vitamins and vitamin placebo. Nine women assigned to placebo estrogen crossed over to open-label estrogen, and one woman assigned to placebo vitamin supplements crossed over to open-label vitamins. Hormone replacement therapy drugs supplied by Wyeth Pharmaceuticals, Collegeville, Pa.

### Risk of bias

| Item                        | Authors’ judgement | Description |
|-----------------------------|--------------------|-------------|
| Allocation concealment?     | Yes                | A - Adequate |

---

Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases (Review)  
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Methods
Randomised, double-blind, placebo-controlled trial with parallel group design.
Generation of the allocation sequence: adequate, on random number basis.
Allocation concealment: adequate, the randomisation allocation co-ordinated by a remote pharmacy, ie, central randomisation. The pharmacy kept all details until the samples had been analysed and the study was complete.
Blinding: adequate, identical placebo pills.
Follow-up: adequate. Seventeen participants failed to attend for endoscopy and 11 participants were not compliant with the trial medication, leaving 72 participants for final analyses. Overall, 14 participants in each group were lost to follow-up.
Intention-to-treat analysis: no.
Sample size calculations: no.

Participants
Country: United Kingdom. Number of participants randomised: 100, mean age 63, 58% males.
Inclusion criteria: patients with Barrett’s oesophagus on long-term (> 12 months) proton pump inhibitors (PPI) treatment attending for surveillance endoscopy.
Exclusion criteria: pregnancy or lactation, previous gastric surgery, serious cardiovascular, respiratory, renal or neurological diseases, history of alcohol or drug abuse or use of non-steroidal antiinflammatory drugs.

Interventions
The participants were randomly assigned to receive:
group 1: vitamin C 100 mg, vitamin E 200 mg, n = 50;
group 2: placebo, n = 50.
Participants were supplemented and followed 12 weeks.

Outcomes
The primary outcome measure was: changes in putative markers of DNA damage in gastric tissue following supplementation with vitamins C and E.

Notes
Plasma vitamin C and E were measured to assess patient compliance.
Additional information about all-cause mortality obtained from the authors.

Risk of bias

| Item                        | Authors’ judgement | Description |
|-----------------------------|--------------------|-------------|
| Allocation concealment?     | Yes                | A - Adequate |
### WHS 2005Low

#### Methods
Women’s Health Study (WHS). Randomised, double-blind, placebo-controlled trial with two-by-two-by-two factorial design in the beginning and than two-by-two. Generation of the allocation sequence: adequate, centrally by computer in batches of blocks of size 16. Allocation concealment: adequate, the randomisation allocation is coded. Shipping department sends out calendar packs (which are identical whether active or placebo) to individual participants depending on this code. All of the calendar packs are in coded boxes, supplied by the drug manufacturer, so that the shippers do not know which drug they are shipping. Blinding: adequate, identical placebo capsules. Follow-up: adequate. Losses to follow-up: 0.01% in beta-carotene group and 0.005% in placebo group. Overall, 132 participants in the active group and 102 participants in the placebo group had unknown vital status. Intention-to-treat analysis: yes. Sample size calculations: yes.

#### Participants
Country: United States of America. Number of participants randomised: 39876 females aged 45 years or older, mean age 54.6 years. Inclusion criteria: female health professionals willing to take part in the trial. Age 45 years or older; no previous history of coronary heart disease, cerebrovascular disease, cancer (except nonmelanoma skin cancer), or other major chronic illnesses; no history of adverse effects from aspirin; no use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) more than once a week, or willingness to forgo their use; no use of anticoagulants or corticosteroids; and no use of individual supplements of vitamin A, E, or beta carotene for more than once a week. Exclusion criteria: history of cancer (except non-melanoma skin cancer), coronary heart disease, or cerebrovascular disease.

#### Interventions
Participants were randomly assigned to one of the eight treatment groups. The active agents were 100 mg of aspirin, given on alternate days; 600 IU of vitamin E, given on alternate days; and 50 mg of beta-carotene, given on alternate days. group 1: aspirin 100 mg, beta carotene 50 mg, vitamin E 600 IU; group 2: aspirin 100 mg, beta carotene 50 mg, vitamin E placebo; group 3: aspirin 100 mg, beta carotene 50 mg placebo, vitamin E 600 IU; group 4: aspirin 100 mg, beta carotene placebo, vitamin E placebo; group 5: aspirin placebo, beta carotene 50 mg, vitamin E 600 IU; group 6: aspirin placebo, beta carotene 50 mg, vitamin E placebo; group 7: aspirin placebo, beta carotene placebo, vitamin E placebo; group 8: aspirin placebo, beta carotene placebo, vitamin E placebo; A total of 19939 women were assigned at random to receive beta-carotene and 19937 to receive placebo in the beginning of April 1993. A total of 19937 women were assigned at random to receive vitamin E and 19939 to receive placebo. The beta-carotene component of the trial was terminated early, on January 18, 1996. The aspirin and vitamin E components of the trial continued uninterrupted. The time from randomisation to the end of beta-carotene component of the study averaged 2.1 years. Authors published results of the beta-carotene component of the trial on February 6, 1998, after a median total follow-up of 4.1 years (2.1 years treatment plus 2.0 years follow-up). From that time trials proceeded as two-arm (vitamin E and placebo). Follow-up and validation of reported end points were completed in February 2005. The average duration of follow-up from randomization to the end of the trial was 10.1 years (range, 8.2-10.9 years).

#### Outcomes
The primary outcome measures were: incidence of invasive cancer (except non-melanoma skin cancer), myocardial infarction, and stroke. The secondary outcome measures were: non-fatal myocardial infarction, non-fatal stroke, death from cardiovascular causes, and death from any cause.

#### Notes
Compliance with treatment was checked by random serum assessments. Compliance with treatment was excellent. At the time of termination of the beta-carotene component, 87% of the active group have taken at least two thirds of the study capsules, while 9.9% of the women in the placebo group have taken beta-carotene or vitamin A supplements outside the trial. The active agents were provided as follows: aspirin by
Bayer AG, Leverkusen, Germany; vitamin E by Natural Source Vitamin E Association, Washington DC; and beta-carotene by Lurotin, BASF Corporation, Wyandotte, MI. Data were extracted from the primary publication, but additional information was received through personal communication with the authors.

### Risk of bias

| Item                      | Authors' judgement | Description     |
|---------------------------|--------------------|-----------------|
| Allocation concealment?   | Yes                | A - Adequate    |

Witte 2005Low

#### Methods

Randomised, double-blind, placebo-controlled trial with parallel group design.

Generation of the allocation sequence: adequate, random numbers generated by computer.

Allocation concealment: adequate, the randomisation allocation co-ordinated by a remote pharmacy with which the investigators had no contact during the study (ie, central randomisation).

Blinding: adequate, identical placebo capsules.

Follow-up: adequate. Losses to follow-up: 1 patient in each arm.

Intention-to-treat analysis: yes.

Sample size calculations: yes.

#### Participants

Country: United States of America.

Number of participants randomised: 32, aged > 70 years.

Inclusion criteria: stable chronic heart failure due to ischaemic heart disease.

Exclusion criteria: neurological or inflammatory conditions or other significant chronic morbidity affecting quality of life (eg, severe rheumatoid arthritis) or requiring long-term systemic steroid or non-steroidal anti-inflammatory drugs therapy (except low-dose aspirin). Patients in persistent atrial fibrillation were also excluded in order to optimise the reproducibility of the estimation of left ventricular function.

#### Interventions

Participants were randomly assigned to receive:

- group 1: calcium 250 mg; magnesium 150 mg; zinc 15 mg; copper 1.2 mg; selenium 50 µg; vitamin A 800 mg; thiamine 200 mg; riboflavin 2 mg; vitamin B6; 200 mg; folate 5 mg; vitamin B12 200 µg; vitamin C 500 mg; vitamin E 400 mg; vitamin D 10 µg; Co-enzyme Q10 150 mg, (n = 16);
- group 2: placebo (n = 16) (cellulose);

four capsules per day for a period of 9 months. Patients were followed for an average of 295 days.

Patients were on otherwise optimal therapy including diuretics, angiotensin-converting enzyme inhibitors, and beta-blockers if tolerated.

#### Outcomes

The primary outcome measures were: left ventricular function, levels of pro-inflammatory cytokines, and quality-of-life in elderly patients with chronic heart failure.

#### Notes

Authors did not measure blood levels of all the micronutrients to assess compliance, although the changes in the ferritin, vitamin B12, and folate levels in the patients, randomised to the micronutrient combination suggest that they took them.
### Witte 2005Low (Continued)

| Item                        | Authors' judgement | Description          |
|-----------------------------|--------------------|----------------------|
| Allocation concealment?     | Yes                | A - Adequate         |

### Wluka 2002Low

**Methods**
- Randomised, double-blind, placebo-controlled trial with parallel group design.
- Generation of the allocation sequence: adequate, computer generating block randomisation program.
- Allocation concealment: adequate, medications were dispensed by the centralised hospital pharmacy in coded bottles.
- Blinding: adequate, identical placebo tablets.
- Follow-up: adequate. Losses to follow-up; 5 patients in the active and 4 in the placebo group.
- Intention-to-treat analysis: yes.
- Sample size calculations: yes.

**Participants**
- Country: Australia.
- Number of patients randomised: 136, 44.5% men and 55.5% women, mean age 64 years.
- Inclusion criteria: men and women aged 40 years and more fulfilling American College of Rheumatology clinical and radiographic criteria for osteoarthritis knee (all had osteophytes), have pain more than half the days of the previous month and at least one pain dimension of the Western Ontario and McMaster University osteoarthritis index (WOMAC) pain score above 20%. Pain that was at least mild in severity (no compromise of daily activities, frequent but tolerable pain that is worsened by unusual activity and patient may take a pain reliever occasionally).
- Exclusion criteria: known sensitivity to vitamin E, current anticoagulation therapy, previous stroke or history of poorly controlled hypertension, major morbidities such as a cancer or life threatening illnesses, inability to co-operate with study requirements and give informed consent, dementia, other forms of arthritis, inability to walk 50 feet without the use of assistive devices, hemiparesis of either lower limb, those awaiting knee replacement, grade IV knee osteoarthritis, and any contraindication to magnetic resonance imaging (MRI) (eg, pacemaker, cerebral aneurism clip, cochlear implant, presence of shrapnel/metal in strategic locations such as in the orbit, and clausrophobia).

**Interventions**
- Patients were randomly assigned to receive:
  - group 1: vitamin E 500 IU (n = 67);
  - group 2: placebo (soybean);
- for a period of 2 years.

**Outcomes**
- The primary outcome measure was: change in cartilage volume in patients with knee osteoarthritis.

**Notes**
- Compliance was assessed by returned pill counts at each visit.
- Average compliance, assessed on the basis of residual capsule counts, was similar in the two groups; 95.7% in the vitamin E group and 97.0% in the placebo group. No side effects were attributed to vitamin E.
### Risk of bias

| Item                          | Authors' judgement | Description   |
|-------------------------------|--------------------|---------------|
| Allocation concealment?       | Yes                | A - Adequate  |

ADCS: Alzheimer's Disease Cooperative Study  
AMDS: Age Related Macular Degeneration Study  
AREDS: Age Related Eye Disease Study  
ASAP: The Antioxidant Supplementation in Atherosclerosis Prevention Study  
ATBC: Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study  
CARET: The Beta-Carotene and Retinol Efficacy Trial  
CHAOS: Cambridge Heart Antioxidant Study  
DATATOP: The Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism  
DATOR: D Alpha Tocopherol atORvastatin  
GISSI: Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico  
HATS: The HDL-Atherosclerosis Treatment Study  
HOPE: The Heart Outcomes Prevention Evaluation Study  
HOPE TOO: The Heart Outcomes Prevention Evaluation Study The Ongoing Outcomes  
HPS: Heart Protection Study  
LAST: Lutein Antioxidant Supplementation Trial  
MAVIS: Mineral And Vitamin Intervention Study  
MINVITAOX: The Geriatrie/MINéraux, VITamines, et AntiOXYdants Network  
NIT: Nutrition Intervention Trial  
NPCT: Nutritional Prevention of Cancer Trial  
NSCPT: Nambour Skin Cancer Prevention Trial  
PPS: Physicians Health Study  
PPP: The Primary Prevention Project  
PPS: The Polyp Prevention Study  
REACT: The Roche European American Cataract Trial  
SCPS: Skin Cancer Prevention Study  
SKICAP-AK: Skin Cancer Prevention Study - Actinic Keratoses  
SPACE: Secondary Prevention with Antioxidants of Cardiovascular disease in End stage renal disease  
SUUVIMAX: The SUPplementation en VItamines et Mine’ raux AntioXYdants  
VEAPS: The Vitamin E Atherosclerosis Prevention Study  
VECAT: Vitamin E, Cataract and Age-Related Maculopathy Trial  
WAVE: Women's Angiographic Vitamin and Estrogen Trial  
WHS: Women's Health Study  
BCC: basal cell skin cancers  
SCC: squamous cell skin cancer  
RDA: recommended daily allowance  
HBsAg: hepatitis B surface antigen  
AFP: alpha fetoprotein  
US: United States  
AST: aspartate aminotransferase  
ALT: alanine aminotransferase  
WBC: white blood cells  
QoL: quality of life
### Characteristics of excluded studies  (ordered by study ID)

| Study ID | Description |
|----------|-------------|
| Abbey 1993 | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |
| Adler 1993 | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |
| Aghdassi 1999 | Randomised clinical trial. There were no deaths during the follow-up period. Additional information obtained through personal communication with authors. |
| Aghdassi 2003 | Randomised clinical trial where stable, but oxidatively stressed Crohn's disease participants (n = 57) were supplemented with vitamins E (800 IU) and C (1000 mg), or their placebo for 4 wk. Oxidative stress measured by breath pentane and ethane output, plasma lipid peroxides, and F2-isoprostane was assessed at baseline and at 4 wk. Disease activity was also monitored by measuring Crohn's disease (CD) activity index and plasma orosomucoid. Authors did not report any deaths during the trial. |
| Aguilo 2004 | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |
| Akova 2001 | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |
| Al-Taie 2003 | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |
| Albanes 1992 | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |
| Alberts 2004 | Randomised, double-blind, placebo-controlled trial to evaluate dose escalation of vitamin A in skin cancer chemoprevention. One hundred and twenty-nine participants with severely sun-damaged skin on their lateral forearms were randomised to receive placebo or 25000, 50000, or 75000 IU/day vitamin A for 12 months. The primary outcome was the clinical and laboratory safety of vitamin A, and the secondary outcomes included quantitative, karyometric image analysis, and assessment of retinoid and rexinoid receptors in sun-damaged skin. Authors did not report any deaths during the trial. |
| Allard 1994 | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |
| Allard 1997 | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |
| Anah 1980 | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |
| Anderson 1974 | Randomised double-blind clinical trial of daily dosage of 3200 IU of vitamin E in patients with angina pectoris during 9 weeks. Authors did not report any deaths during the follow-up period. |
| Anderson 1975 | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |
| Anderson 1997 | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |
| Study               | Design Description                                                                 |
|--------------------|------------------------------------------------------------------------------------|
| Anderson 1999      | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |
| Andreone 2001      | Randomised, double-blind, placebo-controlled trial to evaluate vitamin E supplementation as therapy for chronic hepatitis B in a pilot study including 32 patients. Patients were randomly allocated to receive vitamin E at the dose of 300 mg twice daily for 3 months (15 patients) or no treatment (17 patients). This trial did not meet our inclusion criteria. |
| Angstwurm 1999     | Randomised open-label pilot trial comparing patients with and without selenium replacement. The aim was to determine the effect of selenium replacement on morbidity and mortality in patients with systemic inflammatory response syndrome. Three patients in the active treatment group and two patients in the placebo group had cancer at the time of randomisation. This trial did not meet our inclusion criteria. |
| Arad 2005          | A double-blind, placebo-controlled randomised clinical trial of atorvastatin 20 mg daily, vitamin C 1 g daily, and vitamin E (alpha-tocopherol) 1,000 U daily versus matching placebos in 1,005 asymptomatic, apparently healthy men and women age 50 to 70 years with coronary calcium scores at or above the 80th percentile for age and gender. All trial participants also received aspirin 81 mg daily. Mean duration of treatment was 4.3 years. The aim of the trial was to determine whether lipid-lowering therapy and antioxidants retard the progression of coronary calcification and prevent atherosclerotic cardiovascular disease (ASCVD) events. One patient died, but it is not known in which arm. Authors did not respond to our request for further information. |
| Arvilommi 1983     | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |
| Astley 1999        | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |
| Avery 2003         | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |
| Bacic Vrca 2004    | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |
| Backman 1990       | This is not a randomised trial. |
| Bailey 2001        | Randomised clinical trial. There were no deaths during the follow-up period. Additional information obtained through personal communication with authors. |
| Baines 1988        | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |
| Barany 2001        | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |
| Barbagallo 1999    | Randomised clinical trial. There were no deaths during the follow-up period. Additional information obtained through personal communication with authors. |
| Barbarich 2004     | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |
| Reference       | Description                                                                                                                                 |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------|
| Barringer 2003  | Randomised, double-blind, placebo-controlled trial to assess the effect of a multivitamin and mineral supplement on infection and quality of life. Twenty-eight persons did not complete the trial. There were no deaths during the follow-up period. Additional information obtained through personal communication with authors. |
| Basnayake 1983  | Randomised clinical trial. The authors did not report any deaths during the follow-up period.                                                                 |
| Bassenge 1998   | Randomised clinical trial. The authors did not report any deaths during the follow-up period.                                                                 |
| Bates 1998      | This is not a randomised clinical trial. A cross-sectional analysis of survey data to characterize relationships among blood pressure, pulse rate, vitamin C status, and other protective and risk factors for older British people. |
| Beaton 2002     | Randomised clinical trial. There were no deaths during the follow-up period. Additional information obtained through personal communication with authors. |
| Beckman 2003    | Randomised clinical trial. There were no deaths during the follow-up period. Additional information obtained through personal communication with authors. |
| Benton 1991     | Randomised clinical trial. The possibility that a subclinical deficiency of the trace element selenium might exist in a sample of the British population was examined by giving a selenium supplement for 5 weeks. Using a double-blind cross-over design, 50 participants received either a placebo or 100 mcg selenium on a daily basis. On three occasions they filled in the Profile of Moods States. A food frequency questionnaire was used to estimate the intake of selenium in the diet. Authors did not report any deaths during the trial. |
| Berger 1998     | This randomised, placebo-controlled trial studied clinical and immune effects of trace element supplements. Twenty patients, aged 40 +/- 16 y (mean +/- SD), burned on 48 +/- 17% of their body surfaces, were studied for 30 d after injury. They consumed standard trace element intakes plus supplements (40.4 micromol Cu, 2.9 micromol Se, and 406 micromol Zn; group TE) or standard trace element intakes plus placebo (20 micromol Cu, 0.4 micromol Se, and 100 micromol Zn; group C) for 8 days. Demographic data were similar for both groups. This trial did not fulfil our inclusion criteria. |
| Bernard 2003    | Randomised clinical trial. There were no deaths during the follow-up period. Additional information obtained through personal communication with authors. |
| Berson 1993     | Randomised, clinical, double-masked trial with 2 x 2 factorial design and duration of 4 to 6 years to determine whether supplements of vitamin A or vitamin E alone or in combination affect the course of retinitis pigmentosa. Six-hundred-and-one patients aged 18 through 49 years with retinitis pigmentosa met preset eligibility criteria. Ninety-five per cent of the patients completed the trial (29/601). Four of 29 patients died and 25 decline to continue participation, most after the fourth year. We were not able to extract relevant data about the mortality in each arm from the published article. Authors were not able to provide these data too. |
| Reference                | Description                                                                 |
|--------------------------|-----------------------------------------------------------------------------|
| Bespalov 2004            | A randomised double blind placebo-controlled trial of the drug karinat was  |
|                          | carried out in patients with chronic multifocal atrophic gastritis. Karinat  |
|                          | contains beta-carotene 2.5 mg, alpha-tocopherol 5 mg, ascorbic acid 30 mg,  |
|                          | and garlic powder 150 mg per tablet. Out of 66 patients, 34 received karinat,|
|                          | 32 placebo. There were no participants with gastrointestinal cancers at the  |
|                          | end of the trial. Authors did not report any deaths during the trial.       |
| Bierenbaum 1985          | This is not a randomised clinical trial. The results of two experiments      |
|                          | evaluating the effects of dietary supplementation with vitamin E are        |
|                          | reported.                                                                   |
| Bjorneboe 1988           | Randomised clinical trial. The authors did not report any deaths during the  |
|                          | follow-up period.                                                           |
| Blackhall 2005           | A randomised placebo-controlled single-blind cross-over trial was conducted |
|                          | in 10 renal transplant recipients taking cyclosporin A (CsA) as part of     |
|                          | their immunosuppressive therapy. Each phase of the trial lasted 6 months,   |
|                          | with a 6 month wash-out period in between. During one of the phases,        |
|                          | patients consumed a tablet twice per day, which delivered 400 IU/day of      |
|                          | vitamin E, 500 mg/day of vitamin C, and 6 mg/day of beta-carotene. Authors   |
|                          | did not report any deaths during the trial.                                  |
| Block 2004               | Randomised clinical trial. The authors did not report any deaths during the  |
|                          | follow-up period.                                                           |
| Bloomer 2004             | Randomised clinical trial. There were no deaths during the follow-up period.|
|                          | Additional information obtained through personal communication with authors.|
| Boardley 2000            | Randomised, double-blind, placebo-controlled trial to determine if a daily  |
|                          | micronutrient supplement could attenuate the decline in immune indexes      |
|                          | during the autumn months in a group of elderly women supplemented for a      |
|                          | period of 10 weeks. There were no deaths during the follow-up period.        |
|                          | Additional information obtained through personal communication with authors.|
| Bogden 1990              | This is not randomised clinical trial. The objective of this study was to    |
|                          | determine the effects of a year of Zn supplementation on Zn concentrations  |
|                          | in circulating cells and on cellular immune functions in the elderly.       |
|                          | Participants, aged 60 to 89, were given a placebo, 15 mg Zn, or 100 mg Zn  |
|                          | daily for 12 months. All participants also received a multivitamin/mineral   |
|                          | supplement that contained no additional Zn. Blood samples were drawn and     |
|                          | immune functions assessed prior to and at 3, 6, 12, and 16 months after     |
|                          | beginning Zn supplementation. Participant diets were also assessed at each  |
|                          | visit.                                                                     |
| Bogden 1994              | A placebo-controlled double-blind trial of the effects of daily micronutrient|
|                          | supplements on circulating vitamin and trace metal concentrations and       |
|                          | delayed-hypersensitivity skin test. Participants aged 59 to 85 years, were  |
|                          | randomly assigned to placebo (n = 27) or micronutrient (n = 29) treatment   |
|                          | groups. Delayed-hypersensitivity skin test and circulating concentrations of  |
|                          | nine micronutrients were measured before and after 6 and 12 months of       |
|                          | micronutrient ingestion. Authors reported that one patient died after 1     |
|                          | month of enrolling the study, but did not report in which arm. Letter to    |
|                          | the author was sent. Answer was not received.                              |
| Booth 2004               | Randomised clinical trial. The authors did not report any deaths during the  |
|                          | follow-up period.                                                           |
| Boshtam 2002             | Randomised clinical trial. The authors did not report any deaths during the  |
|                          | follow-up period.                                                           |
| Publication Date | Study Design                  | Findings                                                                 | Additional Information |
|------------------|-------------------------------|--------------------------------------------------------------------------|------------------------|
| Boshtam 2005     | Randomised clinical trial.    | The authors did not report any deaths during the follow-up period.        |                        |
| Bostom 1995      | Randomised clinical trial.    | The authors did not report any deaths during the follow-up period.        |                        |
| Brand 2001       | A six month, double blind,   | Randomised, placebo controlled study of vitamin E 500 IU/day was carried  | Primary outcome        |
|                  | randomised, placebo controlled| out. Primary outcome measures were pain, stiffness, and function. Of       | measures were          |
|                  | study of vitamin E 500 IU/day | seventy-seven participants, 5 withdrew before the end of study. There     | obtained through       |
|                  | were no deaths during the    | were no deaths during the follow-up period. Additional information was    | personal communication |
|                  | follow-up period.            | obtained through personal communication with authors.                    | with authors.          |
| Broome 2004      | Randomised clinical trial.    | There were no deaths during the follow-up period. Additional information   |                        |
|                  | was obtained through         | was obtained through personal communication with authors.                  |                       |
|                  | personal communication with  |                                                                         |                       |
|                  | authors.                     |                                                                         |                       |
| Brouwers 2002    | Randomised clinical trial.    | The authors did not report any deaths during the follow-up period.        |                        |
| Brown 1994       | Randomised clinical trial.    | The authors did not report any deaths during the follow-up period.        |                        |
| Brown 1998       | Randomised clinical trial.    | The authors did not report any deaths during the follow-up period.        |                        |
| Brown 2000       | Randomised clinical trial.    | The authors did not report any deaths during the follow-up period.        |                        |
| Brude 1997       | Randomised clinical trial.    | There were no deaths during the follow-up period. Additional information   |                        |
|                  | was obtained through         | was obtained through personal communication with authors.                  |                        |
|                  | personal communication with  |                                                                         |                        |
|                  | authors.                     |                                                                         |                        |
| Bucca 1989       | Randomised clinical trial.    | The authors did not report any deaths during the follow-up period.        |                        |
| Buchman 1999     | Randomised clinical trial.    | The authors did not report any deaths during the follow-up period.        |                        |
| Bugianesi 2005   | Randomised, double-blind,    | Randomised, double-blind, placebo-controlled trial to compare the        |                        |
|                  | placebo-controlled trial to  | usefulness of metformin versus prescriptive diet or vitamin E in the     |                        |
|                  | compare the usefulness of   | treatment of nonalcoholic fatty liver disease. Nondiabetic nonalcoholic   |                        |
|                  | metformin versus             | fatty liver disease patients were given metformin (2 g/day; n = 55) for   |                        |
|                  | prescriptive diet or vitamin | 12 months. The control cases were given either vitamin E (800 IU/day; n   |                        |
|                  | E in the treatment of       | = 28) or were treated by a prescriptive, weight-reducing diet (n = 27).    |                        |
|                  | nonalcoholic fatty liver     | There were no deaths during the follow-up period. Additional information  |                        |
|                  | disease                     | was obtained through personal communication with authors.                  |                        |
| Bukin 1993       | This is not a randomised     | This is not a randomised trial. Increase of ornithine decarboxylase (ODC) |                        |
|                  | trial. Increase of          | activity is known to be associated with cell proliferation and, very      |                        |
|                  | ornithine decarboxylase (ODC)| likely, with tumour promotion. This prompted us to study the activity of  |                        |
|                  | activity is known to be     | ODC in gastric mucosa of patients with chronic atrophic gastritis that    |                        |
|                  | associated with cell        | has been considered as a precursor of stomach cancer.                     |                        |
|                  | proliferation and, very     |                                                                         |                        |
|                  | likely, with tumour         |                                                                         |                        |
|                  | promotion.                  |                                                                         |                        |
| Bukin 1995       | Randomised clinical trial.    | The authors did not report any deaths during the follow-up period.        |                        |
| Bukin 1997       | Randomised clinical trial.    | The authors did not report any deaths during the follow-up period.        |                        |
| Study            | Type of Study                                      | Description                                                                                   |
|------------------|---------------------------------------------------|----------------------------------------------------------------------------------------------|
| Bunker 1994      | Randomised clinical trial                         | This is not a randomised clinical trial. In this study a balanced nutritional supplement consisting of several macro- and micro-nutrients was administered daily to 27 housebound elderly (aged 70 to 85 years) for 12 weeks. Thirty-one matched participants served as a control group. |
| Bunout 2000      | Randomised clinical trial                         | The authors did not report any deaths during the follow-up period.                             |
| Bursell 1999     | Randomised clinical trial                         | There were no deaths during the follow-up period. Additional information was obtained through personal communication with authors. |
| Bussey 1982      | Randomised, double-blind trial                    | Among the 49 patients, 36 were evaluable. During the trial two participants died, but authors did not report in which group they were. Letter to the author was sent. |
| Butcher 1993     | Randomised clinical trial                         | The authors did not report any deaths during the follow-up period.                             |
| Cadenas 1996     | Randomised clinical trial                         | The authors did not report any deaths during the follow-up period.                             |
| Cafolla 2002     | Randomised clinical trial                         | The authors did not report any deaths during the follow-up period.                             |
| Calabrese 1987   | Randomised clinical trial                         | The authors did not report any deaths during the follow-up period.                             |
| Calzada 1997     | Randomised clinical trial                         | The authors did not report any deaths during the follow-up period.                             |
| Candan 1997      | Randomised clinical trial                         | The authors did not report any deaths during the follow-up period.                             |
| Carpenter 2003   | Randomised clinical trial                         | There were no deaths during the follow-up period. Additional information was obtained through personal communication with authors. |
| Carty 2000       | Randomised clinical trial                         | There were no deaths during the follow-up period. Additional information was obtained through personal communication with authors. |
| Cases 2005       | Randomised clinical trial                         | The authors did not report any deaths during the follow-up period.                             |
| Ceriello 1991    | Randomised clinical trial                         | The authors did not report any deaths during the follow-up period.                             |
| Chan 2005        | Randomised clinical trial                         | The authors did not report any deaths during the follow-up period.                             |
| Chandra 2001     | Randomised, double-blind, placebo-controlled trial | Author reported two deaths during the trial, but not in which arm of the study. The publication on the trial is retracted in 2005. Conflict of interest: Chandra failed to declare that he holds a patent on the tested supplement formula and has a financial stake in it because the supplement was licensed to Javaan Corporation, a company founded by his daughter, that sells the supplement. Letter to the author was sent. |
| Author       | Description                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|--------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Chandra 2002 | Randomised, double-blind placebo-controlled trial to examine the effect of multinutrient supplement on immune responses and infection-related illness in 50 to 65 year old individuals. Authors did not report any deaths during the follow-up period. Letter to the author was sent.                                                                                                                                                                                                                   |
| Chavance 1993| Randomised, double-blind placebo-controlled trial to assess the efficacy of a multivitamin supplement for the prevention of common infections in healthy elderly subjects. The treatment or placebo tablets were to be taken daily for four months. In each group seven participants (6.5%) withdrew from the trial before its end. There were no deaths reported during the trial.                                                                                           |
| Chesney 2000 | The Arterial Disease Multiple Intervention Trial (ADMIT) was designed to determine the efficacy, safety, and compliance of a multifactorial therapy on selected atherosclerotic disease risk factors in patients with peripheral arterial disease. By a $2 \times 2 \times 2$ factorial design, eligible participants ($N = 468$) were randomly assigned to low-dose warfarin, antioxidant vitamins, and niacin or its corresponding placebo, and followed up for 1 year. All participants were encouraged to use aspirin. Pravastatin was added to the drug regimen for those who needed to reduce LDL cholesterol to recommended levels. Authors did not report any deaths during the trial. |
| Cheung 2001  | Randomised clinical trial. The authors did not report any deaths during the follow-up period.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Chuang 2002  | Randomised clinical trial. The authors did not report any deaths during the follow-up period.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Clarke 2003  | Randomised clinical trial. The authors did not report any deaths during the follow-up period.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Clausen 1989 | Randomised clinical trial. Ninety-seven geriatric patients from two Danish homes for old people accepted to participate in a blinded experiment designed to counteract ageing phenomena. The participants were split into two groups, ie, the verum and the placebo group. The verum group received daily for one year an antioxidative cocktail consisting of: 300 micrograms selenium as L-selenomethionine, 45 mg zinc, 270 mg vitamin C, 2.7 mg vitamin A, 6 mg vitamin B-6, and 465 mg vitamin E (d-alfatocopherol). Furthermore, in order to enhance exchange in polyenoic acids, each participant received daily 250 mg gamma-linolenic acid. The placebo groups received similar looking pills and capsules without the active components. Authors did not report any deaths during the trial. |
| Colette 1988 | Randomised clinical trial. There were no deaths during the follow-up period. Additional information was obtained through personal communication with authors.                                                                                                                                                                                                                                                                                                                                                     |
| Corridan 2001| Randomised clinical trial. The authors did not report any deaths during the follow-up period.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Cox 1975     | Randomised clinical trial. The authors did not report any deaths during the follow-up period.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Crary 1987   | Randomised clinical trial. 102 patients with macular degeneration have been supplemented with vitamin C 500 mg, vitamin E 400 IU, beta-carotene 10,000 units and selenium (sodium selenite) 250 microg, and followed 7 to12 years. 176 patients with diabetes mellitus and diabetic macular edema have also been followed for 7 to 12 years. Authors did not report any deaths during the trial.                                                                                   |
| Reference | Description |
|-----------|-------------|
| Crimi 2004 | Randomised, double-blind placebo-controlled trial to examine the effect of antioxidant supplementation in enteral feeding in critically ill patients. Baseline characteristics of patients were reason for exclusion. Eighteen patients in antioxidant group and 16 patients in placebo group had malignancy. This trial did not meet our inclusion criteria. |
| Crogan 2005 | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |
| Dabiri 1994 | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |
| Daga 2003 | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |
| Dakhale 2005 | Randomised clinical trial. There were no deaths during the follow-up period. Additional information was obtained through personal communication with authors. |
| Darko 2002 | Randomised clinical trial. There were no deaths during the follow-up period. Additional information was obtained through personal communication with authors. |
| Davison 2005 | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |
| Dawson 1999 | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |
| De las Heras 2000 | This is not a randomised clinical trial. The purpose of this report is to analyse the results of a 1-year clinical study of antioxidant therapy in the treatment of pain and recurrent inflammatory episodes in patients with chronic and acute recurrent pancreatitis, using a prospective, descriptive, pre-post, open design. The studied patients were with acute recurrent or chronic pancreatitis who had suffered from pain or acute inflammatory episodes the year before the beginning of treatment with a complex containing L-methionine, beta-carotene, vitamin C, vitamin E and organic selenium. |
| de Sanjose 1996 | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |
| de Vet 1991 | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |
| de Waart 1997 | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |
| DeCosse 1989 | Over a 4-year period in a chemoprevention randomised, double-blind, placebo-controlled trial on large bowel neoplasia, patients with familial adenomatous polyposis were treated with 4 g of ascorbic acid (vitamin C)/day plus 400 mg of alpha-tocopherol (vitamin E)/day alone or with a grain fiber supplement (22.5 g/day). Of the 62 randomly assigned patients, 58 were assessable. Four patients withdrew from the study. Authors did not report any deaths during the trial. |
| DeMaio 1992 | Randomised, double-blind placebo-controlled trial to test whether alpha-tocopherol prevents restenosis following percutaneous transluminal coronary angioplasty (PTCA). Patients were randomised after successful PTCA to receive vitamin E in the form of dl-alpha-tocopherol, 1200 IU/day, orally versus an inactive placebo for 4 months. Fifteen participants withdrew from the trial before its end. Authors did not report any deaths during the trial. This trial did not meet our inclusion criteria. |
| Study | Design Type | Follow-up | Additional Information |
|-------|-------------|-----------|------------------------|
| Desideri 2002 | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |  |  |
| Desideri 2002a | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |  |  |
| Devaraj 1997 | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |  |  |
| Dieber-Roth 1991 | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |  |  |
| Diepeveen 2005 | Randomised, double-blind placebo-controlled trial to examine the effects of treatment with atorvastatin, alpha-tocopherol and the combination of both, on lipoproteins and oxidative stress in dialysis patients. A total of 44 clinically stable, non-diabetic patients on dialysis therapy (23 on haemo- and 21 on peritoneal-dialysis) without manifest cardiovascular disease were included in this study. They were randomised for treatment during a period of 12 weeks with 40 mg atorvastatin + placebo alpha-tocopherol (group 1) once daily, 800 IU alpha-tocopherol + placebo atorvastatin once daily (group 2), 40 mg atorvastatin + 800 IU alpha-tocopherol once daily (group 3), or placebo atorvastatin + placebo alpha-tocopherol once daily (group 4). Assessment of lipid profile and oxidative stress was performed at the start of the study and after 12 weeks of treatment. Authors did not report any deaths during the trial. |  |  |
| Dietrich 2002 | Randomised clinical trial. There were no deaths during the follow-up period. Additional information was obtained through personal communication with authors. |  |  |
| Dietrich 2003 | Randomised clinical trial. There were no deaths during the follow-up period. Additional information was obtained through personal communication with authors. |  |  |
| Dorfman-Etrog 1999 | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |  |  |
| Duffy 1999 | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |  |  |
| Duffy 2001 | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |  |  |
| Durthie 1996 | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |  |  |
| Earnest 2003 | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |  |  |
| Economides 2005 | Randomised clinical trial. There were no deaths during the follow-up period. Additional information was obtained through personal communication with authors. |  |  |
| Edmonds 1997 | This double blind and randomised trial used a broad spectrum of clinical and laboratory parameters to investigate whether there was any additional anti-inflammatory or analgesic effects, or both, of orally administered alpha-tocopherol in rheumatoid arthritis patients who were already receiving anti-rheumatic drugs. Forty two patients were enrolled and treated with alpha-tocopherol (n = 20) at a dose of 600 mg twice a day (2 x 2 capsules) or with placebo (n = 22) for 12 weeks. The following parameters were measured: (1) Three clinical indices of inflammation - the Ritchie articular index, the duration of morning stiffness, |  |  |
and the number of swollen joints; (2) three measures of pain—pain in the morning, pain in the evening, and pain after chosen activity; (3) haematological and biochemical measures of inflammatory activity; (4) assays for the oxidative modification of proteins and lipids. There were no deaths during the follow-up period. Additional information obtained through personal communication with authors.

| Study | Design | Findings |
|-------|--------|----------|
| Egan 1992 | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |
| Eiselt 2001 | Randomised clinical trial. There were no deaths during the follow-up period. Additional information was obtained through personal communication with authors. |
| El-Bayoumy 2002 | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |
| Elkashf 1990 | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |
| Ernster 1985 | Randomised, double-blind placebo-controlled trial of the effect of vitamin E on clinically palpable benign breast findings. Women were supplemented mean two months. Eleven participants did not complete the trial. Authors did not report any deaths during the trial. |
| Everett 2002 | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |
| Fairley 1996 | A randomised double-blind placebo controlled trial was designed for 117 women with abnormal cervical morphology. Thirty milligrams of oral beta carotene were administered daily for 12 months. There were no deaths during the follow-up period. Additional information was obtained through personal communication with authors. |
| Fairris 1989 | Since reduced concentrations of selenium in whole blood, plasma and white cells had previously been observed in psoriasis, 69 patients were supplemented daily with either 600 micrograms of selenium-enriched yeast, 600 micrograms of selenium-enriched yeast plus 600 IU of vitamin E, or a placebo for 12 weeks. Before supplementation, the patients’ mean concentrations of selenium in whole blood and plasma were reduced compared with those of matched healthy controls, but their red cell glutathione peroxidase (GSH-Px) activity was normal. During the study, 4 patients were excluded. Authors did not report any deaths during the trial. |
| Falsini 2003 | Non-randomised, comparative clinical study to evaluate the influence of short-term antioxidant supplementation on retinal function in age-related maculopathy (ARM) patients by recording focal electroretinograms. |
| Fang 2002 | Randomised, double-blind, placebo-controlled trial to examine the effect of vitamins C and E on progression of transplant-associated arteriosclerosis. This trial did not meet our inclusion criteria. |
| Farvid 2005 | In a randomised, double-blind, placebo-controlled clinical trial, 69 type 2 diabetic patients were randomly divided into four groups; each group received one of the following daily supplement for 3 months: group M (n = 16), 200 mg Mg and 30 mg Zn; group V (n = 18), 200 mg vitamin C and 100 IU vitamin E; group MV (n = 17), minerals plus vitamins; and group P (n = 18), placebo. The aim of the trial was to assess the effect of magnesium plus zinc, vitamins C plus E, and a combination of these micronutrients on nephropathy |
Continued

| Study            | Type of Trial                                                                 |
|------------------|-----------------------------------------------------------------------------|
| Faure 2004       | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |
| Fawzi 2004       | Randomised, double-blind, placebo-controlled trial in Dar es Salaam, Tanzania, to examine the effects of daily supplements of vitamin A (preformed vitamin A and beta carotene), multivitamins (vitamins B, C, and E), or both on progression of HIV disease, using survival models. Authors reported that a total of 343 women died during follow-up. Of these deaths, 243 were deemed to be due or related to AIDS: 82 were due to AIDS, 61 to pulmonary tuberculosis, 3 to extrapulmonary tuberculosis, 10 to anemia, 14 to meningitis, 5 to stroke, 23 to pneumonia, 21 to diarrhea, and 24 to fever. Only data about the mortality related to AIDS (243 women) were reported. This trial did not meet our inclusion criteria. |
| Fenech 1997      | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |
| Finley 1998      | This is not a randomised clinical trial. Thirty healthy young men were fed diets that provided either 32.6 or 226.5 mg of selenium (Se)/day for 105 days. |
| Fischer 2004     | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |
| Florencio 1981   | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |
| Fogarty 2003     | Randomised, double-blind, placebo-controlled trial to determine whether vitamin C or magnesium supplements improve the clinical control of asthma in primary care patients. Participants were supplemented with 1 g/day vitamin C, 450 mg/day magnesium chelate or matched placebo. Three hundred patients aged 18 to 60 years with physician-diagnosed asthma, controlled with at least one dose of an inhaled corticosteroid daily, were recruited from 24 primary care practices in Nottingham, United Kingdom. The main outcome measures were change in forced expiratory volume in 1 s, forced vital capacity, airway responsiveness to methacholine, mean morning and evening peak flow, symptom scores and bronchodilator use, both individually and as a combined summary statistic. There were no deaths during the follow-up period. Additional information obtained through personal communication with authors. |
| Fortes 1998      | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |
| Fotherby 2000    | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |
| Frank 2004       | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |
| Fuchs 1998       | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |
| Fuller 1996      | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |
| Fuller 2000      | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |

(indexes in type 2 diabetic patients. Urinary albumin excretion and N-acetyl-beta-d-glucosaminidase activity (NAG) in urine were determined at the beginning and at the end of the trial. Treatment effects were analysed by general linear modeling. Authors did not report any deaths during the trial.)
| Study           | Description                                                                                                                                                                                                 |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Fumeron 2005    | This is a prospective, randomised, open-label trial to assess the effects of oral vitamin C supplementation (250 mg three times per week) for 2 months on well-defined oxidative and inflammatory markers in 33 chronic haemodialysis (HD) patients. Seven patients of 40 randomised withdrew from the trial. The authors did not report any deaths during the trial. |
| Gaede 2001      | Randomised, double-blind, cross-over trial to examine the effect of vitamin C and E supplementation on albuminuria and glomerular hypertrophy in type 2 diabetic patients. The 29 patients were randomised and all of these completed the study. There were no deaths during the follow-up period. |
| Gal 1996        | Randomised clinical trial. The authors did not report any deaths during the follow-up period.                                                                                                                 |
| Galley 1997     | Randomised clinical trial. There were no deaths during the follow-up period. Additional information was obtained through personal communication with authors.                                                        |
| Garewal 1999    | Randomised clinical trial. The authors did not report any deaths during the follow-up period.                                                                                                                   |
| Garmyn 1995     | Randomised clinical trial. The authors did not report any deaths during the follow-up period.                                                                                                                    |
| Gartner 2001    | Mini review about the effect of a selenium supplementation on the outcome of patients with severe systemic inflammation, burn and trauma.                                                                         |
| Gartner 2002    | Randomised clinical trial. The authors did not report any deaths during the follow-up period.                                                                                                                    |
| Gazis 1999      | Randomised clinical trial. The authors did not report any deaths during the follow-up period.                                                                                                                     |
| Gertz 1990      | A study of vitamin E in patients with primary systemic amyloidosis. This is not a randomised clinical trial.                                                                                                   |
| Gesch 2002      | Randomised clinical trial. There were no deaths during the follow-up period. Additional information was obtained through personal communication with authors.                                                      |
| Ghatak 1996     | Randomised clinical trial. The authors did not report any deaths during the follow-up period.                                                                                                                    |
| Ghosh 1994      | Randomised clinical trial. The authors did not report any deaths during the follow-up period.                                                                                                                     |
| Gianduzzo 2003  | Randomised clinical trial. The authors did not report any deaths during the follow-up period.                                                                                                                    |
| Gokce 1999      | Randomised clinical trial. There were no deaths during the follow-up period. Additional information was obtained through personal communication with authors.                                                        |
| Goldfarb 2005   | Randomised clinical trial. The authors did not report any deaths during the follow-up period.                                                                                                                    |
| Goldfarb 2005a  | Randomised clinical trial. The authors did not report any deaths during the follow-up period.                                                                                                                     |
| Gollnick 2002   | Randomised clinical trial. The authors did not report any deaths during the follow-up period.                                                                                                                    |
Gomez-Perez 1996  Randomised trial on antioxidant supplements. The aim of the study was to examine the effects of vitamin E on total serum protein glycation (fructosamine), haemoglobin glycation (HbA1c), and serum levels of glucose, total cholesterol, triglycerides, LDL-C, HDL-C, apolipoprotein A1, and apolipoprotein B. Sixty poorly controlled diabetic patients were randomly assigned to receive either 1200 mg/day of vitamin E or identical placebo capsules during a two month period following a double blind cross-over design with a four week wash-out period between regimens. Seven patients withdrew from the trial. There were no deaths during the follow-up period. Additional information was obtained through personal communication with authors.

Goodman 1998  Randomised clinical trial. The authors did not report any deaths during the follow-up period.

Goudev 2000  Randomised clinical trial. The authors did not report any deaths during the follow-up period.

Green 1995  Randomised clinical trial. The authors did not report any deaths during the follow-up period.

Greul 2002  Randomised clinical trial. The authors did not report any deaths during the follow-up period.

Griesinger 2002  Randomised clinical trial. The authors did not report any deaths during the follow-up period.

Grievink 1998  Randomised clinical trial. The authors did not report any deaths during the follow-up period.

Grievink 1999  Randomised clinical trial. The authors did not report any deaths during the follow-up period.

Gueguen 2003  Randomised clinical trial. The authors did not report any deaths during the follow-up period.

Gupta 2001  Randomised clinical trial. The authors did not report any deaths during the follow-up period.

Hajjar 2002  Randomised, double-blind, placebo-controlled trial to examine the effect of vitamin C in the management of hypertension and lipids. No reported deaths during the eight months of follow-up.

Hamilton 2000  Randomised clinical trial. The authors did not report any deaths during the follow-up period.

Harman 1986  Randomised clinical trial to evaluate the effect of vitamin E on the immune response to influenza virus vaccine and the incidence of infectious disease in men. Patients were divided at random into three groups and were given daily for a period of six months either 0 mg (52 patients), 200 mg (26 patients), or 400 mg (25 patients) alpha-tocopherol acetate per day. One month after starting the vitamin E, the patients received polyvalent influenza virus vaccine. The incidence of infections was tabulated monthly throughout the trial. The authors did not report any deaths during the trial.

Harrison 2003  Prospective, double-blind, randomised, placebo-controlled trial with a total enrollment of 49 patients; 45 patients completed the study. All patients were randomised to receive either vitamins E and C (1000 IU and 1000 mg, respectively) or placebo daily for 6 months, based on their initial histologic diagnosis of non-alcoholic steato-hepatitis. Additionally, all patients were given standard weight-loss counseling and encouraged to follow a low fat diet (<30 fat g/day). The pre- and posttreatment liver biopsies were reviewed.
by a single pathologist, who was blinded to the patient's medication. Of 49 participants, 45 completed the trial. Authors did not report any deaths during the follow-up period.

| Study (Year) | Study Details |
|-------------|---------------|
| Hasselmark 1993 | Randomised clinical trial. The aim of this double-blind study was to investigate whether Se supplementation in asthmatic patients may increase GSH-Px activity and possibly bring about clinical improvement. Twenty-four patients suffering from intrinsic asthma were selected and randomised into two groups, and after a preintervention period of 4 weeks, one group received a daily supplement of 100 micrograms sodium selenite for 14 weeks, whereas the other group received placebo. Three participants dropped-out before the end of trial, one from selenium and two from placebo group. Authors did not report any deaths during the trial. |
| Hata 1992 | This study was designed to prevent the patients already with cerebral infarction from recurrence of cerebrovascular accidents by administration of alpha-tocopherol nicotinate. In this article authors described rationales for trial. No results of this study have been published later on. |
| Hawkes 1996 | Randomised phase II clinical trial. The aim of the present double-blind trial was to investigate whether Se supplementation in asthmatic patients may increase GSH-Px activity and possibly bring about clinical improvement. Twenty-four patients suffering from intrinsic asthma were selected and randomised into two groups, and after a preintervention period of 4 weeks, one group received a daily supplement of 100 micrograms sodium selenite for 14 weeks, whereas the other group received placebo. Authors did not report any deaths during the trial. |
| Heinle 1997 | Randomised clinical trial. There were no deaths during the follow-up period. Additional information obtained through personal communication with authors. |
| Heinrich 2003 | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |
| Heitzer 1999 | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |
| Hernandez 2005 | Randomised clinical trial. The Prevention Research Veteran Affairs E-vitamin Nutrition Trial is a randomised, double-blind, placebo controlled trial designed to assess the effects of vitamin E supplementation on biomarkers associated with prostate cancer risk in peripheral blood and prostate tissue. A total of 44 patients with increased prostate specific antigen (PSA) and/or abnormal digital rectal examination on initial evaluation were randomised to receive 400 IU vitamin E (22) versus placebo (22). Serum vitamin E, PSA, dehydroepiandrosterone, testosterone, and insulin-like growth factor-1 (IGF-1) were measured in the 2 groups at baseline and then at 3-month intervals. Results are reported in 28 patients (placebo in 14 and vitamin E in 14) who completed the treatment as specified by the protocol. Three of the 44 randomised patients had biopsy proven prostate cancer at the time of enrollment. This trial did not meet our inclusion criteria. |
| Herraz 1998 | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |
| Herrick 2000 | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |
| Hillert 2001 | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |
| Study | Description |
|-------|-------------|
| Hinger 2001 | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |
| Hodis 1995 | A subgroup analysis of the on-trial antioxidant vitamin intake database acquired in the Cholesterol Lowering Atherosclerosis Study, a randomised, placebo-controlled, serial angiographic clinical trial evaluating the risk and benefit of colestipol-niacin on coronary artery disease progression. |
| Hoffman 1999 | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |
| Hofstad 1998 | In a prospective intervention randomised trial of colorectal adenomas, and intermediary stage in colorectal carcinogenesis, 116 polyp-bearing patients received a placebo-controlled daily mixture of beta-carotene 15 mg, vitamin C 150 mg, vitamin E 75 mg, selenium 101 microg, and calcium (1.6 g daily) as carbonate for a period of 3 years with annual colonoscopic follow-up to test if the mixture was able to reduce polyp growth or recurrence. All polyps of < 10 mm at enrollment or follow-up were left unresected until the end of the study. Of 116 patients randomised, 93 were evaluable at the end of trial. Authors did not report any deaths during the trial. |
| Hornig 1998 | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |
| Huang 2005 | Randomised, double-blind, placebo-controlled clinical trial to determine the effects of vitamin C supplementation for 2 months on serum uric acid concentrations. Ninety-two percent of participants completed the trial. The authors did not report any deaths during the trial. |
| Hughes 1997 | Randomised clinical trial. There were no deaths during the follow-up period. Additional information was obtained through personal communication with authors. |
| Huijuan 1989 | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |
| Iino 1977 | A controlled double-blind randomised trial of effects of dl-alpha-tocopheryl nicotinate for relief of symptoms was performed in 94 participants with hypertension and cerebral arteriosclerosis. Treatment were given to all participants during 6 weeks and in 43 participants for 6 weeks. Of 94 participants 89 completed the study. There were 2 drop-out patients (4.5%) in the experimental treatment group and 3 in the placebo group, because of various individual reasons. There were no deaths reported during the trial. |
| Inagaki 1978 | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |
| Itoh 2000 | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |
| Iwanier 1995 | This is not a randomised clinical trial. The objective of this study was to evaluate the effect of selenium (Se) supplementation on Se concentration and glutathione peroxidase (GSH-Px) activity in blood components and seminal fluid and on spermatozoal quality characteristics in subfertile men. Thirty-three men were supplemented for 12 weeks with 200 micrograms Se/day in the form of yeast-rich Se (group I, n = 16) or sodium selenite (group II, n = 17). Blood samples and sperm were collected at the start of the study and after 2, 4, 8, and 12 weeks following Se supplementation. |
| Author            | Study Design and Details                                                                                                                                                                                                 |
|-------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Jacob 2003        | Randomised clinical trial. The authors did not report any deaths during the follow-up period.                                                                                                                                 |
| Jacques 1995      | Randomised clinical trial. The authors did not report any deaths during the follow-up period.                                                                                                                                 |
| Jain 2002         | Randomised, double-blind, placebo-controlled clinical trial to test the influence of vitamins and trace-elements on the incidence of respiratory infection in the elderly. The authors did not report any deaths during the trial. |
| Jantti 1991       | Randomised clinical trial. Twenty-eight patients suffering from rheumatoid arthritis were divided randomly into five groups, treated for eight weeks with either placebo, or capsules containing omega-3 fatty acids 3 g, selenium 150 microg, vitamin A 9000 IU, or vitamin E 600 mg daily. Clinical status was followed during the treatment and four weeks after that. The authors did not report any deaths during the trial. |
| Jaswal 2003       | Randomised clinical trial. The authors did not report any deaths during the follow-up period.                                                                                                                                 |
| Jeng 1996         | Randomised clinical trial. The authors did not report any deaths during the follow-up period.                                                                                                                                 |
| Jensen 2002       | Randomised clinical trial. There were no deaths during the follow-up period. Additional information was obtained through personal communication with authors.                                                                                                           |
| Jessup 2003       | Randomised clinical trial. The authors did not report any deaths during the follow-up period.                                                                                                                                 |
| Jialal 1992       | Randomised clinical trial. The authors did not report any deaths during the follow-up period.                                                                                                                                 |
| Jialal 1993       | Randomised clinical trial. The authors did not report any deaths during the follow-up period.                                                                                                                                 |
| Jialal 1995       | Randomised clinical trial. The authors did not report any deaths during the follow-up period.                                                                                                                                 |
| Johnson 1995      | Randomised clinical trial. The authors did not report any deaths during the follow-up period.                                                                                                                                 |
| Kaikkonen 1998    | Randomised clinical trial. The authors did not report any deaths during the follow-up period.                                                                                                                                 |
| Kaikkonen 2000    | A phase II randomised, double-blind, placebo-controlled clinical trial to test separate effects and interaction between Q10 and vitamin E in the change of plasma concentrations and in the antioxidative efficiency in 40 participants with mild hypercholesterolemia undergoing statin treatment. Participants were randomly allocated to parallel groups to receive either Q10 (200 mg daily), d-alpha-tocopherol (700 mg daily), both antioxidants or placebo for 3 months. The authors did not report any deaths during the follow-up period. |
| Kaiser 1995       | In this randomised, double-blind trial, 20 patients in an early stage of age-related macular degeneration were included. Over a period of 6 months, 9 patients were treated with visaline and 11 with a placebo. The authors did not report any deaths during the follow-up period. |
| Study                        | Study Design                                                                 | Follow-Up Details                                                                 |
|------------------------------|------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|
| Canter 1993                  | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |                                                                                     |
| Karlovs 1975                 | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |                                                                                     |
| Kawahara 2002                | Randomised clinical trial. There were no deaths during the follow-up period. Additional information was obtained through personal communication with authors. |                                                                                     |
| Keefe 2001                   | A randomised, double-blind, placebo-controlled clinical trial to evaluate the effect of daily beta-carotene (30 mg) versus placebo over a 2-year period on cervical intraepithelial neoplasia grade 2 and 3 lesions. Women were randomised to beta-carotene or placebo, with cytology and colposcopy every 3 months. Twenty-five of 163 patients did not complete the trial. The authors did not report any deaths during the trial. |                                                                                     |
| Keith 1982                   | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |                                                                                     |
| Keith 2001                   | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |                                                                                     |
| Keskes-Ammar 2003            | This randomised and open trial aimed to test the effects of vitamin E and selenium supplementation on lipid peroxidation and on sperm parameters. The trial included 54 voluntary and infertile men who produced semen samples for spermogram and for spectrophotometric measurement of a lipid peroxidation marker, the malondialdehyde (MDA), and produced blood samples for high-performance liquid chromatography assessment of serum vitamin E level. Twenty-eight men were supplemented daily by vitamin E (400 mg) and selenium (225 microg), during 3 months. The remaining 26 patients received vitamin B (4.5 g/day) for the same duration. Of 54 participants 20 completed the trial. The authors did not report any deaths during the trial. |                                                                                     |
| Kessopoulou 1995             | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |                                                                                     |
| Khajehdehi 2000              | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |                                                                                     |
| Khajehdehi 2001              | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |                                                                                     |
| Khassaf 2003                 | Randomised clinical trial. There were no deaths during the follow-up period. Additional information was obtained through personal communication with authors. |                                                                                     |
| Kim 2001                     | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |                                                                                     |
| King 1997                    | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |                                                                                     |
| Kinlay 2004                  | Randomised clinical trial. There were no deaths during the follow-up period. Additional information was obtained through personal communication with authors. |                                                                                     |
| Kiremidjian-S 1994           | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |                                                                                     |
| Study            | Design                          | Description                                                                 |
|------------------|---------------------------------|-----------------------------------------------------------------------------|
| Kitagawa 1989    | Randomised clinical trial       | A trial was conducted to investigate the effects of a megadosage of free RRR-alpha-tocopherol in healthy college student volunteers. Of 19 volunteers, 14 were given daily doses of 600 mg (900 IU) of RRR-alpha-tocopherol for 12 weeks, and the remaining 5 were given identical placebo capsules. The investigation was performed by the single-blind method. Alpha-tocopherol levels were measured in plasma, red blood cells (RBCs), platelets, leucocytes (WBCs), and buccal mucosal cells. The authors did not report any deaths during the trial. |
| Koh 1999         | Randomised clinical trial       | There were no deaths during the follow-up period. Additional information was obtained through personal communication with authors. |
| Konen 2000       | Randomised clinical trial       | The authors did not report any deaths during the follow-up period.          |
| Korpela 1989     | Randomised clinical trial       | The effect of selenium supplementation was evaluated in 81 patients with acute myocardial infarction in a double-blind, placebo-controlled trial. Patients were randomised into two treatment groups receiving either selenium-rich yeast (100 micrograms/day) or placebo in addition to conventional drug therapy for a 6-month period. During treatment the mean serum selenium concentration increased from 82 micrograms/l to 122 micrograms/l (P less than 0.001) in the selenium supplemented group and remained unaltered in the placebo group (83 micrograms/l). The trial did not meet our inclusion criteria. This is a tertiary prevention trial. |
| Kugiyama 1999    | Randomised clinical trial       | There were no deaths during the follow-up period. Additional information was obtained through personal communication with authors. |
| La Ruche 1991    | Randomised clinical trial       | The authors did not report any deaths during the follow-up period.          |
| Li 2000          | Randomised clinical trial       | To study the preventive effects of selenium on primary liver cancer. After screening of blood samples in 18000 males from 20 to 65 years-old in Qidong, Jiangsu province (a high risk area for liver cancer), 2065 participants HBsAg positive, AFP negative and normal liver function (normal ALT values) were found. The participants were randomly divided into two groups, based on their residence areas; 1,112 people (experimental group) received one tablet of sodium selenite (0.5 mg Se) every day, and 953 people (control group) received one placebo tablet every day. The authors did not report any deaths during the trial. |
| Li 2004          | A double-blind randomised trial | A total of 2526 and 2507 persons were randomly enrolled into intervention group and control group respectively from 288 natural villages of seven communities in Qixia County, Shandong Province, China. Each person of the intervention group orally took 200 mg synthetic allitridum every day and 100 microg selenium every other day for one month of each year during November 1989 to December 1991. At the same time, people in control group were given 2 placebo capsules containing cornoid with the identical appearance to that in the intervention group. Authors did not report any deaths during the trial. |

(Co)
| Date       | Study Details                                                                                                                                                                                                 |
|------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| London 1983| In a double-blind, randomised dose-response trial, 75 women with benign breast disease were administered a written questionnaire in which they scored the severity of premenstrual syndrome (PMS) symptoms before and after two months of treatment with placebo or alpha-tocopherol (150, 300, or 600 IU/day). The authors did not report any deaths during the trial. |
| London 1985| Randomised clinical trial. The authors did not report any deaths during the follow-up period.                                                                                                                  |
| London 1987| Randomised clinical trial. The authors did not report any deaths during the follow-up period.                                                                                                                  |
| London 1991| Randomised clinical trial. The authors did not report any deaths during the follow-up period.                                                                                                                  |
| Loots 2004 | Randomised clinical trial. There were no deaths during the follow-up period. Additional information was obtained through personal communication with authors.                                                          |
| Lovat 1993 | Randomised clinical trial. The authors did not report any deaths during the follow-up period.                                                                                                                  |
| Lykkesfeldt 2000 | Randomised clinical trial. The authors did not report any deaths during the follow-up period.                                                                                                  |
| Mackerras 1999 | A double-blind, placebo-controlled, randomised, factorial trial using a daily oral administration of 30 mg beta-carotene and/or 500 mg vitamin C was conducted in 141 women with colposcopically and histologically confirmed minor squamous atypia or cervical intra-epithelial neoplasia (CIN) I. Over approximately 2 years of follow-up, 43 lesions regressed to normal and 13 progressed to CIN II. Of 147 women randomised, 6 did not return for follow-up. The authors did not report any deaths during the trial. |
| MacLennan 1995 | Randomised partially double-blinded, placebo-controlled factorial trial. The aim was to assess the effects on the incidence of adenomas of reducing dietary fat to 25% of total calories and supplementing the diet with 25 g of wheat bran daily and a capsule of beta carotene (20 mg daily). Half the patients were assigned to each intervention, resulting in seven intervention groups and one control group. Eligibility criteria included histologic confirmation of at least one colorectal adenoma and confidence expressed by the colonoscopist that all polyps had been removed. Dietary changes were individually initiated and monitored by dietitians and research nurses. At surveillance colonoscopy, the size and location of all polyps were recorded, and their histology was later centrally reviewed. Among 424 patients who were randomly assigned in the trial, 13 were found to be ineligible upon histologic review. Among the remaining 411, complete outcome data were collected from 390 at 24 months and from 306 at 48 months. Eight participants died during the trial, but authors did not report in which arm they were. Letter to the author sent. We did not receive the answer. |
| MacPherson 1995 | Randomised clinical trial. The authors did not report any deaths during the follow-up period.                                                                                                              |
| Mader 1988 | Randomised clinical trial. The authors did not report any deaths during the follow-up period.                                                                                                                  |
| Makinson 1948 | Randomised clinical trial examining the influence of vitamin E on angina pectoris. Participants were supplemented over a period of 3 weeks. The authors did not report any deaths during the follow-up period.       |
| Malo 1986 | Randomised clinical trial. The authors did not report any deaths during the follow-up period.                                                                                                                  |
| Reference       | Description                                                                                                                                                                                                                                                                                                                                 |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Mann 1987       | A randomised, prospective, placebo-controlled trial of daily multivitamin supplementation in 101 noninstitutionalized ambulatory elderly persons (median age, 64 years). Vitamin levels were assayed at baseline, and at two and four months of supplementation. The authors did not report any deaths during the follow-up period. |
| Manzella 2001   | A double-blind randomised controlled trial; 50 patients with type 2 diabetes were assigned to treatment with vitamin E (600 mg/d) or placebo for 4 months. The possible effects of vitamin E on the cardiac autonomic nervous system, as assessed by analysis of heart rate variability, in patients with type 2 diabetes and cardiac autonomic neuropathy were investigated. |
| Margaritis 2003 | Randomised clinical trial. The authors did not report any deaths during the follow-up period.                                                                                                                                                                                                                                               |
| Marotta 2003    | The aim of this randomised clinical trial was to test the effect of antioxidants on enzymatic abnormalities and free radicals-modified DNA adducts associated with pre-malignant changes in HP-negative chronic atrophic gastritis patients. Sixty patients with and intestinal metaplasia underwent a GI endoscopy with biopsy samples for histology and for: alpha-tocopherol, malonyldialdehyde, xanthine oxidase, ornithine decarboxylase and 8-hydroxydeoxyguanosine. Patients were randomly allocated into three groups supplemented for 6 months with: vitamin E, 300 mg/day; multivitamin, 2 tablets/day, and a certified fermented papaya preparation 6 g/nocte (Immune-Age FPP, Osato Research Institute, Gifu, Japan). Ten dyspeptic patients without histological abnormalities served as control. Histological and biochemical parameters were blindly repeated at 3 and 6 months. The authors did not report any deaths during the follow-up period. |
| Martinez-Abun 2001 | Randomised clinical trial. There were no deaths during the follow-up period. Additional information was obtained through personal communication with authors.                                                                                                                                 |
| Massey 2005     | Randomised clinical trial. There were no deaths during the follow-up period. Additional information was obtained through personal communication with authors.                                                                                                                                                                                            |
| Mastaloudis 2004 | Randomised clinical trial. There were no deaths during the follow-up period. Additional information was obtained through personal communication with authors.                                                                                                                                                                                                 |
| Mathews-Roth 1972 | Randomised clinical trial. The authors did not report any deaths during the follow-up period.                                                                                                                                                                                                                                                   |
| McAuliffe 1998  | Randomised clinical trial. The authors did not report any deaths during the follow-up period.                                                                                                                                                                                                                                                   |
| McDowell 1994   | Randomised clinical trial. There were no deaths during the follow-up period. Additional information was obtained through personal communication with authors.                                                                                                                                                                                              |
| McGavin 2001    | Randomised clinical trial. The authors did not report any deaths during the follow-up period.                                                                                                                                                                                                                                                   |
| McKay 2000      | Randomised, double-blind, placebo-controlled trial to determine whether a daily multivitamin/mineral supplement can improve micronutrient status, plasma antioxidant capacity and cytokine production in healthy, free-living older adults already consuming a fortified diet. The authors did not report any deaths during the trial.                                                                 |
Meagher 2001
Randomised clinical trial. There were no deaths during the follow-up period. Additional information was obtained through personal communication with authors.

Meijer 2001
Randomised clinical trial. The authors did not report any deaths during the follow-up period.

Meltzer 1997
Randomised clinical trial. The authors did not report any deaths during the follow-up period.

Meydani 1990
Randomised double-blind, placebo-controlled trial. The effect of vitamin E supplementation on the immune response of healthy older adults was studied. Participants (n = 32) resided in a metabolic research unit and received placebo or vitamin E (800 mg dl-alpha-tocopheryl acetate) for 30 days. Alpha-tocopherol content of plasma and peripheral blood mononuclear cells, delayed-type hypersensitivity skin test, mitogen-stimulated lymphocyte proliferation, as well as interleukin (IL)-1, IL-2, prostaglandin E2, and serum lipid peroxides were evaluated before and after treatment. There were no deaths during the follow-up period. Additional information was obtained through personal communication with authors.

Meydani 1994
Randomised clinical trial. The authors did not report any deaths during the follow-up period.

Meydani 1997
Randomised, double-blind, placebo-controlled trial to determine whether long-term supplementation with vitamin E enhances in vivo, clinically relevant measures of cell-mediated immunity in healthy elderly people. There were no deaths during the follow-up period. Additional information was obtained through personal communication with authors.

Meyer 1990
A randomised, double-blind, placebo-controlled trial. To evaluate the efficacy of treatment by means of mammography as the objective and sensitive parameter, 105 women were randomly selected and entered into a double-blind, placebo-controlled crossover trial. All patients had mammographic evidence of benign breast disease. They received 600 mg of placebo and alpha-tocopherol acetate in 3-month treatment phases. Breast examinations and mammography were done, after each treatment, at approximately the same phase of the patients menstrual cycle. Of 105 women 83 completed the trial. There were no deaths during the follow-up period. Additional information was obtained through personal communication with authors.

Micheletta 2004
Randomised clinical trial. There were no deaths during the follow-up period. Additional information was obtained through personal communication with authors.

Micozzi 1992
Randomised clinical trial. The authors did not report any deaths during the follow-up period.

Miller 1997
Randomised clinical trial. The authors did not report any deaths during the follow-up period.

MIVIT 2005
A randomised, double-blind, placebo-controlled trial to test the effects of antioxidant vitamins C and E on the clinical outcome of patients with acute myocardial infarction. Eight-hundred patients (mean age 62) were randomly allocated to receive, on top of routine medication, one of two treatments: vitamin C (1000 mg/12 h infusion) followed by 1200 mg/24 h orally and vitamin E (600 mg/24 h) or matching placebo for 30 days. The trial did not meet our inclusion criteria.

Mohsenin 1987
Randomised clinical trial. The authors did not report any deaths during the follow-up period.
| Study                      | Design and Follow-up Details                                                                                                                                                                                                 |
|---------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Moller 2004               | Randomised clinical trial. The authors did not report any deaths during the follow-up period.                                                                                                                                  |
| Mosca 1997                | Randomised trial on antioxidant supplements to determine the effect of antioxidant supplementation on the susceptibility of low density lipoprotein to oxidation in patients with established cardiovascular disease. Patients with cardiovascular disease (n = 45) were randomised to (1) placebo control; (2) 400 IU of vitamin E, 500 mg of vitamin C, 12 mg of beta-carotene (mid-dose); or (3) 800 IU of vitamin E, 1,000 mg of vitamin C, 24 mg of beta-carotene (high dose) daily. Reduced susceptibility of low density lipoprotein to oxidation was estimated by an increase in lag phase (minutes). Baseline and 6- and 12-week measurements of lipoproteins and lag phase were obtained. Plasma levels of antioxidants were measured at baseline and 12 weeks. There were no deaths during the follow-up period. Additional information was obtained through personal communication with authors. |
| Mottram 1999              | Randomised clinical trial. There were no deaths during the follow-up period. Additional information was obtained through personal communication with authors.                                                                            |
| Mulholland 1993           | Randomised clinical trial. The authors did not report any deaths during the follow-up period.                                                                                                                                  |
| Mulholland 1996           | Randomised clinical trial. The authors did not report any deaths during the follow-up period.                                                                                                                                  |
| Mullan 2002               | Randomised clinical trial. There were no deaths during the follow-up period. Additional information obtained through personal communication with authors.                                                                           |
| Munoz 1985                | A randomised double-blind intervention trial was carried out in Huixian, Henan Province, People’s Republic of China, to determine whether combined treatment with retinol, riboflavin, and zinc could lower the prevalence of precancerous lesions of the oesophagus. Six-hundred and ten participants in the age group 35 to 64 were randomised to receive once a week the active treatment (15 mg [50,000 IU] retinol, 200 mg riboflavin, and 50 mg zinc) or placebo. Both at entry to the study and at the end of the treatment, 13.5 months later, the participants were examined, with an emphasis on signs of vitamin A and riboflavin deficiencies, and riboflavin, retinol, beta-carotene, and zinc levels were measured. Compliance was excellent. The final examination, on 567 (93%) participants, included oesophagoscopy and at least two biopsies. During the study, one person died, but the authors did not report in which arm this happen, and additional information was not received. |
| Munoz 2001                | Randomised clinical trial. There were no deaths during the follow-up period. Additional information was obtained through personal communication with authors.                                                                           |
| Mustad 2002               | Randomised clinical trial. The authors did not report any deaths during the follow-up period.                                                                                                                                  |
| Nelson 2003               | Randomised clinical trial. The authors did not report any deaths during the follow-up period.                                                                                                                                  |
| Nenster 1995              | Randomised clinical trial. The authors did not report any deaths during the follow-up period.                                                                                                                                  |
| Neunteufl 2000            | Randomised clinical trial. There were no deaths during the follow-up period. Additional information was obtained through personal communication with authors.                                                                           |
| Study            | Type of Study                                                                 | Details                                                                                                                                                                                                 |
|------------------|-------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Nieman 1997      | Randomised clinical trial.                                                     | The authors did not report any deaths during the follow-up period.                                                                                                                                       |
| Nieman 2002      | Randomised clinical trial.                                                     | The authors did not report any deaths during the follow-up period.                                                                                                                                       |
| Nimmagadda 1998  | This is an open-label study to assess the effect of short-term beta-carotene administration (180 mg/d with meals for 4 weeks) on the plasma human immunodeficiency virus (HIV) RNA levels and CD4+ lymphocyte counts in 21 HIV-infected patients. The trial did not meet our inclusion criteria. |
| Nyyssonen 1994   | Randomised clinical trial.                                                     | There were no deaths during the follow-up period. Additional information was obtained through personal communication with authors.                                                                           |
| O’Byrne 2000     | Randomised clinical trial.                                                     | The authors did not report any deaths during the follow-up period.                                                                                                                                       |
| Olmedilla 2002   | Randomised clinical trial.                                                     | The authors did not report any deaths during the follow-up period.                                                                                                                                       |
| Olmedilla 2003   | A randomised, double-blind, placebo-controlled trial investigated the effect of long-term antioxidant supplementation (lutein and alpha-tocopherol) on serum levels and visual performance in patients with cataracts. The authors did not report any deaths during the follow-up period. |
| Ono 1985         | Randomised clinical trial.                                                     | The authors did not report any deaths during the follow-up period.                                                                                                                                       |
| Onofrj 2002      | Randomised clinical trial testing the hypothesis that new cholinesterase inhibitors like donepezil (DPZ) may have an effect on the often abnormal P300 of patients with Alzheimer’s Disease (AD), and, therefore, that P300 recordings might simplify the evaluation of responses to cholinesterase inhibitor in patients with mild and moderate-severe AD. It evaluated 60 patients with AD: 30 patients with ‘mild’ (Mini Mental State Examination 26-19) and 30 patients with ‘moderate-severe’ (Mini Mental State Examination 18-10), according to the National Institute of Neurological and Communicative Disorders and Alzheimer’s Disease and Related Disorders Association criteria in comparison with 40 age-matched controls. All participants underwent P300 recordings and neuropsychologic examinations (Alzheimer’s Disease Assessment Scale-Cognition and Wechsler Adult Intelligence Scale) during the 6-month follow-up. The participants were divided into four groups of 15 patients each: group I DPZ (10 mg/day) and group I vitamin E (2000 IU/day) with ‘mild’ AD; group II DPZ and group II vitamin E with ‘moderate-severe’ AD and same drug dosages. Seven of 67 patients dropped out. The authors did not report any deaths during the trial. |
| Orndahl 1994     | A randomised, double-blind, placebo-controlled trial to study the effect of a combined selenium and vitamin E treatment in patients with myotonic dystrophy. Twenty-seven patients with myotonic dystrophy divided into an experimental (n = 13) and a control (n = 14) group. The experimental group was given increasing doses for 4 months up to a maximum of 1.6 mg selenium and 800 mg vitamin E daily and the control group a corresponding number of placebo tablets. The total treatment period was 2 years. Muscle strength (knee extension, knee flexion, hand-grip), maximal walking speed for 30 m, function in daily activities (disability), well-being and cognitive functioning. The authors did not report any deaths during the trial. |
| Osilesi 1991     | Randomised clinical trial.                                                     | The authors did not report any deaths during the follow-up period.                                                                                                                                       |
### (Continued)

| Reference            | Study Design                               | Details                                                                                                                                 |
|----------------------|--------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------|
| Paganelli 1992       | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |
| Pallast 1999         | A phase II, randomised, double-blind, placebo-controlled trial to study the effects of 6 month supplementation with 50 and 100 mg vitamin E on cellular immune responsiveness. The authors did not report any deaths during the trial. |
| Paolisso 1993        | A phase II, randomised, double-blind, placebo-controlled trial to study the effects of 6 months supplementation with 50 and 100 mg vitamin E on cellular immune responsiveness. The authors did not report any deaths during the trial. Ten control (healthy) participants and 15 non-insulin-dependent diabetics underwent an oral glucose-tolerance test and a euglycemic hyperinsulinemic glucose clamp before and after vitamin E supplementation (900 mg/d for 4 mo). The authors did not report any deaths during the follow-up period. |
| Paolisso 1993a       | A randomised, double-blind, placebo-controlled trial to study the effects of 6 months supplementation with 50 and 100 mg vitamin E. The authors did not report any deaths during the follow-up period. |
| Paolisso 1994        | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |
| Paolisso 1995        | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |
| Paolisso 1995a       | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |
| Paolisso 2000        | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |
| Park 2002            | Randomised clinical trial. There were no deaths during the follow-up period. Additional information was obtained through personal communication with authors. |
| Pasantes-Morale 2002 | Randomised, double blind, placebo, trial assessing the effect of the formula taurine/diltiazem/vitamin E on the progression of visual field loss in retinitis pigmentosa in 62 patients: visual field threshold values were obtained in a Humphrey Field Analyzer from center (30 degrees) and periphery (30 to 60 degrees), every 4 months during 3-year follow-up. The authors did not report any deaths during the trial. |
| Patrignani 2000      | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |
| Pearson 2004         | Randomised, double-blind, placebo-controlled trial to investigate the effect of supplementation with vitamin E for 6 weeks on bronchial hyperresponsiveness in atopic adults with asthma. Eight participants did not finish trial per protocol. The authors did not report any deaths during the trial. |
| Pellegrini 2004      | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |
| Peretz 2001          | Double blind multi-centric placebo-controlled randomised trial assessing the effects of selenium supplementation in rheumatoid arthritis. Fifty-five patients with moderate rheumatoid arthritis received during 90 days either capsules containing selenium-enriched yeast (200 microg/d) or a placebo. A total of 7 patients did not complete the trial. The authors did not report any deaths during the trial. |
| Study                  | Description                                                                                                                                                                                                 |
|-----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Peters 1993           | Randomised clinical trial conducted to determine whether daily supplementation with 600 mg vitamin C would reduce the incidence of symptoms of upper-respiratory-tract (URT) infections after participation in a competitive ultramarathon race (> 42 km). Ultramarathon runners with age-matched controls were randomly divided into placebo and experimental (vitamin C-supplemented) groups. Symptoms of URT infections were monitored for 14 days after the race. Of the 92 runners, 84 complied with all the protocol requirements. The authors did not report any deaths during the follow-up period. |
| Peters 2001           | Randomised clinical trial. There were no deaths during the follow-up period. Additional information obtained through personal communication with authors.                                                                 |
| Petersen 2001         | Randomised clinical trial. The authors did not report any deaths during the follow-up period.                                                                                                                                                                           |
| Peyser 1995           | A randomized, double-blind, placebo-controlled trial investigated the effect of high dose of vitamin E on slowing the progress of Huntington's disease. Of 81 participants 74 completed one year follow-up. There were no deaths reported during the trial. Treatment with d-alpha-tocopherol had no effect on neurologic and neuropsychiatric symptoms in the treatment group overall. The authors did not report any deaths during the follow-up period. |
| Pfeiffer 1999         | Randomised clinical trial. There were no deaths during the follow-up period. Additional information was obtained through personal communication with authors.                                                                                                                   |
| Pinkney 1999          | Randomised clinical trial. The authors did not report any deaths during the follow-up period.                                                                                                                                                                           |
| Ponz-de-Leon 1997     | Randomised clinical trial in which antioxidant vitamins or lactulose were used in an attempt to prevent the recurrence of colorectal polyps after their endoscopic removal. Authors did not report any deaths during the trial.                                                                 |
| Porkkala-S 1998       | A single-blind, placebo-controlled, randomised trial to examine the effect of 200 mg RRR-alpha-tocopheryl acetate/d on the oxidation resistance of atherogenic lipoproteins (VLDL+LDL, including intermediate-density lipoproteins) in 40 smoking men. A part of a Multiple Antioxidant Supplementation Intervention Study. The authors did not report any deaths during the trial. |
| Preziosi 1998         | Randomised clinical trial. The authors did not report any deaths during the follow-up period.                                                                                                                                                                           |
| Prieme 1997           | In a randomised placebo-controlled trial we investigated the effect of dietary supplementation with antioxidants on a biomarker of oxidative DNA damage with mechanistic relation to carcinogenesis. One hundred forty-two smoking men aged 35 to 65 years were randomly assigned to one of the following seven treatments for 2 mo: 100 mg D-alpha-tocopheryl acetate plus 250 mg slow-release ascorbic acid twice a day (n = 20), 100 mg D-alpha-tocopheryl acetate twice a day (n = 20), 250 mg ascorbic acid twice a day (n = 21), 250 mg slow-release ascorbic acid twice a day (n = 21), 30 mg coenzyme Q10 in oil three times a day (n = 20), 30 mg coenzyme Q10 as granulate three times a day (n = 20), or placebo twice a day (n = 20). The trial outcome was the urinary excretion rate of 8-oxo-7, 8-dihydro-2-deoxyguanosine (8-oxodG)-a repair product of oxidative DNA damage. The authors did not report any deaths during the trial. |
| Study                | Design                          | Results                                                                 | Additional Information |
|---------------------|---------------------------------|-------------------------------------------------------------------------|-------------------------|
| Princen 1992        | Randomised clinical trial       | There were no deaths during the follow-up period. Additional information was obtained through personal communication with authors. |                         |
| Protegente 2000     | Randomised clinical trial       | The authors did not report any deaths during the follow-up period.       |                         |
| Racek 2005          | Randomised clinical trial       | The authors did not report any deaths during the follow-up period.       |                         |
| Raitakari 2000      | Randomised clinical trial       | The authors did not report any deaths during the follow-up period.       |                         |
| Ramos 2005          | Randomised clinical trial       | The authors did not report any deaths during the follow-up period.       |                         |
| Range 2003          | Randomised clinical trial of zinc and multi-micronutrient (MMN) supplementation in pulmonary TB patients in Tanzania. A total of 499 pulmonary TB patients were included in the trial after being confirmed sputum-positive by microscopy or culture. This study did not meet our inclusion criteria. |                         |                         |
| Rasool 2003         | Randomised clinical trial aiming at establishing whether vitamin E improves arterial stiffness in post-menopausal women after 10 weeks of supplementation. Of 20 women, 3 withdrew before the end of trial. There were no deaths during the follow-up period. Additional information was obtained through personal communication with authors. |                         |                         |
| Rayment 2003        | Randomised clinical trial       | There were no deaths during the follow-up period. Additional information was obtained through personal communication with authors. |                         |
| Reaven 1994         | Randomised clinical trial       | There were no deaths during the follow-up period. Additional information was obtained through personal communication with authors. |                         |
| Reaven 1995         | Randomised clinical trial with an aim to evaluate the effect of vitamin E supplementation on the susceptibility of low-density lipoprotein (LDL) and LDL subfractions to oxidation and on protein glycation in non-insulin-dependent diabetes mellitus (NIDDM). Twenty-one men with NIDDM (HbA1c = 6-10%), ages 50-70, were randomly assigned to either 1,600 IU/day of vitamin E or placebo for 10 weeks after a 4-week placebo period. Of 21 participants, 20 completed the study. There were no deaths during the follow-up period. Additional information was obtained through personal communication with authors. |                         |                         |
| Remans 2004         | Randomised clinical trial with parallel group design to investigate the effects of a nutrient supplement, containing, among other ingredients, the omega-3 fatty acids eicosapentaenoic acid (1.4 g EPA), docosahexaenoic acid (0.211 g DHA), omega-6 fatty acid gamma-linolenic acid (0.5 g GLA), and micronutrients in patients with active rheumatoid arthritis (RA). RA patients were randomised to receive either daily liquid nutrient supplementation or placebo for 4 months. The primary end point was the change in tender joint count at 2 and 4 months. A total of 11 participants dropped out during the 4 months treatment period. The authors did not report any deaths during the trial. |                         |                         |
| Richards 1990       | Randomised clinical trial       | There were no deaths during the follow-up period. Additional information was obtained through personal communication with authors. |                         |
| Reference          | Study Description                                                                                                                                                                                                 |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Rinzler 1950       | Randomised clinical trial. Forty-one ambulatory patients with chronic chest pain and with arteriosclerotic and/or hypertensive heart disease were selected at random. Active group was supplemented with tocopherol acetate 300 mg by mouth daily for two or more months. Effects were compared to placebo group. Three patients withdrew from the study. The authors did not report any deaths during the trial. |
| Robinson 1997      | Randomised clinical trial. The authors did not report any deaths during the follow-up period.                                                                                                                                 |
| Robson 2003        | Randomised clinical trial. The authors did not report any deaths during the follow-up period.                                                                                                                                 |
| Rokitzki 1994      | Randomised clinical trial. The authors did not report any deaths during the follow-up period.                                                                                                                                 |
| Rokitzki 1994a     | Randomised clinical trial. The authors did not report any deaths during the follow-up period.                                                                                                                                 |
| Romieu 1998        | Randomised clinical trial using a double-blind cross-over design to evaluate whether acute effects of ozone on lung functions could be attenuated by antioxidant vitamin supplementation. Of 47 participants, 34 completed the trial. The authors did not report any deaths during the trial. |
| Romney 1997        | Randomised clinical trial. Women with histopathologically confirmed cervical intraepithelial neoplasia (CIN) were followed at 3-month intervals in order to evaluate the efficacy of beta-carotene to cause regression of CIN. Of ninety-eight patients randomised, 69 had an outcome assessment. Authors did not report any deaths during the 9 months trial. |
| Roncucci 1993      | Randomised clinical trial evaluating the effect of antioxidant vitamins or lactulose on the recurrence rate of adenomatous polyps. After polypectomy, 255 individuals were randomised into three groups. Group 1 was given vitamin A (30,000 IU/day), vitamin C (1 g/day), and vitamin E (70 mg/day); group 2 was given lactulose (20 g/day); group 3 received no treatment. Forty-six participants had to be excluded because the histologic diagnosis was not consistent with adenoma. The remaining 209 individuals were included in the analysis according to the 'intention to treat' criterion, though 34 did not adhere to the scheduled treatment, or were lost during the follow-up. The participants were followed at regular intervals for an average of 18 months. Polyps recurring before one year from index colonoscopy were considered missed by the endoscopist. Two people died during the trial, but the authors did not report in which arm they were. |
| Roodenburg 2000    | Randomised clinical trial. There were no deaths during the follow-up period. Additional information was obtained through personal communication with authors.                                                                                   |
| Rossig 2001        | Randomised clinical trial. The authors did not report any deaths during the follow-up period.                                                                                                                                 |
| Sacheck 2003       | Randomised clinical trial. The authors did not report any deaths during the follow-up period.                                                                                                                                 |
| Salonen 1991       | Randomised clinical trial. The authors did not report any deaths during the follow-up period.                                                                                                                                 |
| Samet 2001         | Randomised clinical trial. There were no deaths during the follow-up period. Additional information was obtained through personal communication with authors.                                                                     |
| Study Year     | Study Description                                                                 |
|---------------|-----------------------------------------------------------------------------------|
| Samman 1997   | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |
| Sampson 2001  | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |
| Sankaranarayana 1997 | Randomised clinical trial evaluating the chemopreventive potential of either vitamin A alone or beta carotene alone in people with oral leukoplakia in Kerala, India. The 160 fishermen and women with oral precancerous lesions were randomised to receive oral vitamin A (retinyl acetate 300,000 IU/week x 12 months, n = 50), or beta carotene (360 mg/week x 12 months, n = 55), or placebo (n = 55). Blood, saliva and urine samples were collected at baseline and at exit to study serum micronutrients and mutagenicity assays. Biopsies of the mucosal lesions at entry were performed for histopathological exclusion of malignancy. The patients were examined once every 2 months to establish clinical response of lesions and toxicity, if any. The results are based on 43 compliant participants on placebo, 42 on vitamin A and 46 on beta carotene. The authors did not report any deaths during the trial. |
| Schachter 1982 | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |
| Schlebusch 2000 | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |
| Schneider 2003 | Randomised clinical trial. There were no deaths during the follow-up period. Additional information was obtained through personal communication with authors. |
| Schorah 1981 | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |
| Schroder 2001 | Randomised clinical trial. There were no deaths during the follow-up period. Additional information was obtained through personal communication with authors. |
| Schutte 2004 | Randomised clinical trial. There were no deaths during the follow-up period. Additional information was obtained through personal communication with authors. |
| Scott 1998 | Randomised clinical trial trying to determine whether the decline in selenium intake and selenium status in men in the West of Scotland might be a contributory factor to male subfertility. Two semen samples were collected from patients attending a subfertility clinic, and those patients with samples showing reduced motility were invited to participate in an ethically approved double-blind clinically controlled trial with informed consent. Sixty-nine patients were recruited and received either placebo, selenium alone, or selenium plus vitamins A, C and E daily for 3 months. A further semen sample was collected at the end of the trial. Plasma selenium status was determined at the beginning and end of the trial period, as was total sperm density and motility. Sixty-four of sixty-nine participants completed the study. The authors did not report any deaths during the trial. |
| Scott 2005 | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |
| SECURE 2001 | Randomised clinical trial with a prospective, double-blind, 3x2 factorial design trial. The Study to Evaluate Carotid Ultrasound changes in patients treated with ramipril and vitamin E (SECURE) was a substudy of the Heart Outcomes Prevention Evaluation (HOPE) trial, that evaluated the effects of long-term treatment |
with the angiotensin-converting enzyme inhibitor ramipril and vitamin E on atherosclerosis progression in high-risk patients.

| Study            | Design                     | Findings                                                                 |
|------------------|----------------------------|---------------------------------------------------------------------------|
| Seppanen 2000    | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |
| Serwin 2003      | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |
| Shafat 2004      | Randomised clinical trial. There were no deaths during the follow-up period. Additional information was obtained through personal communication with authors. |
| Shahar 2004      | Randomised clinical trial. There were no deaths during the follow-up period. Additional information was obtained through personal communication with authors. |
| Shriqui 1992     | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |
| Simon-Schnass 1990 | Randomised clinical trial. There were no deaths during the follow-up period. Additional information was obtained through personal communication with authors. |
| Simone 2002      | Randomised clinical trial. There were no deaths during the follow-up period. Additional information was obtained through personal communication with authors. |
| Simons 1996      | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |
| Simons 1999      | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |
| Singh 1992       | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |
| Singh 2002       | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |
| Sisto 1995       | Randomised clinical trial. Eighty-one patients with coronary artery disease were randomised into four study groups: group 1 (n = 20) patients had stable disease and received oral vitamin E for 4 weeks, and vitamin C and allopurinol 2 days before and 1 day after coronary artery bypass grafting. Group 2 (n = 25) consisted of their controls. Group 3 patients (n = 17) had more unstable disease and received the same medications as group 1, except that vitamin E was given only 2 days before the operation. Group 4 (n = 19) was their controls. This trial did not meet our inclusion criteria. |
| SKICAP S/B 1997  | Randomised clinical trial to examine the effect of retinol and isotretinoin on the incidence of non-melanoma skin cancer in high-risk participants. Participants were randomly assigned to receive oral retinol (25,000 units), isotretinoin (5 mg to 10 mg), or placebo supplementation daily for 3 years. There were no deaths during the trial. Additional information was obtained through personal communication with authors. |
| Skyrme-Jones 2000 | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |
| Spiller 1985     | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |
| Reference          | Type of Study                                                                 | Findings/Details                                                                 |
|--------------------|-------------------------------------------------------------------------------|---------------------------------------------------------------------------------|
| Stampfer 1988      | Randomised clinical trial.                                                     | There were no deaths during the follow-up period. Additional information was    |
|                    |                                                                               | obtained through personal communication with authors.                          |
| Stark 1985         | Observational study in attempt to prevent the senile degeneration of the macula | Treatment with cosaldon A+E.                                                    |
| Steck-Scott 2004   | Randomised clinical trial.                                                     | Authors did not report any deaths during the follow-up period.                   |
| Steinberg 1998     | Randomised clinical trial.                                                     | There were no deaths during the follow-up period. Additional information was    |
|                    |                                                                               | obtained through personal communication with authors.                          |
| Steiner 1995       | Randomised clinical trial with 100 patients with transient ischaemic attacks,  | Participants were randomly distributed into two groups; one receiving 200,000 IU   |
|                    | minor strokes, or residual ischaemic neurologic deficits and comparing the    | vitamin A per week (0.14 mg/kg body wt/per day) for 6 months, and the other    |
|                    | effects of aspirin plus vitamin E [0.4 g (400 IU)/d; n = 52] with aspirin     | receiving placebo capsules. There were deaths, but in which arm it is not       |
|                    | alone (325 mg; n = 48). The patients received the trial medication for 2      | reported. The authors did not answer to our requests for additional information. |
|                    | years or until they reached a termination point. The authors did not report   |                                                                                  |
|                    | any deaths during the trial.                                                   |                                                                                  |
| Stich 1986         | Randomised clinical trial.                                                     | The authors did not report any deaths during the follow-up period.               |
| Stich 1988         | Randomised clinical trial.                                                     | A short-term intervention trial of vitamin A therapy. Participants were randomly  |
|                    |                                                                               | distributed into two groups; one receiving 200,000 IU vitamin A per week (0.14   |
|                    |                                                                               | mg/kg body wt/per day) for 6 months, and the other receiving placebo capsules.   |
|                    |                                                                               | There were deaths, but in which arm it is not reported. The authors did not     |
|                    |                                                                               | answer to our requests for additional information.                              |
| Stone 2005         | In a randomised clinical trial, 300 patients with stable coronary disease, a  | Positive exercise treadmill test, 48-hour ambulatory ECG with > or =1 episode of |
|                    |                                                                               | ischemia, and fasting total cholesterol of 180 to 250 mg/dL were assigned to    |
|                    |                                                                               | 1-year treatment with intensive atorvastatin to reduce LDL to < 80 mg/dL (n=96), |
|                    |                                                                               | intensive atorvastatin to reduce LDL to <80 mg/dL plus antioxidant vitamins C   |
|                    |                                                                               | (1000 mg/d) and E (800 mg/d) (n = 101), or diet and low-dose lovastatin, if     |
|                    |                                                                               | needed, to reduce LDL to <130 mg/dL (n = 103; control group). Ischemia end      |
|                    |                                                                               | points, including ambulatory ECG monitoring and exercise treadmill testing, and  |
|                    |                                                                               | endothelial assessment using brachial artery flow-mediated dilation were        |
|                    |                                                                               | obtained at baseline, and at 6 and 12 months. There were no deaths during the    |
|                    |                                                                               | follow-up period. Additional information was obtained through personal        |
|                    |                                                                               | communication with authors.                                                    |
| Studinger 2004     | Randomised clinical trial.                                                     | The authors did not report any deaths during the follow-up period.               |
| Subakir 2000       | Randomised clinical trial.                                                     | The authors did not report any deaths during the follow-up period.               |
| Subudhi 2004       | Randomised clinical trial.                                                     | The authors did not report any deaths during the follow-up period.               |
| Sumida 1997        | Randomised clinical trial.                                                     | The authors did not report any deaths during the follow-up period.               |
| Sureda 2004        | Randomised clinical trial.                                                     | The authors did not report any deaths during the follow-up period.               |
| Surmen-Gur 1999    | Randomised clinical trial.                                                     | The authors did not report any deaths during the follow-up period.               |
| Study Year | Description |
|------------|-------------|
| Tahir 2005 | Randomised clinical trial to determine the impact of the combination of vitamins C and E or vitamin C only on serum levels of cell adhesion molecules and C-reactive protein in patients with chronic degenerative AS, with or without concomitant coronary artery disease. One hundred patients with asymptomatic or mildly symptomatic moderate AS were randomised in 2:2:1 format in an open-label trial. Forty-one patients received vitamin E (400 IU) and vitamin C (1000 mg) daily, 39 patients received vitamin C (1000 mg) only, and 20 patients were followed as controls. The authors did not report any deaths during the trial. |
| Tardif 1997 | Randomised clinical trial. One month before angioplasty, 317 patients were randomly assigned to receive one of four treatments: placebo, probucol (500 mg), multivitamins (30,000 IU of beta carotene, 500 mg of vitamin C, and 700 IU of vitamin E), or both probucol and multivitamins—all given twice daily. Patients were treated for four weeks before and six months after angioplasty. The patients received an extra 1000 mg of probucol, 2000 IU of vitamin E, both probucol and vitamin E, or placebo 12 hours before angioplasty, according to their treatment assignments. Base-line and follow-up angiograms were interpreted by blinded investigators using a quantitative approach. This trial did not meet our inclusion criteria. |
| Tarng 2004 | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |
| Tarp 1985 | Randomised clinical trial assessing a possible antirheumatic effect of selenium. Forty patients with active RA were included in a 6-month double-blind clinical study of selenium versus placebo. The patients in the selenium group were given daily supplements of 256 micrograms selenium in selenium-enriched yeast. Although concentrations of selenium in serum and erythrocytes increased considerably, no significant antirheumatic effect of selenium could be demonstrated. All patients completed the trial. |
| Tauler 2002 | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |
| Tessier 1995 | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |
| Thomson 1988 | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |
| Title 2000 | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |
| Tofler 2000 | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |
| Tolonen 1985 | Randomised clinical trial. Sodium selenate (8 mg/d, organic selenium (50 microg/d) and d-alpha-tocopherol acetate (400 mg/d) were administered for 1 year to 15 geriatric patients. Fifteen comparable controls received placebo. The mean age of both groups was 76 years. There were no deaths during the follow-up period. |
| Tousoulis 2003 | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |
| Trebble 2003 | Randomised clinical trial. The authors did not report any deaths during the follow-up period. |
| Trebble 2005 | Randomised clinical trial. There were no deaths during the follow-up period. Additional information obtained through personal communication with authors. |
| Reference          | Study Design                      | Description                                                                                     |
|--------------------|-----------------------------------|-------------------------------------------------------------------------------------------------|
| Trenga 2001        | Randomised clinical trial.        | The authors did not report any deaths during the follow-up period.                               |
| Tsai 1978          | Randomised clinical trial         | Examining the effect of megavitamin supplementation in healthy college student volunteers. Two hundred-two participants were randomly assigned to either of the two treatment groups (vitamin E 600 IU and placebo) for a period of four weeks. The authors did not report any deaths during the trial. |
| Tutunçu 1998       | Randomised clinical trial.        | The authors did not report any deaths during the follow-up period.                               |
| Uden 1990          | Randomised clinical trial.        | In a 20-week double-blind double-dummy cross-over trial, active treatment was given as two types of tablets providing daily doses of 600 micrograms organic selenium, 9000 IU beta carotene, 0.54 g vitamin C, 270 IU vitamin E and 2 g methionine. Of 28 patients enrolled, 20 adhered to the full protocol (idiopathic chronic 8, alcoholic chronic 7, idiopathic acute 5). Of 28 patients, 23 completed the trial. The authors did not report any deaths during the trial. |
| Upritchard 2000    | Randomised clinical trial.        | There were no deaths during the follow-up period. Additional information was obtained through personal communication with authors. |
| Upritchard 2003    | Randomised clinical trial.        | The authors did not report any deaths during the follow-up period.                               |
| Van Amsterdam 2005 | Randomised clinical trial.        | The authors did not report any deaths during the follow-up period.                               |
| Van Gossum 1995    | Randomised clinical trial.        | The authors did not report any deaths during the follow-up period.                               |
| Van Hoydonck 2004  | Randomised clinical trial.        | The authors did not report any deaths during the follow-up period.                               |
| Van Poppel 1994    | Randomised clinical trial.        | The authors did not report any deaths during the follow-up period.                               |
| Van Rhijn 1990     | Randomised clinical trial to evaluate dietary supplementation with compounds containing zinc and selenium, as these elements are reduced in brain tissues in Alzheimer's disease, and with fatty acids, as compensation for the putative reduction in antioxidant activity. Thirty-six participants with early dementia of Alzheimer's type were randomly allocated to evening primrose oil/zinc/selenium or olive oil treatment for 20 weeks, and 30 completed the trial. Four participants were excluded from the analysis. There were no deaths during the follow-up period. Additional information was obtained through personal communication with authors. |
| Van Straten 2002   | Randomised clinical trial.        | The authors did not report any deaths during the follow-up period.                               |
| Van Tits 2003      | Randomised clinical trial.        | The authors did not report any deaths during the follow-up period.                               |
| Vannas 1958        | This is not a randomised clinical trial. A clinico-pathological investigation; an attempt to cure the atherosclerotic changes seen in the fundus and affecting vision, and to compare the results achieved by different methods of treatment inclusive of placebo. |
| Study                          | Design                      | Outcome Description                                                                                                                                                                                                 |
|-------------------------------|-----------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Vasankari 1997                | Randomised clinical trial.  | The authors did not report any deaths during the follow-up period.                                                                                                                                                  |
| Vasankari 1998                | Randomised clinical trial.  | The authors did not report any deaths during the follow-up period.                                                                                                                                                  |
| Vega-Lopez 2004               | Randomised clinical trial.  | The authors did not report any deaths during the follow-up period.                                                                                                                                                  |
| Vela 2000                     | Randomised clinical trial.  | The authors did not report any deaths during the follow-up period.                                                                                                                                                  |
| Venn 2003                     | Randomised clinical trial.  | The authors did not report any deaths during the follow-up period.                                                                                                                                                  |
| Verret 2005                   | Randomised clinical trial.  | Among 121 men and women chronically exposed to arsenic in drinking water was conducted in rural Bangladesh. Participants were randomised to one of four treatment arms: vitamin E, selenium, vitamin E and selenium (combination), or placebo and were treated for 6 months. The aim of the trial was to determine whether supplementation of vitamin E (alpha-tocopherol), selenium (L-selenomethionine), or their combination improves arsenical skin lesions. The authors did not report any deaths during the trial. |
| Vertrugno 2001                | Randomised clinical trial.  | To evaluate the effect of a high dose vitamin A and E supplementation on corneal re-epithelialisation time, visual acuity and haze following photorefractive keratectomy (PRK). Two groups of 20 patients who underwent myopic PRK were supplemented with either 25 000 IU retinol palmitate and 230 mg alpha tocopheryl nicotinate or a placebo. Clinical outcomes were evaluated up to 360 days. This trial did not meet our inclusion criteria. |
| Viscovich 2004                | Randomised clinical trial.  | The authors did not report any deaths during the follow-up period.                                                                                                                                                  |
| Volkovova 2005                | Randomised clinical trial.  | The authors did not report any deaths during the follow-up period.                                                                                                                                                  |
| von Herbay 1997               | Randomised clinical trial.  | Using a double-blind cross-over design to evaluate whether treatment of hepatitis C patients refractory to alpha-interferon therapy with high doses of vitamin E (2 x 400 IU RRR-alpha-tocopherol/day) for 12 weeks improves the aminotransferase status. This trial did not meet our inclusion criteria. |
| Wander 1996                   | Randomised clinical trial.  | The authors did not report any deaths during the follow-up period.                                                                                                                                                  |
| Watanabe 1997                 | Randomised clinical trial.  | The authors did not report any deaths during the follow-up period.                                                                                                                                                  |
| Watanabe 1998                 | Randomised clinical trial.  | The authors did not report any deaths during the follow-up period.                                                                                                                                                  |
| Watson 1991                   | Randomised clinical trial.  | The effects of various doses (0, 15, 30, 45, and 60 mg/day) of supplementary beta-carotene were evaluated. The percentage of lymphoid cells with surface markers for T-helper and natural killer (NK) cells and cells with interleukin 2 (IL-2) and transferrin receptors were significantly and substantially increased in peripheral blood mononuclear cells collected from older human adult volunteers after supplementation with greater than or equal to 30 mg beta-carotene/day for 2 months. There were no deaths during the trial. |
| Reference       | Description                                                                                                                                                                                                 |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Welch 1999      | Randomised clinical trial. There were no deaths during the follow-up period. Additional information was obtained through personal communication with authors.                                                             |
| Wen 1997        | Randomised clinical trial. The effect of 4 weeks pharmacological supplementation with vitamin C 1 g day on copper induced LDL oxidation and lipid peroxidation. Blood samples were obtained at baseline and at the end of 4 weeks supplementation from 11 healthy non-smokers and also from nine control subjects. The authors did not report any deaths during the trial. |
| Wen 1999        | Randomised clinical trial. The authors did not report any deaths during the follow-up period.                                                                                                                                 |
| Wenzel 1993     | Quasi-randomised clinical study including 56 patients suffering from acute alcohol hepatitis. Patients were randomized using the date of birth. This study was originally included in our JAMA review but during assessment of the review we realized our mistake. |
| Werninghaus 1994| Randomised clinical trial. The authors did not report any deaths during the follow-up period.                                                                                                                                 |
| Wesnes 2003     | Randomised clinical trial. There were no deaths during the follow-up period. Additional information was obtained through personal communication with authors.                                                             |
| Wijnen 2002     | Randomised clinical trial to examine the effect of antioxidants on the activation and sequestration of white blood cells and muscle injury during infra-abdominal aortic aneurysm repair. Forty-two patients undergoing elective infrarenal aneurysm repair were randomised to either standard therapy (22 patients) or standard therapy with additional multiantioxidant supplementation (20 patients). Vitamin E and C, allopurinol, N-acetylcysteine, and mannitol was administered perioperatively. White blood cell count, serum creatine kinase, aspartateaminotransferase, lactate, and lipofuscine were measured. This trial did not meet our inclusion criteria. |
| Willett 1983     | Randomised clinical trial. The authors did not report any deaths during the follow-up period.                                                                                                                                 |
| Willett 1984     | Randomised clinical trial. There were no deaths during the follow-up period. Additional information was obtained through personal communication with authors.                                                             |
| Williams 2001   | Randomised clinical trial. The authors did not report any deaths during the follow-up period.                                                                                                                                 |
| Winkler 2005    | Randomised clinical trial. The authors did not report any deaths during the follow-up period.                                                                                                                                 |
| Wittenborg 1998 | In a randomised clinical trial comparison the antiphlogistic and analgetic efficacy of high-dosed vitamin E (3 x 400 mg RRR-alpha-Tocopherolacetat/d) versus diclofenac-sodium has been investigated in hospitalized patients with established chronic rheumatoid arthritis. After 3 weeks of treatment, the vitamin E group (n = 42) as well as the diclofenac group (n = 43) showed a significant improvement of all assessed clinical parameters. There were no deaths during the trial. |
| Wolters 2005     | Randomised clinical trial. The authors did not report any deaths during the follow-up period.                                                                                                                                 |
| Study                                      | Description                                                                                                                                                                                                 |
|-------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Wood 1999                                 | Randomised clinical trial evaluated immunological changes in free-living, healthy aged humans (57 to 84 years of age) given a placebo, beta-carotene (45 mg/day), and/or selenium (400 microg/day) supplement for 6 months and after 2 months of discontinuation. Peripheral blood lymphocytes were evaluated and subtyped using flow cytometry. Natural killer (NK) cell cytotoxicity was determined by a fluorescent method. Plasma diene conjugates were assessed to evaluate changes in oxidative stress. Of 45 participants, 10 withdrew from the trial. There were no deaths during the follow-up period. Additional information was obtained through personal communication with authors. |
| Woodside 1999                             | Randomised clinical trial. There were no deaths during the follow-up period. Additional information was obtained through personal communication with authors.                                                                                                    |
| Wu 2004                                   | Randomised clinical trial. The authors did not report any deaths during the follow-up period.                                                                                                                                                                           |
| Wu 2004                                   | Randomised clinical trial. The authors did not report any deaths during the follow-up period.                                                                                                                                                                           |
| Xia 2005                                  | Randomised clinical trial in a selenium-deficient population in China to assess the requirement for selenium as selenite and as selenomethionine. One-hundred-twenty participants with an average selenium intake of 10 mug/d were randomly assigned and administered tablets containing no selenium or amounts as high as 66 mug Se/d for 20 wk. Plasma was sampled before supplementation and at 4-wk intervals during supplementation and was assayed for the 2 plasma selenoproteins, glutathione peroxidase and selenoprotein P. There were no deaths during the follow-up period. Additional information was obtained through personal communication with authors. |
| Xu 1992                                   | Randomised clinical trial. The authors did not report any deaths during the follow-up period.                                                                                                                                                                           |
| Yu 1990                                   | Randomised clinical trial. The authors did not report any deaths during the follow-up period.                                                                                                                                                                           |
| Yu 1991                                   | The purpose of this trial was to evaluate the effect of selenium (Se) in the prevention of human primary liver cancer. Three intervention trials were conducted among the residents at high risk to primary liver cancer (PLC) in Qidong county, Jiang-su province, the People’s Republic of China. This area has the second highest rate of PLC in China. One trial was undertaken among the general population in a township with supplement of table salt fortified with 15 ppm anhydrous sodium selenite (Se-salt) for 5 y and the other four townships with similar PLC incidence rate served as the controls using normal table salt. The second trial was undertaken among hepatitis B virus surface antigen carriers (HBVsAg+) receiving supplement of 200 micrograms Se in form of selenized yeast (Se-yeast) daily vs placebo for 4 y. The third trial was carried out in members of families with high PLC incidence using Se-yeast (200 micrograms of Se daily) versus placebo for 2 years. |
| Yu 1997                                   | An intervention trial was undertaken among the general population of 130,471. Individuals in five townships were involved for observation of the preventive effect of Se. The 8-year follow-up data showed reduced PLC incidence by 35.1% in selenized table salt supplemented versus the nonsupplemented population. On withdrawal of Se from the treated group, PLC incidence rate began to increase. However, the inhibitory response to HBV was sustained during the 3-year cessation of treatment. The clinical study among 226 hepatitis B surface antigen (HBsAg)-positive persons provided either 200 micrograms of Se in the form of selenized yeast tablet or an identical placebo of yeast tablet daily for 4 years. |
Zaridze 1993
Randomised clinical trial. This intervention trial carried out in Uzbekistan (former USSR) in an area with a high incidence of oral and esophageal cancer involved random allocation of 532 men, 50 to 69 years old, with oral leukoplakia and/or chronic esophagitis to one of four arms in a double-blind, two-by-two factorial design, with active arms defined by the administration of (a) riboflavin; (b) a combination of retinol, beta-carotene, and vitamin E; or (c) both. Weekly doses were 100,000 IU of retinol, 80 mg of vitamin E, and 80 mg of riboflavin. The dose of beta-carotene was 40 mg/d. Men in the trial were followed for 20 months after randomisation. The aim of the trial was to determine whether treatment with these vitamins or their combination could affect the prevalence of oral leukoplakia and/or protect against progression of oral leukoplakia and esophagitis, conditions considered to be precursors of cancer of the mouth and esophagus. Among 519 men, 32 gave up taking supplements. The authors did not report any deaths during the trial.

Zhu 2002
Randomised, double-blind, placebo-controlled clinical trial with an aim to evaluate the roles of folic acid and beta-carotene in the chemoprevention of gastric and other gastrointestinal (GI) cancers. A total of 216 patients with atrophic gastritis were randomly assigned to one of the four groups: (1) folate (FA, 20 mg per day plus vitamin B12 1 mg, intramuscularly, per month for one year, then 20 mg two times a week plus 1 mg per three months for the next year); (2) natural beta-carotene (N-betaC, 30 mg per day for first year, then 30 mg two times a week for the next); (3) synthetic beta-carotene (S-betaC, administered as in N-betaC); and (4) placebo. Follow-ups continued from 1994 to 2001. The authors did not report any deaths during the trial.

Zielinski 1978
Not a randomised clinical trial. Cosaldon A+E (containing vitamin A and vitamin E) was applied in 61 patients, most of whom presented severe vascular degenerative retinochoroidal circulatory disorders and chronic glaucoma.

Zimmermann 1997
In this study the effect of antioxidant therapy with sodium selenite was investigated in patients with systemic inflammatory response syndrome and multiple organ failure. Forty patients were included and observed over a period of 28 days. This study did not meet our inclusion criteria.

Zollinger 1999
Randomised clinical trial. The authors did not report any deaths during the follow-up period.

PPT: Polyp Prevention Trial
wk = week

Characteristics of ongoing studies  [ordered by study ID]

| Trial name or title | Australian Prostate Cancer Prevention Trial Using Selenium (APPOSE). Randomised double-blind, placebo-controlled trial with parallel group design. |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------|

Methods
### APPOSE 2001 (Continued)

| Participants | Country: Australia.  
| Number of participants randomised: 6000 men who are at increased risk because of a first-degree relative with prostate cancer. |
| Interventions | Participants will be supplemented with selenium. |
| Outcomes | The primary outcome measure is incidence of prostate cancer. |
| Starting date | 2001 |
| Contact information | Anthony J. Costello, MD, Level 1, 77 Victoria Parade, Fitzroy, Melbourne 3065, Australia |
| Notes | |

### PHS II 2000

| Trial name or title | Physicians' Health Study II (PHS II). Randomised double-blind, placebo-controlled trial with two-by-two-by-two-by-two factorial design. |
| Methods | |
| Participants | Country: United States of America.  
| Number of participants randomised: 15,000 US male physicians, aged 55 years and older.  
| Inclusion criteria: willing and eligible physicians to take part in this trial, including all willing and eligible participants from Physician Health Study I. |
| Interventions | Physicians' Health Study II utilized a two-by-two-by-two-by-two factorial design to test alternate day beta-carotene, alternate day vitamin E, daily vitamin C, and a daily multivitamin. During the first half of 2003 the beta-carotene component of the ongoing Physicians' Healthy Study II has been terminated. It continues to examine a multivitamin, vitamin C, and vitamin E. |
| Outcomes | The primary outcome measures are the incidence of total and prostate cancer, cardiovascular and eye disease. |
| Starting date | 1999 |
| Contact information | Charles H. Hennekens MD  
1415 W. Camino Real, Boca Raton, FL 33486, United States of America |
| Notes | |
### SELECT 2003

| Trial name or title | The selenium and vitamin E cancer prevention trial, SELECT. Randomised double-blind, placebo-controlled trial with two-by-two factorial design. |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Methods             | Country: United States of America. Number of participants randomised: 32,400 males, aged 50 years or older. Inclusion criteria: age > 55 years for Caucasians and > 50 years for African-Americans, digital rectal examination not suspicious for prostate cancer, total serum prostate specific antigen < 4.0 ng/ml, no prior history of prostate cancer or high-grade prostatic intraepithelial neoplasia, no anticoagulation therapy, except low-dose aspirin, normal blood pressure (systolic blood pressure < 150 mm Hg and diastolic blood pressure < 90 mm Hg), willing to restrict supplementation of selenium and vitamin E during participation. |
| Participants        | Participants were randomly assigned to receive either 200 µg of 1-selenomethionine, 400 mg of racemic alpha-tocopherol, and an optional multivitamin containing no selenium or vitamin E. The racemic mix of alpha-tocopherol will include both the d- and l-isomers. Participants will be divided in four group according to two-by-two factorial design: group 1: placebo (n = 8100); group 2: vitamin E (n = 8100); group 3: selenium (n = 8100); group 4: vitamin E and selenium (n = 8100). |
| Interventions       | The primary outcome measure is the clinical incidence of prostate cancer as determined by a clinical diagnostic work-up, including yearly digital rectal examination and serum prostate specific antigen level. Secondary outcome measures will include prostate cancer-free survival, all cause mortality, and the incidence and mortality of other cancers and diseases potentially impacted by the chronic use of selenium and vitamin E. Other trial objectives will include periodic quality of life assessments, assessment of serum micronutrient levels and prostate cancer risk, and studies of the evaluation of biological and genetic markers with the risk of prostate cancer. |
| Outcomes            | 2001 |
| Starting date       | Contact information | Contact information: Eric A. Klein, Section of Urologic Oncology, Department of Urology, Cleveland Clinic Foundation, Cleveland, OH, USA Tel.: +1-216-444-5591; Fax: +1-216-445-3532, e-mail address: klein@ccf.org. |
| Notes               | |
## WACS 1995

| Trial name or title | The Women's Antioxidant and Cardiovascular Study (WACS). Randomised double-blind, placebo-controlled secondary prevention trial. |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------|
| Methods             |                                                                                                                                  |
| Participants        | Country: United States of America  
|                     | Number of participants randomised: 8000 females, aged 40 years and older.  
|                     | Inclusion criteria: preexisting cardiovascular disease.                                                                 |
| Interventions       | The Women's Antioxidant and Cardiovascular Study utilized two-by-two factorial design. Participants were randomly assigned to receive: beta-carotene, 50 mg, (Lurotin, supplied by BASF) or placebo on alternate days; and/or natural vitamin E, 600 IU (alpha-tocopherol, supplied by Henkel Corporation), or placebo on alternate days; and/or vitamin C 500 mg, (supplied by BASF) or placebo daily. |
| Outcomes            | The composite primary outcome measure is nonfatal myocardial infarction, nonfatal stroke, coronary revascularization procedures defined as coronary artery bypass or angioplasty, and cardiovascular disease mortality. |
| Starting date       | 1995                                                                                                                           |
| Contact information | JoAnn Manson, MD, DrPH, 900 Commonwealth Avenue East, Boston, MA 02215-1204, United States of America                         |
| Notes               |                                                                                                                                  |

WACS: The Women's Antioxidant and Cardiovascular Study  
PHS II: Physicians’ Health Study II  
SELECT: The selenium and vitamin E cancer prevention trial
## DATA AND ANALYSES

### Comparison 1. Antioxidants versus placebo/no intervention

| Outcome or subgroup title | No. of studies | No. of participants | Statistical method                      | Effect size |
|---------------------------|----------------|---------------------|-----------------------------------------|-------------|
| 1 Mortality in trials with a low or high risk of bias | 67 | 232550 | Risk Ratio (M-H, Random, 95% CI) | 1.02 [0.99, 1.06] |
| 1.1 Trials with low risk of bias | 47 | 180938 | Risk Ratio (M-H, Random, 95% CI) | 1.05 [1.02, 1.08] |
| 1.2 Trials with high risk of bias | 20 | 51612 | Risk Ratio (M-H, Random, 95% CI) | 0.92 [0.85, 0.99] |
| 2 Mortality in primary and secondary prevention trials with a low or high risk of bias | 67 | 232550 | Risk Ratio (M-H, Random, 95% CI) | 1.02 [0.99, 1.06] |
| 2.1 Primary prevention trials with a low risk of bias | 14 | 126407 | Risk Ratio (M-H, Random, 95% CI) | 1.05 [0.98, 1.12] |
| 2.2 Primary prevention trials with a high risk of bias | 7 | 38032 | Risk Ratio (M-H, Random, 95% CI) | 0.95 [0.85, 1.06] |
| 2.3 Secondary prevention trials with a low risk of bias | 33 | 54531 | Risk Ratio (M-H, Random, 95% CI) | 1.03 [0.98, 1.08] |
| 2.4 Secondary prevention trials with a high risk of bias | 13 | 13580 | Risk Ratio (M-H, Random, 95% CI) | 0.89 [0.80, 1.00] |
| 3 Mortality after excluding trials administrating extra supplements in the antioxidant group | 56 | 197509 | Risk Ratio (M-H, Random, 95% CI) | 1.03 [1.00, 1.07] |
| 3.1 Trials with low risk of bias | 39 | 175683 | Risk Ratio (M-H, Random, 95% CI) | 1.05 [1.02, 1.09] |
| 3.2 Trials with high risk of bias | 17 | 21826 | Risk Ratio (M-H, Random, 95% CI) | 0.91 [0.82, 1.00] |
| 4 Mortality after excluding trials with extra supplements for both intervention groups | 58 | 229622 | Risk Ratio (M-H, Random, 95% CI) | 1.02 [0.99, 1.06] |
| 4.1 Trials with low risk of bias | 43 | 179252 | Risk Ratio (M-H, Random, 95% CI) | 1.05 [1.01, 1.08] |
| 4.2 Trials with high risk of bias | 15 | 50570 | Risk Ratio (M-H, Random, 95% CI) | 0.93 [0.86, 1.00] |
| 5 Mortality after excluding factorial trials with potential confounding | 47 | 55939 | Risk Ratio (M-H, Random, 95% CI) | 1.01 [0.94, 1.09] |
| 5.1 Low-bias risk trials | 34 | 48369 | Risk Ratio (M-H, Random, 95% CI) | 1.11 [1.05, 1.17] |
| 5.2 High-bias risk trials | 13 | 7570 | Risk Ratio (M-H, Random, 95% CI) | 0.84 [0.73, 0.98] |
| 6 Mortality after excluding factorial trials with potential confounding and trials with extra supplements | 33 | 49719 | Risk Ratio (M-H, Random, 95% CI) | 1.01 [0.91, 1.12] |
| 6.1 Low-bias risk trials | 24 | 42960 | Risk Ratio (M-H, Random, 95% CI) | 1.12 [1.07, 1.19] |
| 6.2 High-bias risk trials | 9 | 6759 | Risk Ratio (M-H, Random, 95% CI) | 0.84 [0.73, 0.98] |
| 7 Mortality after excluding trials with any potential confounding | 19 | 27889 | Risk Ratio (M-H, Random, 95% CI) | 1.16 [1.09, 1.23] |
| Trial Type                                      | Trials | Risk Ratio (M-H, Random, 95% CI) |
|------------------------------------------------|--------|----------------------------------|
| **Mortality in beta-carotene trials with a low or high risk of bias** |        |                                  |
| 8 Mortality in beta-carotene trials            | 25     | 1.02 [0.97, 1.08]                |
| 8.1 Trials with a low risk of bias             | 20     | 1.05 [1.00, 1.10]                |
| 8.2 Trials with a high risk of bias            | 5      | 0.81 [0.62, 1.07]                |
| **Mortality in vitamin A trials with a low or high risk of bias** |        |                                  |
| 9 Mortality in vitamin A trials                | 15     | 1.05 [0.93, 1.19]                |
| 9.1 Trials with a low risk of bias             | 10     | 1.09 [0.93, 1.28]                |
| 9.2 Trials with a high risk of bias            | 5      | 0.96 [0.84, 1.08]                |
| **Mortality in vitamin C trials with a low or high risk of bias** |        |                                  |
| 10 Mortality in vitamin C trials               | 33     | 0.99 [0.92, 1.06]                |
| 10.1 Trials with a low risk of bias            | 23     | 1.01 [0.93, 1.10]                |
| 10.2 Trials with a high risk of bias           | 10     | 0.93 [0.83, 1.05]                |
| **Mortality in vitamin E trials with a low or high risk of bias** |        |                                  |
| 11 Mortality in vitamin E trials               | 54     | 1.02 [1.00, 1.05]                |
| 11.1 Trials with a low risk of bias            | 37     | 1.04 [1.01, 1.06]                |
| 11.2 Trials with a high risk of bias           | 17     | 0.92 [0.85, 0.99]                |
| **Mortality in selenium trials with a low or high risk of bias** |        |                                  |
| 12 Mortality in selenium trials                | 20     | 0.90 [0.83, 0.98]                |
| 12.1 Trials with a low risk of bias            | 14     | 0.90 [0.80, 1.01]                |
| 12.2 Trials with a high risk of bias           | 6      | 0.90 [0.80, 1.01]                |
| **Mortality in low-bias risk beta-carotene trials without selenium** |        |                                  |
| 13 Mortality in low-bias risk beta-carotene trials without selenium | 12     | 1.07 [1.02, 1.11]                |
| **Mortality in low-bias risk vitamin A trials without selenium** |        |                                  |
| 14 Mortality in low-bias risk vitamin A trials without selenium | 5      | 1.16 [1.10, 1.24]                |
| **Mortality in low-bias risk vitamin C trials without selenium** |        |                                  |
| 15 Mortality in low-bias risk vitamin C trials without selenium | 13     | 1.06 [0.94, 1.20]                |
| **Mortality in low-bias risk vitamin E trials without selenium** |        |                                  |
| 16 Mortality in low-bias risk vitamin E trials without selenium | 26     | 1.04 [1.01, 1.07]                |
### Analysis 1.1. Comparison 1 Antioxidants versus placebo/no intervention, Outcome 1 Mortality in trials with a low or high risk of bias.

Review: Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases

Comparison: Antioxidants versus placebo/no intervention

Outcome: Mortality in trials with a low or high risk of bias

| Study or subgroup | Antioxidants n/N | Control n/N | Risk Ratio M-H,Random,95% CI | Weight | Risk Ratio M-H,Random,95% CI |
|-------------------|-----------------|-------------|-------------------------------|--------|-------------------------------|
| **1 Trials with low risk of bias** | | | | | |
| Allsup 2004Low | 4/81 | 4/83 | 0.1 % | 1.02 [ 0.27, 3.96 ] |
| AMDS 1996Low | 2/39 | 2/32 | 0.0 % | 0.82 [ 0.12, 5.50 ] |
| AREDS 2001Low | 251/2370 | 240/2387 | 3.5 % | 1.05 [ 0.89, 1.25 ] |
| ASAP 2003Low | 19/390 | 3/130 | 0.1 % | 2.11 [ 0.63, 7.02 ] |
| ATBC 2003Low | 8226/21846 | 2605/7287 | 16.1 % | 1.05 [ 1.02, 1.09 ] |
| CARET 2004Low | 1855/9420 | 1509/8894 | 12.0 % | 1.16 [ 1.09, 1.23 ] |
| CHAOS 1996Low | 68/1035 | 52/967 | 0.9 % | 1.22 [ 0.86, 1.73 ] |
| Collins 2003Low | 1/26 | 1/26 | 0.0 % | 1.00 [ 0.07, 15.15 ] |
| Correa 2000Low | 16/739 | 2/237 | 0.1 % | 2.57 [ 0.59, 11.08 ] |
| DATATOP 2005Low | 154/399 | 142/401 | 3.1 % | 1.09 [ 0.91, 1.31 ] |
| DATOR 2004Low | 1/12 | 0/12 | 0.0 % | 3.00 [ 0.13, 67.06 ] |
| Desnuelle 2001Low | 34/144 | 35/144 | 0.7 % | 0.97 [ 0.64, 1.47 ] |
| Graat 2005Low | 3/499 | 5/153 | 0.1 % | 0.18 [ 0.04, 0.76 ] |
| Graf 2005Low | 31/83 | 28/77 | 0.7 % | 1.03 [ 0.68, 1.54 ] |
| HATS 2001Low | 1/84 | 1/76 | 0.0 % | 0.90 [ 0.06, 14.22 ] |
| HOPE TOO 2005Low | 799/4761 | 801/4780 | 8.5 % | 1.00 [ 0.92, 1.10 ] |
| HPS 2002Low | 1446/10269 | 1389/10267 | 11.1 % | 1.04 [ 0.97, 1.11 ] |
| Jacobson 2000Low | 0/57 | 1/55 | 0.0 % | 0.32 [ 0.01, 7.74 ] |
| LAST 2004Low | 0/30 | 2/31 | 0.0 % | 0.21 [ 0.01, 4.13 ] |
| Limburg 2005Low | 1/180 | 0/180 | 0.0 % | 3.00 [ 0.12, 73.16 ] |
| MAVIS 2005 Low | 8/456 | 4/454 | 0.1 % | 1.99 [ 0.60, 6.57 ] |
| Meydani 2004Low | 39/311 | 44/306 | 0.7 % | 0.87 [ 0.58, 1.30 ] |
| Mezey 2004Low | 4/25 | 5/26 | 0.1 % | 0.83 [ 0.25, 2.75 ] |
| MINVITAOX 1999Low | 155/543 | 51/182 | 1.5 % | 1.02 [ 0.78, 1.33 ] |

(Continued ...)
| Study or subgroup | Antioxidants | Control | Risk Ratio | Weight | (... Continued) |
|------------------|--------------|---------|------------|--------|----------------|
|                  | n/N          | n/N     | M-H, Random, 95% CI |        | M-H, Random, 95% CI |
| Mooney 2005Low   | 1/142        | 0/142   |             | 0.0 %  | 3.00 [ 0.12, 73.03 ] |
| Murphy 1992Low   | 4/53         | 2/56    |             | 0.0 %  | 2.11 [ 0.40, 11.06 ] |
| NITZ 1993Low     | 157/1657     | 167/1661|             | 2.5 %  | 0.94 [ 0.77, 1.16 ] |
| NPCT 1996Low     | 108/653      | 129/659 |             | 2.0 %  | 0.84 [ 0.67, 1.07 ] |
| NSCPT 1999Low    | 15/820       | 22/801  |             | 0.3 %  | 0.67 [ 0.35, 1.27 ] |
| PHS 1996Low      | 979/11036    | 968/11035|            | 9.0 %  | 1.01 [ 0.93, 1.10 ] |
| Pike 1995Low     | 1/24         | 0/23    |             | 0.0 %  | 2.88 [ 0.12, 67.29 ] |
| PPS 1994Low      | 30/650       | 14/214  |             | 0.3 %  | 0.71 [ 0.38, 1.31 ] |
| Prince 2003Low   | 1/29         | 0/32    |             | 0.0 %  | 3.30 [ 0.14, 77.95 ] |
| Rayman 2006Low   | 1/380        | 0/121   |             | 0.0 %  | 0.96 [ 0.04, 23.43 ] |
| REACT 2002Low    | 9/149        | 3/148   |             | 0.1 %  | 2.98 [ 0.82, 10.79 ] |
| SCPS 1999Low     | 79/913       | 72/892  |             | 1.2 %  | 1.07 [ 0.79, 1.46 ] |
| SKICAP AK 1997Low| 62/1157      | 53/1140 |             | 0.9 %  | 1.15 [ 0.81, 1.65 ] |
| SPACE 2000Low    | 31/97        | 29/99   |             | 0.7 %  | 1.09 [ 0.72, 1.66 ] |
| SLVMAX 2004Low   | 76/6481      | 98/6336 |             | 1.3 %  | 0.78 [ 0.58, 1.05 ] |
| Tam 2005Low      | 1/20         | 1/19    |             | 0.0 %  | 0.95 [ 0.06, 14.13 ] |
| VEAPS 2002Low    | 2/177        | 1/176   |             | 0.0 %  | 1.99 [ 0.18, 21.73 ] |
| VECAT 2004Low    | 20/595       | 11/598  |             | 0.2 %  | 1.83 [ 0.88, 3.78 ] |
| WAVE 2002Low     | 16/212       | 6/211   |             | 0.1 %  | 2.65 [ 1.06, 6.65 ] |
| White 2002Low    | 1/50         | 1/50    |             | 0.0 %  | 1.00 [ 0.06, 15.55 ] |
| WHS 2005Low      | 636/19937    | 615/19939|           | 6.7 %  | 1.03 [ 0.93, 1.15 ] |
| Witte 2005Low    | 1/16         | 1/16    |             | 0.0 %  | 1.00 [ 0.07, 14.64 ] |
| Wluka 2002Low    | 1/67         | 0/69    |             | 0.0 %  | 3.07 [ 0.13, 74.50 ] |

**Subtotal (95% CI)**

| 99114          |

| Total events: 15350 (Antioxidants), 9119 (Control) |

Heterogeneity: Tau² = 0.00, Chi² = 49.73, df = 46 (P = 0.33); I² = 8%

Test for overall effect: Z = 2.98 (P = 0.0029)

2 Trials with high risk of bias

ADCS 1 1997

ADCS 2 2005

Bonelli 1998

Chandra 1992

de la Maza 1995

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
| Study or subgroup | Antioxidants | Control | Risk Ratio (95% CI) | Weight |
|------------------|--------------|---------|---------------------|--------|
| de Waart 2001    | 0/109        | 1/109   | 0.33 [0.01, 8.09]   | 0.0 %  |
| Gillilan 1977    | 2/26         | 2/26    | 1.00 [0.15, 6.57]   | 0.0 %  |
| Girodon 1997     | 18/61        | 7/20    | 0.84 [0.41, 1.72]   | 0.2 %  |
| GISSI 1999       | 488/5660     | 529/5664| 0.92 [0.82, 1.04]   | 6.0 %  |
| Hogarth 1996     | 7/54         | 6/52    | 1.12 [0.40, 3.12]   | 0.1 %  |
| McKeeown-Eyssen 1988 | 4/96    | 3/89    | 1.24 [0.28, 5.37]   | 0.1 %  |
| NITI 1993        | 1847/25886   | 280/3698| 0.94 [0.84, 1.06]   | 5.8 %  |
| Penn 1991        | 1/15         | 0/15    | 3.00 [0.13, 68.26]  | 0.0 %  |
| PPP 2001         | 72/2231      | 68/2264 | 1.07 [0.78, 1.49]   | 1.1 %  |
| Sasazuki 2003    | 6/222        | 18/217  | 1.33 [0.13, 0.81]   | 0.1 %  |
| ST 2001          | 38/1706      | 43/1705 | 0.88 [0.57, 1.36]   | 0.6 %  |
| Stevic 2001      | 3/16         | 6/12    | 0.38 [0.12, 1.20]   | 0.1 %  |
| Takagi 2003      | 10/51        | 16/42   | 0.51 [0.26, 1.01]   | 0.3 %  |
| Takamatsu 1995   | 1/74         | 0/73    | 2.96 [0.12, 71.50]  | 0.0 %  |
| ter Riet 1995    | 3/43         | 5/45    | 0.63 [0.16, 2.47]   | 0.1 %  |

**Subtotal (95% CI)**

Total events: 2530 (Antioxidants), 1017 (Control)

Heterogeneity: Tau² = 0.00, Chi² = 15.21, df = 19 (P = 0.71); I² = 0.0%

Test for overall effect: Z = 2.11 (P = 0.035)

**Total (95% CI)**

Total events: 17880 (Antioxidants), 10136 (Control)

Heterogeneity: Tau² = 0.00, Chi² = 75.97, df = 66 (P = 0.19); I² = 13%

Test for overall effect: Z = 1.35 (P = 0.18)
### Analysis 1.2. Comparison 1 Antioxidants versus placebo/no intervention, Outcome 2 Mortality in primary and secondary prevention trials with a low or high risk of bias

Review: Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases

Comparison: 1 Antioxidants versus placebo/no intervention

Outcome: 2 Mortality in primary and secondary prevention trials with a low or high risk of bias

| Study or subgroup | Antioxidants n/N | Control n/N | Risk Ratio M-H,Random,95% CI | Weight M-H,Random,95% CI |
|------------------|-----------------|-------------|-----------------------------|--------------------------|
| **1 Primary prevention trials with a low risk of bias** | | | | |
| ASAP 2003Low | 19/390 | 3/130 | 0.1% | 2.11 [0.63, 7.02] |
| ATBC 2003Low | 8226/21846 | 2605/7287 | 16.1% | 1.05 [1.02, 1.09] |
| CARET 2004Low | 1855/9420 | 1509/8894 | 12.0% | 1.16 [1.09, 1.23] |
| Graat 2002Low | 3/499 | 5/153 | 0.1% | 0.18 [0.04, 0.76] |
| Jacobson 2000Low | 0/57 | 1/55 | 0.0% | 0.32 [0.01, 7.74] |
| MAVIS 2005 Low | 8/456 | 4/454 | 0.1% | 1.99 [0.60, 6.57] |
| Meydani 2004Low | 39/311 | 44/306 | 0.7% | 0.87 [0.58, 1.30] |
| Mooney 2005Low | 1/142 | 0/142 | 0.0% | 3.00 [0.12, 73.03] |
| PHS 1996Low | 979/11036 | 968/11035 | 9.0% | 1.01 [0.93, 1.10] |
| Pike 1995Low | 1/24 | 0/23 | 0.0% | 2.88 [0.12, 67.29] |
| Rayman 2006Low | 1/380 | 0/121 | 0.0% | 0.96 [0.04, 23.43] |
| SUVIMAX 2004Low | 76/6481 | 98/6536 | 1.3% | 0.78 [0.58, 1.05] |
| VEAPS 2002Low | 2/177 | 1/176 | 0.0% | 1.99 [0.18, 21.73] |
| WHS 2005Low | 636/19937 | 615/19939 | 6.7% | 1.03 [0.93, 1.15] |
| **Subtotal (95% CI)** | 71156 | 55251 | 46.1% | 1.05 [0.98, 1.12] |

Total events: 11846 (Antioxidants), 5853 (Control)

Heterogeneity: $\tau^2 = 0.01; \chi^2 = 24.47, df = 13 (P = 0.03); I^2 = 47%$

Test for overall effect: $Z = 1.33 (P = 0.18)$

| Study or subgroup | Antioxidants n/N | Control n/N | Risk Ratio M-H,Random,95% CI | Weight M-H,Random,95% CI |
|------------------|-----------------|-------------|-----------------------------|--------------------------|
| **2 Primary prevention trials with a high risk of bias** | | | | |
| Chandra 1992 | 0/48 | 2/48 | 0.0% | 0.20 [0.01, 4.06] |
| de-Waart 2001 | 0/109 | 1/109 | 0.0% | 0.33 [0.01, 8.09] |
| Giroud 1997 | 18/61 | 7/20 | 0.2% | 0.84 [0.41, 1.72] |
| NIT 1 1993 | 1847/25886 | 280/3698 | 5.8% | 0.94 [0.84, 1.06] |
| PPP 2001 | 72/2231 | 68/2264 | 1.1% | 1.07 [0.78, 1.49] |
| STT 2001 | 38/1706 | 43/1705 | 0.6% | 0.88 [0.57, 1.36] |
| Takamatsu 1995 | 1/74 | 0/73 | 0.0% | 2.96 [0.12, 71.50] |

(Continued …)
### Study or subgroup

| Study or subgroup | Antioxidants | Control | Risk Ratio | Weight |
|------------------|--------------|---------|------------|--------|
|                 | n/N          | n/N     | M-H,Random | M-H,Random |
| **Subtotal (95% CI)** | 301/15      | 791/17  | 7.8 %      | 0.95 [ 0.85, 1.06 ] |

**Total events:** 1976 (Antioxidants), 401 (Control)

Heterogeneity: $\tau^2 = 0.0$, $\chi^2 = 2.71$, $df = 6$ ($P = 0.84$); $I^2 = 0.0$

Test for overall effect: $Z = 0.97$ ($P = 0.33$)

### 3 Secondary prevention trials with a low risk of bias

| Study or subgroup | Antioxidants | Control | Risk Ratio | Weight |
|------------------|--------------|---------|------------|--------|
| Allsup 2004Low    | 4/81         | 4/83    | 0.1 %      | 1.02 [ 0.27, 3.96 ] |
| AMDS 1996Low      | 2/39         | 2/32    | 0.0 %      | 0.82 [ 0.12, 5.50 ] |
| AREDS 2001Low     | 25/2370      | 240/2387| 3.5 %      | 1.05 [ 0.89, 1.25 ] |
| CHAOS 1996Low     | 68/1035      | 52/967  | 0.9 %      | 1.22 [ 0.86, 1.73 ] |
| Collins 2003Low   | 1/26         | 1/26    | 0.0 %      | 1.00 [ 0.07, 15.15 ] |
| Corea 2000Low     | 167/39       | 2/237   | 0.1 %      | 2.57 [ 0.59, 11.08 ] |
| DATATOP 2005Low   | 154/399      | 142/401 | 3.1 %      | 1.09 [ 0.91, 1.31 ] |
| DATOR 2004Low     | 1/12         | 0/12    | 0.0 %      | 3.00 [ 0.13, 67.06 ] |
| Desnuelle 2001Low | 34/144       | 35/144  | 0.7 %      | 0.97 [ 0.64, 1.47 ] |
| Graf 2005Low      | 31/83        | 28/77   | 0.7 %      | 1.03 [ 0.68, 1.54 ] |
| HATS 2001Low      | 1/84         | 1/76    | 0.0 %      | 0.90 [ 0.06, 14.22 ] |
| HOPE TOO 2005Low  | 799/4761     | 801/4780| 8.5 %      | 1.00 [ 0.92, 1.10 ] |
| HPS 2002Low       | 144/10269    | 1389/10267| 11.1 %     | 1.04 [ 0.97, 1.11 ] |
| LAST 2004Low      | 0/30         | 2/31    | 0.0 %      | 0.21 [ 0.01, 4.13 ] |
| Limburg 2005Low   | 1/180        | 0/180   | 0.0 %      | 3.00 [ 0.12, 73.16 ] |
| Mezey 2004Low     | 4/25         | 5/26    | 0.1 %      | 0.83 [ 0.25, 2.75 ] |
| MINVITAOX 1999Low | 155/543      | 51/182  | 1.5 %      | 1.02 [ 0.78, 1.33 ] |
| Murphy 1992Low    | 4/53         | 2/56    | 0.0 %      | 2.11 [ 0.40, 11.06 ] |
| NIT2 1993Low      | 157/1657     | 167/1661| 2.5 %      | 0.94 [ 0.77, 1.16 ] |
| NPCT 1996Low      | 108/653      | 129/659 | 2.0 %      | 0.84 [ 0.67, 1.07 ] |
| NSCPT 1995Low     | 15/820       | 22/801  | 0.3 %      | 0.67 [ 0.35, 1.27 ] |
| PPS 1994Low       | 30/650       | 14/214  | 0.3 %      | 0.71 [ 0.38, 1.31 ] |
| Prince 2003Low    | 1/29         | 0/32    | 0.0 %      | 3.30 [ 0.14, 77.95 ] |
| REACT 2002Low     | 9/149        | 3/148   | 0.1 %      | 2.98 [ 0.82, 10.79 ] |
| SCPS 1990Low      | 79/13        | 72/892  | 1.2 %      | 1.07 [ 0.79, 1.46 ] |
| SKICAP AK 1997Low | 62/1157      | 53/1140 | 0.9 %      | 1.15 [ 0.81, 1.65 ] |
| SPACE 2000Low     | 31/97        | 29/99   | 0.7 %      | 1.09 [ 0.72, 1.66 ] |
| Tam 2005Low       | 1/20         | 1/19    | 0.0 %      | 0.95 [ 0.06, 14.13 ] |

*Favours antioxidants* | *Favours control* | *Continued...*
| Study or subgroup | Antioxidants | Control | Risk Ratio | Weight |
|------------------|--------------|---------|------------|--------|
|                  | n/N          | n/N     | M-H,Random,95% CI |        |
| VECAT 2004Low    | 20/595       | 11/598  | —          | 0.2 %  |
| WAVE 2002Low     | 16/212       | 6/211   | —          | 0.1 %  |
| White 2002Low    | 1/50         | 1/50    | —          | 0.0 %  |
| Witte 2005Low    | 1/16         | 1/16    | —          | 0.0 %  |
| Wluka 2002Low    | 1/67         | 0/69    | —          | 0.0 %  |
| **Subtotal (95% CI)** | **27958** | **26573** | —          | **38.8 %** |

Total events: 3504 (Antioxidants), 3266 (Control)
Heterogeneity: Tau² = 0.0, Ch² = 23.60, df = 32 (P = 0.86); I² =0.0%
Test for overall effect: Z = 1.27 (P = 0.20)

4 Secondary prevention trials with a high risk of bias

| Study or subgroup | Antioxidants | Control | Risk Ratio | Weight |
|------------------|--------------|---------|------------|--------|
|                  | n/N          | n/N     | M-H,Random,95% CI |        |
| ADCS 1 1997      | 19/170       | 22/171  | —          | 0.4 %  |
| ADCS 2 2005      | 5/257        | 5/259   | —          | 0.1 %  |
| Bonelli 1998     | 1/147        | 0/157   | —          | 0.0 %  |
| de la Maza 1995  | 5/37         | 4/37    | —          | 0.1 %  |
| Gillian 1977     | 2/26         | 2/26    | —          | 0.0 %  |
| GISSI 1999       | 488/5660     | 529/5664| —          | 0.6 %  |
| Hogarth 1996     | 7/54         | 6/52    | —          | 0.1 %  |
| McKeeon-Eyssen 1988 | 4/96   | 3/89    | —          | 0.1 %  |
| Penn 1991        | 1/15         | 0/15    | —          | 0.0 %  |
| Sasazuki 2003    | 6/222        | 18/217  | —          | 0.1 %  |
| Stevic 2001      | 3/16         | 6/12    | —          | 0.1 %  |
| Takagi 2003      | 10/51        | 16/42   | —          | 0.3 %  |
| ter Riet 1995    | 3/43         | 5/45    | —          | 0.1 %  |
| **Subtotal (95% CI)** | **6794** | **6786** | —          | **7.3 %** |

Total events: 554 (Antioxidants), 616 (Control)
Heterogeneity: Tau² = 0.0, Ch² = 11.93, df = 12 (P = 0.45); I² =0.0%
Test for overall effect: Z = 2.02 (P = 0.043)

**Total (95% CI)**

| Study or subgroup | Antioxidants | Control | Risk Ratio | Weight |
|------------------|--------------|---------|------------|--------|
|                  | n/N          | n/N     | M-H,Random,95% CI |        |
|                  |              |         |             |        |

Total events: 17880 (Antioxidants), 11036 (Control)
Heterogeneity: Tau² = 0.00, Ch² = 75.97, df = 66 (P = 0.19); I² =13%
Test for overall effect: Z = 1.35 (P = 0.18)

---

Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases (Review)
### Analysis 1.3. Comparison 1 Antioxidants versus placebo/no intervention, Outcome 3 Mortality after excluding trials administrating extra supplements in the antioxidant group.

**Review:** Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases

**Comparison:** 1 Antioxidants versus placebo/no intervention

**Outcome:** 3 Mortality after excluding trials administrating extra supplements in the antioxidant group

| Study or subgroup | Supplements n/N | Control n/N | Risk Ratio M-H,Random,95% CI | Weight | Risk Ratio M-H,Random,95% CI |
|-------------------|----------------|-------------|--------------------------------|--------|----------------------------|
| 1 Trials with low risk of bias | | | | | |
| AREDS 2001Low | 251/2370 | 240/2387 | 3.6 % 1.05 [ 0.89, 1.25 ] | 2.11 [ 0.63, 7.02 ] |
| ASAP 2003Low | 19/390 | 3/130 | 19.1 % 1.05 [ 1.02, 1.09 ] | 1.16 [ 1.09, 1.23 ] |
| ATBC 2003Low | 8226/21846 | 2605/7287 | 13.6 % 1.03 [ 1.02, 1.05 ] | 1.00 [ 0.98, 1.01 ] |
| CARET 2004Low | 1855/9420 | 1509/8894 | 19.1 % 1.05 [ 1.02, 1.09 ] | 1.16 [ 1.09, 1.23 ] |
| CHAOS 1996Low | 68/1035 | 52/946 | 1.0 % 1.05 [ 0.89, 1.25 ] | 1.22 [ 0.86, 1.73 ] |
| Collins 2003Low | 1/26 | 1/26 | 0.0 % 1.00 [ 0.07, 15.15 ] | 2.57 [ 0.59, 11.08 ] |
| Correa 2000Low | 16/739 | 2/237 | 3.2 % 1.09 [ 0.91, 1.31 ] | 1.03 [ 0.68, 1.54 ] |
| DATATOP 2005Low | 154/399 | 142/401 | 0.1 % 2.11 [ 0.40, 11.06 ] | 0.97 [ 0.64, 1.47 ] |
| DATOR 2004Low | 1/12 | 0/12 | 0.7 % 1.03 [ 0.68, 1.54 ] | 1.03 [ 0.68, 1.54 ] |
| Desnuelle 2001Low | 34/144 | 35/144 | 0.7 % 1.03 [ 0.68, 1.54 ] | 1.03 [ 0.68, 1.54 ] |
| Graf 2005Low | 31/83 | 28/77 | 0.7 % 1.03 [ 0.68, 1.54 ] | 1.03 [ 0.68, 1.54 ] |
| HATS 2001Low | 1/84 | 1/76 | 0.7 % 1.03 [ 0.68, 1.54 ] | 1.03 [ 0.68, 1.54 ] |
| HOPE TOO 2005Low | 799/4761 | 801/4780 | 9.2 % 1.00 [ 0.92, 1.10 ] | 1.04 [ 0.97, 1.11 ] |
| HPS 2002Low | 1446/10269 | 1389/10267 | 12.4 % 1.00 [ 0.92, 1.10 ] | 1.04 [ 0.97, 1.11 ] |
| Jacobson 2000Low | 0/57 | 1/55 | 0.0 % 0.32 [ 0.01, 7.74 ] | 0.32 [ 0.01, 7.74 ] |
| Limburg 2005Low | 1/180 | 0/180 | 0.0 % 3.00 [ 0.12, 73.16 ] | 0.03 [ 0.01, 0.12 ] |
| Meydani 2004Low | 39/311 | 44/306 | 0.7 % 0.87 [ 0.58, 1.30 ] | 0.87 [ 0.58, 1.30 ] |
| Mezey 2004Low | 4/25 | 5/26 | 0.1 % 0.83 [ 0.25, 2.75 ] | 0.83 [ 0.25, 2.75 ] |
| MINVITAOX 1999Low | 155/543 | 51/182 | 1.6 % 1.02 [ 0.78, 1.33 ] | 1.02 [ 0.78, 1.33 ] |
| Mooney 2005Low | 1/142 | 0/142 | 0.0 % 3.00 [ 0.12, 73.03 ] | 3.00 [ 0.12, 73.03 ] |
| Murphy 1992Low | 4/53 | 2/56 | 0.0 % 2.11 [ 0.40, 1.10 ] | 0.03 [ 0.03, 0.35 ] |
| NPCT 1996Low | 108/653 | 129/659 | 2.1 % 0.84 [ 0.67, 1.07 ] | 0.84 [ 0.67, 1.07 ] |
| NSCPT 1999Low | 15/820 | 22/801 | 0.3 % 0.67 [ 0.35, 1.27 ] | 0.67 [ 0.35, 1.27 ] |
| PHS 1996Low | 979/11036 | 968/11035 | 9.8 % 1.01 [ 0.93, 1.10 ] | 1.01 [ 0.93, 1.10 ] |

(Continued ...)

Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases (Review)

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
| Study or subgroup | Supplements n/N | Control n/N | Risk Ratio M-H,Random,95% CI | Weight |
|------------------|----------------|-------------|-----------------------------|--------|
| PPS 1994Low | 30/650 | 14/214 | 0.3 % 0.71 [ 0.38, 1.31 ] | 0.3 % |
| Prince 2003Low | 1/29 | 0/32 | 0.0 % 3.30 [ 0.14, 77.95 ] | 0.0 % |
| Rayman 2006Low | 1/380 | 0/121 | 0.0 % 0.96 [ 0.04, 23.43 ] | 0.0 % |
| REACT 2002Low | 9/149 | 3/148 | 0.1 % 2.98 [ 0.82, 10.79 ] | 0.1 % |
| SCPS 1990Low | 79/913 | 72/892 | 1.2 % 1.07 [ 0.79, 1.46 ] | 1.2 % |
| SKICAP AK 1997Low | 62/157 | 53/140 | 0.9 % 1.15 [ 0.81, 1.65 ] | 0.9 % |
| SPACE 2000Low | 31/97 | 29/99 | 0.1 % 1.09 [ 0.72, 1.66 ] | 0.1 % |
| SLUMVMAX 2004Low | 76/681 | 98/633 | 1.3 % 0.78 [ 0.58, 1.05 ] | 1.3 % |
| Tam 2005Low | 1/20 | 1/19 | 0.0 % 0.95 [ 0.06, 14.13 ] | 0.0 % |
| VEAPS 2002Low | 2/177 | 1/176 | 0.0 % 1.99 [ 0.18, 21.73 ] | 0.0 % |
| VECAT 2004Low | 20595 | 11598 | 0.2 % 1.83 [ 0.88, 3.78 ] | 0.2 % |
| WAVE 2002Low | 16/212 | 6/211 | 0.1 % 2.65 [ 1.06, 6.65 ] | 0.1 % |
| White 2002Low | 1/50 | 1/50 | 0.0 % 1.00 [ 0.06, 15.55 ] | 0.0 % |
| WHS 2005Low | 63/1937 | 615/1939 | 7.1 % 1.03 [ 0.93, 1.15 ] | 7.1 % |
| Wuuka 2002Low | 1/67 | 0/69 | 0.0 % 3.09 [ 0.13, 74.50 ] | 0.0 % |

**Subtotal (95% CI)**

96312 79371 90.4 % 1.05 [ 1.02, 1.09 ]

Total events: 15174 (Supplements), 8934 (Control)

Heterogeneity: Tau² = 0.00; Chi² = 40.08, df = 38 (P = 0.38); I² = 5%

Test for overall effect: Z = 3.53 (P = 0.00041)

2 Trials with high risk of bias

ADCS 1 1997 19/170 22/171 0.4 % 0.87 [ 0.49, 1.55 ]

ADCS 2 2005 5/257 5/259 0.1 % 1.01 [ 0.30, 3.44 ]

Boneli 1998 1/147 0/157 0.0 % 3.20 [ 0.13, 78.00 ]

de la Maza 1995 5/37 4/37 0.0 % 1.25 [ 0.36, 4.29 ]

de Waart 2001 0/109 1/109 0.0 % 0.33 [ 0.01, 8.09 ]

Gillian 1977 2/26 2/26 0.0 % 1.00 [ 0.15, 6.57 ]

Girodon 1997 18/61 7/20 0.2 % 0.84 [ 0.41, 1.72 ]

GISSI 1999 4785660 5295664 6.4 % 0.92 [ 0.82, 1.04 ]

McKeown-Eyssen 1988 496 3/89 0.1 % 1.24 [ 0.28, 5.37 ]

Penn 1991 1/15 0/15 0.0 % 3.00 [ 0.13, 68.26 ]

PPP 2001 722231 682264 1.1 % 1.07 [ 0.78, 1.49 ]

Sasazuki 2003 6/222 18/217 0.1 % 0.33 [ 0.13, 0.81 ]

ST 2001 381706 431705 0.6 % 0.88 [ 0.57, 1.36 ]

**Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases (Review)**

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
| Study or subgroup | Supplements | Control | Risk Ratio | Weight | Risk Ratio |
|------------------|-------------|---------|------------|--------|------------|
|                  | n/N         | n/N     | M-H,Random,95% CI |        | M-H,Random,95% CI |
| Stevic 2001      | 3/16        | 6/12    |             | 0.1 %  | 0.38 [0.12, 1.20] |
| Takagi 2003      | 10/51       | 16/42   |             | 0.3 %  | 0.51 [0.26, 1.01] |
| Takamatsu 1995   | 1/74        | 0/73    |             | 0.0 %  | 2.96 [0.12, 71.50] |
| ter Riet 1995    | 3/43        | 5/45    |             | 0.1 %  | 0.63 [0.16, 2.47] |
| **Subtotal (95% CI)** | **10921**   | **10905** | **9.6 %** |         | **0.91 [0.82, 1.00]** |
|                  |             |         |             |        |             |
|                  |             |         |             |        |             |

Total events: 676 (Supplements), 729 (Control)
Heterogeneity: Tau² = 0.0; Chi² = 13.83, df = 16 (P = 0.61); I² = 0.0%
Test for overall effect: Z = 1.94 (P = 0.052)

| Study or subgroup | Antioxidants | Control | Risk Ratio | Weight | Risk Ratio |
|------------------|--------------|---------|------------|--------|------------|
|                  | n/N          | n/N     | M-H,Random,95% CI |        | M-H,Random,95% CI |
| 1 Trials with low risk of bias |             |         |             |        |             |
| Allsop 2004Low   | 4/81         | 4/83    |             | 0.1 %  | 1.02 [0.27, 3.96] |
| AMDS 1996Low     | 2/39         | 2/32    |             | 0.0 %  | 0.82 [0.12, 5.50] |
| AREDS 2001Low    | 251/2370     | 240/2387 |             | 3.7 %  | 1.05 [0.89, 1.25] |
| ASAP 2003Low     | 19/390       | 3/130   |             | 0.1 %  | 2.11 [0.63, 7.02] |
| ATBC 2003Low     | 8226/21846   | 2605/7287 |             | 16.6 % | 1.05 [1.02, 1.09] |
| CARET 2004Low    | 1855/9420    | 1509/8894 |             | 12.5 % | 1.16 [1.09, 1.23] |
| CHAOS 1996Low    | 68/1035      | 52/967  |             | 1.0 %  | 1.22 [0.86, 1.73] |
| Collins 2003Low  | 1/26         | 1/26    |             | 0.0 %  | 1.00 [0.07, 15.15] |

Analysis 1.4. Comparison 1 Antioxidants versus placebo/no intervention, Outcome 4 Mortality after excluding trials with extra supplements for both intervention groups.

Review: Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases

Comparison: 1 Antioxidants versus placebo/no intervention

Outcome: 4 Mortality after excluding trials with extra supplements for both intervention groups
| Study or subgroup | Antioxidants | Control | Risk Ratio | Weight |
|------------------|-------------|---------|------------|--------|
|                  | n/N         | n/N     | M-H,Random,95% CI | M-H,Random,95% CI |
| Correa 2000     | 16/739      | 2/237   |                 | 0.1 % 2.57 [0.59, 11.08] |
| DATOR 2004      | 1/12        | 0/12    |                 | 0.0 % 3.00 [0.13, 67.06] |
| Desnuelle 2001  | 34/144      | 35/144  |                 | 0.7 % 0.97 [0.64, 1.47] |
| Graat 2002      | 3/499       | 5/153   |                 | 0.1 % 0.18 [0.04, 0.76] |
| Graf 2005       | 3/83        | 28/77   |                 | 0.7 % 1.03 [0.68, 1.54] |
| HOPE TOO 2005   | 799/4761    | 801/4780|                 | 8.9 % 1.00 [0.92, 1.10] |
| HPS 2002        | 1446/10269  | 1389/10267 |                 | 11.5 % 1.04 [0.97, 1.11] |
| Jacobson 2000   | 0/57        | 1/55    |                 | 0.0 % 0.32 [0.01, 7.74] |
| LAST 2004       | 0/30        | 2/31    |                 | 0.0 % 0.21 [0.01, 4.13] |
| Limburg 2005    | 1/180       | 0/180   |                 | 0.0 % 3.00 [0.12, 73.16] |
| MAVIS 2005      | 8/456       | 4/454   |                 | 0.1 % 1.79 [0.60, 6.57] |
| Mezey 2004      | 4/25        | 5/26    |                 | 0.1 % 0.83 [0.25, 2.75] |
| MINVITAOX 1999  | 155/543     | 51/182  |                 | 1.6 % 1.02 [0.78, 1.33] |
| Mooney 2005     | 1/142       | 0/142   |                 | 0.0 % 3.00 [0.12, 73.03] |
| Nit2 1993       | 157/1657    | 167/1661|                 | 2.6 % 0.94 [0.77, 1.16] |
| NPCT 1996       | 108/653     | 129/659 |                 | 2.1 % 0.84 [0.67, 1.07] |
| NSCPT 1999      | 15/820      | 22/801  |                 | 0.3 % 0.67 [0.35, 1.27] |
| PHS 1996        | 979/11036   | 968/1035|                 | 9.4 % 1.01 [0.93, 1.10] |
| Pike 1995       | 1/24        | 0/23    |                 | 0.0 % 2.88 [0.12, 67.29] |
| PPS 1994        | 30/650      | 14/214  |                 | 0.3 % 0.71 [0.38, 1.31] |
| Prince 2003     | 1/29        | 0/32    |                 | 0.0 % 3.30 [0.14, 77.95] |
| Rayman 2006     | 1/380       | 0/121   |                 | 0.0 % 0.96 [0.04, 23.43] |
| REACT 2002      | 9/149       | 3/148   |                 | 0.1 % 2.98 [0.82, 10.79] |
| SCPS 1990       | 79/913      | 72/892  |                 | 1.3 % 1.07 [0.79, 1.46] |
| Skicap AK 1997  | 62/1157     | 53/1140 |                 | 1.0 % 1.15 [0.81, 1.65] |
| SPACE 2000      | 31/977      | 29/999  |                 | 0.7 % 1.09 [0.72, 1.66] |
| Suvimax 2004    | 76/6481     | 98/6536 |                 | 1.3 % 0.78 [0.58, 1.05] |
| Tam 2005        | 1/20        | 1/19    |                 | 0.0 % 0.95 [0.06, 14.13] |
| VEAPS 2002      | 2/177       | 1/176   |                 | 0.0 % 1.99 [0.18, 21.73] |
| VECAT 2004      | 205/959     | 115/988 |                 | 0.2 % 1.83 [0.88, 3.78] |
| WAVE 2002       | 16/212      | 6/211   |                 | 0.2 % 2.65 [1.06, 6.65] |

(Continued...)
| Study or subgroup          | Antioxidants n/N | Control n/N | Risk Ratio M-H, Random, 95% CI | Weight | Risk Ratio M-H, Random, 95% CI |
|---------------------------|-----------------|-------------|--------------------------------|--------|-------------------------------|
| White 2002 low            | 1/50            | 1/50        |                                | 0.0 %  | 1.00 [ 0.06, 15.55 ]          |
| WHS 2005 low              | 636/19937       | 615/19939   |                                | 7.0 %  | 1.03 [ 0.93, 1.15 ]           |
| Witte 2005 low            | 1/16            | 1/16        |                                | 0.0 %  | 1.00 [ 0.07, 14.64 ]          |
| Wuuka 2002 low            | 1/67            | 0/69        |                                | 0.0 %  | 3.09 [ 0.13, 74.50 ]          |
| **Subtotal (95% CI)**     | **98267**       | **80985**   |                                | **84.5 %** | **1.05 [ 1.01, 1.08 ]**       |
| Total events: 15152       |                 |             |                                |        |                               |
| Heterogeneity: Tau² = 0.00; Chi² = 48.06, df = 42 (P = 0.24); I² = 13% |
| Test for overall effect: Z = 2.48 (P = 0.013) |
| 2 Trials with high risk of bias |
| ADCS 1 1997               | 19/170          | 22/171      |                                | 0.4 %  | 0.87 [ 0.49, 1.55 ]           |
| Bonelli 1998              | 1/147           | 0/157       |                                | 0.0 %  | 3.20 [ 0.13, 78.00 ]          |
| Chandra 1992              | 0/48            | 2/48        |                                | 0.0 %  | 0.20 [ 0.01, 4.06 ]           |
| de la Maza 1995           | 5/37            | 4/37        |                                | 0.1 %  | 1.25 [ 0.36, 4.29 ]           |
| de Waart 2001             | 0/109           | 1/109       |                                | 0.0 %  | 0.33 [ 0.01, 8.09 ]           |
| Girodon 1997              | 18/61           | 7/20        |                                | 0.2 %  | 0.84 [ 0.41, 1.72 ]           |
| GISSI 1999                | 488/5660        | 529/5664    |                                | 6.3 %  | 0.92 [ 0.82, 1.04 ]           |
| Hogarth 1996              | 7/54            | 6/52        |                                | 0.1 %  | 1.12 [ 0.40, 3.12 ]           |
| McKeown-Eysen 1988        | 4/96            | 3/89        |                                | 0.1 %  | 1.24 [ 0.28, 5.37 ]           |
| NIT 1 1993                | 1847/25886      | 280/3698    |                                | 6.1 %  | 0.94 [ 0.84, 1.06 ]           |
| Penn 1991                 | 1/15            | 0/15        |                                | 0.0 %  | 3.00 [ 0.13, 68.26 ]          |
| PPP 2001                  | 72/2231         | 68/2264     |                                | 1.1 %  | 1.07 [ 0.78, 1.49 ]           |
| ST 2001                   | 38/1706         | 43/1705     |                                | 0.7 %  | 0.88 [ 0.57, 1.36 ]           |
| Stevic 2001               | 3/16            | 6/12        |                                | 0.1 %  | 0.38 [ 0.12, 1.20 ]           |
| Takagi 2003               | 10/51           | 16/42       |                                | 0.3 %  | 0.51 [ 0.26, 1.01 ]           |
| **Subtotal (95% CI)**     | **36287**       | **14083**   |                                | **15.5 %** | **0.93 [ 0.86, 1.00 ]**       |
| Total events: 2513         |                 |             |                                |        |                               |
| Heterogeneity: Tau² = 0.0; Chi² = 9.27, df = 14 (P = 0.81); I² = 0.0% |
| Test for overall effect: Z = 1.90 (P = 0.057) |
| **Total (95% CI)**        | **134554**      | **95068**   |                                | **100.0 %** | **1.02 [ 0.99, 1.06 ]**       |
| Total events: 17665        |                 |             |                                |        |                               |
| Heterogeneity: Tau² = 0.00; Chi² = 66.96, df = 57 (P = 0.17); I² = 15% |
| Test for overall effect: Z = 1.35 (P = 0.18) |
Analysis 1.5. Comparison 1 Antioxidants versus placebo/no intervention, Outcome 5 Mortality after excluding factorial trials with potential confounding.

Review: Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases

Comparison: 1 Antioxidants versus placebo/no intervention

Outcome: 5 Mortality after excluding factorial trials with potential confounding

| Study or subgroup | Antioxidants n/N | Placebo n/N | Risk Ratio M-H,Random,95% CI |
|-------------------|------------------|-------------|----------------------------|
| Allsup 2004Low    | 4/81 4/83        | 1.02 [0.27, 3.96] |
| AMDS 1996Low      | 2/39 2/32        | 0.82 [0.12, 5.50] |
| CARET 2004Low     | 1855/9420 1509/8894 | 1.16 [0.10, 12.33] |
| CHAOS 1996Low     | 68/1035 52/697 | 1.22 [0.86, 1.73] |
| Collins 2003Low   | 1/13 0/12       | 2.79 [0.12, 62.48] |
| DATOR 2004Low     | 1/12 0/12       | 3.00 [0.13, 67.06] |
| Desnuelle 2001Low | 3/1/44 35/144    | 0.97 [0.14, 6.47] |
| Graf 2005Low      | 31/83 28/77     | 1.03 [0.68, 1.94] |
| HATS 2001Low      | 0/42 0/38       | 0.00 [0.00, 0.00] |
| Jacobson 2000Low  | 0/57 1/55       | 0.32 [0.01, 7.74] |
| LAST 2004Low      | 0/30 2/31       | 0.21 [0.01, 4.13] |
| Limburg 2005Low   | 1/90 0/90       | 3.00 [0.12, 72.68] |
| MAVIS 2005 Low    | 8/456 4/454     | 1.99 [0.60, 6.57] |
| Meydani 2004Low   | 39/311 44/306   | 0.87 [0.58, 1.30] |
| Mezey 2004Low     | 4/25 5/26       | 0.83 [0.25, 2.75] |
| Mooney 2005Low    | 1/142 0/142     | 3.00 [0.12, 73.03] |
| Murphy 1992Low    | 4/53 2/56       | 2.11 [0.40, 11.06] |
| NITZ 1993Low      | 157/1657 167/1661 | 0.94 [0.77, 1.16] |
| NPCT 1996Low      | 108/653 129/659 | 0.84 [0.67, 1.07] |
| Pike 1995Low      | 1/24 0/23       | 2.88 [0.12, 67.29] |
| Prince 2003Low    | 1/29 0/32       | 3.30 [0.14, 77.95] |
| Rayman 2006Low    | 1/380 0/121     | 0.96 [0.04, 23.43] |
| REACT 2002Low     | 9/149 3/148     | 2.98 [0.82, 10.79] |
| SCPs 1990Low      | 79/913 72/892   | 1.07 [0.79, 1.46] |

(Continued...)
| Study or subgroup | Antioxidants | Placebo | Risk Ratio M-H,Random,95% CI |
|------------------|--------------|---------|-----------------------------|
| SKICAP AK 1997Low | 62/1157      | 53/1140 | 1.15 [ 0.81, 1.65 ]         |
| SPACE 2000Low     | 31/97        | 29/99   | 1.09 [ 0.72, 1.66 ]         |
| SULIMAX 2004Low   | 76/6481      | 98/6536 | 0.78 [ 0.58, 1.05 ]         |
| Tam 2005Low       | 1/20         | 1/19    | 0.95 [ 0.06, 14.13 ]        |
| VEAP 2002Low      | 2/177        | 1/176   | 1.99 [ 0.18, 21.73 ]        |
| VECAT 2004Low     | 20/595       | 11/598  | 1.83 [ 0.88, 3.78 ]         |
| WAVE 2002Low      | 6/105        | 2/108   | 3.09 [ 0.64, 14.95 ]        |
| White 2002Low     | 1/50         | 1/50    | 1.00 [ 0.06, 15.55 ]        |
| Witte 2005Low     | 1/16         | 1/16    | 1.00 [ 0.07, 14.64 ]        |
| Wluka 2002Low     | 1/67         | 0/69    | 3.09 [ 0.13, 74.50 ]        |
| **Subtotal (95% CI)** | **24603**   | **23766** | **1.11 [ 1.05, 1.17 ]**     |

Total events: 2610 (Antioxidants), 2256 (Placebo)
Heterogeneity: Tau² = 0.0; Chi² = 29.65, df = 32 (P = 0.59); I² = 0.0%
Test for overall effect: Z = 3.91 (P = 0.000091)

2 High-bias risk trials
- ADCS 1 1997
- ADCS 2 2005
- Bonelli 1998
- Chandra 1992
- de la Maza 1995
- de Waart 2001
- Gillan 1977
- GISSI 1999
- McKeown-Eyssen 1988
- Penn 1991
- Stivic 2001
- Takagi 2003
- Takamatsu 2002

| Study or subgroup | Antioxidants | Placebo | Risk Ratio M-H,Random,95% CI |
|------------------|--------------|---------|-----------------------------|
| 206Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases (Review) Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. |
### Analysis 1.6. Comparison 1 Antioxidants versus placebo/no intervention, Outcome 6 Mortality after excluding factorial trials with potential confounding and trials with extra supplements.

Review: Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases

Comparison: 1 Antioxidants versus placebo/no intervention

Outcome: 6 Mortality after excluding factorial trials with potential confounding and trials with extra supplements

| Study or subgroup | Antioxidants n/N | Placebo n/N | Risk Ratio M-H Random, 95% CI | Weight | Risk Ratio M-H Random, 95% CI |
|-------------------|-----------------|-------------|-----------------------------|--------|-----------------------------|
| **Low-bias risk trials** |                 |             |                             |        |                             |
| CARET 2004 Low    | 1855/9420       | 1509/8894   | 20.9 %                      |        | 1.16 [1.09, 1.23]           |
| CHAOS 1996 Low   | 68/1035         | 52/967      | 6.3 %                       |        | 1.22 [0.86, 1.73]           |
| Collins 2003 Low | 1/13            | 0/12        | 0.1 %                       |        | 2.79 [0.12, 62.48]          |
| DATOR 2004 Low   | 1/12            | 0/12        | 0.1 %                       |        | 3.00 [0.13, 67.06]          |
| Desruelle 2001 Low | 34/144          | 35/144      | 4.9 %                       |        | 0.97 [0.64, 1.47]           |
| Graf 2005 Low    | 31/83           | 28/77       | 5.1 %                       |        | 1.03 [0.68, 1.54]           |
| Jacobson 2000 Low| 0/57            | 1/55        | 0.1 %                       |        | 0.32 [0.01, 7.74]           |
| Limburg 2005 Low | 1/90            | 0/90        | 0.1 %                       |        | 3.00 [0.12, 72.68]          |
| Mezey 2004 Low   | 4/25            | 5/26        | 0.7 %                       |        | 0.83 [0.25, 2.75]           |
| Mooney 2005 Low  | 11/42           | 0/42        | 0.1 %                       |        | 3.00 [0.12, 73.03]          |
| NPCT 1996 Low    | 108/653         | 129/659     | 10.6 %                      |        | 0.84 [0.67, 1.07]           |
| Prince 2003 Low  | 1/29            | 0/32        | 0.1 %                       |        | 3.30 [0.14, 77.95]          |
| Rayman 2006 Low  | 1/380           | 0/121       | 0.1 %                       |        | 0.96 [0.04, 23.43]          |
| REACT 2002 Low   | 9/149           | 3/148       | 0.6 %                       |        | 2.98 [0.82, 10.79]          |
| SCPs 1990 Low    | 79/913          | 72/892      | 7.6 %                       |        | 1.07 [0.79, 1.46]           |
| SKICAP AK 1997 Low | 62/157          | 53/1140     | 6.1 %                       |        | 1.15 [0.81, 1.65]           |
| Study or subgroup | Antioxidants n/N | Placebo n/N | Risk Ratio M-H,Random,95% CI | Weight M-H,Random,95% CI |
|-------------------|------------------|-------------|----------------------------|--------------------------|
| SPACE 2000Low     | 31/97            | 29/99       | 4.8 % 1.09 [0.72, 1.66]    |                          |
| SUVIMAX 2004Low   | 76/6481          | 98/6536     | 7.9 % 0.78 [0.58, 1.05]    |                          |
| Tam 2005Low       | 1/20             | 1/19        | 0.1 % 0.95 [0.06, 14.13]   |                          |
| VEAPS 2002Low     | 2/177            | 1/176       | 0.2 % 1.99 [0.18, 21.73]   |                          |
| VECAT 2004Low     | 20/595           | 11/598      | 1.9 % 1.83 [0.88, 3.78]    |                          |
| WAVE 2002Low      | 6/105            | 2/108       | 0.4 % 3.09 [0.64, 14.95]   |                          |
| White 2002Low     | 1/50             | 1/50        | 0.1 % 1.00 [0.06, 15.55]   |                          |
| Wluka 2002Low     | 1/67             | 0/69        | 0.1 % 3.09 [0.13, 74.50]   |                          |

**Subtotal (95% CI)** 21894 21066 79.2 % 1.12 [1.07, 1.19]

Total events: 2394 (Antioxidants), 2030 (Placebo)
Heterogeneity: Tau² = 0.0; Chi² = 22.46, df = 23 (P = 0.49); I² = 0.0%
Test for overall effect: Z = 4.26 (P = 0.000021)

| Study or subgroup | Antioxidants n/N | Placebo n/N | Risk Ratio M-H,Random,95% CI | Weight M-H,Random,95% CI |
|-------------------|------------------|-------------|----------------------------|--------------------------|
| ADCTS 1 1997      | 12/85            | 12/84       | 1.8 % 0.99 [0.47, 2.07]    |                          |
| Bonelli 1998      | 1/147            | 0/157       | 0.1 % 3.20 [0.13, 78.00]   |                          |
| de la Maza 1995   | 5/37             | 4/37        | 0.7 % 1.25 [0.36, 4.29]    |                          |
| de Waart 2001     | 0/109            | 1/109       | 0.1 % 0.33 [0.01, 8.09]    |                          |
| GISSI 1999        | 252/2830         | 293/2828    | 14.7 % 0.86 [0.73, 1.01]   |                          |
| McKeown-Eysen 1988| 4/96             | 3/89        | 0.5 % 1.24 [0.28, 5.37]    |                          |
| Penn 1991         | 1/15             | 0/15        | 0.1 % 3.00 [0.13, 68.26]   |                          |
| Stevic 2001       | 3/16             | 6/12        | 0.8 % 0.38 [0.12, 1.20]    |                          |
| Takagi 2003       | 10/51            | 16/42       | 2.1 % 0.51 [0.26, 1.01]    |                          |

**Subtotal (95% CI)** 3386 3373 20.8 % 0.84 [0.73, 0.98]

Total events: 288 (Antioxidants), 335 (Placebo)
Heterogeneity: Tau² = 0.0; Chi² = 6.42, df = 8 (P = 0.60); I² = 0.0%
Test for overall effect: Z = 2.26 (P = 0.024)

| Study or subgroup | Antioxidants n/N | Placebo n/N | Risk Ratio M-H,Random,95% CI | Weight M-H,Random,95% CI |
|-------------------|------------------|-------------|----------------------------|--------------------------|
| Autoimmune       | 2682             | 2365        | 100.0 % 1.01 [0.91, 1.12]   |                          |

Total events: 2682 (Antioxidants), 2365 (Placebo)
Heterogeneity: Tau² = 0.01; Chi² = 41.64, df = 32 (P = 0.12); I² = 23%
Test for overall effect: Z = 0.25 (P = 0.81)
Analysis 1.7. Comparison 1 Antioxidants versus placebo/no intervention, Outcome 7 Mortality after excluding trials with any potential confounding.

Review: Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases

Comparison: 1 Antioxidants versus placebo/no intervention

Outcome: 7 Mortality after excluding trials with any potential confounding

| Study or subgroup | Antioxidants | Placebo | Risk Ratio M-H,Random,95% CI | Weight | Risk Ratio M-H,Random,95% CI |
|------------------|--------------|---------|-------------------------------|--------|-------------------------------|
| CARET 2004Low    | 1855/9420    | 1509/8894 | 84.4 % 1.16 [ 1.09, 1.23 ]    | 84.4 % 1.16 [ 1.09, 1.23 ]    |
| CHAOS 1996Low    | 68/1035      | 52/967   | 2.6 % 1.22 [ 0.86, 1.73 ]     | 2.6 % 1.22 [ 0.86, 1.73 ]     |
| Collins 2003Low  | 1/13         | 0/12     | 0.0 % 2.79 [ 0.12, 62.48 ]    | 0.0 % 2.79 [ 0.12, 62.48 ]    |
| DATOR 2004Low    | 1/12         | 0/12     | 0.0 % 3.00 [ 0.13, 67.06 ]    | 0.0 % 3.00 [ 0.13, 67.06 ]    |
| Desnuelle 2001Low| 34/144       | 35/144   | 1.9 % 0.97 [ 0.64, 1.47 ]     | 1.9 % 0.97 [ 0.64, 1.47 ]     |
| Graf 2005Low     | 31/83        | 28/77    | 1.9 % 1.03 [ 0.68, 1.54 ]     | 1.9 % 1.03 [ 0.68, 1.54 ]     |
| Jacobson 2000Low | 0/57         | 1/55     | 0.0 % 0.32 [ 0.01, 7.74 ]     | 0.0 % 0.32 [ 0.01, 7.74 ]     |
| Mezey 2004Low    | 4/25         | 5/26     | 0.2 % 0.83 [ 0.25, 2.75 ]     | 0.2 % 0.83 [ 0.25, 2.75 ]     |
| Mooney 2005Low   | 1/142        | 0/142    | 0.0 % 3.00 [ 0.12, 73.03 ]    | 0.0 % 3.00 [ 0.12, 73.03 ]    |
| REACT 2002Low    | 9/149        | 3/148    | 0.2 % 2.98 [ 0.82, 10.79 ]    | 0.2 % 2.98 [ 0.82, 10.79 ]    |
| SCPS 1990Low     | 79/913       | 72/892   | 3.4 % 1.07 [ 0.79, 1.46 ]     | 3.4 % 1.07 [ 0.79, 1.46 ]     |
| SKICAP AK 1997Low| 62/1157      | 53/1140  | 2.5 % 1.15 [ 0.81, 1.65 ]     | 2.5 % 1.15 [ 0.81, 1.65 ]     |
| SPACE 2000Low    | 31/97        | 29/99    | 1.8 % 1.09 [ 0.72, 1.66 ]     | 1.8 % 1.09 [ 0.72, 1.66 ]     |
| Tam 2005Low      | 1/20         | 1/19     | 0.0 % 0.95 [ 0.06, 14.13 ]    | 0.0 % 0.95 [ 0.06, 14.13 ]    |
| VEAPS 2002Low    | 2/177        | 1/176    | 0.1 % 1.99 [ 0.18, 21.73 ]    | 0.1 % 1.99 [ 0.18, 21.73 ]    |
| VECAT 2004Low    | 20/595       | 11/598   | 0.6 % 1.83 [ 0.88, 3.78 ]     | 0.6 % 1.83 [ 0.88, 3.78 ]     |
| WAVE 2002Low     | 6/105        | 2/108    | 0.1 % 3.09 [ 0.64, 14.95 ]    | 0.1 % 3.09 [ 0.64, 14.95 ]    |
| White 2002Low    | 1/50         | 1/50     | 0.0 % 1.00 [ 0.06, 15.55 ]    | 0.0 % 1.00 [ 0.06, 15.55 ]    |
| Wluka 2002Low    | 1/67         | 0/69     | 0.0 % 3.09 [ 0.13, 74.50 ]    | 0.0 % 3.09 [ 0.13, 74.50 ]    |
| **Total (95% CI)** | **14261** | **13628** | **100.0 % 1.16 [ 1.09, 1.23 ]** | **100.0 % 1.16 [ 1.09, 1.23 ]** |

Total events: 2207 (Antioxidants), 1803 (Placebo)

Heterogeneity: Tau² = 0.0, Chi² = 9.05, df = 18 (P = 0.96); I² = 0.0%

Test for overall effect: Z = 5.09 (P < 0.00001)
### Analysis 1.8. Comparison 1 Antioxidants versus placebo/no intervention, Outcome 8 Mortality in beta-carotene trials with a low or high risk of bias.

**Review:** Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases

**Comparison:** 1 Antioxidants versus placebo/no intervention

**Outcome:** 8 Mortality in beta-carotene trials with a low or high risk of bias

| Study or subgroup | Beta-carotene n/N | Control n/N | Risk Ratio M-H,Random 95% CI | Weight | Risk Ratio M-H,Random 95% CI |
|-------------------|-------------------|-------------|-----------------------------|--------|-----------------------------|
| 1 Trials with a low risk of bias | | | | | |
| AMDS 1996 Low | 2/39 | 2/32 | 0.1 % | 0.82 [0.12, 5.50] | |
| AREDS 2001 Low | 251/2370 | 240/2387 | 6.6 % | 1.05 [0.89, 1.25] | |
| ATBC 2003 Low | 5555/14560 | 2605/7287 | 16.2 % | 1.07 [1.03, 1.11] | |
| CARET 2004 Low | 1855/9420 | 1509/8894 | 14.3 % | 1.16 [1.09, 1.23] | |
| Coore 2000 Low | 13/498 | 2/237 | 0.1 % | 3.09 [0.70, 13.60] | |
| Grant 2002 Low | 0/335 | 0/153 | 0.0 % | 0.04 [0.00, 0.75] | |
| HATS 2001 Low | 1/84 | 1/76 | 0.0 % | 0.90 [0.06, 14.22] | |
| HPS 2002 Low | 1446/10269 | 1389/10267 | 13.7 % | 1.04 [0.97, 1.11] | |
| Jacobson 2000 Low | 0/57 | 1/55 | 0.0 % | 0.32 [0.01, 7.74] | |
| LAST 2004 Low | 0/30 | 2/31 | 0.0 % | 0.21 [0.01, 4.13] | |
| MINVITOX 1999 Low | 100/361 | 51/182 | 3.0 % | 0.99 [0.74, 1.32] | |
| NIT2 1993 Low | 157/1657 | 167/1661 | 5.0 % | 0.94 [0.77, 1.16] | |
| NSCPT 1999 Low | 15/820 | 72/801 | 0.7 % | 0.67 [0.35, 1.27] | |
| PHS 1996 Low | 979/11036 | 968/10335 | 12.3 % | 1.01 [0.93, 1.10] | |
| PPS 1994 Low | 25/425 | 14/214 | 0.7 % | 0.90 [0.48, 1.69] | |
| Prince 2003 Low | 1/29 | 0/32 | 0.0 % | 3.30 [0.14, 77.95] | |
| REACT 2002 Low | 9/149 | 3/148 | 0.2 % | 2.98 [0.82, 10.79] | |
| SCPS 1990 Low | 79/913 | 72/892 | 2.7 % | 1.07 [0.79, 1.46] | |
| SUVIMAX 2004 Low | 76/6481 | 98/6536 | 2.8 % | 0.78 [0.58, 1.05] | |
| WHS 2005 Low | 636/19937 | 615/19939 | 10.3 % | 1.03 [0.93, 1.15] | |
| **Subtotal (95% CI)** | **79470** | **70859** | **88.7 %** | **1.05 [1.00, 1.10]** | |

Total events: 11200 (Beta-carotene), 7766 (Control)

Heterogeneity: Tau² = 0.00; Chi² = 29.30; df = 19 (P = 0.06); I² = 35%

Test for overall effect: Z = 1.89 (P = 0.059)

2 Trials with a high risk of bias

| Study or subgroup | Beta-carotene n/N | Control n/N | Risk Ratio M-H,Random 95% CI | Weight | Risk Ratio M-H,Random 95% CI |
|-------------------|-------------------|-------------|-----------------------------|--------|-----------------------------|
| Chandra 1992 | 0/48 | 2/48 | 0.0 % | 0.20 [0.01, 4.06] | |

(Continued . . .)
### Analysis 1.9. Comparison 1. Antioxidants versus placebo/no intervention, Outcome 9. Mortality in vitamin A trials with a low or high risk of bias.

Review: Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases.

Comparison: 1. Antioxidants versus placebo/no intervention.

Outcome: 9. Mortality in vitamin A trials with a low or high risk of bias.

#### Study or subgroup

| Study or subgroup | Beta-carotene | Control | Risk Ratio | Weight |
|------------------|---------------|---------|------------|--------|
| Girodon 1997     | 12/41         | 7/20    | 0.5 %      | 0.84 [0.39, 1.79] |
| NIT 1993         | 101/814792    | 280/3698| 8.9 %      | 0.91 [0.80, 1.03] |
| Sasazuki 2003    | 6/222         | 18/217  | 0.4 %      | 0.33 [0.13, 0.81] |
| ST 2001          | 38/1706       | 43/1705 | 1.5 %      | 0.88 [0.57, 1.36] |

**Subtotal (95% CI)**: 16809 5688 11.3 % 0.81 [0.62, 1.07]

Total events: 1074 (Beta-carotene), 350 (Control).
Heterogeneity: Tau² = 0.03; Chi² = 5.82, df = 4 (P = 0.21); I² = 31%
Test for overall effect: Z = 1.47 (P = 0.14)

| Study or subgroup | Vitamin A | Control | Risk Ratio | Weight |
|------------------|-----------|---------|------------|--------|
| Allsup 2004Low   | 4/81      | 4/83    | 0.9 %      | 1.02 [0.27, 3.96] |
| CARET 2004Low    | 1855/9420 | 1509/8894 | 36.9 % | 1.16 [1.09, 1.23] |
| Grant 2002Low    | 0/335     | 5/153   | 0.2 %      | 0.04 [0.00, 0.75] |
| LAST 2004Low     | 0/30      | 2/31    | 0.2 %      | 0.21 [0.01, 4.13] |
| MAVIS 2005 Low   | 8/456     | 4/454   | 1.1 %      | 1.99 [0.60, 6.57] |
| Murphy 1992Low   | 4/53      | 2/56    | 0.6 %      | 2.11 [0.40, 11.06] |
| NIT 1993 Low     | 157/1657  | 167/1661 | 19.5 % | 0.94 [0.77, 1.16] |
| Pike 1995Low     | 1/24      | 0/23    | 0.2 %      | 2.88 [0.12, 67.29] |

Total events: 12274 (Beta-carotene), 8116 (Control).
Heterogeneity: Tau² = 0.00; Chi² = 43.87, df = 24 (P = 0.01); I² = 45%
Test for overall effect: Z = 0.71 (P = 0.48)
### Study or subgroup

| Study or subgroup | Vitamin A | Control | Risk Ratio | Weight |
|------------------|-----------|---------|------------|--------|
| SKICAP AK 1997Low | 62/1157   | 53/1140 | M-H,Random,95% CI | 9.6 % | 1.15 [ 0.81, 1.65 ] |
| Witte 2005Low    | 1/16      | 1/16    | M-H,Random,95% CI | 0.2 % | 1.00 [ 0.07, 14.64 ] |
| **Subtotal (95% CI)** | **13229** | **12511** | * | **69.2 %** | **1.09 [ 0.93, 1.28 ]** |

**Total events: 2092 (Vitamin A), 1747 (Control)**

- Heterogeneity: $\tau^2 = 0.01; \chi^2 = 11.63, df = 9 (P = 0.24); I^2 = 23\%$
- Test for overall effect: $Z = 1.11 (P = 0.27)$

2 Trials with a high risk of bias

| Study or subgroup | Vitamin A | Control | Risk Ratio | Weight |
|------------------|-----------|---------|------------|--------|
| Boneli 1998      | 1/147     | 0/157   | M-H,Random,95% CI | 0.2 % | 3.20 [ 0.13, 78.00 ] |
| Chandra 1992     | 0/48      | 2/48    | M-H,Random,95% CI | 0.2 % | 0.20 [ 0.01, 4.06 ] |
| Hogarth 1996     | 7/54      | 6/52    | M-H,Random,95% CI | 1.5 % | 1.12 [ 0.40, 3.12 ] |
| NIT1 1993        | 1067/14792 | 280/3698 | M-H,Random,95% CI | 28.8 % | 0.95 [ 0.84, 1.08 ] |
| Penn 1991        | 1/15      | 0/15    | M-H,Random,95% CI | 0.2 % | 3.00 [ 0.13, 68.26 ] |
| **Subtotal (95% CI)** | **15056** | **3970** | * | **30.8 %** | **0.96 [ 0.84, 1.08 ]** |

**Total events: 1076 (Vitamin A), 288 (Control)**

- Heterogeneity: $\tau^2 = 0.0; \chi^2 = 2.20, df = 4 (P = 0.70); I^2 = 0.0\%$
- Test for overall effect: $Z = 0.70 (P = 0.48)$

**Total (95% CI)** *(Continued)*

| Study or subgroup | Vitamin A | Control | Risk Ratio | Weight |
|------------------|-----------|---------|------------|--------|
| Nit 2005         | 1/15      | 0/15    | M-H,Random,95% CI | 0.2 % | 3.00 [ 0.13, 68.26 ] |
| **Subtotal (95% CI)** | **28285** | **16481** | * | **100.0 %** | **1.05 [ 0.93, 1.19 ]** |

**Total events: 3168 (Vitamin A), 2035 (Control)**

- Heterogeneity: $\tau^2 = 0.01; \chi^2 = 20.21, df = 14 (P = 0.12); I^2 = 31\%$
- Test for overall effect: $Z = 0.78 (P = 0.44)$
Analysis 1.10. Comparison I Antioxidants versus placebo/no intervention, Outcome 10 Mortality in vitamin C trials with a low or high risk of bias.

Review: Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases

Comparison: 1 Antioxidants versus placebo/no intervention

Outcome: 10 Mortality in vitamin C trials with a low or high risk of bias

| Study or subgroup | Vitamin C n/N | Control n/N | Risk Ratio M-H,Random,95% CI | Weight | Risk Ratio M-H,Random,95% CI |
|-------------------|---------------|-------------|-------------------------------|--------|-------------------------------|
| 1 Trials with a low risk of bias | | | | | |
| Allsup 2004 Low | 4/81 | 4/83 | 0.2 % | 1.02 [ 0.27, 3.96 ] | |
| AMDS 1996 Low | 2/39 | 2/32 | 0.1 % | 0.82 [ 0.12, 5.50 ] | |
| AREDS 2001 Low | 2512370 2402387 | 13.0 % | 1.05 [ 0.89, 1.25 ] | |
| ASAP 2003 Low | 2/260 | 1/130 | 0.1 % | 1.00 [ 0.09, 1.09 ] | |
| Correa 2000 Low | 3/241 | 2/237 | 0.1 % | 1.48 [ 0.25, 8.75 ] | |
| Grant 2002 Low | 0/335 | 5/153 | 0.1 % | 0.04 [ 0.00, 0.75 ] | |
| HATS 2001 Low | 1/84 | 1/76 | 0.1 % | 0.90 [ 0.06, 14.22 ] | |
| HPS 2002 Low | 144610269 138910267 | 40.2 % | 1.04 [ 0.97, 1.11 ] | |
| Jacobson 2000 Low | 0/57 | 1/55 | 0.0 % | 0.32 [ 0.01, 7.74 ] | |
| LAST 2004 Low | 0/30 | 2/31 | 0.1 % | 0.21 [ 0.01, 4.13 ] | |
| MAVIS 2005 Low | 8/456 | 4/454 | 0.3 % | 1.99 [ 0.60, 6.57 ] | |
| MINVITAOX 1999 Low | 100361 51/182 | 13.0 % | 0.99 [ 0.74, 1.32 ] | |
| Mooney 2005 Low | 1/142 | 0/142 | 0.0 % | 3.00 [ 0.12, 73.03 ] | |
| NIT2 1993 Low | 1571657 1671661 | 9.1 % | 0.94 [ 0.77, 1.16 ] | |
| Pike 1995 Low | 1/24 | 0/23 | 0.0 % | 2.88 [ 0.12, 67.29 ] | |
| PPS 1994 Low | 15433 142/14 | 0.9 % | 0.53 [ 0.26, 1.08 ] | |
| Prince 2003 Low | 1/29 | 0/32 | 0.0 % | 3.30 [ 0.14, 77.95 ] | |
| REACT 2002 Low | 9/149 | 3/48 | 0.3 % | 2.98 [ 0.82, 10.79 ] | |
| SULVIMAX 2004 Low | 766481 986536 | 4.7 % | 0.78 [ 0.58, 1.05 ] | |
| Tam 2005 Low | 1/20 | 1/19 | 0.1 % | 0.95 [ 0.06, 14.13 ] | |
| WAVE 2002 Low | 16212 6211 | 0.5 % | 2.65 [ 1.06, 6.65 ] | |
| White 2002 Low | 1/50 | 1/50 | 0.1 % | 1.00 [ 0.06, 15.55 ] | |
| Witte 2005 Low | 1/16 | 1/16 | 0.1 % | 1.00 [ 0.07, 14.64 ] | |
| Subtotal (95% CI) | 23796 23139 | 75.3 % | 1.01 [ 0.93, 1.10 ] |

Favours vitamin C Favours control

(Continued...)
### Study or subgroup

| Study or subgroup       | Vitamin C | Control | Risk Ratio | Weight |
|------------------------|-----------|---------|------------|--------|
|                        | n/N       | n/N     | M-H,Random,95% CI | M-H,Random,95% CI |
| Total events: 2096 (Vitamin C), 1993 (Control) | | |
| Heterogeneity: Tau² = 0.00; Chi² = 23.37, df = 22 (P = 0.38); I² = 6% |
| Test for overall effect: Z = 0.20 (P = 0.84) |
| 2 Trials with a high risk of bias |
| Bonelli 1998 | 1/147 | 0/157 | 0.0 % | 3.20 [ 0.13, 78.00 ] |
| Chandra 1992 | 0/48 | 2/48 | 0.0 % | 0.20 [ 0.01, 4.06 ] |
| Girodon 1997 | 12/41 | 7/20 | 0.8 % | 0.84 [ 0.39, 1.79 ] |
| Hogarth 1996 | 7/54 | 6/52 | 0.4 % | 1.12 [ 0.40, 3.12 ] |
| McKeown-Eysen 1988 | 4/96 | 3/89 | 0.2 % | 1.24 [ 0.28, 5.37 ] |
| NIT 1 1993 | 1069/14792 | 280/3698 | 20.0 % | 0.95 [ 0.84, 1.08 ] |
| Penn 1991 | 1/15 | 0/15 | 0.0 % | 3.00 [ 0.13, 68.26 ] |
| Sasazuki 2003 | 6/222 | 18/217 | 0.5 % | 0.33 [ 0.13, 0.81 ] |
| SIT 2001 | 38/1706 | 43/1705 | 2.3 % | 0.88 [ 0.57, 1.36 ] |
| ter Riet 1995 | 3/43 | 5/45 | 0.2 % | 0.63 [ 0.16, 2.47 ] |
| **Subtotal (95% CI)** | 17164 | 6046 | 24.7 % | 0.93 [ 0.83, 1.05 ] |
| Total events: 1141 (Vitamin C), 364 (Control) |
| Heterogeneity: Tau² = 0.00; Chi² = 8.17, df = 9 (P = 0.52); I² = 0.0% |
| Test for overall effect: Z = 1.20 (P = 0.23) |
| **Total (95% CI)** | 40960 | 29185 | 100.0 % | 0.99 [ 0.92, 1.06 ] |
| Total events: 3237 (Vitamin C), 2357 (Control) |
| Heterogeneity: Tau² = 0.00; Chi² = 33.56, df = 32 (P = 0.39); I² = 5% |
| Test for overall effect: Z = 0.32 (P = 0.75) |

---

**Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases (Review)**

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
### Analysis 1.11. Comparison 1 Antioxidants versus placebo/no intervention, Outcome 11 Mortality in vitamin E trials with a low or high risk of bias.

**Review:** Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases

**Comparison:** 1 Antioxidants versus placebo/no intervention

**Outcome:** 11 Mortality in vitamin E trials with a low or high risk of bias

| Study or subgroup          | Vitamin E n/N | Control n/N | Risk Ratio M-H,Random,95% CI | Weight | Risk Ratio M-H,Random,95% CI |
|----------------------------|---------------|-------------|-------------------------------|--------|-----------------------------|
| **Trials with a low risk of bias** |               |             |                               |        |                             |
| Allsup 2004Low             | 4/81          | 4/83        | 0.0 %                         | 1.02   | [0.27, 3.96]                |
| AMDS 1996Low               | 2/39          | 2/32        | 0.0 %                         | 0.82   | [0.12, 5.50]                |
| AREDS 2001Low              | 251/2370      | 240/2387    | 2.4 %                         | 1.05   | [0.89, 1.25]                |
| ASAP 2003Low               | 4/260         | 1/130       | 0.0 %                         | 0.00   | [0.02, 17.71]               |
| ATBC 2003Low               | 5433/4564     | 2605/7287   | 49.4 %                        | 1.04   | [1.01, 1.08]                |
| CHAOS 1996Low              | 68/1035       | 52/967      | 0.6 %                         | 1.22   | [0.86, 1.73]                |
| Collins 2003Low            | 1/26          | 1/26        | 0.0 %                         | 1.00   | [0.07, 15.15]               |
| DATATOP 2005Low            | 154/399       | 142/401     | 2.1 %                         | 1.09   | [0.91, 1.31]                |
| DATOR 2004Low              | 1/12          | 0/12        | 0.0 %                         | 3.00   | [0.13, 67.06]               |
| Desmuelle 2001Low          | 34/144        | 35/144      | 0.4 %                         | 0.97   | [0.64, 1.47]                |
| Graa 2002Low               | 3/499         | 5/153       | 0.0 %                         | 0.18   | [0.04, 0.76]                |
| Graf 2005Low               | 3/83          | 28/77       | 0.4 %                         | 1.03   | [0.68, 1.54]                |
| HATS 2001Low               | 1/84          | 1/76        | 0.0 %                         | 0.90   | [0.06, 14.22]               |
| HOPE TOO 2005Low           | 799/4761      | 801/4780    | 8.6 %                         | 1.00   | [0.09, 11.0]                |
| HPS 2002Low                | 1446/10269    | 1389/10267  | 14.7 %                        | 1.04   | [0.97, 1.11]                |
| Jacobson 2000Low           | 0/57          | 1/55        | 0.0 %                         | 0.32   | [0.01, 7.74]                |
| LAST 2004Low               | 0/30          | 2/31        | 0.0 %                         | 0.21   | [0.01, 4.13]                |
| MAVIS 2005 Low             | 8/456         | 4/454       | 0.0 %                         | 1.99   | [0.60, 6.57]                |
| Meydani 2004Low            | 39/311        | 44/306      | 0.4 %                         | 0.87   | [0.58, 1.30]                |
| Mezey 2004Low              | 4/25          | 5/26        | 0.0 %                         | 0.83   | [0.05, 2.75]                |
| MINVITAOX 1999Low          | 100361        | 51/182      | 0.8 %                         | 0.99   | [0.74, 1.32]                |
| Mooney 2005Low             | 1/142         | 0/142       | 0.0 %                         | 3.00   | [0.12, 73.03]               |
| NIT2 1993Low               | 1571/657      | 1671/661    | 1.6 %                         | 0.94   | [0.77, 1.16]                |
| Pike 1995Low               | 1/24          | 0/23        | 0.0 %                         | 0.00   | [0.00, 0.25]                |

(Continued...)
| Study or subgroup | Vitamin E | Control | Risk Ratio | Weight | (Continued) |
|------------------|-----------|---------|------------|--------|-------------|
|                  | n/N       | n/N     | M-H,Random,95% CI |        |             |
| PPS 1994Low      | 15/433    | 14/214  | 0.53 [0.26, 1.08] | 0.1 % |             |
| Prince 2003Low   | 1/29      | 0/32    | 3.30 [0.14, 77.95] | 0.0 % |             |
| REACT 2002Low    | 9/149     | 3/148   | 2.98 [0.82, 10.79] | 0.0 % |             |
| SPACE 2000Low    | 31/97     | 29/99   | 1.09 [0.72, 1.66]  | 0.4 % |             |
| SUPRMAX 2004Low  | 76/6481   | 98/6536 | 0.78 [0.58, 1.05]  | 0.8 % |             |
| Tam 2005Low      | 1/20      | 1/19    | 0.95 [0.06, 14.13] | 0.0 % |             |
| VEAPS 2002Low    | 2/177     | 1/176   | 1.99 [0.18, 21.73] | 0.1 % |             |
| VECAT 2004Low    | 20/595    | 11/598  | 1.83 [0.88, 3.78]  | 0.1 % |             |
| WAVE 2002Low     | 16/212    | 6/211   | 2.65 [1.06, 6.65]  | 0.1 % |             |
| White 2002Low    | 1/50      | 1/50    | 1.00 [0.06, 15.55] | 0.0 % |             |
| WHS 2005Low      | 636/19937 | 615/19939 | 1.03 [0.93, 1.15] | 5.8 % |             |
| Witte 2005Low    | 1/16      | 1/16    | 1.00 [0.07, 14.64] | 0.0 % |             |
| Wilka 2002Low    | 1/67      | 0/69    | 3.09 [0.13, 74.50] | 0.0 % |             |

**Subtotal (95% CI)**

| Study or subgroup | Vitamin E | Control | Risk Ratio | Weight | (Continued) |
|------------------|-----------|---------|------------|--------|-------------|
|                  | n/N       | n/N     | M-H,Random,95% CI |        |             |
|                  | 65952     | 57809   | 89.1 %     | 1.04 [1.01, 1.06] |             |

Total events: 9352 (Vitamin E), 6360 (Control)

Heterogeneity: Tau² = 0.0; Chi² = 31.07, df = 36 (P = 0.70); I² = 0.0%

Test for overall effect: Z = 2.47 (P = 0.014)

2 Trials with a high risk of bias

| Study or subgroup | Risk Ratio | Weight | (Continued) |
|------------------|------------|--------|-------------|
|                  | n/N        |        |             |
| ADCS 1 1997      | 12/85      | 0.1 %  | 0.99 [0.47, 2.07] |
| ADCS 2 2005      | 5/257      | 0.0 %  | 1.01 [0.30, 3.44] |
| Boneli 1998      | 1/147      | 0.0 %  | 3.20 [0.13, 78.00] |
| Chandra 1992     | 0/48       | 0.0 %  | 0.20 [0.01, 4.06] |
| de la Maza 1995  | 5/37       | 0.0 %  | 1.25 [0.36, 4.29] |
| de Waart 2001    | 0/109      | 0.0 %  | 0.33 [0.01, 8.09] |
| Gillian 1977     | 2/26       | 0.0 %  | 1.00 [0.05, 65.7] |
| Girodon 1997     | 12/41      | 0.1 %  | 0.84 [0.39, 1.79] |
| GISSI 1999       | 488/5660   | 5.0 %  | 0.92 [0.82, 1.04] |
| McKeown-Eysen 1988 | 4/96   | 0.0 %  | 1.24 [0.28, 5.37] |
| NIT 1 1993       | 1018/14792 | 4.2 %  | 0.91 [0.80, 1.03] |
| Penn 1991        | 1/15       | 0.0 %  | 3.00 [0.13, 68.26] |
| PPP 2001         | 72/2231    | 0.6 %  | 1.07 [0.78, 1.49] |
| SIT 2001         | 38/1706    | 0.4 %  | 0.88 [0.57, 1.36] |
| Stevic 2001      | 3/16       | 0.1 %  | 0.38 [0.12, 1.20] |

0.01 0.1 1 10 100

Favours vitamin E  Favours control

(Continued ...)

Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases (Review)
Analysis 1.12. Comparison 1 Antioxidants versus placebo/no intervention, Outcome 12 Mortality in selenium trials with a low or high risk of bias.

Review: Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases

Comparison: 1 Antioxidants versus placebo/no intervention

Outcome: 12 Mortality in selenium trials with a low or high risk of bias
| Study or subgroup | Selenium n/N | Control n/N | Risk Ratio M-H,Random,95% CI | Weight | Risk Ratio M-H,Random,95% CI |
|------------------|-------------|-------------|-------------------------------|--------|-----------------------------|
| Prince 2003 Low  | 1/29        | 0/32        | 0.1 % 3.30 [0.14, 77.95]     | 0.1 %  | 3.30 [0.14, 77.95]          |
| Rayman 2006 Low  | 1/380       | 0/121       | 0.1 % 0.96 [0.04, 23.43]     | 0.1 %  | 0.96 [0.04, 23.43]          |
| SUVIMAX 2004 Low| 76/6481     | 98/6536     | 7.9 % 0.78 [0.58, 1.05]      | 0.1 %  | 0.78 [0.58, 1.05]           |
| Witte 2005 Low  | 1/16        | 1/16        | 0.1 % 1.00 [0.07, 14.64]     | 0.1 %  | 1.00 [0.07, 14.64]          |

**Subtotal (95% CI)**

| 10639 | 10068 | 51.4 % | 0.90 [0.80, 1.01] |

Heterogeneity: Tau² = 0.0; Chi² = 9.59, df = 13 (P = 0.73); I² = 0.0%
Test for overall effect: Z = 1.72 (P = 0.085)

2 Trials with a high risk of bias:
- Bonelli 1998
- Chandra 1992
- Girodon 1997
- NIT1 1993
- ST1 2001
- Stevic 2001

**Subtotal (95% CI)**

| 16750 | 5640 | 48.6 % | 0.90 [0.80, 1.01] |

Heterogeneity: Tau² = 0.0; Chi² = 3.76, df = 5 (P = 0.58); I² = 0.0%
Test for overall effect: Z = 1.76 (P = 0.078)

**Total (95% CI)**

| 27389 | 15708 | 100.0 % | 0.90 [0.83, 0.98] |

Heterogeneity: Tau² = 0.0; Chi² = 13.32, df = 19 (P = 0.82); I² = 0.0%
Test for overall effect: Z = 2.46 (P = 0.014)
### Analysis 1.13. Comparison 1 Antioxidants versus placebo/no intervention, Outcome 13 Mortality in low-bias risk beta-carotene trials without selenium.

**Review:** Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases

**Comparison:** 1 Antioxidants versus placebo/no intervention

**Outcome:** 13 Mortality in low-bias risk beta-carotene trials without selenium

| Study or subgroup | Beta-carotene n/N | Placebo n/N | Risk Ratio M-H, Random, 95% CI | Weight | Risk Ratio M-H, Random, 95% CI |
|-------------------|------------------|------------|-------------------------------|--------|-----------------------------|
| AREDS 2001Low     | 251/2370         | 240/2387   | 5.6 % 1.05 [0.89, 1.25]       |        |                             |
| ATBC 2003Low      | 5555/14560       | 2605/7287  | 27.1 % 1.07 [1.03, 1.11]      |        |                             |
| CARET 2004Low     | 1855/9420        | 1509/8894  | 20.2 % 1.16 [1.09, 1.23]      |        |                             |
| Correa 2000Low    | 13/498           | 2/237      | 0.1 % 3.09 [0.70, 13.60]      |        |                             |
| HPS 2002Low       | 1446/10269       | 1389/10267 | 18.4 % 1.04 [0.97, 1.11]      |        |                             |
| Jacobson 2000Low  | 0/57             | 1/55       | 0.0 % 3.02 [0.01, 7.74]       |        |                             |
| NSCPT 1999Low     | 15/820           | 22/801     | 0.4 % 0.67 [0.35, 1.27]       |        |                             |
| PHS 1996Low       | 979/1036         | 968/1035   | 14.8 % 1.01 [0.93, 1.10]      |        |                             |
| PPS 1994Low       | 25/425           | 14/214     | 0.5 % 0.90 [0.48, 1.69]       |        |                             |
| REACT 2002Low     | 9/149            | 3/148      | 0.1 % 2.98 [0.82, 10.79]      |        |                             |
| SCPS 1990Low      | 79/913           | 72/892     | 1.9 % 1.07 [0.79, 1.46]       |        |                             |
| WHS 2005Low       | 636/19937        | 615/19939  | 10.8 % 1.03 [0.93, 1.15]      |        |                             |

**Total (95% CI):** 70454 62156 100.0 % 1.07 [1.02, 1.11]

Total events: 10863 (Beta-carotene), 7440 (Placebo)

Heterogeneity: Tau² = 0.00; Chi² = 16.77, df = 11 (P = 0.11); I² = 34%

Test for overall effect: Z = 2.90 (P = 0.0038)
### Analysis 1.14. Comparison 1 Antioxidants versus placebo/no intervention, Outcome 14 Mortality in low-bias risk vitamin A trials without selenium.

Review: Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases

Comparison: 1 Antioxidants versus placebo/no intervention

Outcome: 14 Mortality in low-bias risk vitamin A trials without selenium

| Study or subgroup       | Vitamin A n/N | Placebo n/N | Risk Ratio M-H,Random 95% CI M-H,Random | Weight | Risk Ratio M-H,Random 95% CI M-H,Random |
|-------------------------|--------------|-------------|----------------------------------------|--------|----------------------------------------|
| CARET 2004 Low          | 1855/9420    | 1509/8894   | 1.16 [1.09, 1.23]                      | 96.7%  | 1.16 [1.09, 1.23]                      |
| MAVIS 2005 Low          | 8456         | 4454        | 1.99 [0.60, 6.57]                      | 0.3%   | 1.99 [0.60, 6.57]                      |
| Murphy 1992 Low         | 453          | 256         | 2.11 [0.40, 11.06]                     | 0.1%   | 2.11 [0.40, 11.06]                     |
| Pike 1995 Low           | 124          | 023         | 2.88 [0.12, 67.29]                     | 0.0%   | 2.88 [0.12, 67.29]                     |
| SKICAP AK 1997 Low      | 62/1157      | 53/1140     | 1.15 [0.81, 1.65]                      | 2.9%   | 1.15 [0.81, 1.65]                      |

**Total (95% CI)**

| Vitamin A n/N | Placebo n/N | Risk Ratio M-H,Random 95% CI M-H,Random | Weight | Risk Ratio M-H,Random 95% CI M-H,Random |
|---------------|-------------|----------------------------------------|--------|----------------------------------------|
| 11110         | 10567       | 1.16 [1.10, 1.24]                      | 100.0% | 1.16 [1.10, 1.24]                      |

Total events: 1930 (Vitamin A), 1568 (Placebo)

Heterogeneity: Tau² = 0.0, Chi² = 1.61, df = 4 (P = 0.81); I² = 0.0%

Test for overall effect: Z = 4.91 (P < 0.00001)
**Analysis 1.15.** Comparison 1 Antioxidants versus placebo/no intervention, Outcome 15 Mortality in low-bias risk vitamin C trials without selenium.

Review: Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases

Comparison: 1 Antioxidants versus placebo/no intervention

Outcome: 15 Mortality in low-bias risk vitamin C trials without selenium

| Study or subgroup | Vitamin C | Placebo | Risk Ratio M-H,Random,95% CI | Weight | Risk Ratio M-H,Random,95% CI |
|-------------------|-----------|---------|-----------------------------|--------|-----------------------------|
| AREDS 2001Low     | 25/2370   | 240/2387| 0.89 [ 0.89, 1.25 ]         | 31.0 % | 1.05 [ 0.89, 1.25 ]         |
| ASAP 2003Low      | 2/260     | 1/130   | 1.00 [ 0.09, 10.93 ]         | 0.3 %  | 2.15 [ 0.47, 9.87 ]         |
| Correa 2000Low    | 9/496     | 2/237   | 0.6 %  | 1.04 [ 0.97, 1.11 ]         |
| HPS 2002Low       | 1466/10269| 1389/10267| 0.3 %  | 1.00 [ 0.09, 10.93 ]         |
| Jacobson 2000Low  | 0/57      | 1/55    | 0.32 [ 0.01, 7.74 ]         |
| MAVIS 2005 Low    | 8/456     | 4/454   | 1.0 %  | 1.99 [ 0.60, 6.57 ]         |
| Mooney 2005Low    | 1/42      | 0/42    | 0.30 [ 0.12, 7.36 ]         |
| Pike 1995Low      | 1/24      | 0/23    | 0.1 %  | 2.88 [ 0.12, 67.29 ]        |
| PPS 1994Low       | 15/433    | 14/214  | 0.2 %  | 0.53 [ 0.26, 1.08 ]         |
| REACT 2002Low     | 9/496     | 3/148   | 0.9 %  | 2.98 [ 0.82, 10.79 ]        |
| Tam 2005Low       | 1/20      | 1/19    | 0.2 %  | 0.95 [ 0.06, 14.13 ]        |
| WAVE 2002Low      | 16/212    | 6/211   | 1.7 %  | 2.65 [ 1.06, 6.65 ]         |
| White 2002Low     | 1/50      | 1/50    | 0.2 %  | 1.00 [ 0.06, 15.55 ]        |
| **Total (95% CI)**| **14938** | **14337**| 100.0 % | 1.06 [ 0.94, 1.20 ]        |

Total events: 1760 (Vitamin C), 1662 (Placebo)

Heterogeneity: Tau² = 0.01; Ch² = 13.38, df = 12 (P = 0.34); I² = 10%

Test for overall effect: Z = 1.00 (P = 0.32)

---

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
**Analysis 1.16.** Comparison 1 Antioxidants versus placebo/no intervention, Outcome 16 Mortality in low-bias risk vitamin E trials without selenium.

Review: Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases

Comparison: 1 Antioxidants versus placebo/no intervention

Outcome: 16 Mortality in low-bias risk vitamin E trials without selenium

| Study or subgroup | Vitamin E n/N | Placebo n/N | Risk Ratio M-H,Random,95% CI | Weight | Risk Ratio M-H,Random,95% CI |
|-------------------|---------------|-------------|-----------------------------|--------|-----------------------------|
| AREDS 2001Low     | 251/2370      | 240/2387    | 2.9 % 1.05 [0.89, 1.25]     |        |                             |
| ASAP 2003Low      | 4/260         | 1/30        | 0.0 % 2.00 [0.23, 17.71]    |        |                             |
| ATBC 2003Low      | 543/14564     | 260/5278    | 57.9 % 1.04 [1.01, 1.08]    |        |                             |
| CHAOS 1996Low     | 68/1035       | 52/767      | 0.7 % 1.22 [0.86, 1.73]     |        |                             |
| Collins 2003Low   | 1/26          | 1/26        | 0.0 % 1.00 [0.07, 15.15]    |        |                             |
| DATATOP 2005Low   | 154/399       | 142/401     | 2.5 % 1.09 [0.91, 1.31]     |        |                             |
| DATOR 2004Low     | 1/12          | 0/12        | 0.0 % 3.00 [0.13, 67.06]    |        |                             |
| Desnuelle 2001Low | 3/144         | 3/144       | 0.5 % 0.97 [0.64, 1.47]     |        |                             |
| Graf 2005Low      | 31/83         | 28/77       | 0.5 % 1.03 [0.68, 1.54]     |        |                             |
| HOPE TOO 2005Low  | 799/4761      | 801/4780    | 10.1 % 1.00 [0.92, 1.10]    |        |                             |
| HPS 2002Low       | 1446/10269    | 1389/10267  | 17.2 % 1.04 [0.97, 1.11]    |        |                             |
| Jacobson 2000Low  | 0/57          | 1/55        | 0.0 % 0.32 [0.01, 7.74]     |        |                             |
| MAVIS 2005 Low    | 8/456         | 4/454       | 0.1 % 1.99 [0.60, 6.57]     |        |                             |
| Mezey 2004Low     | 4/25          | 5/26        | 0.1 % 0.83 [0.25, 2.75]     |        |                             |
| Mooney 2005Low    | 1/142         | 0/142       | 0.0 % 3.00 [0.12, 73.03]    |        |                             |
| Pike 1995Low      | 1/24          | 0/23        | 0.0 % 2.88 [0.12, 67.29]    |        |                             |
| PPS 1994Low       | 15/433        | 14/214      | 0.2 % 0.53 [0.26, 1.08]     |        |                             |
| REACT 2002Low     | 9/149         | 3/148       | 0.0 % 2.94 [0.82, 10.79]    |        |                             |
| SPACE 2000Low     | 31/97         | 29/999      | 0.5 % 1.09 [0.72, 1.66]     |        |                             |
| Tam 2005Low       | 1/20          | 1/19        | 0.0 % 0.95 [0.06, 14.13]    |        |                             |
| VEAPS 2002Low     | 2/177         | 1/176       | 0.0 % 1.99 [0.08, 58.73]    |        |                             |
| VECAT 2004Low     | 20/595        | 11/598      | 0.2 % 1.83 [0.88, 3.78]     |        |                             |
| WAVE 2001Low      | 16/212        | 6/211       | 0.1 % 2.45 [1.06, 6.65]     |        |                             |
| White 2002Low     | 1/50          | 1/50        | 0.0 % 1.00 [0.06, 15.55]    |        |                             |
| WHS 2005Low       | 636/19937     | 615/19939   | 6.8 % 1.03 [0.93, 1.15]     |        |                             |

(Continued ...)
Study employed inappropriate statistical analysis, 5 June 2008

Summary

Study employed inappropriate statistical analysis

Steve Hickey¹, Claus Hancke, Rob Verkerk², Gert Schuitemaker³, Andrew Hickey, Hilary Roberts, and Len Noriega⁴

¹Faculty of Computing Engineering and technology, Staffordshire University, Beaconside, Stafford, England.
²Alliance for Natural Health, Dorking, Surrey, England.
³International Society for Orthomolecular Medicine, Ortho Institute, Toronto, Canada.
The review by Bjelakovic et al. (2008) has statistical inconsistencies, which bring its conclusions into doubt. Moreover, its statistical assumptions are biologically unsound. Furthermore, Bjelakovic et al. used non-blind selection of trials and post hoc selection of statistical tests.

1. The study selected the trials in a non-blind fashion, thereby introducing bias. Blinding is crucially important, as previous knowledge may cause reviewers to distort comparisons. More importantly, the authors have not addressed this critical objection, despite it having been published as a specific and direct refutation of the earlier version of this review. This study is thus a statement of the opinion of the authors and depends on their prior prejudice.

2. The results of this conflicting review should be considered a tentative modification of the prior probability of substantial positive effects (Bayes’ theorem). Since the claimed effects are relatively small, and the N value is large, the importance of these effects may be considered minimal in the light of existing knowledge.

3. The presentation of results appears biased. For example, one of the main reported results claimed increased risk with beta-carotene if selenium was not included. We might ask what the results would be if selenium were included, or if vitamins C and E were excluded, and so on. The analyses in the last section (10.13-10.16) exclude selenium, but each of the antioxidants studied, that is vitamin A (which is not an antioxidant) and the other interventions, could have been excluded. However, results for the exclusion of selenium alone are reported. The authors’ suggestion that this is not post hoc design because it is based on their previous review on antioxidants and gastrointestinal cancer, appears to be a circular argument. The current review contains 10 trials of antioxidant supplements in gastrointestinal cancers, and the studies in the two reviews overlap.

4. Did using only the first period from crossover trials introduce bias? To show that this is not the case the results from the full datasets could have been provided.

5. The review reported no effect on mortality, in the more appropriate random effects model. The fixed effects model is inappropriate in this heterogeneous group of studies involving multiple interventions. It is not acceptable that such heterogeneity is ignored. Pooled studies must be compatible. The use of two such analytical approaches (tests) should be balanced by a decrease in the acceptable confidence level, which was not done.

6. Failure to include a full description of the analyses invalidates all conclusions, as they could have arisen from repeated testing.

7. The analyses performed included multiple subgroups and comparisons, yet the authors report no specific calculation to support the validity of this procedure. Again, the potential for bias is substantial.

8. The reported statistics are inconsistent; for example, the abstract claims: low-bias risk trials on selenium found no significant effect on mortality (RR 0.91, 95% CI 0.76 to 1.09) but analysis 01.12 gives “0.90 [0.80, 1.01]” for low risk trials and exactly the same output results for high risk trials. Moreover, the combined result showed a significant benefit “0.90 [0.83, 0.98]”.

9. It is invalid to assume that weighting studies based on the N value alone minimizes bias, especially if a small number of large studies receive a high weighting. Systematic bias from the methods employed occurs in experiments regardless of their scale. For example, on page 185, two studies, ATBC and CARET, involving smokers (and asbestos workers), were weighted 47.3% of the total. Overall, the presentation of statistical results in the review suggests a high degree of experimenter choice. The review does not provide sufficient detail of the actual and totality of tests performed to evaluate the results with true statistical meaning.

The conclusions cannot be considered as more than the prior prejudice of the authors. Cochrane should make clear the subjective nature of this review.

1 Higgins J.P.T. Green S. (2006) Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [updated September 2006]. In: The Cochrane Library, Issue 4, John Wiley & Sons, Ltd.
2 S. Hickey H.J. Roberts and L.A. Noriega (2007) Poor methodology in meta-analysis of vitamins, JOM, 22(1), 8-10.
3 Hemilä H. (2007) Antioxidant Supplements and Mortality. Vol. 298 No.
Reply

We have read the letter from Hickey et al with interest. Overall, we disagree that our statistical analyses are inappropriate. As described in our review, our analyses were planned in advance. We do not understand why our assumptions are ‘biologically unsound’. We employ methodology of reviewing systematically all randomised trials we could identify. This is the soundest scientific method incorporating biological knowledge regarding interpretation of beneficial and harmful effects of interventions. We used the Cochrane well-established procedure for selecting trials for inclusion in our review and no one can accuse us of performing a biased selection of trials. The selection of statistical analyses was not post hoc, but according to our protocol and to the standard methodology within the Cochrane Hepato-Biliary Group.

We know that our conclusions have stirred a debate and have received several comments from people who disagree with our approach and suggest a number of different subgroup analyses, sensitivity analyses, and other post-hoc analyses to test the overall result. However, since systematic reviews with meta-analyses are observational, although based on data that were originally gathered in a prospective and controlled manner, we believe that it is crucial to maintain a rigorous approach. Therefore, we have not changed our analytical strategy, but will of course consider all relevant comments in future reviews. Below please also see our point-to-point reply to the comments.

1. The selection of trials was based on criteria specified in our protocol and described in the methods section of our review. None of the authors of the review have participated in clinical trials that were excluded or included in the present review. We were of course familiar with some of the literature at the protocol stage. There were no financial, academic, or personal interests on the side of the authors that may be construed as a conflict of interest. Furthermore, to the best of our knowledge there is no clear evidence demonstrating the negative effects of selecting trials in a non-blinded manner. This is what is usually conducted in Cochrane systematic reviews. And where are - by the way - the trials that we wrongly included and excluded?

When results like our present become published, many people may react based on different backgrounds. Hickey and co-authors accuse us for not having responded to a previous critical objection published by them in JOM, ie, Journal of Orthomolecular Medicine. First, we do not have access to this journal. Second, none of the authors have sent us their objections. Third, Hickey and co-authors should know that the usual academic procedure is to submit such objections to JAMA, which in 2007 published an abbreviated version of our review. Had they done so, we would of course have responded to any of their objections.

2. We have assessed the evidence regarding the primary and secondary preventive effects of antioxidant supplements with traditional meta-analytic methodology of randomised clinical trials. Randomised clinical trials - and especially those having low risk of bias - are to be found at the top of the evidence hierarchy. We did not employ Baysian meta-analyses. That Hickey and co-authors might have had prior probabilities being more positive towards antioxidant supplements than a neutral prior could be due to them placing too much confidence in results of observational studies and in basic research findings from in vivo and in vitro studies. The literature is loaded with examples where evidence from randomised trials does not concur with evidence from lower levels of the evidence hierarchy. That antioxidant supplements could be another of these examples does not come as a surprise to us.

3. Our 2004 Cochrane Hepato-Biliary Group systematic review on antioxidant supplements including 14 randomised trials, among which only 9 trials provided data on overall mortality, led us to observe an increased mortality in participants on antioxidant supplements. At that time we were informed in an Editorial accompanying our paper in The Lancet that this conclusion could be wrong due to the fact that we had only included the randomised trials that looked on antioxidant supplement prevention of gastrointestinal cancers. Our present Cochrane Hepato-Biliary Group systematic review on antioxidant supplements is a response to the request for a broader meta-analysis, including all randomised preventive trials on antioxidant supplements that report mortality. We do, therefore, agree with Hickey and co-authors that the results of our previous review influenced our present review, now including 67 randomised trials. It is also correct that our analyses excluding selenium trials can be seen as a post-hoc decision. However, it should be seen as a post-hoc decision following our findings in our 2004 Cochrane Hepato-Biliary Group systematic review on antioxidant supplements. It is not a post-hoc decision taken following the analyses of data in our present review. We think this distinction is of central importance to the inferences drawn from our analyses. So, when we write: “The sensitivity analysis removing selenium trials from our analysis to evaluate their influence on our conclusions was therefore not a post hoc decision”, we should have added perhaps “taken after the analyses of trials in the present review”. Of course, we let us informed of our previous results. Isn’t this the whole meaning of doing research?
In retrospect, we are not so sure that we did a fair mix of antioxidants by including selenium. We feel that it is fair science to take this understanding into consideration, now that we have looked at a larger group of antioxidant trials. If we do not learn from previous mistakes, where would we end up?

Hickey and co-authors do not consider vitamin A as an antioxidant. We refer the reader to our discussion on that topic in our review.

Hickey and co-authors point to the fact that there is an overlap between our primary systematic review on antioxidant supplements for prevention of cancer and our present review on antioxidants on prevention of mortality. This overlap is not at all surprising or wrong. We would have been accused of slicing up the evidence if we had excluded previously reviewed trials that contained information on mortality in our present review.

4. Among the 67 included trials, only two trials (Gililan 1977; Prince 2003) are of cross-over design. We did not include data from the second period of cross-over trials to avoid mixing acute effects with more protracted effects (ie, carry over effects). This could have biased our analyses. The exclusion of the second phase from cross-over trials is an unlikely cause of bias. First, the vast majority of the cross-over trials were trials with relatively short duration and, therefore, not very likely to inform us on mortality data. Second, as antioxidants seem to increase mortality, the inclusion of the second phase of cross-over trials would have risked our results to become biased towards no difference (when in fact a difference exists in reality). Third, the approach we used on cross-over trials is the approach selected in the majority of Cochrane reviews including cross-over trials (Lathyrakis DN, Trikalinos TA, Ioannidis JP. Evidence from crossover trials: empirical evaluation and comparison against parallel arm trials. Int J Epidemiol. 2007;36(2):422-30).

5. The random-effects model analyses provided a more conservative estimate of the effects of antioxidants than the fixed-effect model analyses, based on the fact that the former analysis puts more weight on small trials (which are more often biased) compared to the latter analyses, which weight more the results from larger trials. Such larger trials are considered trustworthy both considering the risk for systematic error and risk for random error.

When we look at the analyses based on the 47 low-bias risk trials, we would like to draw attention to the fact that our random-effects model and our fixed-effect model analyses fully concur: RR 1.05, 95% CI 1.02 to 1.08, P = 0.003 in the random-effects model compared to RR 1.05, 95% CI 1.03 to 1.08, P = 0.00001 in the fixed-effect model. In these analyses, on which we place our largest confidence, we find no substantial heterogeneity ($I^2 = 7.5\%$). So, we do not understand the accusation that we ignored heterogeneity and that we did not see increased mortality in the antioxidant supplemented group by using the random-effects model.

6. We did not exclude any analyses. We agree that we conducted a number of analyses and this may make it difficult to evaluate all of our findings. We also agree that meta-analyses as presently conducted both within and outside The Cochrane Collaboration run the risk of reaching statistically significant results due to repeated testing of accumulating data in cumulative meta-analyses (Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. J Clin Epidemiol 2008;61:64-75).

In response to this criticism, we would like to draw attention to the following. First, the $P$-values we observed were generally small and unlikely to be affected by, eg, Bonferroni correction. Second, we observed a detrimental effect of antioxidant supplements. It is more likely that there are unpublished trial results with detrimental data than unpublished trials with positive results. Therefore, significant negative findings in meta-analyses should be considered firmer evidence than if we were dealing with positive observations. This is due to the strong publication bias that appears to affect most areas of clinical research. We are in the process of analysing our data with trial sequential analyses.

7. We agree that subgroup analyses may open for biased results. The grouping of trials according to bias-risk was planned in our protocol. The subgroup analyses excluding trials with potential confounders were conducted to present as fair comparisons between antioxidant supplements and placebos as possible - running the risk of losing the statistical power that meta-analysis introduces. From these analyses, we got the clear impression that these ‘fairest’ comparisons only substantiated the detrimental effect of antioxidant supplements observed in our primary analyses (relative risk of death due to antioxidant supplements after exclusion of all trials with potential confounding 1.16, 95% CI 1.09 to 1.23, P < 0.00001 without significant heterogeneity ($I^2 = 0.0\%$)). This is equal to an increased mortality caused by antioxidant supplements of 16%.
8. Hickey and co-authors are correct. The intervention effects regarding selenium is wrongly quoted in the abstract: RR 0.91, 95% CI 0.76 to 1.09 should become RR 0.90, 95% CI 0.80 to 1.01, as we correctly report in the results section. We have now amended this mistake.

We do not advice to base conclusions that include high-bias risk trials. Such results are likely to be biased.

9. Contrary to what Hickey and co-authors seem to assume we have put much effort into weighting both systematic errors and random errors in our reviews. It is through putting focus on both types of errors that we obtain clinical research results that are internally valid and can be used for discussing external validity. Hickey and co-authors note that both the ATBC trial and the CARET trial carry a large weight. We notice that having these trials included does not cause substantial heterogeneity ($I^2 = 7.5\%$), and both trials included almost 50 000 of the about 181 000 participants in the low-bias risk trials. So no wonder the two trials carry a large weight. In this post hoc decision-making process, should these two trials be excluded due to the smokers and asbestos workers participating in them or should they stay because they both fulfilled our a priori-defined inclusion criteria?

To elucidate the impact of the two trials on our findings, we excluded them from the analysis of the 47 low-bias risk trials. Comparing the intervention effect of antioxidant supplements in the remaining 45 randomised trials did not show any significant difference compared to the meta-analysis of the effect in the ATBC and CARET trials (test of interaction, $z = -1.44$, $P = 0.15$). When we excluded the CARET trial from the 19 trials without any potential confounders and compared the remaining 18 trials to the results of the CARET trial, we did not observe significant differences (test of interaction, $z = -0.22$, $P = 0.83$).

So, we do not think our analyses are biased by any prejudice, but as always regarding bias: others may be better to judge than oneself. In a similar vein, we would like to draw the readers' attention to the previous publications of Hickey and co-authors as well as the institutions they work. These pieces of information make us ask: 'What kind of bias may they have?'

Contributors
Christian Gluud,
Lise Lotte Gluud,
Dimitrinka Nikolova,
Rosanna Simonetti,
Goran Bjelakovic.

Subjective, selective, and biased, 5 June 2008

Summary

Subjective, selective, and biased
Gert Schuitemaker¹, Bo Jonson¹ï, Stephen Lawson¹ï¹, Steve Hickey⁴, Len Noriega⁵, Hilary Roberts, Damien Downing⁵

¹International Society for Orthomolecular Medicine, Ortho Institute, Toronto, Canada.
¹ïDepartment of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
¹ï¹Linus Pauling Institute, Oregon State University, Corvallis, OR, USA.
⁴Faculty of Computing Engineering and Technology, Staffordshire University, Beaconside, Stafford, England.
⁵British Society for Ecological Medicine, England.

The review on antioxidant supplements and mortality by Bjelacovic et al (2008) essentially is a repeated publication of a review that has been highly criticized. The criticisms cover both the background biology and the statistical methods employed.

Main conclusions
The report's main conclusion, "we found no evidence to support antioxidant supplements for primary or secondary prevention", is not derived from the nature of the study, which was on mortality. The sole outcome measure in this review was all-cause mortality.
The report’s secondary finding “vitamin A, beta-carotene, and vitamin E may increase mortality.” is in the author's conclusions. This result was only produced by statistical manipulation when the effects of selenium were excluded, and the number of statistical tests was not reported.

The report’s third finding, “future randomized trials could evaluate the potential effects of vitamin C and selenium for primary and secondary prevention”, is inappropriate, given the nature of this study of mortality. The additional statement “such trials should be closely monitored for potential harmful effects” implies bias and a lack of appreciation that such factors are normally monitored in well-designed trials.

The report’s final main finding, “antioxidant supplements need to be considered medicinal products and should undergo sufficient evaluation before marketing”, is a political statement that is not justified by the scientific content of this review.

### Statistical problems

1. The authors refer to the previous publication of their review but ignore the detailed scientific and methodological criticisms that it attracted.\(^1\)\(^,\)\(^2\)

2. A meta-analysis of mortality should not be used as a vehicle to promote a controversial viewpoint on the role of nutrition in primary or secondary prevention of disease. Moreover, the authors of such studies should be required to answer the existing major criticisms in their work before producing a repeated publication.

The study pooled study data from both the sick and the healthy and included several other interventions that increased the variability in the data. This increased variability could hide positive effects. The sick had a variety of conditions each of which needed to be considered separately in the design. Pooling these groups is not biologically valid because of the different sources of variation in the data. Pooling sick and healthy groups confuses nutrition and pharmacology.

3. Studies with no deaths were excluded, 405 studies showed no deaths compared with the 67 included studies, and relative statistics were reported. Any inference about the role of supplements in causing such deaths is unwarranted; there may have been deaths that had no relation to supplement use. There was no valid calculation to demonstrate that gross bias did not result. In the classic book “How to Lie with Statistics”, Darrel Huff used relative measure to show how statistics can mislead.\(^3\)

4. The report of the “sensitivity analysis” involving 14 studies with no deaths to show that excluding such studies had no effect was flawed. The studies were not listed. Similarly, the reports of the analysis with one death were insufficiently well described for the reader to evaluate their meaning.

5. “Participants lost to follow-up were considered survivors.” There is no justification for this assumption, no estimate of the proportions in each of the groups for each statistical test employed, and no calculation of its impact on the results.

6. The selection of trials defined as “high bias” or “low bias”, with inadequate criteria, gives differing results. Since the selection process was not blind, these results are unreliable, since a greater bias than that controlled could arise from the subjective selection.

7. Two large trials with positive results (GISSI and NIT1) were allocated to the high-risk group, the reasons are not clear and may be inappropriate.

### Pharmacology and nutrition

1. The use of placebo controls in study selection is inappropriate and poor science, as placebo effects would not cause or prevent death, which is a definitive and objective outcome.\(^4\)

2. Vitamin A is not a dietary antioxidant. The author’s suggestion that vitamin A has antioxidant activity is spurious, as numerous dietary substances have some redox activity.

3. Dietary antioxidants have complex redox mechanisms and it is oversimplistic to assume that consumption of a particular dose or molecular form of an “antioxidant” will produce a physiological antioxidant effect.\(^5\)
4. The antioxidant supplements studied were a small subset of available dietary supplements. Several redox active substances, such as rutin, coenzyme Q10, and iron, used in the included studies were not addressed in the analysis.

5. The doses of Vitamin C studied were too small and too infrequent to be effective. Taken alone, this point invalidates the vitamin C element of the study. Claims for the effects of vitamin C relate to doses 10–100 times larger than those in the Bjelakovic paper.

6. The paper fails to distinguish between different forms of selenium, such as sodium selenite or methylselenocysteine, which have different pharmacological and redox effects. Without a description of the different forms, the results are unclear and confusing.

7. The term “vitamin E”, as used in the paper, is vague. Vitamin E is a generic term for members of two families of molecules, the tocopherols and the tocotrienols. In addition, several other lipid-soluble antioxidants show vitamin E activity. The tocopherols consist of a set of four molecules, alpha-, beta-, delta-, and gamma-tocopherols, and the tocotrienols are similarly grouped. These molecules are subdivided further, in terms of molecular configuration. Taking alpha-tocopherol as an example, the naturally occurring RRR-alpha-tocopherol is usually called d-alpha-tocopherol. Synthetic “dl-alpha-tocopherol” consists of roughly equal amounts of the eight possible stereoisomers (RRR, RSS, RSR, RSS, SSS, SSR, SRS and SRR) and may contain several additional unnatural molecules. Basic pharmacology indicates that each of these molecules has specific effects in the body and thus the indiscriminate results for “vitamin E” are misleading.

8. The authors’ suggestion that the effect of antioxidants is one of the most adequately researched areas indicates a lack of knowledge of fundamental questions in redox biology and medicine.

9. Trials that included children and pregnant women were excluded from the study “since they may be in need of certain antioxidant supplements”. This introduces bias against antioxidants.

10. The authors claim that unpublished studies of antioxidants are more likely to be negative than positive. They provide no direct or specific evidence to support this claim. The equally valid counter argument is that some commercial sources of funding would prefer not to publish trials favouring antioxidants to profitable drugs.

Conclusions
As Sir Bradford Hill pointed out in his landmark “rules” paper,7 epidemiology should rigorously conform to the constraints of basic science and physiology. This study by Bjelakovic is a particularly confused application of statistical methods, as it involves a varied intake of antioxidant supplements, other nutrients, and drugs, in heterogeneous populations of both sick and healthy people. With such diversity, the meaning of results is unclear and the study’s conclusions have little validity.

The authors may wish to return to their analysis to provide sufficient information for an objective assessment of their results to be made. Without such a re-analysis, this review may be considered biased.

1 Hickey S, Roberts H, Noriega L. (2007) Poor methodology in meta-analysis of vitamins, JOM, 22(1), 8-10.
2 Albanes D. (2007) Antioxidant Supplements and Mortality. JAMA, 298(4), 402-403.
3 Huff D. (1993) How to Lie With Statistics, W. W. Norton & Company.
4 Hróbjartsson A, Gøtzsche PC. Placebo interventions for all clinical conditions. Cochrane Database of Systematic Reviews 2003, Issue 1. Art. No.: CD003974.
5 Block G, Jensen C.D, Morrow J.D, Holland N, Norkus E.P, Milneb G.L, Hudesa M, Dalvia T,B, Crawford P.B, Fung E.B, Schumacher L, Harmatz P. (2008) The effect of vitamins C and E on biomarkers of oxidative stress depends on baseline level, Free Radical Biology and Medicine, doi:10.1016/j.freeradbiomed.2008.04.005.
6 S. Hickey H.J. Roberts and R.F. Cathcart (2005) Dynamic flow, JOM, 20(4), 237-244.
7 Hill A.B. (1965) The environment and disease: Association or causation? Proc Roy Soc Med, 58, 295-300.

Reply
As stated in our review, an abbreviated version of the review was published in JAMA (Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: Systematic review and meta-analysis. JAMA. 2007;297(8):842-857). We have previously answered to all critical comments raised to that paper (Gluud LL, Bjelakovic G, Nikolova D, Simonetti RG, Gluud C. Antioxidant supplements and mortality-Reply. JAMA. 2007;298(4):402-403).

On 'Main conclusions'
We have responded to major parts of these allegations in the letter by Hickey et al above, and we refer readers to those responses.

We are well aware of the correct way to monitor trials dealing with potential harmful interventions. The fact is, however, that the vast majority of trials are insufficiently monitored. For example, only 27% of the clinical trials (470) used a data monitoring committee and only 7% (116) reported some form of interim analysis out of 1722 randomised trials published in eight major journals during 2000 to 2005 (Tharmanathan P, Calvert M, Hampton J, Freemantle N. The use of interim data and Data Monitoring Committee recommendations in randomized controlled trial reports: frequency, implications and potential sources of bias. BMC Med Res Methodol. 2008;8:12).

We agree with Schuitemaker and co-authors that our request for more proper regulatory overview is urgently needed concerning antioxidant supplements, and that our statement may be seen as a political statement. We expressed this with the hope that some politicians and regulatory authorities will act as brave individuals and not servants of the industry.

On 'Statistical problems'
1. We have responded to the criticism raised in JAMA (Gluud LL, Bjelakovic G, Nikolova D, Simonetti RG, Gluud C. Antioxidant supplements and mortality-Reply. JAMA. 2007;298(4):402-403). This is the normal and usual academic procedure. Schuitemaker and co-authors accuse us for not having responded to a previous critical objection published by them in JOM, ie, Journal of Orthomolecular Medicine. First, we do not have access to this journal. Second, none of the authors have sent us their objections. Third, Schuitemaker and co-authors should know that the usual academic procedure is to submit such objections to JAMA, which in 2007 published an abbreviated version of our review. Had they done so, we would, of course, have responded to any of their objections.

2. We produced the abbreviated version of our review for the JAMA and the long version for The Cochrane Library more or less in parallel. The short version is about 15 printed pages long, and had a much shorter review process. The long version is about 200 printed pages long and had a much longer and elaborate review process. That Cochrane Reviews are published both as electronic versions in The Cochrane Library with sister publications in paper journals are an often encountered procedure.

It was part of our protocol that we would include both healthy participants and patients without active diseases. The effect of antioxidants did not differ significantly between the two subgroups.

As every trial is accounted for and displayed we do not understand the accusation that we are hiding positive effects.

3. We have dealt with this issue extensively in our review. Trials without deaths were excluded. First, they provide very little information. Second, most of these trials were not ‘preventive trials’, but rather explanatory trials assessing the impact of antioxidant supplements on potential surrogate outcome measures. Third, we assessed the influence of trials with zero events in the treatment or control group by re-calculating the random-effects meta-analyses with 0.5, 0.05, and 0.005 continuity corrections. Fourth, we also performed additional meta-analyses including one large hypothetical trial with one event in the treatment and control group and a sample size corresponding to the total number of participants in the 405 zero events trials. All these analyses confirmed the results of our primary analyses.

4. We have dealt with this issue extensively in our review as well as above. We refer the reader to these for further explanation. We do not know what Schuitemaker and co-authors refer to when they speak of “sensitivity analysis involving 14 studies”.

5. Schuitemaker and co-authors point to the fact that we considered any drop-outs as survivors. First, all low-bias risk trials had adequate reporting of follow-up. The details are reported in Table of included trials. Here, Schuitemaker and co-authors can see trial by trial how well follow-up was reported. All low-bias risk trials had adequate reporting of follow-up. Second, the trials having losses to follow up usually had few losses. Third, the outcome in question was all-cause mortality, an outcome that could usually be determined in the countries in which the trials were performed. Fourth, we had chosen the option to consider drop-outs as survivors at the protocol stage - which is among the options one may choose according to 16.1.2 of the Cochrane Collaboration Handbook (Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]. In: The Cochrane Library, Issue 3, 2005. Chichester, UK: John Wiley & Sons, Ltd.). Considering that antioxidant supplements seem to increase mortality, we think we might have biased our analyses for the benefit of antioxidant supplements.
We will acknowledge that missing data may bias meta-analyses and when updating this review we shall examine this aspect in greater detail.

6. We think Schuitemaker and co-authors erred on these points and recommend them to read the Cochrane Collaboration Handbook (Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]. In: The Cochrane Library, Issue 3, 2005. Chichester, UK: John Wiley & Sons, Ltd.).

7. Again we think Schuitemaker and co-authors erred on these points and recommend them to read our criteria for including a trial among the low-bias risk trials as well as the Table describing the included studies. Here, we describe that GISSI was not placebo controlled (ie, there was no intervention in the control group). Therefore, this trial was considered having a high risk of bias. In the Table describing the included studies we also describe that NITI had inadequate follow-up as losses to follow-up were not reported. Therefore, this trial was considered a high risk of bias trial.

On 'Pharmacology and nutrition'

1. We think Schuitemaker and co-authors erred on these points and recommend that they re-read Hróbjartsson and Gøtzsche's article on placebo. Placebo is not given to cause or prevent death. Placebo is given to blind participants, investigators, and assessors to avoid reporting bias, collateral intervention bias, and outcome assessment bias.

2. Schuitemaker and co-authors do not consider vitamin A as an antioxidant. We refer the reader to our discussion on that topic in our review.

3. We agree with Schuitemaker and co-authors that the antioxidant field has been influenced by a measure of naivety. We think their criticism should go to the investigators and companies behind the conducted trials - we are only reviewing and meta-analysing the evidence that we are able to find.

4. We agree. We only looked at a handful of antioxidant supplements. We still think that we assessed some of the more commonly used antioxidants, which can be witnessed by the large number of randomised trials that we identified. Meta-analyses cannot cover all interventions. We strongly support further systematic reviews of other antioxidant supplements.

5. But claims are not valid proof.

6. We may agree. But again, we followed our protocol to look at selenium irrespective of form.

7. We may agree. But again, we followed our protocol to look at 'vitamin E' irrespective of form.

8. We may obtain consensus when we explain that what we meant was that this area was one of the best researched areas when we take into account the very large number of low-bias risk trials with large participant groups. Hereby both systematic error and random error are contained, and internal validity maximised. Where else does one find 47 trials offering such high internal validity?

9. Not at all. We are not dealing with children, pregnant women, or patients with active disease because some of these groups may be in need of one or more antioxidant supplements.

10. The problem with publication bias has been known for more than 50 years. This bias usually affects trials with neutral and harmful findings (Dickersin K, Rennie D. Registering clinical trials. JAMA. 2003;290(4):516-23). Now Schuitemaker and co-authors suggest that the pharmaceutical industry has withheld positive studies showing benefits of antioxidant supplements. We do not think this is very likely. First, the industry supporting the included trials had produced a median of 6 publications per trial (range 1 to 44 publications per trial). This is an extraordinary marketing achievement, considering that randomised trials are usually only published twice (Gluud C, Nikolova D. Likely country of origin in publications on randomised controlled trials and controlled clinical trials during the last 60 years. Trials. 2007;8:7). Second, the same industry has been sued and ordered to pay very large fines due to cartel price fixing (and it has been able to pay) (Connor JM. Global Price Fixing. Second Ed., Springer-Verlag, Berlin Heidelberg, 2007). Witnessing the exorbitant large fines, we are quite confident that this industry has not had a net loss on these products. But we must admit, we do not know.

On 'Conclusions'

The recommendations that Sir Bradford Hill outlined in 1965 - before the introduction of systematic reviews - did not say that basic science and physiology should trump systematic reviews of low-bias risk trials. Although basic science and physiology should be studied intensely, it may never make us ignore empirical research results.
As stated above, we intend to analyse our data from different aspects in future updates to try to accommodate the concerns that have been raised.

Contributors
Christian Gluud,
Lise Lotte Gluud,
Dimitrinka Nikolova,
Rosanna Simonetti,
Goran Bjelakovic.

Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases, 14 September 2008

Summary
Feedback by Enrico Magosso*, Kah Hay Yuen*, Yogheswaran Gopalan* *School of Pharmaceutical Sciences Universiti Sains Malaysia, 11800 Penang Malaysia
correspondence to: magosso.ld08@student.usm.my
It is indeed impressive the authors have put together this review involving over 230,000 patients in 67 trials. The antioxidants considered in the trials were vitamin A, vitamin E (mostly as alpha-tocopherol), beta-carotene, vitamin C and selenium, used either alone or in combination.

However, this range of antioxidants has to be considered as extremely limited compared to those found in nature and other natural compounds with antioxidant properties are increasingly being described. For example vitamin E is the generic name given to a family of 8 homologue compounds comprising alpha, beta-, gamma- and delta-tocopherols as well as alpha-, beta-, gamma- and delta-tocotrienols. These homologues have been shown to exert individual functions (Brigelius-Flohè and Traber, 1999; McIntyre et al., 2000; Schaffer et al., 2004). Tocopherols and tocotrienols share similar structural features of the chromanol ring or ‘head’ and are similarly named as alpha-, beta-, gamma- and delta- depending on the number and position of the methyl groups attached to the ‘head’. The main chemical difference between tocopherols and tocotrienols lies in the phyleryl chain or ‘tail’, saturated in the former and unsaturated in the latter. Natural alpha-tocopherol occurs only as d- (or RRR-) isomer, while synthetic alpha-tocopherol (that is derived from petroleum) is the d,l-racemic mixture. Tocotrienols are of natural origin and are exclusively d-isomers. The majority of investigations have used the form of vitamin E that is alpha-tocopherol (mostly of synthetic origin) to the extent that alpha-tocopherol and vitamin E became synonymous.

Sen and co-authors have highlighted the tangible differences, in efficacy as well as in toxicity, between tocopherols and tocotrienols. The following passage is taken from Sen et al. (2006): ‘An expanding body of evidence support that members of the vitamin E family are functionally unique. In recognition of this fact, title claims in manuscripts should be limited to the specific form of vitamin E studied. For example, evidence for toxicity of a specific form of tocopherol in excess may not be used to conclude that high-dosage “vitamin E” supplementation may increase all-cause mortality. Such conclusion incorrectly implies that tocotrienols are toxic as well under conditions where tocotrienols were not even considered.’

Similar arguments apply to beta-carotene, which is a single homologue of a range of about 600 carotenoids found in nature, 50 of which exert the role of vitamin A precursors and occurring as cis/trans racemic mixture at a variable ratio (Schieber and Carle, 2005; Krinsky and Johnson, 2005). Lyn (2000) in his review suggested ‘the efficient uptake of synthetic all-trans beta-carotene [?] appears to make the synthetic form more desirable for effective absorption. But the tendency of synthetic beta-carotene to alter normal serum trans/cis ratios in favor of the trans-isomer may not be a beneficial effect’ and that ‘the consequences of using all-trans synthetic beta-carotenes are at this point unknown’. It has been suggested the negative outcome in clinical trials involving beta-carotene might be ascribed to the use of the purified, synthetic form (Ben-Amotz and Levy, 1996; Lyn, 2000).

In the review entitled ‘The use of antioxidant therapies during chemotherapy’, Drisko and co-authors (2003) highlighted the importance of natural mixed carotenoids, suggesting that ‘the use of synthetic beta-carotene as a single agent rather than natural mixed carotenoids may actually promote cancer formation’.

In all but a handful of studies considered in this review synthetic alpha-tocopherol and synthetic beta-carotene were used.

Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases (Review)
In addition to many examples in which different isomers of the same compound present different level of activity and toxicity, the FDA does not register new pharmaceuticals without chiral definition (FDA, 1992; FDA, 1995; FDA 1997).

We believe certain aspects of the review should consider the following to reflect objectively several facts:

1) The origin of the antioxidants, either synthetic or natural, was not mentioned with regard to the included studies. Thus assuming that there are not biological differences between the two sources.
2) Tocotrienols were not present in any of the preparations administered in the studies considered, but the authors did not differentiate them from the generic name of vitamin E or alpha-tocopherol and thus shared the same detrimental effect on survival rate.
3) Since the authors' conclusion as currently stated all but prohibit further antioxidant trials it will be helpful to perform a subgroup analysis by natural or synthetic origin of the antioxidants administered and the range of antioxidants to which the conclusion is applicable needs to be stated.

References:

Ben-Amotz A, Levy Y (1996). Bioavailability of a natural isomer mixture compared with synthetic all-trans &#946;-carotene in human serum. Am.J.Clin. Nutr. 63:729-734
Brigelius-Flohé R, Traber MG (1999). Vitamin E: function and metabolism. FASEB J. 13: 1145-1155
Drisko JA, Chapman J, Hunter VJ (2003). The use of antioxidant therapies during chemotherapy. Gynec. Onc. 88: 434-439
Food and Drug Administration (1992).
http://www.fda.gov/cder/guidance/stereo.htm
Food and Drug Administration (1995). http://www.fda.gov/cder/guidance/phase1.pdf
Food and Drug Administration (1997). http://www.fda.gov/cder/guidance/old038fn.pdf
Krisnesky NI, Johnson EJ (2005). Carotenoid actions and their relation to health and disease. Molecular Asp. Med. 26: 459-516
Lyn P (2000). Beta-Carotene: The Controversy Continues. Altern. Med. Rev. 5 (6): 530-545
McIntyre B, Briski KP, Gapor A, Sylvester PW (2000). Antiproliferative and apoptotic effects of tocopherols and tocotrienols on preneoplastic and neoplastic mouse mammary epithelial cells. P.S.E.B.M. 224: 292-301
Schaffer S, Miller WE, Eckert GP (2005). Tocotrienols: constitutional effects in aging and disease. J.Nutr. 135: 151-154
Schieber A, Carle R (2005). Occurrence of carotenoids cis-isomers in food: Technological, analytical and nutritional implications. Trends Food Sc.Tech. 16: 416-422
Sen CK, Khanna S, Roy S (2006). Tocotrienols: Vitamin E beyond tocopherols. Life Sci. 78 (18): 2088-98

Submitter has modified conflict of interest statement:
EM, KHY, YG research on tocotrienols has been funded by Malaysian Palm Oil Board and supported by pharmaceutical industry.

Reply

Magosso, Yuen, and Gopalan wrote:
It is indeed impressive the authors have put together this review involving over 230,000 patients in 67 trials. The antioxidants considered in the trials were vitamin A, vitamin E (mostly as alpha-tocopherol), beta-carotene, vitamin C and selenium, used either alone or in combination.

- We thank Magosso, Yuen, and Gopalan for these most positive comments.

Magosso, Yuen, and Gopalan wrote:
However, this range of antioxidants has to be considered as extremely limited compared to those found in nature and other natural compounds with antioxidant properties are increasingly being described. For example vitamin E is the generic name given to a family of 8 homologue compounds comprising alpha, beta-, gamma- and delta-tocopherols as well as alpha-, beta-, gamma- and delta-tocotrienols. These homologues have been shown to exert individual functions (Brigelius-Flohé and Traber, 1999; McIntyre et al., 2000; Schaffer et al., 2004). Tocopherols and tocotrienols share similar structural features of the chromanol ring or 'head' and are similarly named as alpha-, beta-, gamma- and delta- depending on the number and position of the methyl groups attached to the 'head'. The main chemical difference between tocopherols and tocotrienols lies in the phytyl chain or 'tail', saturated in the former and unsaturated in the latter. Natural alpha-tocopherol occurs only as d- (or RRR-) isomer, while synthetic alpha-tocopherol (that is derived from petroleum) is the d,l-racemic mixture. Tocotrienols are of natural origin and are exclusively d-isomers. The majority of investigations have used the form of vitamin E that is alpha-tocopherol (most of synthetic origin) to the extent that alpha-tocopherol and vitamin E became synonymous. Sen and co-authors have highlighted the tangible differences, in efficacy as well as in toxicity, between tocopherols and tocotrienols.
tocotrienols. The following passage is taken from Sen et al. (2006): 'An expanding body of evidence support that members of the vitamin E family are functionally unique. In recognition of this fact, title claims in manuscripts should be limited to the specific form of vitamin E studied. For example, evidence for toxicity of a specific form of tocopherol in excess may not be used to conclude that high-dosage “vitamin E” supplementation may increase all-cause mortality. Such conclusion incorrectly implies that tocotrienols are toxic as well under conditions where tocotrienols were not even considered.'

- We are aware of the facts mention above. However, we could not include trials with tocotrienols, gamma tocopherol, or any other form of vitamin E because such randomised trials have not been published. The majority of the trials conducted tested alphatocopherol. We will in future updates try to highlight this issue.

Magosso, Yuen, and Gopalan wrote:
Similar arguments apply to beta-carotene, which is a single homologue of a range of about 600 carotenoids found in nature, 50 of which exert the role of vitamin A precursors and occurring as cis/trans racemic mixture at a variable ratio (Schieber and Carle, 2005; Krinsky and Johnson, 2005). Lyn (2000) in his review suggested ‘the efficient uptake of synthetic all-trans beta-carotene [?] appears to make the synthetic form more desirable for effective absorption. But the tendency of synthetic beta-carotene to alter normal serum trans/cis ratios in favor of the trans-isomer may not be a beneficial effect’ and that ‘the consequences of using all-trans synthetic beta-carotenes are at this point unknown’. It has been suggested the negative outcome in clinical trials involving beta-carotene might be ascribed to the use of the purified, synthetic form (Ben-Amotz and Levy, 1996; Lyn, 2000).

In the review entitled ‘The use of antioxidant therapies during chemotherapy’, Drisko and co-authors (2003) highlighted the importance of natural mixed carotenoids, suggesting that ‘the use of synthetic beta-carotene as a single agent rather than natural mixed carotenoids may actually promote cancer formation’.

- The answer is as above. We included trials with beta-carotene that we were able to identify. We will in future updates try to highlight the raised issues.

Magosso, Yuen, and Gopalan wrote:
In all but a handful of studies considered in this review synthetic alpha-tocopherol and synthetic beta-carotene were used.

- We included the trials that we were able to identify according to our protocol. Further trials and systematic reviews have to access whether there are certain benefits or harms connected to ‘synthetic’ as well as ‘natural’ vitamins.

Magosso, Yuen, and Gopalan wrote:
In addition to many examples in which different isomers of the same compound present different level of activity and toxicity, the FDA does not register new pharmaceuticals without chiral definition (FDA, 1992; FDA, 1995; FDA 1997).

- It would be much better for the FDA and other regulatory agencies to require that dietary supplements sold to the public claiming health benefits are subjected to adequate assessment of benefits and harms before market release, similar to any other drug.

Magosso, Yuen, and Gopalan wrote:
We believe certain aspects of the review should consider the following to reflect objectively several facts:
1) The origin of the antioxidants, either synthetic or natural, was not mentioned with regard to the included studies. Thus assuming that there are not biological differences between the two sources.

- We mentioned the form of antioxidant used in the table ‘Characteristics of included studies’. The origin of the antioxidants was mentioned in the majority of the trials, but in some of them not.

Magosso, Yuen, and Gopalan wrote:
2) Tocotrienols were not present in any of the preparations administered in the studies considered, but the authors did not differentiate them from the generic name of vitamin E or alpha-tocopherol and thus shared the same detrimental effect on survival rate.

- We were not able to identify such trials. In case that at any future review updates, we identify randomised trials with tocotrienols, we will include them in our meta-analyses. As already stated, we will address this issue in further updates.

Magosso, Yuen, and Gopalan wrote:
3) Since the authors' conclusion as currently stated all but prohibit further antioxidant trials it will be helpful to perform a subgroup analysis by natural or synthetic origin of the antioxidants administered and the range of antioxidants to which the conclusion is applicable needs to be stated.

- If we identify enough number of trials with natural antioxidant supplements, we can perform subgroup analyses. However, we are of the opinion that we have fulfilled the main Cochrane criterion to look at the totality of evidence for the effects of a specific intervention. If you are aware of any randomised trials with 'natural' antioxidant supplements that is not included in our analyses, we will appreciate to receive this information from you.

A large population based randomised clinical trial (Physician Health Study II) has recently been completed. Its authors concluded that neither vitamin E nor vitamin C supplementation reduced the risk of major cardiovascular events. A second trial (SELECT) stopped supplementation after the Data and Safety Monitoring Committee reviewed the available data and found that selenium and vitamin E supplements failed to prevent prostate cancer. Participants taking vitamin E had a small increase in prostate cancer, while participants taking only selenium were more likely to develop diabetes. These results strongly support the findings of our review.

1. Sesso HD, Buring JE, Christen WG, Kurth T, Belanger C, MacFadyen J, Bubes V, Manson JE, Glynn RJ, Gaziano JM. Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. JAMA 2008;300:2123-33.
2. http://www.crab.org/select/ (Assessed 19 November 2008).

Contributors
Goran Bjelakovic,
Christian Gluud,
Dimitrinka Nikolova.

WHAT'S NEW
Last assessed as up-to-date: 19 February 2008.

| Date            | Notes                                      |
|-----------------|--------------------------------------------|
| 11 November 2008| Feedback has been incorporated              |
|                 | Replies to the comments by E Magosso, K.H. Yuen, and Y Gopalan. |

HISTORY
Protocol first published: Issue 2, 2003
Review first published: Issue 2, 2008

| Date            | Notes                                      |
|-----------------|--------------------------------------------|
| 12 August 2008  | Feedback has been incorporated              |
|                 | Replies to two multi-author comments.       |
| 17 April 2008   | Amended                                    |
|                 | Converted to new review format.             |
CONTRIBUTIONS OF AUTHORS

GB had full access to all data in the review and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Study concept and design: GB, DN, LLG, RGS, CG.
Acquisition of data: GB, DN, CG.
Analysis and interpretation of data: GB, DN, LLG, RGS, CG.
Drafting of the manuscript: GB, DN, LLG, RGS, CG.
Critical revision of the manuscript for important intellectual content: GB, DN, LLG, RGS, CG.
Statistical analysis: GB, LLG, RGS, CG.
Obtained funding: CG.
Administrative, technical, or material support: DN, CG.
Study supervision: GB, CG.

DECLARATIONS OF INTEREST

None known. The funding sources had no role in the conduct of the study, collection of data, management, analysis, interpretation of the data, or preparation of the manuscript.

SOURCES OF SUPPORT

Internal sources

• The Copenhagen Trial Unit, Centre for Clinical Intervention Research, Rigshospitalet, Denmark.

External sources

• Knowledge and Research Centre for Alternative Medicine (ViFAB), Denmark.

NOTES

The protocol for this review was published with a title 'Antioxidants for preventing gastrointestinal cancers'. The contents of this review have already been published in JAMA (Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA 2007;297(8):842-857) with corrections appearing in JAMA 2008 (Data Errors in: Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA 2008;299(7):765-766). The present version of the review incorporates all these corrections. Furthermore, we have realised that we included a quasi-randomised study in our JAMA version. This study has been excluded of our present Cochrane review. This has not materially changed the results.

In Issue 1 2009, we made the following change for the AMDS trial (AMDS 1996Low ). Being mislead by the wording of the text in one of its publications, we had registered it as a beta-carotene trial. Our revision of the published literature on this trial confirmed that it was a vitamin A trial. Now this is corrected throughout the text. This correction led to minor changes in the values in the analyses, but did not lead to any significant change of results nor conclusions.
INDEX TERMS

Medical Subject Headings (MeSH)

*Health Status; *Mortality; Antioxidants [*administration & dosage; adverse effects]; Ascorbic Acid [*administration & dosage; adverse effects]; beta Carotene [*administration & dosage; adverse effects]; Primary Prevention [*methods]; Randomized Controlled Trials as Topic; Selenium [*administration & dosage; adverse effects]; Vitamin A [*administration & dosage; adverse effects]; Vitamin E [*administration & dosage; adverse effects]

MeSH check words

Humans